10-Q

0001479290-15-000010.txt : 20151111 0001479290-15-000010.hdr.sgml : 20151111 20151110171129 ACCESSION NUMBER: 0001479290-15-000010 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151110 DATE AS OF CHANGE: 20151110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 151219726 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 10-Q 1 rvncq31510q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-36297

Revance Therapeutics, Inc.

(Exact name of registrant as specified in its charter)



Delaware		77-0551645
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

7555 Gateway Boulevard Newark, California 94560 (510) 742-3400 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	¨	Accelerated filer	¨

Non-accelerated filer	x (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Number of shares outstanding of the registrant's common stock, par value $0.001 per share, as of November 9, 2015: 28,062,233

Table of Contents




		Page
PART I. FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements	4
	Condensed Consolidated Balance Sheets at September 30, 2015 and December 31, 2014 (unaudited)	4
	Condensed Consolidated Statement of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2015 and 2014 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2015 and 2014 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	32
Item 4.	Controls and Procedures	32

PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	33
Item 1A.	Risk Factors	33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	61
Item 3.	Defaults Upon Senior Securities	62
Item 4.	Mine Safety Disclosures	62
Item 5.	Other Information	62
Item 6.	Exhibits	62

Signatures		63

Exhibit Index		63

“Revance Therapeutics,” the Revance logos and other trademarks or service marks of Revance appearing in this quarterly report on Form 10-Q are the property of Revance Therapeutics, Inc. This Form 10-Q contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. Condensed Consolidated Financial Statements

Table of Contents

REVANCE THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)



	September 30,			December 31,
	2015			2014
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	90,494		$	171,032
Short-term investments	51,364			—
Restricted cash, current portion	35			75
Prepaid expenses and other current assets	1,604			1,624
Total current assets	143,497			172,731
Property and equipment, net	19,254			19,274
Long-term investments	2,357			—
Restricted cash, net of current portion	400			435
Other non-current assets	6			29
TOTAL ASSETS	$	165,514		$	192,469
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable	$	2,731		$	3,149
Accruals and other current liabilities	5,990			4,145
Financing obligation, current portion	3,018			307
Notes payable, current portion and net of discount	—			2,635
Total current liabilities	11,739			10,236
Financing obligation, net of current portion	6,176			598
Derivative liabilities associated with Medicis settlement	1,481			1,541
Deferred rent	3,762			3,725
TOTAL LIABILITIES	23,158			16,100
Commitments and Contingencies (Note 9)
STOCKHOLDERS’ EQUITY
Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of September 30, 2015 and December 31, 2014, respectively; 24,313,222 and 23,774,465 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	24			24
Additional paid-in capital	452,501			435,142
Accumulated other comprehensive income	10			—
Accumulated deficit	(310,179		)	(258,797		)
TOTAL STOCKHOLDERS’ EQUITY	142,356			176,369
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	165,514		$	192,469

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

Table of Contents

REVANCE THERAPEUTICS, INC.

Condensed Consolidated Statement of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Revenue	$	75		$	75		$	225		$	308
Operating expenses:
Research and development	13,016			8,600			32,573			24,261
General and administrative	5,827			5,300			18,183			14,250
Total operating expenses	18,843			13,900			50,756			38,511
Loss from operations	(18,768		)	(13,825		)	(50,531		)	(38,203		)
Interest income	68			14			144			18
Interest expense	(390		)	(228		)	(834		)	(10,336		)
Change in fair value of derivative liabilities associated with the convertible notes	—			—			—			4,032
Changes in fair value of derivative liabilities associated with Medicis settlement	13			67			60			(426		)
Change in fair value of common stock warrant liability	—			—			—			(2,151		)
Change in fair value of convertible preferred stock warrant liability	—			—			—			(210		)
Loss on settlement of preferred stock warrant	—			—			—			(1,356		)
Other expense, net	(98		)	(5		)	(221		)	(73		)
Net loss	(19,175		)	(13,977		)	(51,382		)	(48,705		)
Unrealized gain on available for sale securities	22			—			10			—
Comprehensive loss	$	(19,153	)	$	(13,977	)	$	(51,372	)	$	(48,705	)
Net loss attributable to common stockholders (Note 12):
Basic	$	(19,175	)	$	(13,977	)	$	(51,382	)	$	(48,705	)
Diluted	$	(19,175	)	$	(13,977	)	$	(51,382	)	$	(48,705	)
Net loss per share attributable to common stockholders:
Basic	$	(0.81	)	$	(0.60	)	$	(2.17	)	$	(2.70	)
Diluted	$	(0.81	)	$	(0.60	)	$	(2.17	)	$	(2.70	)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders:
Basic	23,755,199			23,331,104			23,625,869			18,009,537
Diluted	23,755,199			23,331,104			23,625,869			18,009,537

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

Table of Contents

REVANCE THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)



	Nine Months Ended September 30,
	2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(51,382	)	$	(48,705	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,586			1,561
Amortization of premium on investment	364			—
Amortization of discount on debt and capital leases	5			1,198
Amortization of debt issuance cost	39			148
Change in fair value of derivative liabilities associated with the convertible notes	—			(4,032		)
Changes in fair value of derivative liabilities associated with Medicis settlement	(60		)	426
Change in fair value of common stock warrant liability	—			2,151
Change in fair value of convertible preferred stock warrant liability	—			210
Loss on settlement of preferred stock warrant	—			1,356
Loss on extinguishment of 2013 Notes	—			8,331
Stock-based compensation expense	7,314			4,611
Interest for 2013 Notes and Essex Notes upon issuance, non-cash	—			271
Capitalized interest	—			(649		)
Effective interest on financing obligation	226			66
Loss on disposal of fixed assets	29			—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(134		)	(2,654		)
Other non-current assets	24			(1,238		)
Accounts payable	(477		)	(3,524		)
Accruals and other current liabilities	3,096			1,178
Payments against Medicis liabilities	—			(7,073		)
Deferred rent	152			500
Deferred revenue	—			(83		)
Net cash used in operating activities	(39,218		)	(45,951		)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(2,849		)	(5,444		)
Purchases of investments	(54,087		)	—
Change in restricted cash	75			75
Net cash used in investing activities	(56,861		)	(5,369		)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of deferred follow-on public offering costs	—			131,882
Proceeds from issuance of common stock, net of deferred initial public offering costs	—			102,672
Proceeds from issuance of convertible notes and notes payable	—			6,750
Proceeds from issuance of common stock, net of deferred at-the-market offering costs	10,154			—
Principal payments made on capital leases and financing obligation	(1,768		)	(146		)
Net settlement of restricted stock awards to settle employee taxes	(762		)	—

Table of Contents

REVANCE THERAPEUTICS, INC.



Principal payments made on notes payable	(2,652	)	(6,230	)
Proceeds from sale and leaseback financing	9,831		—
Proceeds from the exercise of stock options and employee stock purchase plan	738		1,402
Payments to settle warrants	—		(1,438	)
Net cash provided by financing activities	15,541		234,892
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(80,538	)	183,572
CASH AND CASH EQUIVALENTS — Beginning of period	171,032		3,914
CASH AND CASH EQUIVALENTS — End of period	90,494		187,486
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	564		971
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accruals and other current liabilities	95		832
Write-off of fixed assets	28		—
Conversion of Series E-1, E-2, E-3, E-4 and E-5 preferred stock into common stock	—		123,982
Conversion of 2013 Notes into common stock	—		26,206
Issuance of common stock upon net exercise of common stock warrants in connection with IPO	—		6,490
Fair value in excess of debt host for derivative liabilities associated with convertible notes	—		1,050
Deferred public offering costs	84		4,574
Conversion of preferred stock warrants to common stock warrants	—		1,441
Conversion of Essex Notes into financing obligations	—		1,095
Termination of stock option repurchase right	—		58
Issuance of common stock warrants in connection with the 2013 Notes	—		981
Issuance of convertible preferred stock warrants	—		80

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. The Company and Basis of Presentation

Revance Therapeutics, Inc., or the Company, was incorporated in Delaware on August 10, 1999 under the name Essentia Biosystems, Inc. The Company commenced operations in June 2002 and on April 19, 2005, changed its name to Revance Therapeutics, Inc. The Company is a clinical-stage specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The Company is leveraging its proprietary portfolio of botulinum toxin type A compounds, combined with its patented TransMTS® peptide delivery system to address unmet needs in large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin type A through two investigational drug product candidates, RT001, also referred to as RTT150 (Botulinum Toxin Type A) Topical Gel, and RT002, or RTT150 (Botulinum Toxin Type A) for Injection. The Company is pursuing clinical development for RT001 and RT002 in a broad spectrum of aesthetic and therapeutic indications. The Company holds worldwide rights for all indications of RT001, RT002, and its TransMTS technology platform.

Since commencing operations in 2002, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, and raising capital. The Company has devoted predominantly all of its resources to preclinical, clinical, and manufacturing development of RT001 and RT002. The Company has never been profitable and has not commenced commercial operations.

Since the Company's inception, the Company has incurred losses and negative cash flows from operations. The Company has not generated significant revenue from product sales to date and will continue to incur significant research and development and other expenses related to its ongoing operations. For the three and nine months ended September 30, 2015, the Company had a net loss of $19.2 million and $51.4 million and used $39.2 million of cash for operating activities during the nine months ended September 30, 2015. As of September 30, 2015, the Company had a working capital surplus of $131.8 million and an accumulated deficit of $310.2 million. The Company has funded its operations primarily through the sale and issuance of common stock, convertible preferred stock, notes payable, and convertible notes. As of September 30, 2015, the Company had capital resources consisting of cash, cash equivalents, and investments of $144.2 million. The Company believes that its existing cash, cash equivalents, and investments will allow the Company to fund its operations for at least the next 12 months.

Follow-on Public Offering

In November 2015, the Company completed a public offering, pursuant to which the Company issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements, in the opinion of management, include all adjustments which the Company considers necessary for the fair statement of the Condensed Consolidated Results of Operations and Comprehensive Loss and Cash Flows for the interim periods covered and the Condensed Consolidated Financial Position of the Company at the date of the balance sheets. The December 31, 2014 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America, or US GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2015, or any other future period.

The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission, or SEC, on March 4, 2015.

The Condensed Consolidated Financial Statements of the Company include the Company’s accounts and those of the Company’s wholly-owned subsidiary and have been prepared in conformity with US GAAP.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

2. Summary of Significant Accounting Policies

Significant accounting policies are described in Note 2 to the consolidated financial statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. There have been no changes to the Company’s significant accounting policies during the three and nine months ended September 30, 2015, except as described below.

Use of Estimates

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investment securities with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents may include cash on deposit, money market funds, and debt securities.

Investments

Short-term investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. All of its investments are classified as available-for-sale and carried at fair value, with the change in unrealized gains and losses reported as a separate component of other comprehensive income (loss) on the Condensed Consolidated Statements of Operations and Comprehensive Loss and accumulated as a separate component of stockholders' equity on the Condensed Consolidated Balance Sheets. Interest income, net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of investments, if any. The cost of securities sold is based on the specific-identification method. The Company monitors its investment portfolio for potential impairment on a quarterly basis. If the carrying amount of an investment in debt securities exceeds its fair value and the decline in value is determined to be other-than-temporary, the carrying amount of the security is reduced to fair value and a loss is recognized in operating results for the amount of such decline. In order to determine whether a decline in value is other-than-temporary, the Company evaluates, among other factors, the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, and its intent and ability to hold the security to maturity or forecasted recovery. The Company mitigates its credit risk by investing in money market funds and U.S. government agency obligations which limits the amount of investment exposure as to credit quality and maturity.

Fair Value of Financial Instruments

The Company uses fair value measurements to record fair value adjustments to certain financial and non-financial assets and liabilities to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The three levels of inputs that may be used to measure fair value are as follows:



Level 1	—	Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

Level 2	—	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3	—	Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

Accounting Pronouncements

In August 2014, the FASB issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), which will require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year of the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The guidance defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. The guidance is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Company’s financial statements.

3. Medicis Settlement

In October 2012, the Company entered into a settlement and termination agreement with Medicis Pharmaceutical Corporation, or Medicis. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to $25.0 million, comprised of (i) an upfront payment of $7.0 million, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of $14.0 million due upon specified capital raising achievements by the Company, of which $6.9 million was paid in 2013 and the remaining $7.1 million was paid in 2014, and (iii) $4.0 million to be paid upon the achievement of regulatory approval for RT001 or RT002 by the Company, or Product Approval Payment.

As of September 30, 2015, the Company determined the fair value of its liability for the Product Approval Payment was $1.5 million, which was measured by assuming a term of 3.75 years, a risk-free rate of 1.09% and a credit risk adjustment of 7.25%. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2019. The Company did not make any payments under the Product Approval Payment during the nine months ended September 30, 2015.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

4. Cash Equivalents and Investments

The Company's cash equivalents and investments consist of money market funds and U.S. government agency obligations, which are classified as available-for-sale securities.

The following table is a summary of amortized cost, unrealized gain and loss, and fair value (in thousands):



	September 30, 2015									December 31, 2014
			Gross Unrealized									Gross Unrealized
	Cost		Gains		Losses			Fair Value		Cost		Gains		Losses		Fair Value
Money market funds	$	72,454	$	—	$	—		$	72,454	$	166,038	$	—	$	—	$	166,038
U.S. government agency obligations	53,711		12		(2		)	53,721		—		—		—		—
Total cash equivalents and available-for-sale securities	$	126,165	$	12	$	(2	)	$	126,175	$	166,038	$	—	$	—	$	166,038

Classified as:
Cash equivalents								$	72,454							$	166,038
Short-term investments								51,364								—
Long-term investments								2,357								—
Total cash equivalents and available-for-sale securities								$	126,175							$	166,038

As of September 30, 2015 and December 31, 2014, the remaining contractual maturities of available-for-sale securities were less than two years.

There have been no significant realized gains or losses on available-for-sale securities for the periods presented. No significant available-for-sale securities held as of September 30, 2015 have been in a continuous unrealized loss position for more than 12 months. As of September 30, 2015, unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the cost basis of the investment will be recovered. The Company believes it has no other-than-temporary impairments on its securities as it does not intend to sell these securities and believes it is not more likely than not that it will be required to sell these securities before the recovery of their amortized cost basis. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in fair value.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

5. Fair Value Measurements

The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. These liabilities, consisting of the Medicis settlement, are considered Level 3 instruments, while the assets, consisting of money market funds and U.S. government agency obligations, are considered Level 1 and Level 2 instruments, respectively. The fair value of these instruments was as follows (in thousands):



	As of September 30, 2015
	Fair Value		Level 1		Level 2		Level 3
Assets
Money market funds	$	72,454	$	72,454	$	—	$	—
U.S. government agency obligations	53,721		—		53,721		—
Total assets measured at fair value	$	126,175	$	72,454	$	53,721	$	—

Liabilities
Derivative liabilities associated with the Medicis settlement	$	1,481	$	—	$	—	$	1,481
Total liabilities measured at fair value	$	1,481	$	—	$	—	$	1,481



	As of December 31, 2014
	Fair Value		Level 1		Level 2		Level 3
Assets
Money market funds	$	166,038	$	166,038	$	—	$	—
Total assets measured at fair value	$	166,038	$	166,038	$	—	$	—

Liabilities
Derivative liabilities associated with the Medicis settlement	$	1,541	$	—	$	—	$	1,541
Total liabilities measured at fair value	$	1,541	$	—	$	—	$	1,541

The fair value of the U.S. government agency obligations are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. The Company did not transfer any assets or liabilities measured at fair value on a recurring basis to or from Level 1 and Level 2 during the nine months ended September 30, 2015 and the year ended December 31, 2014.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):



	Derivative Liability Associated with the Medicis Settlement
Fair value as of December 31, 2014	$	1,541
Change in fair value	(60		)
Fair value as of September 30, 2015	$	1,481

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

The fair value of the derivative liability resulting from the Medicis litigation settlement, specifically the derivative related to the Product Approval Payment (Note 3), was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment. The significant unobservable inputs used in the fair value measurement of the Product Approval Payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.

6. Notes Payable and Financing Obligation

Hercules Notes Payable

In September 2011, the Company entered into a loan and security agreement with Hercules Technology Growth Capital for $22.0 million, referred to as the Hercules Notes Payable.

The Hercules Notes Payable, which matured in March 2015 and has been repaid in full, was collateralized by all assets of the Company, and bore interest at the greater of (i) 9.85% per annum or (ii) 9.85% per annum plus the difference of the prime rate less 3.25% per annum and contained covenants that required, among other things, that the Company seek consent from Hercules prior to certain corporate changes and provide certain unaudited financial information within 45 days after the end of each quarter and within 90 days after each year end. Starting in July 2012, the loan was repaid in 33 equal monthly payments of principal and interest of $0.8 million plus an end of term payment of $0.5 million if the loan is prepaid, or $0.4 million if paid upon maturity. In March 2015, the Hercules Notes Payable was repaid in full, including the end of term payment of $0.4 million.

In connection with the Hercules Notes Payable, the Company issued warrants to purchase 17,977 shares of Series D convertible preferred stock at $66.75 per share, which converted to warrants to purchase common stock upon the Company's initial public offering, or IPO. The fair value of the warrants of $0.1 million was recorded as a debt discount and was amortized to interest expense using the straight-line method over the loan term. The Company incurred $0.5 million of debt issuance costs in connection with the Hercules Notes Payable which was also amortized to interest expense over the loan term.

The Company made principal and interest payments on the Hercules Notes Payable of $0 and $2.6 million and $2.3 million and $6.9 million during the three and nine months ended September 30, 2015 and 2014, respectively.

Essex Capital Notes

On December 20, 2013, the Company signed a Loan and Lease Agreement to borrow up to $10.8 million in the form of Secured Promissory Notes from Essex Capital, or the Essex Notes, to finance the completion and installation of the Company’s RT001 commercial fill/finish line, or the Fill/Finish Line. Under the Loan and Lease Agreement, with the issuance of each Note, the Company issued warrants to purchase its capital stock. The Essex Notes incurred interest at 11.5% per annum through the completion of the IPO in February 2014 and 10.375% per annum thereafter. In December 2013, the Company drew down $2.5 million under short-term notes pursuant to the Loan and Lease Agreement, and an additional $2.5 million in January 2014. In May 2014, pursuant to the terms of this agreement, the Company sold equipment to Essex Capital, resulting in partial settlement of the outstanding loan balance of $1.1 million, and sold and leased the equipment back from Essex Capital for fixed monthly payments to be paid over 3 years. This transaction did not qualify for sale-leaseback accounting due to the Company’s continuing involvement in the equipment. Therefore, the Company accounted for this transaction as a financing obligation using the effective interest rate method.

On December 17, 2014, the Company entered into the First Amendment to the Loan and Lease Agreement with Essex Capital. Under the terms of this Amendment, the Company repaid the outstanding debt balance of $3.9 million and issued warrants to purchase 44,753 shares of common stock. Additionally, the Company made interest payments on the Essex Notes in the amount of $0.1 million and $0.3 million for the three and nine months ended September 30, 2014. In February 2015, the Company executed the Second Amendment to the Loan and Lease Agreement, under which the term of the facility was extended to April 15, 2015, and the purchase price of the equipment was increased by $0.1 million to approximately $9.8 million. In accordance with the terms of the Loan and Lease Agreement, in April 2015, the Company sold equipment to Essex Capital for approximately $9.8 million, and concurrently with this sale, entered into a lease for the equipment with a fixed monthly payment to be paid over 3 years. This transaction also did not qualify for sale-leaseback accounting due to the Company’s continuing involvement in the equipment. Therefore, the Company accounted for this transaction as a financing obligation using the effective interest rate method.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

In June 2015, the Company exercised its option to purchase all equipment sold and leased back from Essex Capital for 10% of the original purchase amount, or approximately $1.1 million, at the conclusion of the lease terms.

As of September 30, 2015, the aggregate total future minimum lease payments under the financing obligation were as follows (in thousands):



Year Ending December 31,
2015	$	1,054
2016	4,217
2017	3,971
2018	949
Total payments	$	10,191

7. Convertible Notes, Warrants, and Related Derivatives

2013 Convertible Notes, Common Stock Warrants, and Related Derivatives

In February 2014, in connection with the Company’s IPO, the 2013 Notes with a principal amount of $23.7 million, accrued interest through the date of the IPO, remaining interest due through October 7, 2014, and derivative liability totaling $26.2 million converted into 1,637,846 shares of the Company’s common stock.

In connection with the issuance of the 2013 Notes, the Company issued warrants to purchase 409,450 shares of common stock, which were net exercised for 405,594 shares of common stock upon the IPO.

Additionally, the 2013 Notes had conversion and redemption features which were determined to be embedded derivatives, requiring bifurcation and separate fair value accounting. Immediately prior to the conversion, the Company determined that the fair value of the derivative liabilities associated with the convertible notes was reduced to $1.9 million, the value of interest due to note holders from the date of the IPO through the maturity date of the loan in October 2014.

Upon the conversion of the 2013 Notes into shares of common stock, the Company applied extinguishment accounting resulting in a loss of $8.3 million. As of the date of conversion, the Company was in compliance with all covenants in the 2013 Notes.

During the three months ended March 31, 2014, the Company recognized non-cash interest expense of $9.6 million related to the 2013 Notes, including amortization of warrant-related debt discount of approximately $0.4 million up to the date of conversion, amortization of the derivative-related debt discount of $0.6 million up to the date of conversion, accrued interest of $0.3 million up to the date of conversion and a loss on extinguishment of $8.3 million upon conversion of the 2013 Notes into common stock.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

8. Interest Expense

Interest expense, includes cash and non-cash components with the non-cash components consisting of (i) interest recognized from the amortization of debt issuance costs, which were capitalized on the Condensed Consolidated Balance Sheets and are generally derived from cash payments related to the issuance of convertible notes and notes payable, (ii) interest recognized from the amortization of debt discounts, which were capitalized on the Condensed Consolidated Balance Sheets and derived from the issuance of warrants and derivatives issued in conjunction with convertible notes and notes payable, (iii) interest recognized on the 2013 convertible notes, or 2013 Notes, which was not paid but rather converted into shares of common stock, (iv) interest capitalized for assets constructed for use in operations, (v) interest related to the extinguishment of debt, which is classified as a loss on debt extinguishments, and (vi) effective interest recognized on the financing obligation. The capitalized amounts related to the debt issuance costs and debt discounts are generally amortized to interest expense over the term of the related debt instruments.

The interest expense by cash and non-cash components is as follows (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Interest expense
Cash related interest expense (1)	$	(264	)	$	(276	)	$	(564	)	$	(971	)

Non-cash interest expense
Non-cash interest expense — debt issuance costs	—			(48		)	(39		)	(148		)
Non-cash interest expense — warrant and derivative related debt discounts	—			(76		)	(5		)	(219		)
Non-cash interest expense — convertible notes	—			—			—			(1,250		)
Loss on extinguishment of 2013 Notes	—			—			—			(8,331		)
Effective interest on financing obligation	(126		)	(66		)	(226		)	(66		)
Non-cash capitalized interest expense (2)	—			238			—			649
Total non-cash interest expense	(126		)	48			(270		)	(9,365		)

Total interest expense	$	(390	)	$	(228	)	$	(834	)	$	(10,336	)


(1)	Cash related interest expense includes interest payments to Hercules Notes Payable, Essex Notes, and Financing Obligations.


(2)	Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.

9. Commitments and Contingencies

Facility Lease

In January 2010, the Company entered into a non-cancelable facility lease that requires monthly payments through January 2022. This facility will be used for research, manufacturing, and administrative functions.

In February 2014, the Company extended the term of the Lease by thirty-six (36) months to January 2025. Under the terms of the lease agreement, the payments escalate over the term of the lease with the exception of a decrease in payments at the beginning of 2022; however, the Company recognizes the expense on a straight-line basis over the life of the lease.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

Rent expense was $1.3 million and $3.9 million for each of the three and nine months ended September 30, 2015 and 2014. As of September 30, 2015, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands):



Year Ending December 31,
2015	$	1,269
2016	5,222
2017	5,394
2018	5,578
2019 and thereafter	32,354
Total payments	$	49,817

Other Milestone-Based Commitments

The Company has one remaining obligation to make a future milestone payment to List Laboratories that becomes due and payable on the achievement of a certain regulatory milestone. The Company is obligated to pay royalties to List Laboratories on future sales of botulinum toxin products. The Company also has one remaining future milestone payment of $4.0 million due and payable to Valeant Pharmaceuticals International, Inc. upon the achievement of regulatory approval for RT001 or RT002 (Note 3).

Purchase Commitments

The Company has certain commitments from outstanding purchase orders primarily related to clinical trial development and other costs related to the Company’s manufacturing facility. These agreements, which total $22.4 million, are cancellable at any time with the Company required to pay all costs incurred through the cancellation date.

Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. As of May 2015, the Company became subject to a securities class action complaint, captioned City of Warren Police and Fire Retirement System v. Revance Therapeutics Inc., et al, CIV 533635, which was filed on behalf of City of Warren Police and Fire Retirement System in the Superior Court for San Mateo County, California against the Company and certain of its directors and executive officers at the time of the June 2014 follow-on public offering, and the investment banking firms that acted as the underwriters in the follow-on public offering. In general, the complaint alleges that the defendants misrepresented the then-present status of the RT001 clinical program and made false and misleading statements regarding the formulation, manufacturing and efficacy of its drug candidate, RT001, for the treatment of lateral canthal lines at the time of the follow-on public offering. The complaint has been brought as a purported class action on behalf of those who purchased common stock in the follow-on public offering and seeks unspecified monetary damages and other relief.

The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. At this time, neither the outcome of this matter, nor an estimate of the maximum potential exposure or the range of possible loss can be determined. The Company believes that the class action lawsuit is without merit and intends to vigorously defend the action. Nevertheless, this litigation, as any other litigation, is subject to uncertainty and there can be no assurance that this litigation will not have a material adverse effect on the Company's business, results of operations, financial position or cash flows.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

Indemnification

The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.

The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.

No amounts associated with such indemnifications have been recorded to date.

10. Warrants

As of September 30, 2015, the Company has warrants to purchase 198,662 shares of common stock outstanding and no convertible preferred stock warrants outstanding.

11. Equity

Common Stock Outstanding

As of September 30, 2015, the Company had 24,313,222 shares of common stock outstanding. In March 2015, the Company entered into an At-The-Market Issuance Sales Agreement, or the ATM agreement, with Cowen and Company, LLC, or Cowen, under which the Company may offer and sell our common stock having aggregate proceeds of up to $50.0 million from time to time through Cowen as our sales agent. Sales of common stock through Cowen will be made by means of ordinary brokers’ transactions on the NASDAQ Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by the Company and Cowen. Cowen will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions we may impose). The Company agreed to pay Cowen a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the ATM agreement. As of September 30, 2015, the Company sold 352,544 shares of common stock under the ATM agreement at a weighted average price of $30.76 per share resulting in net proceeds of approximately $10.1 million, after underwriting discounts, commissions, and other offering expenses. As of September 30, 2015, common stock for aggregate gross proceeds of $39.2 million remained available under this facility, subject to certain conditions as specified in the ATM agreement.

2014 Equity Incentive Plan

On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Equity Incentive Plan, or 2014 EIP, automatically increased by 4% of the total number of shares of the Company’s common stock outstanding on December 31, 2014, or 950,978 shares. During the nine months ended September 30, 2015, the Company granted stock options for 725,838 shares of common stock and 157,286 restricted stock awards under the 2014 EIP, including a stock option grants for 90,000 shares to non-employee directors. As of September 30, 2015, there were 286,984 shares available for issuance under the 2014 EIP.

2014 Inducement Plan

As of September 30, 2015, there were 145,571 shares available for issuance under the 2014 Inducement Plan, or 2014 IN.

The fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Expected term (in years)	6.1		6.2		6.3		6.1
Expected volatility	61.3	%	61.5	%	62.7	%	57.4	%
Risk-free interest rate	1.7	%	1.6	%	1.5	%	1.9	%
Expected dividend rate	—	%	—	%	—	%	—	%

Fair Value of Common Stock. The fair value of the shares of common stock is based on the Company's stock price as quoted by the NASDAQ. Prior to the IPO, the fair value of the shares of common stock underlying the stock options had historically been determined by the Board of Directors. Because there was no public market for the Company’s common stock, the Board of Directors had determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, amongst other factors.

Expected Term. The expected term for employees and directors is based on the simplified method, as the Company’s stock options have the following characteristics: (i) granted at-the-money; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable, or “plain vanilla” options, and the Company has limited history of exercise data. The expected term for non-employees is based on the remaining contractual term.

Expected Volatility. Since the Company was a private entity until February 2014 with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available.

Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury constant maturity rates with remaining terms similar to the expected term of the options.

Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend rate of zero in the valuation model.

Forfeitures. The Company is required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.

The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Expected term (in years)	8.2		8.9		8.4		9.1
Expected volatility	73.5	%	57.2	%	72.4	%	57.5	%
Risk-free interest rate	2.0	%	2.5	%	2.0	%	2.5	%
Expected dividend rate	—	%	—	%	—	%	—	%

2014 Employee Stock Purchase Plan

On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Employee Stock Purchase Plan, or 2014 ESPP, automatically increased by 1% of the total number of shares of the Company’s capital stock outstanding on December 31, 2014, or 237,744 shares. As of September 30, 2015, there were 404,073 shares available for issuance under the 2014 ESPP.

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Expected term (in years)	0.5		0.5		0.5		0.5
Expected volatility	50.8	%	42.5	%	50.5	%	46.4	%
Risk-free interest rate	0.1	%	0.1	%	0.1	%	0.1	%
Expected dividend rate	—	%	—	%	—	%	—	%

Fair Value of Common Stock. The fair value of the shares of common stock is based on the Company’s stock price as quoted by the NASDAQ.

Expected Term. The expected term is based on the term of the purchase period under the 2014 ESPP.

Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury constant maturity treasury rates with remaining terms similar to the expected term.

Total Stock-Based Compensation

Total stock-based compensation expense related to options and restricted stock awards granted to employees and nonemployees and the employee stock purchase plan was allocated as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Research and development	$	1,182	$	557	$	2,879	$	1,644
General and administrative	1,408		1,728		4,435		2,967
Total stock based compensation expense	$	2,590	$	2,285	$	7,314	$	4,611

Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):



	Unrealized Gains and Losses on Available-for-Sale Securities
Balance at December 31, 2014	$	—
Other comprehensive income (loss) before reclassifications	10
Reclassifications from accumulated other comprehensive income (loss)	—
Net current period other comprehensive income (loss)	10
Balance at September 30, 2015	$	10

Table of Contents

REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements — (Continued)

(Unaudited)

12. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2015 and 2014 (in thousands, except for share and per share amounts):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Net loss attributable to common stockholders, basic	$	(19,175	)	$	(13,977	)	$	(51,382	)	$	(48,705	)
Net loss attributable to common stockholders, diluted	$	(19,175	)	$	(13,977	)	$	(51,382	)	$	(48,705	)
Net loss per share attributable to common stockholders
Basic	$	(0.81	)	$	(0.60	)	$	(2.17	)	$	(2.70	)
Diluted	$	(0.81	)	$	(0.60	)	$	(2.17	)	$	(2.70	)
Weighted-average shares used in computing net loss per share attributable to common stockholders:
Basic	23,755,199			23,331,104			23,625,869			18,009,537
Diluted	23,755,199			23,331,104			23,625,869			18,009,537

The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:



	As of September 30,
	2015	2014
Stock options	2,374,055	1,877,949
Common stock warrants	198,662	153,909
Unvested restricted stock awards	308,193	253,625
Shares expected to be purchased on December 31 under the 2014 ESPP	7,945	6,426

13. Subsequent Events

On October 31, 2015, we entered into a separation agreement with Arthur P. Bertolino, M.D., Ph.D., our Chief Medical Officer and Executive Vice President, pursuant to which he resigned his employment with the Company, effective as of December 31, 2015. Dr. Bertolino will not be entitled to cash severance payments in connection with his departure; however, the Company agreed to accelerate vesting for a portion of his outstanding stock options and restricted stock awards, such that if he remains employed with the Company through November 15, 2015, an aggregate of 76,286 stock options and 23,740 restricted stock awards will have vested. If he remains employed through December 31, 2015, an aggregate of 114,428 stock options and 35,610 restricted stock awards will have vested.

Table of Contents



ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the accompanying notes appearing elsewhere in this Quarterly Report on this Form 10-Q and in our other Securities and Exchange Commission, or SEC, filings, including our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 4, 2015. The words “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially,” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. The following discussion and analysis contains forward-looking statements within meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements include, but are not limited to, statements concerning the following:


•	our expectations regarding the results and the timing of clinical trials in our development of RT001 for the treatment of crow’s feet, hyperhidrosis or other indications;


•	our expectations regarding the results and the timing of clinical trials of RT002 for the treatment of glabellar lines, muscle movement disorders, including cervical dystonia, or other indications;


•	our expectations regarding our future development of RT001 and RT002 for other therapeutic or aesthetic indications;


•	our expectation regarding the timing of our regulatory submissions for approval of RT001 for the treatment of crow’s feet in the United States, Europe and other countries or for the treatment of hyperhidrosis in the United States;


•	the potential for commercialization of RT001 and RT002, if approved, by us;


•	our expectations regarding the potential market size, opportunity and growth potential for RT001 and RT002, if approved for commercial use;


•	our belief that RT001 and RT002 can expand the overall botulinum toxin market;


•	our ability to build our own sales and marketing capabilities, or seek collaborative partners including distributors, to commercialize our product candidates, if approved;


•	our ability to transfer manufacturing from third parties to our facility and to scale up our manufacturing capabilities if our product candidates are approved;


•	estimates of our expenses, future revenue, capital requirements and our needs for additional financing;


•	the timing or likelihood of regulatory filings and approvals;


•	our ability to advance product candidates into, and successfully complete, clinical trials;


•	the implementation of our business model, strategic plans for our business, product candidates and technology;


•	the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs;


•	the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;


•	our ability to establish collaborations or obtain additional funding;


•	our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act;


•	our financial performance; and


•	developments and projections relating to our competitors and our industry.

Table of Contents

These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in “Risk Factors” included in Part II, Item 1A and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Table of Contents

Overview

Revance Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. We are leveraging our proprietary portfolio of botulinum toxin type A compounds, combined with our patented TransMTS® peptide delivery system, to address unmet needs in large and growing neurotoxin markets. Our proprietary TransMTS technology enables delivery of botulinum toxin type A through two investigational drug product candidates, RT001, also referred to as RTT150 (Botulinum Toxin Type A) Topical Gel, and RT002, or RTT150 (Botulinum Toxin Type A) for Injection. We are pursuing clinical development for RT001 and RT002 in a broad spectrum of aesthetic and therapeutic indications. We hold worldwide rights for all indications of RT001, RT002, and our TransMTS technology platform.

RT001 has the potential to be the first commercially available non-injectable dose form of botulinum toxin type A. We are studying RT001 for aesthetic indications, such as crow’s feet (wrinkles around the eyes, also known as lateral canthal lines), and therapeutic indications, such as hyperhidrosis (excessive sweating). RT002 is a novel, injectable formulation of botulinum toxin type A designed to be a targeted and long-lasting injectable botulinum toxin type product. We are studying injectable RT002 for aesthetic indications, such as glabellar (frown) lines, and therapeutic uses, such as muscle movement disorders, including cervical dystonia. Both products may have the potential to expand into additional aesthetic and therapeutic indications in the future.

RT002 or RTT150 (Botulinum Toxin Type A) for Injection

We are developing RT002, an injectable formulation of botulinum toxin type A, for indications where deep delivery of the botulinum toxin is required and a long-lasting effect is desired. We believe RT002 may provide targeted delivery of botulinum toxin to intended treatment sites, while reducing the unwanted spread of botulinum toxin to adjacent areas. We believe, and our preclinical and clinical studies indicate, that this targeted delivery, enabled by our proprietary peptide technology, may permit safe administration of higher doses of botulinum toxin and may result in long-lasting effect. We have demonstrated these properties in preclinical studies and have tested RT002 in a four-cohort, dose escalating, open-label Phase 1/2 clinical trial outside of the United States for the treatment of glabellar lines, the vertical lines between the eyebrows and above the nose. Data from this clinical trial indicated that RT002 appears to be well tolerated and met efficacy endpoints at all four doses. We also reported duration of effect of seven months from the last cohort of this trial, the only cohort for which duration of effect was measured.

Based upon the results to date, we are further developing RT002 for the treatment of glabellar lines and reported interim results from BELMONT, a Phase 2, active comparator, placebo-controlled clinical trial against the market leader BOTOX® Cosmetic, on October 29, 2015. The topline interim data from the trial showed that RT002 achieved its primary efficacy measurement at four weeks for all doses of RT002 and that such efficacy was highly statistically significant as compared to placebo. In addition, the 40 Unit dose of RT002 demonstrated a 23.6-week median duration versus BOTOX® Cosmetic with an 18.8-week median duration. Across all cohorts, RT002 appeared to be generally safe and well-tolerated. We plan to report final results from our BELMONT trial and conduct an End-of-Phase 2 meeting with the United States Food and Drug Administration, or FDA, in the first half of 2016. We then expect to begin Phase 3 clinical studies of RT002 for the treatment of glabellar lines in the second half of 2016. If approved, we believe RT002 has the potential to satisfy significant unmet needs in this market.

We have also initiated a Phase 2 dose-escalating, open-label clinical study of RT002 in the therapeutic indication of cervical dystonia. The Phase 2 study will evaluate safety, preliminary efficacy, and duration of effect of RT002 for injection in subjects with moderate-to-severe isolated cervical dystonia symptoms of the neck. We expect to release interim results in 2016. The category of muscle movement disorders, which includes cervical dystonia, accounts for a large proportion of therapeutic neurotoxin sales globally.

Table of Contents

RT001 or RTT150 (Botulinum Toxin Type A) Topical Gel

We are developing and plan to commercialize RT001 for indications where topical application provides a meaningful advantage over injectable administration. RT001 is designed to have primary advantages, which include painless topical administration, no bruising, ease of use and limited dependence on administration technique by physicians and medical staff. We believe these potential advantages may improve the experience of patients undergoing botulinum toxin procedures and make RT001 suitable for multiple indications.

The first indications we are pursuing are in the fields of dermatology and plastic surgery. If approved, we believe RT001 can expand the overall botulinum toxin aesthetic market by appealing to new patients who would prefer a needle-free approach to treatment. The aesthetic dermatology market is attractive because we believe that patients in this market tend to be open to trying new products and are willing to pay for aesthetic procedures out of pocket, reducing reliance on reimbursement. We are focused on this market not only because of its size and growth potential but also because, in the United States and Europe, this market can be easily accessed by a specialty sales force and distributor network.

We are in a Phase 3 development program of RT001 in North America for the treatment of crow's feet. During the third quarter of 2015, we initiated REALISE 1, a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of a single, bilateral administration of RT001 topical gel compared to placebo in subjects with moderate to severe crow's feet. We expect to report efficacy data from this study in the first half of 2016. To date, we have conducted seventeen clinical trials with RT001 for the treatment of crow's feet, with a total of over 1,600 subjects. In two of our Phase 2b clinical trials, RT001 demonstrated a statistically significant and clinically meaningful reduction in crow’s feet visible to both physicians and subjects. After completing our Phase 2b clinical trials, we modified the formulation of the RT001 diluent. We then conducted a Phase 3 clinical trial with this new diluent formulation to evaluate the efficacy and safety of RT001. Data generated from this clinical trial were inconsistent with the data from our previous three Phase 2b clinical trials for the treatment of crow’s feet. Specifically, we observed no improvement from baseline in either the placebo or RT001 group. We initiated two open-label studies to further assess our RT001 investigational topical drug product candidate. Following analysis of the data available from these open-label studies, taken together with our analysis of prior studies and early data from newly developed clinical methods, we decided to proceed with a RT001 U.S. Phase 3 clinical trial for the treatment of crow's feet. Our clinical and other studies have consistently indicated that RT001 appears to be well tolerated with no serious adverse events related to the study drug or study treatment procedures or other safety concerns.

We are also developing RT001 for therapeutic applications where botulinum toxin has shown efficacy and that are particularly well suited for needle-free treatments. We have completed initial Phase 2 clinical trials for the treatment of primary axillary, or underarm, hyperhidrosis, and for the prevention of chronic migraine headache. In the third quarter of 2015, we initiated an additional randomized, double-blinded, dose-ranging, placebo-controlled Phase 2 clinical trial designed to evaluate the safety and efficacy of a single, bilateral application of RT001 Topical Gel for the treatment of primary axillary hyperhidrosis and, in the fourth quarter of 2015, completed enrollment for the trial. We expect to report interim results later in the fourth quarter of 2015.

Since commencing operations in 2002, we have devoted substantially all our efforts to identifying and developing product candidates for the aesthetic and therapeutic markets, recruiting personnel and raising capital. We have devoted predominantly all of our resources to the preclinical and clinical development of, and manufacturing capabilities for, RT001 and RT002. We have retained all rights to develop and commercialize RT001 and RT002 worldwide. We have not filed for approval with the FDA for the commercialization of RT001 or RT002 and we have not generated any revenue from product sales for RT001 or RT002.

We have funded substantially all of our operations through the sale and issuance of our common stock, preferred stock, venture debt and convertible debt. On November 9, 2015, we completed a follow-on public offering, pursuant to which we issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million. In March 2015, we entered into an At-The-Market, or ATM, sales agreement, or the ATM agreement, with Cowen and Company, LLC, or Cowen, under which we may offer and sell our common stock having aggregate proceeds of up to $50.0 million from time to time. As of September 30, 2015, we sold 352,544 shares of our common stock under the ATM agreement at a weighted average price of $30.76 per share resulting in net proceeds of approximately $10.1 million, after underwriting discounts, commissions and other offering expenses. On June 19, 2014, we completed a follow-on public offering, pursuant to which we issued 4,600,000 shares of

Table of Contents

common stock at $30.50 per share, including the exercise of the underwriters’ option to purchase 600,000 additional shares of common stock, for net proceeds of $131.3 million, after underwriting discounts, commissions and other offering expenses. On February 6, 2014, we completed our initial public offering, or IPO, for sale of 6,900,000 shares of common stock at $16.00 per share, including the exercise of the underwriters’ option to purchase an additional 900,000 shares of common stock, for net proceeds of $98.6 million, after underwriting discounts, commissions and other offering expenses. We also raised $23.7 million through the issuance of convertible notes in the fourth quarter of 2013 and January 2014.

We have never been profitable and, as of September 30, 2015, had an accumulated deficit of $310.2 million. We incurred net losses of $19.2 million and $51.4 million and $14.0 million and $48.7 million in the three and nine months ended September 30, 2015 and 2014, respectively. As of September 30, 2015, we had cash, cash equivalents, and investments of $144.2 million. We expect to continue to incur net operating losses for at least the next several years as we advance RT001 and RT002 through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization. We have the ability to manufacture our own botulinum toxin type A product to support our clinical trials and eventually, our commercial production. Additionally, we currently utilize third party clinical research organizations, or CROs, to carry out our clinical development and we do not yet have a sales organization. We will need substantial additional funding to support our operating activities, especially as we approach anticipated regulatory approval in the United States and other territories and begin to establish our sales capabilities. Adequate funding may not be available to us on acceptable terms, or at all. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations, and financial condition.

Results of Operations

Revenue

The following table presents our revenue for the periods indicated and related changes from the prior period:



	Three Months Ended September 30,					Nine Months Ended September 30,
	2015		2014		Change	2015		2014		Change
	(In thousands, except percentages)
Relastin Royalty	$	75	$	75	—%	$	225	$	225	—%
Licensing Revenue	—		—		N/A	—		83		100%
Total revenue	$	75	$	75	—%	$	225	$	308	(3)%

Our total revenue for the three months ended September 30, 2015 remained unchanged, compared to the same period in 2014, due to minimum royalty payment obligations pursuant to the Relastin royalty agreement. We entered into the Relastin royalty agreement in August 2011, to sell the business related to our Relastin® product line, to Precision Dermatology, Inc., or PDI. The Relastin royalty agreement provided for minimum royalty payment of $0.3 million per year, to be paid quarterly for up to 15 years from the execution date; however, the royalty agreement could be terminated with 90 days’ notice with the rights to the Relastin product line reverting back to us. PDI was subsequently acquired by Valeant Pharmaceuticals International, Inc., or Valeant, in July 2014. On April 23, 2015, we received notice from Valeant terminating the royalty agreement effective as of July 23, 2015; however, as of September 30, 2015, reversion of the Relastin intellectual property rights had not been completed and we are entitled to the minimum royalty payment until such rights are reverted back to us. We recognized the annual minimum royalty payment on a pro rata basis in the amount of $0.1 million and $0.2 million for each of the three and nine months ended September 30, 2015 and 2014 as set forth in the Relastin asset purchase agreement.

Our total revenue for the nine months ended September 30, 2015 decreased by 3%, compared to the same period in 2014, due to a decrease in license revenue in connection with an exclusive technology evaluation agreement with Procter & Gamble.

In June 2013, we received an upfront payment of $0.3 million, which was initially recorded as deferred revenue and recognized over the estimated performance period. During the three months ended March 31, 2014, the remaining $0.1 million of the upfront payment related to the exclusive technology evaluation agreement was recognized as license revenue.

Operating Expenses

Table of Contents



	Three Months Ended September 30,					Nine Months Ended September 30,
	2015		2014		Change	2015		2014		Change
	(In thousands, except percentages)
Research and development	$	13,016	$	8,600	51%	$	32,573	$	24,261	34%
General and administrative	5,827		5,300		10%	18,183		14,250		28%
Total operating expenses	$	18,843	$	13,900	36%	$	50,756	$	38,511	32%

Research and Development Expenses

Research and development expenses for the three and nine months ended September 30, 2015 increased by 51% and 34%, respectively, compared to the same periods in 2014, primarily due to increased costs related to personnel, stock-based compensation, pre-clinical and toxicology studies, and clinical trial expenditures, which increased primarily due to our ongoing RT002 Phase 2 study for the treatment of glabellar lines and initiation of our RT001 Phase 2 study for the treatment of hyperhidrosis, our RT002 Phase 2 study for the treatment of cervical dystonia, and our RT001 Phase 3 program for the treatment of moderate to severe lateral canthal lines.

Our research and development expenses fluctuate as projects transition from one development phase to the next. Depending on the stage of completion and level of effort related to each development phase undertaken, we may reflect variations in our research and development expense. We expense both internal and external research and development expenses as they are incurred. We typically share employees, consultants and infrastructure resources between the RT001 and RT002 programs.

Stock-based compensation for research and development was $1.2 million and $2.9 million and $0.6 million and $1.6 million for the three and nine months ended September 30, 2015 and 2014, respectively.

General and Administrative Expenses

General and administrative expenses for the three and nine months ended September 30, 2015 increased by 10% and 28%, respectively, compared to the same periods in 2014, primarily due to increased costs related to personnel, legal matters, and stock-based compensation offset by a decrease in professional fees. Following our IPO, in February 2014, we incurred increased costs related to personnel and administrative activities to support the operation of a public company.

Stock-based compensation for general and administration was $1.4 million and $4.4 million and $1.7 million and $3.0 million for the three and nine months ended September 30, 2015 and 2014, respectively.

Other Expense

Interest Income

Interest income consists primarily of interest income earned on our deposit, money market fund, and investment balances. We expect interest income to vary each reporting period depending on our average deposit, money market fund, and investment balances during the period and market interest rates. To date, our interest income has not been significant in any individual period.

Interest Expense

Interest expense primarily consists of the interest charges associated with our convertible notes, notes payable, financing obligations, capital lease obligations, and capitalized interest. Notes payable under our term loan agreement with Hercules bore interest at a rate which was the greater of (i) 9.85% per annum or (ii) 9.85% per annum plus the difference of the prime rate less 3.25%. The interest charge on our convertible notes and capital lease obligations was fixed at the inception of the related transaction based on the incremental borrowing rate in effect on such date. Our interest expense also includes cash and non-cash components with the non-cash components consisting of (i) interest recognized from the amortization of debt issuance costs, which were capitalized on the Condensed Consolidated Balance Sheets and are generally derived from cash payments related to the issuance of convertible notes and notes payable, (ii) interest recognized from the amortization of debt discounts, which were capitalized on the Condensed Consolidated Balance Sheets, and derived from the issuance of warrants and derivatives issued in conjunction with convertible notes and notes payable, (iii) interest recognized on the 2013 convertible notes, or 2013 Notes, which was not paid but rather converted into shares of common stock, (iv) interest capitalized for assets

Table of Contents

constructed for use in operations, (v) interest related to the extinguishment of debt, which is classified as a loss on debt extinguishments, and (vi) effective interest recognized on the financing obligation. The capitalized amounts related to the debt issuance costs and debt discounts are generally amortized to interest expense over the term of the related debt instruments.

Additionally, our note payable with Hercules matured and was fully paid off in March 2015.

The interest expense by cash and non-cash components is as follows:



	Three Months Ended September 30,							Nine Months Ended September 30,
	2015			2014			Change	2015			2014			Change
	(In thousands, except percentages)
Interest expense
Cash related interest expense⁽¹⁾	$	(264	)	$	(276	)	(4)%	$	(564	)	$	(971	)	(42)%

Non-cash interest expense
Non-cash interest expense — debt issuance costs	—			(48		)	(100)%	(39		)	(148		)	(74)%
Non-cash interest expense — warrant and derivative related debt discounts	—			(76		)	(100)%	(5		)	(219		)	(98)%
Non-cash interest expense — convertible notes	—			—			N/A	—			(1,250		)	(100)%
Loss on extinguishment of 2013 Notes	—			—			N/A	—			(8,331		)	(100)%
Non-cash interest expense - financing obligation	(126		)	(66		)	91%	(226		)	(66		)	242%
Non-cash capitalized interest expense ⁽²⁾	$	—		$	238		(100)%	$	—		$	649		(100)%
Total non-cash interest expense	$	(126	)	$	48		(363)%	$	(270	)	$	(9,365	)	(97)%

Total interest expense	$	(390	)	$	(228	)	71%	$	(834	)	$	(10,336	)	(92)%


(1)	Cash related interest expense included interest payments to the Hercules Facility, Essex Capital Facility, and Financing Obligations.


(2)	Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.

Interest expense for the three months ended September 30, 2015 increased by 71%, compared to the same period in 2014, primarily due to an increase in interest expense for the financing obligations offset by a lower weighted average of debt outstanding and a decrease in capitalization of interest expense for construction-in-progress.

Interest expense for the nine months ended September 30, 2015 decreased by 92%, compared to the same period in 2014, primarily due to the loss on extinguishment of the 2013 Notes, conversion of the 2013 Notes into common stock, and less cash paid for interest expense on the Hercules Notes Payable offset by a decrease in capitalization of interest expense for construction-in-progress. In February 2014, our IPO triggered an acceleration of interest on the 2013 Notes through the end of the notes, which combined with the outstanding principal balance, then converted into 1,637,846 shares of common stock.

Change in Fair Value of Derivative Liabilities Associated with Convertible Notes

Our derivative liabilities associated with 2013 Notes were classified as liabilities on our Condensed Consolidated Balance Sheets and remeasured to fair value at each balance sheet date with the corresponding gain or loss from the adjustment recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss. We recorded the fair value of the derivative liabilities as a debt discount, which was amortized using the effective interest method over the term of the 2013 Notes. The amortization of this debt discount was accelerated upon the completion of our IPO with the corresponding expense recorded in our Condensed Consolidated Statement of Operations and Comprehensive Loss. See Note 7 to our Condensed Consolidated Financial Statements included elsewhere in this Form 10-Q.

Change in Fair Value of Derivative Liabilities Associated with the Medicis Settlement

The Product Approval Payment associated with the Medicis settlement is classified as a liability on our Condensed Consolidated Balance Sheet. This liability will be remeasured to fair value at each balance sheet date with the corresponding

Table of Contents

gain or loss from the adjustment recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. We will continue to record adjustments to the fair value of the Medicis settlement derivative liability until the Product Approval Payment has been paid.

Change in Fair Value of Common Stock Warrant Liability

Common stock warrants issued in connection with the 2013 Notes were classified as liabilities on our Condensed Consolidated Balance Sheet and required remeasurement at each balance sheet date. Upon the completion of our IPO, these common stock warrants liabilities were remeasured to fair value and settled in conjunction with the cashless net exercise of these warrants. See Note 7 to our Condensed Consolidated Financial Statements included elsewhere in this Form 10-Q.

Change in Fair Value of Convertible Preferred Stock Warrant Liability

Our previously outstanding convertible preferred stock warrants were classified as liabilities on our Condensed Consolidated Balance Sheets at fair value as they were contingently redeemable because they obligated us to transfer assets to the holders at a future date under certain circumstances, such as a deemed liquidation event. The convertible preferred stock warrants were remeasured to fair value at each balance sheet date with the corresponding gain or loss from the adjustment recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Upon the IPO in February 2014, these preferred stock warrants were remeasured to fair value and converted into common stock warrants with the corresponding liability reclassified to additional paid in capital.



	Three Months Ended September 30,							Nine Months Ended September 30,
	2015			2014			Change	2015			2014			Change
	(In thousands, except percentages)
Interest income	$	68		$	14		385%	$	144		$	18		699%
Interest expense	(390		)	(228		)	71%	(834		)	(10,336		)	(92)%
Change in fair value of derivative liabilities associated with convertible notes	—			—			N/A	—			4,032			(100)%
Change in fair value of derivative liabilities associated with the Medicis settlement	13			67			(81)%	60			(426		)	(114)%
Change in fair value of common stock warrant liability	—			—			N/A	—			(2,151		)	(100)%
Change in fair value of convertible preferred stock warrant liability	—			—			N/A	—			(210		)	(100)%
Loss on settlement of preferred stock warrant	—			—			N/A	—			(1,356		)	(100)%
Other expense, net	(98		)	(5		)	1,857%	(221		)	(73		)	203%
Total other expense	$	(407	)	$	(152	)	168%	$	(851	)	$	(10,502	)	(92)%

Our total other expense for the three months ended September 30, 2015 increased by 168%, compared to the same period in 2014, primarily due to an increase in interest expense, which is described above, offset by a decrease in the fair value of the Medicis derivative liabilities associated with the Medicis settlement.

Our total other expense for the nine months ended September 30, 2015 decreased by 92%, compared to the same period in 2014, primarily due to a decrease in interest expense, which is described above, a decrease in the fair value of the Medicis derivative liabilities, no loss on settlement of preferred stock warrants in the current period, and other one-time charges related to our IPO, including conversion of common stock warrants and our convertible notes into common stock upon the IPO and conversion of preferred stock warrants into equity-based common stock warrants.

Table of Contents

Liquidity and Capital Resources

As of September 30, 2015, we had capital resources consisting of cash, cash equivalents, and investments of $144.2 million, a decrease of $26.8 million, from December 31, 2014. In April 2015, we received $9.8 million from the sale of equipment to Essex Capital and concurrently entered into a three year lease agreement for such equipment. In March 2015, we entered into the ATM agreement with Cowen under which we may offer and sell our common stock having aggregate proceeds of up to $50.0 million from time to time. As of September 30, 2015, we sold 352,544 shares of our common stock under the ATM agreement at a weighted average price of $30.76 per share resulting in net proceeds of approximately $10.1 million, after underwriting discounts, commissions and other offering expenses. As of September 30, 2015, common stock for aggregate gross proceeds of $39.2 million remained available under this facility, subject to certain conditions as specified in the ATM agreement.

Since our inception, we have incurred losses and negative cash flows from our operations. For the three and nine months ended September 30, 2015, we had a net loss of $19.2 million and $51.4 million, respectively. For the nine months ended September 30, 2015, we used $39.2 million of cash to fund operating activities. As of September 30, 2015, we had a working capital surplus of $131.8 million and an accumulated deficit of $310.2 million. We believe that our existing cash, cash equivalents, and investments, including net proceeds from our IPO of $98.6 million, net proceeds from our June 2014 follow-on public offering of $131.3 million, net proceeds from our ATM offering of $10.1 million, gross proceeds from our November 2015 follow-on public offering of $134.6 million and proceeds of $10.9 million from sale of equipment to Essex Capital will allow us to fund our operations for at least the next 12 months.

Cash Flows

We derived the following summary of our Condensed Consolidated Cash Flows for the periods indicated from our unaudited Condensed Consolidated Financial Statements included elsewhere in this Form 10-Q (in thousands):



	Nine Months Ended September 30,
	2015			2014
Net cash used in operating activities	$	(39,218	)	$	(45,951	)
Net cash used in investing activities	(56,861		)	(5,369		)
Net cash provided by financing activities	15,541			234,892

Cash Flows from Operating Activities

Our cash used in operating activities is primarily driven by personnel-related expenditures, manufacturing costs, clinical development costs, and costs related to our facilities. Our cash flows from operating activities will continue to be affected principally by our working capital requirements and the extent to which we increase spending on personnel and research and development activities as our business grows.

Cash used in operating activities of $39.2 million during the nine months ended September 30, 2015 resulted primarily from our net loss of $51.4 million, offset by stock-based compensation expense of $7.3 million, depreciation expense of $1.6 million, and other adjustments of $0.6 million. The $2.7 million increase in our net operating assets and liabilities was primarily due to an increase in accruals and other current liabilities and deferred rent by $3.2 million offset by decreases in prepaid and other currents assets, other non-current assets, and accounts payable by $0.5 million.

Cash used in operating activities of $46.0 million for the nine months ended September 30, 2014 resulted in part from our net loss of $48.7 million, non-cash adjustments for the revaluation of derivative liabilities associated with our convertible notes of $4.0 million, and capitalized interest of $0.6 million offset by loss on extinguishment of our 2013 Notes of $8.3 million, revaluation of common stock warrant liability of $2.2 million, loss on extinguishment of warrant liability upon exercise of put option by warrant holder of $1.4 million, amortization of debt discounts of $1.2 million, revaluation of convertible preferred stock warrant liability of $0.2 million, stock-based compensation expense of $4.6 million, depreciation expense of $1.6 million, revaluation of derivative liability associated with Medicis settlement of $0.4 million, and interest upon issuance of new debt of $0.3 million. The $12.9 million decrease in our net operating assets and liabilities was primarily due to a decrease for payments to Medicis of $7.1 million and decreases in prepaid and other currents assets, other non-current assets, accounts payable, and deferred revenue by $7.5 million offset by an increase in accruals and other current liabilities and deferred rent by $1.7 million.

Table of Contents

Cash Flows from Investing Activities

Cash used in investing activities was $56.9 million for the nine months ended September 30, 2015 consisting of $54.1 million for purchases of investments and $2.8 million in purchases of property and equipment which were partially offset by a reduction of our restricted cash of $0.1 million.

Cash used in investing activities of $5.3 million for the nine months ended September 30, 2014 consisting of $5.4 million in purchases of property and equipment which were partially offset by a reduction of our restricted cash of $0.1 million.

Cash Flows from Financing Activities

Cash provided by financing activities was $15.5 million for the nine months ended September 30, 2015 comprised of proceeds of $10.2 million from issuance of common stock in connection with our ATM offering, net of deferred offering costs, and proceeds from sale of equipment to Essex Capital of $9.8 million, and proceeds from the exercise of stock options and ESPP of $0.8 million offset by principal payments on our notes payable of $2.7 million, principal payments on our financing obligation and capital leases of $1.8 million, and net settlement of restricted stock awards to settle employee tax obligations of $0.8 million.

Cash provided by financing activities of $234.9 million for the nine months ended September 30, 2014 primarily comprised of net proceeds of $102.7 million from issuance of common stock in connection with our IPO in February 2014, net proceeds of $131.8 million from issuance of common stock in connection with our follow-on public offering in June 2014, proceeds of $6.7 million from issuance of convertible notes and note payable, and proceeds from exercise of stock options and ESPP of $1.4 million. These increases were partially offset by principal payments on our notes payable of $6.2 million, principal payments on our financing obligation and capital leases of $0.1 million, and payments to settle warrants of $1.4 million.

Operating and Capital Expenditure Requirements

We have not achieved profitability on a quarterly or annual basis since our inception and we expect to continue to incur net losses for the foreseeable future. We expect our cash expenditures to increase in the near term as we initiate and complete clinical trials and other associated programs relating to RT001 for the treatment of crow's feet and hyperhidrosis and as we initiate and complete additional clinical trials and associated programs related to RT002 for the treatment of glabellar lines and indications in muscle movement disorders, such as cervical dystonia. We believe that our existing capital resources will be sufficient to fund our operations for at least the next 12 months. However, we anticipate that we will need to raise substantial additional capital in the future to fund our operations. In order to meet these additional cash requirements, we may seek to sell additional equity or convertible debt securities that may result in dilution to our stockholders. If we raise additional funds through the issuance of convertible debt securities, these securities could have rights senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt, making capital expenditures or declaring dividends. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations, and financial condition.

If adequate funds are not available to us on a timely basis, or at all, we may be required to terminate or delay clinical trials or other development activities for RT001, RT002 and any future product candidates, or delay our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates, if we obtain marketing approval. We may elect to raise additional funds even before we need them if the conditions for raising capital are favorable. Our future capital requirements depend on many factors, including:


•	the results of our clinical trials for RT001 and RT002;


•	the timing of, and the costs involved in, obtaining regulatory approvals for RT001, RT002 or any future product candidates;


•	the number and characteristics of any additional product candidates we develop or acquire;


•	the scope, progress, results and costs of researching and developing RT001, RT002 or any future product candidates, and conducting preclinical and clinical trials;

Table of Contents


•	the cost of commercialization activities if RT001, RT002 or any future product candidates are approved for sale, including marketing, sales and distribution costs;


•	the cost of manufacturing RT001, RT002 or any future product candidates and any products we successfully commercialize;


•	our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms of and timing such arrangements;


•	the degree and rate of market acceptance of any future approved products;


•	the emergence, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;


•	any litigation, including litigation costs and the outcome of such litigation;


•	any product liability or other lawsuits related to our products;


•	the expenses needed to attract and retain skilled personnel;


•	the costs associated with being a public company;


•	the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and


•	the timing, receipt and amount of sales of, or royalties on, future approved products, if any.

Please see “Item 1A. Risk Factors” for additional risks associated with our substantial capital requirements.

We have not generated revenue from RT001 or RT002 and we do not know when, or if, we will generate such revenue. We do not expect to generate significant revenue unless or until we obtain marketing approval of, and commercialize RT001 or RT002. We expect our continuing operating losses to result in increases in cash used in operations over the next several years.

We have based our estimates of future capital requirements on a number of assumptions that may prove to be wrong, and changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate. For example, our ongoing clinical trials of RT001 and RT002 may encounter technical or other difficulties that could increase our development costs more than we currently expect or the FDA may require us to conduct additional clinical trials prior to approving RT001 or RT002. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials beyond 2015.

Critical Accounting Policies

There have been no material changes in our critical accounting policies during the three and nine months ended September 30, 2015, as compared to those disclosed in Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 4, 2015, except as described within Note 2 of our Condensed Consolidated Financial Statements included elsewhere in this Form 10-Q.

Contractual Obligations

Our minimum contractual commitments were reported in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC. In April 2015, we received $9.8 million from the sale of equipment to Essex Capital and concurrently entered into a three year lease agreement for such equipment. Except with respect to the foregoing, our future minimum contractual commitments have not changed materially from the amounts previously reported.

Off-Balance Sheet Arrangements

Table of Contents

As of September 30, 2015, we did not have any off-balance sheet arrangements or any relationships with any entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.



ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in foreign currency exchange rates and interest rates. We do not hold or issue financial instruments for trading purposes.

Interest Rate Sensitivity

Our exposure to market risk for changes in interest rates relates primarily to our cash, cash equivalents, and investments. We had cash, cash equivalents, and investments of $144.2 million and $171.0 million as of September 30, 2015 and December 31, 2014, respectively. As of September 30, 2015, our cash, cash equivalents, and investments were held in deposit, money market fund accounts, and U.S. government agency obligations. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. A hypothetical 10% movement in interest rates would not be expected to have a material impact on our Condensed Consolidated Financial Statements.

Foreign Exchange

Our operations are primarily conducted in the United States using the U.S. Dollar. However, we conduct limited operations in foreign countries, primarily for clinical and regulatory services, whereby settlement of our obligations are denominated in the local currency. Transactional exposure arises when transactions occur in currencies other than the U.S. Dollar. Transactions denominated in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction with the resulting liabilities being translated into the U.S. Dollar at exchange rates prevailing at the balance sheet date. The resulting gains and losses, which were insignificant for the three and nine months ended September 30, 2015 and 2014, are included in other expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss. A hypothetical 10% movement in foreign currency rates would not be expected to have a material impact on our Condensed Consolidated Financial Statements. We do not use currency forward exchange contracts to offset the related effect on the underlying transactions denominated in a foreign currency.



ITEM 4.	CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Management, with the participation of our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2015. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2015, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the nine months ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION



ITEM 1.	LEGAL PROCEEDINGS

From time to time, we may be involved in litigation relating to claims arising out of our operations. On May 1, 2015, a securities class action complaint, captioned City of Warren Police and Fire Retirement System v. Revance Therapeutics Inc., et al, CIV 533635, was filed on behalf of City of Warren Police and Fire Retirement System in the Superior Court for San Mateo County, California against us and certain of our directors and executive officers at the time of our June 2014 follow-on public offering, and the investment banking firms that acted as the underwriters in our follow-on public offering.

In general, the complaint alleges that the defendants misrepresented the then-present status of our RT001 clinical program and made false and misleading statements regarding the formulation, manufacturing and efficacy of our drug candidate, RT001, for the treatment of lateral canthal lines at the time of our follow-on public offering. The complaint has been brought as a purported class action on behalf of those who purchased our common stock in our follow-on public offering and seeks unspecified monetary damages and other relief.

We believe that the class action lawsuit is without merit and intend to vigorously defend the action. Nevertheless, this litigation, as any other litigation, is subject to uncertainty and there can be no assurance that this litigation will not have a material adverse effect on our business, results of operations, financial position or cash flows.

Except as provided above, we are not currently involved in any material legal proceedings.



ITEM 1A.	RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as all other information included in this Form 10-Q, including our Condensed Consolidated Financial Statements, the notes thereto and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before you decide to purchase shares of our common stock. If any of the following risks actually occurs, our business, prospects, financial condition and operating results could be materially harmed. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and stock price.

We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K for the year ended December 31, 2014.

Risks Related to Our Business and Strategy

We are substantially dependent on the clinical and commercial success of our product candidates, primarily our topical product candidate RT001 and our injectable product candidate RT002. *

To date, we have invested most of our efforts and financial resources in the research and development of RT001, also referred to as RTT150 (Botulinum Toxin Type A) Topical Gel, our topical formulation of botulinum toxin. We are in a Phase 3 development program for RT001 for the treatment of crow's feet. In October 2014, we initiated an open-label study designed to confirm successful transfer of the production of our topical RT001 drug product to our manufacturing facility. Following a comprehensive analysis of the data obtained in such study, we subsequently commenced and completed a second open-label study using RT001 in the first half of 2015. Following analysis of the data obtained from these open-label studies, taken together with our analysis of prior studies and early data from newly developed clinical methods, we decided to proceed with a RT001 U.S. pivotal Phase 3 clinical trial for the treatment of crow's feet, which commenced during the third quarter of 2015. To date, we have conducted 17 clinical trials for RT001, with a total of over 1,600 subjects, for the treatment of crow's feet. In the third quarter of 2015, we also initiated a Phase 2 clinical trial for the treatment of primary axillary hyperhidrosis and, in the fourth quarter of 2015, completed enrollment for the trial.

We have also invested in the research and development of an injectable form of botulinum toxin, RT002, also referred to as RTT150 (Botulinum Toxin Type A) for Injection. Based upon the results to date, we are further developing RT002 for the treatment of glabellar lines and reported interim results from BELMONT, a Phase 2 active comparator clinical trial against the market leader BOTOX® Cosmetic, on October 29, 2015. The topline interim data from the trial showed that RT002 achieved

Table of Contents

its primary efficacy measurement at four weeks for all doses of RT002 and that such efficacy was highly statistically significant as compared to placebo. In addition, RT002 demonstrated a 23.6-week median duration versus BOTOX® Cosmetic with an 18.8-week median duration. Across all cohorts, RT002 appeared to be generally safe and well-tolerated. We plan to report final results from our BELMONT trial and conduct an End-of-Phase 2 meeting with the United States Food and Drug Administration, or FDA, in the first half of 2016. We then expect to begin Phase 3 clinical studies of RT002 for the treatment of glabellar lines in the second half of 2016. If approved, we believe RT002 has the potential to satisfy significant unmet needs in this market. Final results may differ from interim results.

We continue to explore therapeutic indications for muscle movement disorders such as cervical dystonia, which account for a large proportion of neurotoxin therapeutic sales globally, using RT002. In September 2015, we initiated a Phase 2 dose-escalating, open-label clinical study of RT002 in the therapeutic indication of cervical dystonia.

Our near-term prospects, including our ability to finance our company and generate revenue, will depend heavily on the successful development, regulatory approval and commercialization of RT001 and RT002, as well as any future product candidates. The clinical and commercial success of our product candidates will depend on a number of factors, including the following:


•	timely completion of, or need to conduct additional, clinical trials, including our clinical trials for RT001, RT002 and any future product candidates, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the number and design of such trials and the accurate and satisfactory performance of third party contractors;


•	our ability to demonstrate the effectiveness and duration of effect of our product on a consistent basis as compared to existing or future therapies;


•	our ability to demonstrate to the satisfaction of the FDA, the safety and efficacy of RT001, RT002 or any future product candidates through clinical trials;


•	whether we are required by the FDA or other similar foreign regulatory agencies to conduct additional clinical trials to support the approval of RT001, RT002 or any future product candidates;


•	the acceptance of parameters for regulatory approval, including our proposed indication, primary endpoint assessment and primary endpoint measurement relating to our lead indications of RT001;


•	our success in educating physicians and patients about the benefits, administration and use of RT001, RT002 or any future product candidates, if approved;


•	the prevalence and severity of adverse events experienced with our product candidates or future approved products;


•	the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;


•	the ability to raise additional capital on acceptable terms and in the time frames necessary to achieve our goals;


•	achieving and maintaining compliance with all regulatory requirements applicable to RT001, RT002 or any future product candidates or approved products;


•	the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;


•	the effectiveness of our own or our future potential strategic collaborators’ marketing, sales and distribution strategy and operations;


•	our ability to manufacture clinical trial supplies of RT001, RT002 or any future product candidates and to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP;


•	our ability to successfully commercialize RT001, RT002 or any future product candidates, if approved for marketing and sale, whether alone or in collaboration with others;


•	our ability to enforce our intellectual property rights in and to RT001, RT002 or any future product candidates;


•	our ability to avoid third party patent interference or intellectual property infringement claims;


•	acceptance of RT001, RT002 or any future product candidates, if approved, as safe and effective by patients and the medical community; and


•	the continued acceptable safety profile of RT001, RT002 or any future product candidates following approval.

If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, we

Table of Contents

cannot assure you that we will be able to generate sufficient revenue through the sale of RT001, RT002 or any future product candidate to continue our business.

We may be unable to obtain regulatory approval for RT001, RT002 or future product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations. *

To gain approval to market a biologic product such as RT001 and RT002, we must provide the FDA and foreign regulatory authorities with data that adequately demonstrate the safety, purity and potency of the product for the intended indication applied for in a Biologics License Application, or BLA, or other respective regulatory filings. The development of biologic products is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in clinical trials, including in Phase 3 development, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct. In particular, we have conducted two Phase 2b controlled clinical trials of RT001, in which RT001 met the primary efficacy and all secondary endpoints. We have also conducted one open-label, Phase 2b safety trial, which demonstrated that sequential applications of RT001 appear to be safe and well tolerated, even at an accelerated frequency. However, we have conducted one Phase 3 clinical efficacy trial using a modified diluent formulation, the results of which were inconsistent with our previous Phase 2b clinical trials and which did not show improvement from baseline in either the placebo or RT001 group. In October 2014, we conducted an open-label clinical trial of our topical RT001 drug product. The safety analysis from the 43 subjects enrolled in the open-label trial indicated that RT001 appeared to be well tolerated. The efficacy analysis showed clinically meaningful efficacy measured by the one-point investigator’s global assessment, or IGA, and the one-point patient severity assessment, or PSA, as well as in the aggregate for the composite one-point assessment. The two-point response rates for the individual IGA and composite IGA and PSA assessments, however, did not meet the endpoints for the subjects enrolled in the trial. Following a comprehensive analysis of the data obtained in this trial, we determined that the preliminary composite results were not adequate to move forward with our Phase 3 pivotal trial at such time.

In the first half of 2015, we then commenced and completed an additional open-label clinical trial using RT001. We designed this study to evaluate the attributes of different RT001 drug products aimed at improving the interaction between our peptide and toxin. The safety analysis from the 69 subjects enrolled in this study indicated that RT001 appeared to be well tolerated. The efficacy analysis for two of the RT001 drug products evaluated in this open-label trial showed clinically meaningful efficacy measured by the one-point IGA and the one-point PSA as well as in the aggregate for the composite one-point assessment. In the same two RT001 drug products evaluated, we observed some two-point composite response but given the small number of subjects enrolled in this trial, the patient response and other results observed are not necessarily predictive of future clinical trial results. Following analysis of the data available from these open-label studies, taken together with our analysis of prior studies and early data from newly developed clinical methods, we decided to proceed with a RT001 U.S. Phase 3 clinical trial for the treatment of crow's feet using a drug product that incorporates attributes of the drug products evaluated in the 2015 open-label trial.

If this RT001 drug product, Phase 3 clinical trial or any of our clinical trials do not demonstrate the safety and efficacy to our satisfaction, or to the satisfaction of the FDA, we may be required to conduct additional clinical trials and the timing and our ability to obtain regulatory approval for RT001 could be materially and adversely affected.

Our topical product candidate RT001 is currently in Phase 3 development, and our injectable product candidate RT002 is in Phase 2 development. Our business currently depends substantially on their successful development, regulatory approval and commercialization. We currently have no drug or biologic products approved for sale, and we may never obtain regulatory approval to commercialize RT001 or RT002. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market RT001 or RT002 in the United States until we receive approval of a BLA from the FDA. We are also not permitted to market RT001 or RT002 in any foreign countries until we receive the requisite approval from the regulatory authorities of such countries.

The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates, including RT001 and RT002, for many reasons, including:


•	our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that RT001, RT002 or any future product candidates are safe and effective for the requested indication;

Table of Contents


•	the FDA’s or the applicable foreign regulatory agency’s disagreement with our trial protocol or the interpretation of data from preclinical studies or clinical trials;


•	our inability to demonstrate that clinical and other benefits of RT001, RT002 or any future product candidates outweigh any safety or other perceived risks;


•	the FDA’s or the applicable foreign regulatory agency’s requirement for additional preclinical or clinical studies;


•	the FDA’s or the applicable foreign regulatory agency’s non-approval of the formulation, labeling or the specifications of RT001, RT002 or any future product candidates;


•	the FDA’s or the applicable foreign regulatory agency’s failure to approve our manufacturing processes or facilities, or the manufacturing processes or facilities of third party manufacturers with which we contract; or


•	the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.

Of the large number of drugs, including biologics, in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. We are not conducting and do not plan to conduct our U.S. Phase 3 clinical trials for RT001 under a Special Protocol Assessment, or SPA. In the absence of an agreed SPA, there can be no assurance that the FDA will agree with REALISE 1, our Phase 3 pivotal clinical trial protocols.

Further, after our Phase 2 clinical trials, we used the FDA’s Formal Dispute Resolution process to obtain confirmation from the FDA that our proposed indication, primary endpoint assessment and primary endpoint measurement were acceptable for continued clinical trials. At the end of this process, the FDA indicated that the final indication would depend on the patient populations studied, the data collected, and the interpretation of the data during the BLA review process. The FDA also indicated its expectation for demonstration of the paralytic mechanism of action in RT001 to be assessed at maximum contraction, or "at smile," to inform its analysis of the risks and benefits of RT001. Our clinical development program for RT001 measures effect "at smile" as an additional assessment endpoint to demonstrate botulinum toxin's effect on the relaxation of muscle at maximum contraction. However, age-related crow's feet of the upper face are the lines visible "at rest," and the primary endpoint of our clinical development program measures the efficacy of RT001 by a composite of physician and patient assessments "at rest."

In August 2014, the FDA issued a Draft Guidance prepared by the Division of Dermatology and Dental Products entitled "Upper Facial Lines: Developing Botulinum Toxin Drug Products." The Draft Guidance, among other things, recommends assessing the primary endpoint measurement for efficacy at maximum contraction, recommends defining treatment success as a score of 0 or 1 and at least a two grade reduction on both investigator and subject assessments, and recommends that review of photographs at maximum contraction by a masked independent committee be a required secondary efficacy measurement. We responded to the FDA's request for public comment on the non-binding Draft Guidance on October 30, 2014 and our response was filed as an exhibit to our Current Report on Form 8-K, filed with the SEC on November 4, 2014. We do not know when the guidance will be finalized, if at all, or the recommendations that will be contained therein. Even if final guidance is issued by the FDA, industry may pursue approval using an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. After consultation with our regulatory consultants, and based on the outcome of our Formal Dispute Resolution and related written confirmation from the FDA that we could proceed with Phase 3 development, we plan to complete our RT001 clinical trials using our current primary endpoint assessment by a composite of investigator and patient assessments "at rest," supplemented by an additional assessment "at smile" to demonstrate the paralytic mechanism of action in RT001 is a botulinum toxin effect.

While the FDA provided written confirmation that our proposed indication, primary endpoint assessment and primary endpoint measurement were acceptable for Phase 3 clinical trials, the FDA has not confirmed that our proposed indication, primary endpoint assessment and primary endpoint measurement are acceptable for regulatory approval. Further, while we did obtain written confirmation with respect to these aspects of our Phase 3 clinical trial designs, there is no assurance that the FDA will approve our BLA for RT001, will agree that the benefits of RT001 outweigh its risks or will not raise new concerns regarding our clinical trial designs.

Even if we eventually complete clinical testing and receive approval of any regulatory filing for RT001, RT002 or any future product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA or the applicable foreign regulatory agency also may approve RT001, RT002 or any future product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates and RT001, in particular, would delay or prevent commercialization of RT001 and would materially adversely impact our business, results of operations and prospects.

Table of Contents

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts. *

Since our inception, most of our resources have been dedicated to the research and preclinical and clinical development of our botulinum toxin product candidates RT001 and RT002. In particular, our U.S. clinical programs for RT001 and RT002 will require substantial additional funds to complete. We have recorded net losses of $19.2 million and $51.4 million and $14.0 million and $48.7 million for the three and nine months ended September 30, 2015 and 2014, respectively, had an accumulated deficit through September 30, 2015 of $310.2 million and had a working capital surplus of $131.8 million as of September 30, 2015, primarily as a result of our IPO, 2014 June follow-on public offering, and ATM offering. We have funded our operations primarily through the sale and issuance of convertible preferred stock, common stock, notes payable and convertible notes. As of September 30, 2015, we had capital resources consisting of cash, cash equivalents, and investments of $144.2 million. On February 6, 2014, we sold 6,900,000 shares of common stock at $16.00 per share for aggregate net proceeds of $98.6 million in our IPO, after underwriting discounts, commissions, and other offering expenses. On June 19, 2014, we sold 4,600,000 shares of common stock at $30.50 per share for aggregate net proceeds of $131.3 million in our follow-on public offering, after underwriting discounts, commissions, and other offering expenses. In the third quarter of 2015, we sold 352,544 shares of our common stock under the ATM agreement at a weighted average price of $30.76 per share resulting in net proceeds of approximately $10.1 million, after underwriting discounts, commissions, and other offering expenses. On November 9, 2015, we completed a follow-on public offering, pursuant to which we issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million. We believe that we will continue to expend substantial resources for the foreseeable future for the clinical development of RT001, RT002 and development of any other indications and product candidates that we may choose to pursue. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, and manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of RT001, RT002 and any future product candidates.

We believe that our existing cash, cash equivalents, and investments including the net proceeds from our IPO, follow-on public offering, and ATM offering will allow us to fund our operations for at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional capital sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe that we have sufficient funds for our current or future operating plans.

Our future capital requirements depend on many factors, including:


•	the results of our clinical trials for RT001 and RT002;


•	the timing of, and the costs involved in, obtaining regulatory approvals for RT001, RT002 or any future product candidates;


•	the number and characteristics of any additional product candidates we develop or acquire;


•	the scope, progress, results and costs of researching and developing RT001, RT002 or any future product candidates, and conducting preclinical and clinical trials;


•	the cost of commercialization activities if RT001, RT002 or any future product candidates are approved for sale, including marketing, sales and distribution costs;


•	the cost of manufacturing RT001, RT002 or any future product candidates and any products we successfully commercialize and maintaining our related facilities;


•	our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms of and timing such arrangements;


•	the degree and rate of market acceptance of any future approved products;


•	the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products or treatments;


•	any product liability or other lawsuits related to our products;


•	the expenses needed to attract and retain skilled personnel;


•	any litigation, including litigation costs and the outcome of such litigation;


•	the costs associated with being a public company;

Table of Contents


•	the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and


•	the timing, receipt and amount of sales of, or royalties on, future approved products, if any.

Additional capital may not be available when needed, on terms that are acceptable to us or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, research, development, manufacturing, sales, marketing or other commercial activities for RT001, RT002 or any future product candidate.

If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted and the terms of any new equity securities may have a preference over our common stock. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures or specified financial ratios, any of which could restrict our ability to commercialize our product candidates or operate as a business.

Even if our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use necessary for commercial success.

The commercial success of RT001, RT002 and any future product candidates, if approved, will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications, including, in the case of RT001, the treatment of crow’s feet and hyperhidrosis, in the case of RT002, the treatment of glabellar lines, and other aesthetic and therapeutic indications that we may seek to pursue. The degree and rate of physician adoption of RT001, RT002 and any future product candidates, if approved, will depend on a number of factors, including:


•	the effectiveness and duration of effect of our product as compared to existing therapies;


•	physician willingness to adopt a new therapy to treat crow’s feet, hyperhidrosis, glabellar lines, cervical dystonia or other therapeutic indications;


•	overcoming any biases physicians or patients may have toward injectable procedures for the treatment of crow’s feet, hyperhidrosis or other indications;


•	patient satisfaction with the results and administration of our product and overall treatment experience;


•	patient demand for the treatment of crow’s feet, hyperhidrosis, glabellar lines, cervical dystonia or other therapeutic indications; and


•	the revenue and profitability that our product will offer a physician as compared to alternative therapies.

If RT001, RT002 or any future product candidates are approved for use but fail to achieve the broad degree of physician adoption necessary for commercial success, our operating results and financial condition will be adversely affected.

Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion.

We expect to enter highly competitive pharmaceutical and medical device markets. Successful competitors in the pharmaceutical and medical device markets have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff. Numerous companies are engaged in the development, patenting, manufacture and marketing of health care products competitive with those that we are developing. Many of these potential competitors are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities.

Upon marketing approval, the first expected use of our products will be in aesthetic medicine. The aesthetic product market, and the facial aesthetic market in particular, is highly competitive and dynamic, and is characterized by rapid and substantial technological development and product innovations. This market is also characterized by competitors obtaining

Table of Contents

patents to protect what they consider to be their intellectual property. We plan to seek regulatory approval of RT001 for the treatment of crow’s feet and RT002 for the treatment of glabellar lines.

We anticipate that RT001, if approved for the treatment of crow's feet, will face significant competition from other facial aesthetic products, including injectable botulinum toxins and dermal fillers. If approved, RT001 may also compete with unapproved and off-label treatments. We anticipate that RT002, if approved, will also face significant competition from existing injectable botulinum toxins and dermal fillers, as well as unapproved and off-label treatments. Further, if approved, in the future we may face competition for both RT001 and RT002 from biosimilar products and products based upon botulinum toxin. To compete successfully in the aesthetic market, we will have to demonstrate that the reduction of crow’s feet with RT001 or the treatment of glabellar lines with RT002 is a worthwhile aesthetic treatment and has advantages over existing therapies. Competing in the aesthetic market could result in price-cutting, reduced profit margins and limited market share, any of which would harm our business, financial condition and results of operations.

Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we face more competition in these markets than in the United States.

We currently make our RT001 clinical drug product exclusively in one manufacturing facility and our RT002 clinical drug product in the same and one other external facility. We plan to utilize certain of these facilities in the future to support commercial production if our product candidates are approved. If these or any future facility or our equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business would be materially harmed.*

We currently manufacture our own clinical drug product to support RT001 exclusively in a single facility and plan to utilize this facility in the future to support commercial production if our product candidate is approved. The drug product to support RT002 clinical trials is manufactured in the same facility, as well as in an external manufacturing facility. We expect that additional manufacturing capacity would need to be established in the future to support commercial production of RT002 if this product candidate is approved. If these or any future facility were to be damaged, destroyed or otherwise unable to operate, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our manufacturing facilities is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are approved, jeopardize our ability to manufacture our products as promptly as our customers expect or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our customers’ expectations, our business, prospects, financial results and reputation could be materially harmed.

Currently, we maintain insurance coverage totaling $27.7 million against damage to our property and equipment, $2.0 million in general liability coverage, a $9.0 million umbrella policy, and an additional $35.0 million to cover business interruption and research and development restoration expenses, subject to deductibles and other limitations. If we have underestimated our insurance needs with respect to an interruption, or if an interruption is not subject to coverage under our insurance policies, we may not be able to cover our losses.

Impairment in the carrying value of long-lived assets could negatively affect our operating results.

We have invested a significant amount of capital to build a larger capacity fill-finish line dedicated to the manufacture of our topical product candidate RT001 and to support our regulatory license applications. Under generally accepted accounting principles, long-lived assets, such as our fill/finish line, are required to be reviewed for impairment whenever adverse events or changes in circumstances indicate a possible impairment. If business conditions or other factors indicate that the carrying value of the asset may not be recoverable, we may be required to record non-cash impairment charges. Additionally, if the carrying value of our capital equipment exceeds current fair value as determined based on the discounted future cash flows of the related product, the capital equipment would be considered impaired and would be reduced to fair value by a non-cash charge to earnings, which could negatively affect our operating results. Events and conditions that could result in impairment in the value of our long-lived assets include adverse clinical trial results, unfavorable changes in competitive landscape, adverse changes in the regulatory environment, or other factors leading to reduction in expected long-term sales or profitability.

Table of Contents

We have a limited operating history and have incurred significant losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future. We have only two product candidates in clinical trials and no commercial sales, which, together with our limited operating history, make it difficult to assess our future viability. *

We are a clinical-stage specialty biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are not profitable and have incurred losses in each year since we commenced operations in 2002. We have only a limited operating history upon which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. To date, we have not obtained any regulatory approvals for any of our product candidates or generated any revenue from product sales relating to RT001 or RT002. We continue to incur significant research and development and other expenses related to our ongoing clinical trials and operations. We have recorded net losses of $19.2 million and $51.4 million and $14.0 million and $48.7 million for the three and nine months ended September 30, 2015 and 2014, respectively, had an accumulated deficit through September 30, 2015 of $310.2 million and had a working capital surplus of $131.8 million as of September 30, 2015, primarily as a result of our IPO, follow-on public offering, and ATM offering. In February 2014, we closed our IPO. The net proceeds from the sale of the shares in our IPO and our June 2014 follow-on public offering, after deducting the underwriters’ discount, commissions, and other offering expenses related to the IPO and follow-on offering were approximately $98.6 million and $131.3 million, respectively. In November 2015, the Company also completed a public offering for gross proceeds of $134.6 million. Our capital requirements to implement our business strategy are substantial, including our capital requirements to develop and commercialize RT001 and RT002. We believe that our currently available capital is sufficient to fund our operations through at least the next 12 months. Given our desired clinical development plans for the next 12 months, our financial statements do not reflect an uncertainty about our ability to continue as a going concern. Accordingly, the financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should we be unable to continue as a going concern.

We expect to continue to incur losses for the foreseeable future, and we anticipate that these losses will increase as we continue our development of, and seek regulatory approvals for, RT001 and RT002, and begin to commercialize RT001 and RT002. Our ability to achieve revenue and profitability is dependent on our ability to complete the development of our product candidates, obtain necessary regulatory approvals and manufacture, market and commercialize our products successfully. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.

Even if RT001, RT002 or any future product candidates obtain regulatory approval, they may never achieve market acceptance or commercial success.

Even if we obtain FDA or other regulatory approvals, RT001, RT002 or any future product candidates may not achieve market acceptance among physicians and patients, and may not be commercially successful.

The degree and rate of market acceptance of RT001, RT002 or any future product candidates for which we receive approval depends on a number of factors, including:


•	the safety and efficacy of the product as demonstrated in clinical trials;


•	the clinical indications for which the product is approved;


•	acceptance by physicians, major operators of clinics and patients of the product as a safe and effective treatment;


•	proper training and administration of our products by physicians and medical staff;


•	the potential and perceived advantages of our products over alternative treatments;


•	the cost of treatment in relation to alternative treatments and willingness to pay for our products, if approved, on the part of physicians and patients;


•	the willingness of patients to pay for RT001, RT002 and other aesthetic treatments in general, relative to other discretionary items, especially during economically challenging times;


•	the willingness of third party payors to reimburse physicians for RT001, RT002 and any future products we may commercialize;


•	relative convenience and ease of administration;


•	the prevalence and severity of adverse events; and


•	the effectiveness of our sales and marketing efforts.

Table of Contents

Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would materially adversely affect our results of operations and delay, prevent or limit our ability to generate revenue and continue our business.

Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. *

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Furthermore, we rely on contract research organizations, or CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we have agreements governing the committed activities of our CROs, we have limited influence over their actual performance. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. The results of preclinical studies and clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Furthermore, final results may differ from interim results. For example, any positive results generated to date in clinical trials for RT001 or RT002 do not ensure that later clinical trials, including our RT001 Phase 3 clinical trials for the treatment of crow’s feet or any RT002 clinical trials for the treatment of glabellar lines, will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety profile and efficacy despite having progressed through preclinical studies and initial clinical trials. In particular, we have conducted two Phase 2b controlled clinical trials of RT001, in which RT001 met the primary efficacy and all secondary endpoints. We have also conducted one open-label, Phase 2b safety trial, which demonstrated that sequential applications of RT001 appear to be safe and well tolerated, even at an accelerated frequency. However, we have conducted one Phase 3 clinical efficacy trial using a modified diluent formulation, the results of which were inconsistent with our previous Phase 2b clinical trials and which did not show improvement from baseline in either the placebo or RT001 group. In October 2014, we conducted an open-label clinical trial of our topical RT001 drug product. The safety analysis from the 43 subjects enrolled in the open-label trial indicated that RT001 appeared to be well tolerated. The efficacy analysis showed clinically meaningful efficacy measured by the one-point investigator’s global assessment, or IGA, and the one-point patient severity assessment, or PSA, as well as in the aggregate for the composite one-point assessment. The two-point response rates for the individual IGA and composite IGA and PSA assessments, however, did not meet the endpoints for the subjects enrolled in the trial. Following a comprehensive analysis of the data obtained in this trial, we determined that the preliminary composite results were not adequate to move forward with our Phase 3 pivotal trial at such time.

A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier clinical trials, and we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates.

Table of Contents

We have in the past and may in the future experience delays in our ongoing clinical trials, and we do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of subjects on time or be completed on schedule, if at all. Clinical trials can be delayed or aborted for a variety of reasons, including delay or failure to:


•	obtain regulatory approval to commence a trial;


•	reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;


•	obtain institutional review board, or IRB, approval at each site;


•	recruit suitable subjects to participate in a trial;


•	have subjects complete a trial or return for post-treatment follow-up;


•	ensure clinical sites observe trial protocol or continue to participate in a trial;


•	address any patient safety concerns that arise during the course of a trial;


•	address any conflicts with new or existing laws or regulations;


•	add a sufficient number of clinical trial sites; or


•	manufacture sufficient quantities of product candidate for use in clinical trials.

Subject enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the data safety monitoring board, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

We have no experience manufacturing our product candidates at full commercial scale. If our product candidates are approved, we will face certain risks associated with scaling up our manufacturing capabilities to support commercial production. *

We have developed an integrated manufacturing, research and development facility located at our corporate headquarters. We manufacture drug substance and finished dose forms of drug product at this facility that we use for research and development purposes and for clinical trials of our product candidates. We do not have experience in manufacturing our product candidates at commercial scale. To meet our strategic objectives, we currently plan to manufacture a significant portion of our drug substance and commercial products in our own facility. If our product candidates are approved, we may need to expand our manufacturing facilities, add manufacturing personnel and ensure that validated processes are consistently implemented in our facilities. For example, we are building a larger capacity fill-finish line dedicated to our topical product candidate RT001 and to support our regulatory license applications, if approved. In addition, we expect to further scale up our RT002 drug product manufacturing. The upgrade and expansion of our facilities will require additional regulatory approvals. In addition, it will be costly and time-consuming to expand our facilities and recruit necessary additional personnel. If we are unable to expand our manufacturing facilities in compliance with regulatory requirements or to hire additional necessary manufacturing personnel, we may encounter delays or additional costs in achieving our research, development and commercialization objectives, including in obtaining regulatory approvals of our product candidates, which could materially damage our business and financial position.

Table of Contents

We currently contract with third-party manufacturers for certain components necessary to produce RT001 for clinical trials and expect to continue to do so to support commercial scale production if RT001 is approved. This increases the risk that we will not have sufficient quantities of RT001 or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We currently rely on third-party manufacturers for certain components necessary to produce RT001 for our clinical trials, including the bulk peptide, diluent and the delivery apparatus and expect to continue to rely on these or other manufacturers to support our commercial requirements if RT001 is approved. Some of our contracts with our manufacturers contain minimum order and pricing provisions and provide for early termination based on regulatory approval milestones.

Reliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third- party manufacturers may not be able to comply with cGMP or Quality System Regulation, or QSR, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of RT001, RT002 or any other product candidates or products that we may develop. Any failure or refusal to supply the components for RT001, RT002 or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.

We depend on single-source suppliers for the raw materials necessary to produce our product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.

We and our manufacturers purchase the materials necessary to produce RT001 and RT002 for our clinical trials from single-source third-party suppliers. There are a limited number of suppliers for the raw materials that we use to manufacture our product candidates and we may need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. In particular, we outsource the manufacture of bulk peptide through American Peptide Company, Inc., the RT001 diluent through Hospira Worldwide, Inc. and our RT001 delivery apparatus through Duoject Medical Systems, Inc. We do not have any control over the process or timing of the acquisition of raw materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe that we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of RT001, RT002 or any future product candidates, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third party supplier could considerably delay completion of our clinical trials, product testing and potential regulatory approval of RT001, RT002 or any future product candidates. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development of RT001, RT002 and any future product candidates, or the commercial launch of any approved products, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.

Furthermore, if there is a disruption to our or our third-party suppliers’ relevant operations, we will have no other means of producing RT001, RT002 or any future product candidates until they restore the affected facilities or we or they procure alternative facilities. Additionally, any damage to or destruction of our or our third party or suppliers’ facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.

We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our corporate headquarters and other facilities, including our sole manufacturing facility, are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.

Table of Contents

If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our manufacturing facility, enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. In particular, because we manufacture botulinum toxin in our facilities, we would be required to obtain further clearance and approval by state, federal or other applicable authorities to continue or resume manufacturing activities. The disaster recovery and business continuity plans we have in place currently are limited and may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Furthermore, integral parties in our supply chain are geographically concentrated and operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.

We currently rely on third parties and consultants to conduct all our preclinical studies and clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize RT001, RT002 or any future product candidates. *

We do not have the ability to independently conduct preclinical studies or clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as CROs, to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of our clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our preclinical studies and clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, commonly referred to as good clinical practices, or GCPs and good laboratory practices (GLP), for conducting, monitoring, recording and reporting the results of clinical and preclinical trials, respectively to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We also rely on consultants to assist in the execution, including data collection and analysis, of our clinical trials.

In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. These third parties may terminate their agreements with us upon as little as 30 days’ prior written notice of a material breach by us that is not cured within 30 days. Many of these agreements may also be terminated by such third parties under certain other circumstances, including our insolvency or our failure to comply with applicable laws. In general, these agreements require such third parties to reasonably cooperate with us at our expense for an orderly winding down of services of such third parties under the agreements. If the third parties or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCP, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for, and will not be able to, or may be delayed in our efforts to, successfully commercialize the product candidate being tested in such trials.

Table of Contents

Our ability to market RT001, if approved, will be limited initially to use for the treatment of crow’s feet, and if we want to expand the indications for which we may market RT001 or seek regulatory approval for RT002, we will need to obtain additional regulatory approvals, which may not be granted.

We plan to seek regulatory approval for RT001 in the United States and Europe for the treatment of crow’s feet. If RT001 is approved, the applicable regulatory agency will restrict our ability to market or advertise RT001 for other indications, which could limit physician and patient adoption. We may attempt to develop, promote and commercialize new treatment indications and protocols for RT001, as well as seek regulatory approval for RT002, in the future, but we cannot predict when or if we will receive the clearances required to do so. In addition, we would be required to conduct additional clinical trials or studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business will be limited.

If RT001 and/or RT002 is approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, and sanctions, product liability claims, and our image and reputation within the industry and marketplace could be harmed.

The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products, such as RT001 and RT002, if approved. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. For example, if we receive marketing approval for RT001 for the treatment of crow’s feet, the first indication we are pursuing, we cannot prevent physicians from using our RT001 products on their patients in a manner that is inconsistent with the approved label, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management’s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry.

Physicians may also misuse our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management’s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. Furthermore, the use of our products for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.

Any of these events could harm our business and results of operations and cause our stock price to decline.

Table of Contents

Even if RT001, RT002 or any future product candidate is approved for commercialization, if there is not sufficient patient demand for such procedures, our financial results and future prospects will be harmed.

Treatment of crow’s feet with RT001 and glabellar lines with RT002, are elective procedures, the cost of which must be borne by the patient, and we do not expect it to be reimbursable through government or private health insurance. The decision by a patient to elect to undergo the treatment of crow’s feet with RT001, the treatment of glabellar lines with RT002 or the treatment of other aesthetic indications we may pursue may be influenced by a number of factors, including:


•	the success of any sales and marketing programs that we, or any third parties we engage, undertake, and as to which we have limited experience;


•	the extent to which physicians recommend RT001 or RT002 to their patients;


•	the extent to which RT001 or RT002 satisfies patient expectations;


•	our ability to properly train physicians in the use of RT001 or RT002 such that their patients do not experience excessive discomfort during treatment or adverse side effects;


•	the cost, safety and effectiveness of RT001 or RT002 versus other aesthetic treatments;


•	consumer sentiment about the benefits and risks of aesthetic procedures generally and RT001 or RT002 in particular;


•	the success of any direct-to-consumer marketing efforts we may initiate; and


•	general consumer confidence, which may be impacted by economic and political conditions.

Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient demand for RT001, or for RT002 or any other future product candidate, once approved.

We are subject to uncertainty relating to reimbursement policies which, if not favorable for RT001, RT002 or any future product candidates, could hinder or prevent their commercial success.

Our ability to commercialize RT001, RT002, or any future product candidates for therapeutic indications such as hyperhidrosis or cervical dystonia will depend in part on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors. As a threshold for coverage and reimbursement, third party payors generally require that drug products have been approved for marketing by the FDA. Third party payors also are increasingly challenging the effectiveness of and prices charged for medical products and services. We may not obtain adequate third party coverage or reimbursement for RT001, RT002 or any future product candidates, or we may be required to sell them at a discount.

We expect that private insurers will consider the efficacy, cost effectiveness and safety of RT001 and RT002 in determining whether to approve reimbursement for RT001 and RT002 and at what level. Obtaining these approvals can be a time-consuming and expensive process. Our business would be materially adversely affected if we do not receive approval for reimbursement of RT001 or RT002 from private insurers on a timely or satisfactory basis. Our business could also be adversely affected if private insurers, including managed care organizations, the Medicare program or other reimbursing bodies or payors limit the indications for which RT001 or RT002 will be reimbursed to a smaller set than we believe they are effective in treating.

In some foreign countries, particularly Canada and European countries, the pricing of prescription pharmaceuticals is subject to strict governmental control. In these countries, pricing negotiations with governmental authorities can take six to 12 months or longer after the receipt of regulatory approval and product launch. To obtain favorable reimbursement for the indications sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products, including RT001 or RT002, to other available therapies. If reimbursement for our product is unavailable in any country in which reimbursement is sought, limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.

Table of Contents

We currently have limited marketing capabilities and no sales organization. If we are unable to establish sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize RT001, RT002 or any other future product candidates, if approved, or generate product revenue. *

We currently have limited marketing capabilities and no sales organization. To commercialize RT001, RT002 or any other future product candidates, if approved, in the United States, Europe and other jurisdictions we seek to enter, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If RT001 or RT002 receives regulatory approval, we expect to market RT001 or RT002, as applicable, through our own sales force in North America, and in Europe and other countries through either our own sales force or a combination of our internal sales force and distributors or partners, which may be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize RT001, RT002 or any future product candidates. If we are not successful in commercializing RT001, RT002 or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.

To establish our sales and marketing infrastructure and expand our manufacturing capabilities, we will need to increase the size of our organization, and we may experience difficulties in managing this growth. *

As of September 30, 2015, we had 102 full-time employees. We will need to continue to expand our managerial, operational, and other resources to manage our operations and clinical trials, continue our development activities and commercialize RT001, RT002 or any other product candidates, if approved. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:


•	manage our clinical trials and manufacturing operations effectively;


•	identify, recruit, retain, incentivize and integrate additional employees;


•	manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and


•	continue to improve our operational, financial and management controls, reporting systems and procedures.

Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives, or disrupt our operations.

Table of Contents

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop.

We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:


•	decreased demand for RT001, RT002 or any future product candidates or products we develop;


•	injury to our reputation and significant negative media attention;


•	withdrawal of clinical trial participants or cancellation of clinical trials;


•	costs to defend the related litigation;


•	a diversion of management’s time and our resources;


•	substantial monetary awards to trial participants or patients;


•	regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;


•	loss of revenue; and


•	the inability to commercialize any products we develop.

Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of RT001, RT002 or any future products we develop. We currently carry product liability insurance covering our clinical trials in the amount of $5.0 million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing RT001 or RT002, we intend to expand our insurance coverage to include the sale of RT001 or RT002, as applicable; however, we may be unable to obtain this liability insurance on commercially reasonable terms.

We have been, and in the future may be, subject to securities class action lawsuits and shareholder derivative actions. These, and potential similar or related litigation, could result in substantial damages and may divert management’s time and attention from our business.*

We have been, and may in the future be, the target of securities class actions or shareholder derivative claims. On May 1, 2015, a securities class action complaint was filed on behalf of City of Warren Police and Fire Retirement System against us and certain of our directors and executive officers at the time of our follow-on public offering, and the investment banking firms that acted as the underwriters in our follow-on public offering. This and any such other actions or claims could result in substantial damages and may divert management’s time and attention from our business.

If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop RT001, RT002 or any future product candidates, conduct our clinical trials and commercialize RT001, RT002 or any future products we develop.

Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of RT001, RT002 or any future products we develop.

Table of Contents

Although we have not historically experienced unique difficulties attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.

If we are not successful in discovering, developing, acquiring and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired. *

Although a substantial amount of our effort will focus on the continued clinical testing and potential approval of RT001 and RT002, a key element of our strategy is to discover, develop and commercialize a portfolio of botulinum toxin products to serve both the aesthetic and therapeutic markets. We are seeking to do so through our internal research programs and may explore strategic collaborations for the development or acquisition of new products. While our two product candidates, RT001 and RT002, are each in the clinical development stage, all of our other potential product candidates remain in the discovery or preclinical stage. Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:


•	the research methodology used may not be successful in identifying potential product candidates;


•	competitors may develop alternatives that render our product candidates obsolete or less attractive;


•	product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;


•	a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;


•	a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;


•	a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and


•	intellectual property rights of third parties may potentially block our entry into certain markets, or make such entry economically impracticable.

If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will be more vulnerable to any problems that we encounter in developing and commercializing RT001 and RT002.

The requirements of being a public company may strain our resources, divert management's attention and affect our ability to attract and retain qualified members of our board of directors.

We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Dodd-Frank Act, the NASDAQ listing rules and other applicable securities rules and regulations. Compliance with these rules and regulations has increased and will continue to increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly, and increase demand on our systems and resources. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management's attention may be diverted from other business concerns, which could harm our business and operating results. Although we have hired additional employees to comply with these requirements, we may need to hire more employees in the future, which will increase our costs and expenses.

Table of Contents

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.

As a public company that is subject to these rules and regulations we may find it is more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors and qualified executive officers.

Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.*

Our research and development and manufacturing activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use and disposal of hazardous materials owned by us, including botulinum toxin type A, a key component of our product candidates, and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We are licensed with the Centers for Disease Control and Prevention, or CDC and with the California Department of Health, Food and Drug Branch for use of botulinum toxin and to manufacture both the active pharmaceutical ingredient, or API, and the finished product in topical and injectable dose forms. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.

Table of Contents

We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful.

We may license or selectively pursue strategic collaborations for the development, validation and commercialization of RT001, RT002 and any future product candidates. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. We cannot control the amount and timing of our collaborators’ resources that will be devoted to performing their responsibilities under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the market for aesthetic medical procedures may be particularly vulnerable to unfavorable economic conditions. We do not expect RT001 for the treatment of crow’s feet or RT002 for the treatment of glabellar lines to be reimbursed by any government or third-party payor and, as a result, demand for the first indications of each of our product candidates will be tied to discretionary spending levels of our targeted patient population. The recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for RT001, RT002 or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

Risks Related to Our Intellectual Property

If our efforts to protect our intellectual property related to RT001, RT002 or any future product candidates are not adequate, we may not be able to compete effectively in our market.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to RT001, RT002 and our development programs. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in our market.

Table of Contents

The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or license may fail to result in issued patents in the United States or foreign countries. Competitors in the field of cosmetics, pharmaceuticals, and botulinum toxin have created a substantial amount of prior art, including scientific publications, patents and patent applications. Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. In addition, recent changes to the patent laws of the United States provide additional procedures for third parties to challenge the validity of issued patents. Patents issued from applications filed after March 15, 2013 may be challenged by third parties using the post-grant review procedure which allows challenges for a number of reasons, including prior art, sufficiency of disclosure, and subject matter eligibility. Under the inter partes review procedure, any third party may challenge the validity of any issued U.S. Patent in the United States Patent and Trademark Office, or USPTO, on the basis of prior art. Because of a lower evidentiary standard necessary to invalidate a patent claim in USPTO proceedings as compared to the evidentiary standard relied on in United States federal court, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to RT001, RT002 or any future product candidates is challenged, then it could threaten our ability to commercialize RT001, RT002 or any future product candidates, and could threaten our ability to prevent competitive products from being marketed. Further, if we encounter delays in our clinical trials, the period of time during which we could market RT001, RT002 or any future product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013, or patents issuing from such applications, an interference proceeding can be provoked by a third party, or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March 16, 2013, the United States transitioned to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to “first-to-file” from “first-to-invent” is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act signed into law on September 16, 2011. Among some of the other changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO.

Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property portfolios than we have.

We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain or enforce and any other elements of our product development processes that involve proprietary know-how, information or technology that is not covered by patents.

Table of Contents

In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, collaborators and advisors to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements, however, may not provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. A breach of confidentiality could significantly affect our competitive position. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, collaborators or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Also, others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and other confidential information.

If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. *

Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties. Competitors in the field of cosmetics, pharmaceuticals and botulinum toxin have developed large portfolios of patents and patent applications in fields relating to our business. For example, there are patents held by third parties that relate to the treatment with botulinum toxin-based products for indications we are currently developing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.

As a result of patent infringement claims, or to avoid potential claims, we may choose or be required to seek licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.

There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming.

Competitors may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied.

An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

Table of Contents

Interference, derivation, inter partes review, post-grant review or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patents or patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management. We may not be able, alone or with our licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws.

Risks Related to Government Regulation

Our business and products are subject to extensive government regulation. *

We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, principally by the FDA, the U.S. Drug Enforcement Administration, or DEA, the CDC, and foreign regulatory authorities. Failure to comply with all applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, or FFDCA, the Public Health Service Act, or PHSA, and Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs.

Table of Contents

After our products receive regulatory approval or clearance, we, and our direct and indirect suppliers, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in the implementation of Risk Evaluation and Mitigation Strategies, or REMS, programs, completion of government mandated clinical trials, and government enforcement action relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls noted above.

The regulatory approval process is highly uncertain and we may not obtain regulatory approval for the commercialization of RT001, RT002 or any future product candidates.

The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. Neither we nor any collaboration partner is permitted to market RT001, RT002 or any future product candidates in the United States until we receive approval of a BLA from the FDA. We have not submitted an application or obtained marketing approval for RT001 or RT002 anywhere in the world. Obtaining regulatory approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable United States and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:


•	warning letters;


•	civil and criminal penalties;


•	injunctions;


•	withdrawal of approved products;


•	product seizure or detention;


•	product recalls;


•	total or partial suspension of production; and


•	refusal to approve pending BLAs or supplements to approved BLAs.

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborator believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all targeted indications.

Regulatory approval of a BLA or BLA supplement is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA can delay, limit or deny approval of a product candidate for many reasons, including the following:


•	a product candidate may not be deemed safe, effective, pure or potent;


•	FDA officials may not find the data from preclinical studies and clinical trials sufficient;


•	the FDA might not approve our third party manufacturers’ processes or facilities; or


•	the FDA may change its approval policies or adopt new regulations.

If RT001, RT002 or any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed.

Table of Contents

Even if we receive regulatory approval for RT001, RT002 or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.

Once regulatory approval has been granted, RT001, RT002, or any approved product will be subject to continual regulatory review by the FDA and/or non-U.S. regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

Any regulatory approvals that we or our collaborators receive for RT001, RT002 or any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the applicable regulatory agency approves RT001, RT002 or any future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with RT001, RT002 or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:


•	restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;


•	fines, warning letters or holds on clinical trials;


•	refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic collaborators, or suspension or revocation of product license approvals;


•	product seizure or detention, or refusal to permit the import or export of products; and


•	injunctions or the imposition of civil or criminal penalties.

Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.

If we fail to obtain regulatory approvals in foreign jurisdictions for RT001, RT002 or any future product candidates, we will be unable to market our products outside of the United States.

In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive the necessary approvals to commercialize our products in markets outside of the United States.

Table of Contents

If approved, RT001, RT002 or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business.

Some participants in our clinical trials have reported adverse events after being treated with RT001. If we are successful in commercializing RT001 or any other products, the FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products.

We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties.

While we do not expect that RT001, if approved for the treatment of crow’s feet, or RT002, if approved for the treatment of glabellar lines, will subject us to the various U.S. federal and state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The federal anti-kickback statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of the anti-kickback laws can result in exclusion from federal health care programs and substantial civil and criminal penalties.

The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA, then our revenues could be adversely affected, which would likely harm our business, financial condition, and results of operations.

State and federal authorities have aggressively targeted medical technology companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines in the hundreds of millions of dollars or more, have been forced to implement extensive corrective action plans, and have often become subject to consent decrees severely restricting the manner in which they conduct their business. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business.

Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.

Table of Contents

Legislative or regulatory health care reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of RT001, RT002 or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained.

From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products, as discussed in more detail in the risk factors in Part II, Item 1A of our Form 10-Q entitled "We may be unable to obtain regulatory approval for RT001, RT002 or future product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations." Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of RT001, RT002 or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:


•	changes to manufacturing methods;


•	recall, replacement, or discontinuance of one or more of our products; and


•	additional recordkeeping.

Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.

Risks Related to the Ownership of Our Common Stock

The trading price of our common stock is volatile, and purchasers of our common stock could incur substantial losses.

The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock markets in general and the markets for pharmaceutical biopharmaceutical and biotechnology stocks in particular have experienced extreme volatility that may have been for reasons that are related or unrelated to the operating performance of the issuer. The market price for our common stock may be influenced by many factors, including:


•	regulatory or legal developments in the United States and foreign countries;


•	results from or delays in clinical trials of our product candidates, including our Phase 3 clinical program for RT001 and our Phase 2 clinical program for RT002;


•	announcements of regulatory approval or disapproval of RT001, RT002 or any future product candidates;


•	FDA or other U.S. or foreign regulatory actions or guidance affecting us or our industry;


•	introductions and announcements of new products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;


•	variations in our financial results or those of companies that are perceived to be similar to us;


•	changes in the structure of health care payment systems;


•	announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments;


•	market conditions in the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts’ reports or recommendations;


•	quarterly variations in our results of operations or those of our future competitors;


•	changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;


•	sales of substantial amounts of our stock by insiders and large stockholders, or the expectation that such sales might occur;


•	general economic, industry and market conditions;


•	additions or departures of key personnel;


•	intellectual property, product liability or other litigation against us;


•	expiration or termination of our potential relationships with customers and strategic partners; and

Table of Contents


•	other factors described in this “Risk Factors” section.

These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical companies, including us, following periods of volatility in their stock prices. Such litigation instituted against us could cause us to incur substantial costs and divert management’s attention and resources.

If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.

As a smaller company, it may be difficult for us to attract or retain the interest of equity research analysts. A lack of research coverage may adversely affect the liquidity of and market price of our common stock. We will not have any control of the equity research analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company, or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.

Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to drop significantly, even if our business is doing well. *

Sales of a substantial number of shares of our common stock in the public market could occur at any time. On March 4, 2015, we entered into the ATM agreement, with Cowen , under which we may offer and sell our common stock having aggregate sales proceeds of up to $50 million from time to time through our sales agent. As of September 30, 2015, common stock for aggregate gross proceeds of $39.2 million remained available to be sold under this facility, subject to certain conditions as specified in the ATM agreement.

If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.

As of September 30, 2015, certain holders of approximately 6,765,042 shares of our common stock, including shares issuable upon the exercise of outstanding warrants, are entitled to certain rights with respect to the registration of their shares under the Securities Act of 1933, as amended, or the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. On October 16, 2015, we filed a shelf registration statement on Form 3, registering the resale of the 8,414,711 shares held by certain selling stockholders identified therein. The shares covered thereby may be offered from time to time by the selling stockholders.

Provisions in our corporate charter documents and under Delaware law could discourage takeover attempts and lead to management entrenchment, and the market price of our common stock may be lower as a result.

Certain provisions in our amended and restated certificate of incorporation and amended and restated bylaws may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock. Our board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.

Our charter documents also contain other provisions that could have an anti-takeover effect, including:


•	only one of our three classes of directors will be elected each year;


•	no cumulative voting in the election of directors;


•	the ability of our board of directors to issues shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;


•	the exclusive right of our board of directors to elect a director to fill a vacancy or newly created directorship;


•	stockholders will not be permitted to take actions by written consent;

Table of Contents


•	stockholders cannot call a special meeting of stockholders;


•	stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;


•	the ability of our board of directors, by a majority vote, to amend the bylaws; and


•	the requirement for the affirmative vote of at least 66 2/3% or more of the outstanding common stock to amend many of the provisions described above.

In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which regulates corporate acquisitions. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that certain investors are willing to pay for our stock.

Our amended and restated certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders.

Insiders have substantial control over us, which could limit your ability to influence the outcome of key transactions, including a change of control.*

As of September 30, 2015, our directors, executive officers and each of our stockholders who own greater than 5% of our outstanding common stock and their affiliates, in the aggregate, beneficially owned approximately 46.9% of our common stock. As a result, these stockholders, if acting together, would be able to influence or control matters requiring approval by our stockholders, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may have interests that differ from yours and may vote in a way with which you disagree and that may be adverse to your interests. This concentration of ownership may have the effect of delaying, preventing or deterring a change of control of our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company and might affect the market price of our common stock.

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third party claims against us and may reduce the amount of money available to us.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.

In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:

•

We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.


•	We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.


•	We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.


•	We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.


•	The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.


•	We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.

Table of Contents

Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains.

We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

We are an “emerging growth company,” and if we decide to comply only with reduced disclosure requirements applicable to emerging growth companies, our common stock could be less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act and, for as long as we continue to be an “emerging growth company,” we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to “emerging growth companies,” including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an “emerging growth company” until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our IPO, (b) in which we have total annual gross revenues of over $1.0 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If some investors find our common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our common stock and our stock price may be more volatile.

Under the JOBS Act, emerging growth companies that become public can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.



ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

Issuer Purchases of Equity Securities

We have not and do not currently intend to retire or repurchase any of our shares other than providing our employees with the option to withhold shares to satisfy tax withholding amounts due from employees upon the vesting of restricted stock awards in connection with our 2014 Equity Incentive Plan.



Period	Total Number of Shares Purchased (i)	Weighted-Average Price Paid per Share (ii)		Total Number of Share Purchased as Part of Publicly Announced Plan or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan or Programs (in thousands)
July 1 through July 31, 2015	120	$	31.03	—	—
August 1 through August 31, 2015	504	29.98		—	—
September 1 through September 30, 2015	4,071	30.27		—	—
Total	4,695	$	30.26	—	—

(i) Consists solely of shares that were withheld to satisfy tax withholding amounts due from employees upon the vesting of previously issued restricted stock awards.

(ii) The weighted-average price paid per share is the weighted-average of the fair market prices at which we calculated the number of shares withheld to cover tax withholdings for the employees.

Table of Contents

Use of Proceeds

There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b) on February 6, 2014. As of September 30, 2015, we have used all of the proceeds from our IPO for working capital and general corporate purposes.



ITEM 3.	DEFAULTS UPON SENIOR SECURITIES

None.



ITEM 4.	MINE SAFETY DISCLOSURES

Not applicable.



ITEM 5.	OTHER INFORMATION

None.



ITEM 6.	EXHIBITS

The documents listed in the Exhibit Index of this Quarterly Report on Form 10-Q are herein incorporated by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




	REVANCE THERAPEUTICS, INC.

Date: November 10, 2015	By:	/s/ L. Daniel Browne
		L. Daniel Browne
		President and Chief Executive Officer (Duly Authorized Principal Executive Officer)

Date: November 10, 2015	By:	/s/ Lauren P. Silvernail
		Lauren P. Silvernail
		Chief Financial Officer and Executive Vice President of Corporate Development (Duly Authorized Principal Financial Officer)

Table of Contents

EXHIBIT INDEX

Exhibit

Number

Exhibit Description

Incorporated by Reference to the Company's

Filed

Herewith

Form

File No.

Exhibit No.

Filed On

3.1

Amended and Restated Certificate of Incorporation

8-K

001-36297

3.1

February 11, 2014

3.2

Amended and Restated Bylaws

S-1

333-193154

3.4

December 31, 2013

4.1

Amended and Restated Investor Rights Agreement, effective as of February 5, 2014, among Revance Therapeutics, Inc. and certain of its stockholders

S-1/A

333-193154

4.3

January 27, 2014

4.2

Form of Common Stock Certificate

S-1/A

333-193154

4.4

February 3, 2014

10.1+

Second Amendment to Development and Supply Agreement, dated August 31, 2015, between Revance Therapeutics, Inc and Hospira Worldwide, Inc.

10.2*

Form of Restricted Stock Unit Award Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan

10.3*

Form of Stock Option Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan

10.4*

Form of Restricted Stock Bonus Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan

10.5*

Form of Stock Option Agreement and Grant Notice under Revance Therapeutics, Inc. 2014 Inducement Plan

10.6*

Form of Restricted Stock Agreement and Grant Notice under Revance Therapeutics, Inc. 2014 Inducement Plan

31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) promulgated under the Exchange Act

31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) promulgated under the Exchange Act

32.1†

Certification of the Chief Executive Officer pursuant to18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2†

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS**

XBRL Instance Document

101.SCH**

XBRL Taxonomy Extension Schema Document

101.CAL**

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF**

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB**

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE**

XBRL Taxonomy Extension Presentation Linkbase Document

Table of Contents


*	Indicates a management contract or compensatory plan or arrangement.


+	Confidential treatment has been requested for certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.

†

The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, and shall not be deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Exchange Act. Such certifications shall not be deemed incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.


**	Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under these sections.

EX-10.1 2 rvnc-q315exhibit101.htm EXHIBIT 10.1 Exhibit

[ ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Exhibit 10.1

SECOND AMENDMENT

DEVELOPMENT AND SUPPLY AGREEMENT

between

REVANCE THERAPEUTICS, INC.

and

HOSPIRA WORLDWIDE, INC.

This Second Amendment to the Development and Supply Agreement (“Amendment”) is made and effective as of the 31^st day of August, 2015 (“Amendment Effective Date”), by and between Revance Therapeutics, Inc. (“Revance”) and Hospira Worldwide, Inc., (“Hospira”), each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).

RECITALS

WHEREAS, Revance and Hospira are Parties to that certain Development and Supply Agreement dated as of December 11, 2009 (the “Agreement”); and

WHEREAS, by an agreement dated May 29, 2013 (“First Amendment”) the Parties have amended Section 9.3 of the Agreement; and

WHEREAS, the Parties now desire further to amend Section 9.3 of the Agreement under the terms and conditions set forth below.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree that the Agreement is amended as follows:


1)	Section 9.3. Section 9.3, as modified by the First Amendment, is hereby replaced in its entirety with the following amended Section 9.3:

9.3 Failure to Obtain Regulatory Approval. Either party may terminate this Agreement by giving to the other party twelve (12) months’ prior written notice if the Product has not received FDA regulatory approval by [***].


2)	Except as expressly amended herein, all other terms and conditions of the Agreement shall remain in full force and effect, and enforceable in accordance with its terms. The terms and conditions of this Amendment are hereby incorporated into and made a part of the Agreement.

This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. The parties may sign and deliver this Amendment by facsimile or sent by electronic mail in portable document format (PDF) and a reproduction of this Amendment made by facsimile or PDF will have the same effect as a signed and delivered original version.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Parties intending to be bound by the terms and conditions hereof have caused this Amendment to be signed by their duly authorized representatives as of the date first above written.



HOSPIRA WORLDWIDE, INC.	REVANCE THERAPEUTICS, INC.

By: /s/ Karen Blair (Signature)	By: /s/ L. Daniel Browne (Signature)

Name: Karen Blair	Name: L. Daniel Browne

Title: President One 2 One Contract Manufacturing Services	Title: President & CEO

EX-10.2 3 rvnc-q315exhibit102.htm EXHIBIT 10.2 Exhibit

REVANCE THERAPEUTICS, INC.

RESTRICTED STOCK UNIT GRANT NOTICE

(2014 EQUITY INCENTIVE PLAN)

Revance Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2014 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this notice of grant (this “Restricted Stock Unit Grant Notice”) and in the Plan and the Restricted Stock Unit Award Agreement (the “Award Agreement”), both of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Award Agreement. In the event of any conflict between the terms in the Award and the Plan, the terms of the Plan shall control.




		Participant:
		ID:
		Date of Grant:
		Grant Number:
		Vesting Commencement Date:
		Number of Restricted Stock Units/Shares:
		Vesting Schedule:




Issuance Schedule:		Subject to any change on a Capitalization Adjustment, one share of Common Stock will be issued for each Restricted Stock Unit that vests at the time set forth in Section 6 of the Award Agreement.

[Vesting Acceleration: Notwithstanding the foregoing, upon the termination without Cause (as such term is defined in the Company’s Employee Equity Vesting Policy) by the Company (or a successor, if appropriate) of Participant’s service as an Employee in connection with or within twelve (12) months following the consummation of a Change in Control, the vesting of this Award shall accelerate in full, effective upon such termination of employment. In the event of a Change in Control, if the Company’s successor does not agree to assume this Award, or to substitute an equivalent award or right for this Award, then the vesting of this Award shall accelerate in full, effective immediately prior to the consummation of such Change in Control.]

Additional Terms/Acknowledgements: Participant acknowledges receipt of, and understands and agrees to, this Restricted Stock Unit Grant Notice, the Award Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Restricted Stock Unit Grant Notice, the Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of the Common Stock pursuant to the Award specified above and supersede all prior oral and written agreements on the terms of this Award with the exception,

123768726 v1

if applicable, of (i) the written employment agreement or offer letter agreement entered into between the Company and Participant specifying the terms that should govern this specific Award, and (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law.

By accepting this Award, Participant acknowledges having received and read the Restricted Stock Unit Grant Notice, the Award Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Participant consents to receive Plan documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.




REVANCE THERAPEUTICS, INC.

By:
		Signature

Title:

Date:

123768726 v1

REVANCE THERAPEUTICS, INC.

2014 EQUITY INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT

Pursuant to the Restricted Stock Unit Grant Notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”), Revance Therapeutics, Inc. (the “Company”) has awarded you (“Participant”) a Restricted Stock Unit Award (the “Award”) pursuant to Section 6(b) of the Company’s 2014 Equity Incentive Plan (the “Plan”) for the number of Restricted Stock Units/shares indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement or the Grant Notice shall have the same meanings given to them in the Plan. The terms of your Award, in addition to those set forth in the Grant Notice, are as follows.

1.GRANT OF THE AWARD. This Award represents the right to be issued on a future date one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 below) as indicated in the Grant Notice. As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the “Account”) the number of Restricted Stock Units/shares of Common Stock subject to the Award. This Award was granted in consideration of your services to the Company.

2.VESTING. Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. Upon such termination of your Continuous Service, the Restricted Stock Units/shares of Common Stock credited to the Account that were not vested on the date of such termination will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such underlying shares of Common Stock.

3.NUMBER OF SHARES. The number of Restricted Stock Units/shares subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan. Any additional Restricted Stock Units, shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units and shares covered by your Award. Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 3. Any fraction of a share will be rounded down to the nearest whole share.

4.SECURITIES LAW COMPLIANCE. You may not be issued any Common Stock under your Award unless the shares of Common Stock underlying the Restricted Stock Units are either (i) then registered under the Securities Act, or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Your Award must also comply with other applicable laws and regulations governing the Award, and you shall not receive such Common Stock if the Company determines that such receipt would not be in material compliance with such laws and regulations.

123768726 v1

5.TRANSFER RESTRICTIONS. Prior to the time that shares of Common Stock have been delivered to you, you may not transfer, pledge, sell or otherwise dispose of this Award or the shares issuable in respect of your Award, except as expressly provided in this Section 5. For example, you may not use shares that may be issued in respect of your Restricted Stock Units as security for a loan. The restrictions on transfer set forth herein will lapse upon delivery to you of shares in respect of your vested Restricted Stock Units.

(a)Death. Your Award is transferable by will and by the laws of descent and distribution. At your death, vesting of your Award will cease and your executor or administrator of your estate shall be entitled to receive, on behalf of your estate, any Common Stock or other consideration that vested but was not issued before your death.

(b)Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your right to receive the distribution of Common Stock or other consideration hereunder, pursuant to a domestic relations order or marital settlement agreement that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this Award with the Company General Counsel prior to finalizing the domestic relations order or marital settlement agreement to verify that you may make such transfer, and if so, to help ensure the required information is contained within the domestic relations order or marital settlement agreement.

6.DATE OF ISSUANCE.

(a) The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. Subject to the satisfaction of the withholding obligations set forth in this Agreement, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 above). The issuance date determined by this paragraph is referred to as the “Original Issuance Date”.

(b) If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day. In addition, if:

(i)the Original Issuance Date does not occur (1) during an “open window period” applicable to you, as determined by the Company in accordance with the Company’s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market, and

(ii)either (1) Withholding Taxes do not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to satisfy the Withholding Taxes by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this Award, and (B) not to permit you to pay your Withholding Taxes in cash,

123768726 v1

then the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company’s Common Stock in the open public market, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, if and only if permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this Award are no longer subject to a “substantial risk of forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d).

(c) The form of delivery (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.

7.DIVIDENDS. You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment.

8.RESTRICTIVE LEGENDS. The shares of Common Stock issued under your Award shall be endorsed with appropriate legends as determined by the Company.

9.EXECUTION OF DOCUMENTS. You hereby acknowledge and agree that the manner selected by the Company by which you indicate your consent to your Grant Notice is also deemed to be your execution of your Grant Notice and of this Agreement. You further agree that such manner of indicating consent may be relied upon as your signature for establishing your execution of any documents to be executed in the future in connection with your Award.

10.AWARD NOT A SERVICE CONTRACT.

(a) Nothing in this Agreement (including, but not limited to, the vesting of your Award or the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Agreement or the Plan shall: (i) confer upon you any right to continue in the employ of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Agreement or Plan; or (iv) deprive the Company of the right to terminate you at will and without regard to any future vesting opportunity that you may have.

(b) The Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a “reorganization”). Such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not limited to, the termination of the right to continue vesting in the Award. This Agreement, the Plan, the transactions contemplated hereunder

123768726 v1

and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Agreement, for any period, or at all, and shall not interfere in any way with the Company’s right to conduct a reorganization.

11.WITHHOLDING OBLIGATIONS.

(a) On each vesting date, and on or before the time you receive a distribution of the shares underlying your Restricted Stock Units, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate that arise in connection with your Award (the “Withholding Taxes”). Additionally, the Company or any Affiliate may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company; (ii) causing you to tender a cash payment; (iii) permitting or requiring you to enter into a “same day sale” commitment, if applicable, with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”) whereby you irrevocably elect to sell a portion of the shares to be delivered in connection with your Restricted Stock Units to satisfy the Withholding Taxes and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Taxes directly to the Company and/or its Affiliates; or (iv) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award with a Fair Market Value (measured as of the date shares of Common Stock are issued to pursuant to Section 6) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld will not exceed the amount necessary to satisfy the Company’s required tax withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and provided, further, that to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Company’s Compensation Committee.

(b) Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any Common Stock.

(c) In the event the Company’s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Company’s withholding obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.

12.TAX CONSEQUENCES. The Company has no duty or obligation to minimize the tax consequences to you of this Award and shall not be liable to you for any adverse tax consequences to you arising in connection with this Award. You are hereby advised to consult with your own personal tax, financial and/or legal advisors regarding the tax consequences of this Award and by

123768726 v1

signing the Grant Notice, you have agreed that you have done so or knowingly and voluntarily declined to do so. You understand that you (and not the Company) shall be responsible for your own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement.

13.UNSECURED OBLIGATION. Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company’s obligation, if any, to issue shares or other property pursuant to this Agreement. You shall not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Agreement until such shares are issued to you pursuant to Section 6 of this Agreement. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.

14.NOTICES. Any notice or request required or permitted hereunder shall be given in writing to each of the other parties hereto and shall be deemed effectively given on the earlier of (i) the date of personal delivery, including delivery by express courier, or delivery via electronic means, or (ii) the date that is five (5) days after deposit in the United States Post Office (whether or not actually received by the addressee), by registered or certified mail with postage and fees prepaid, addressed at the following addresses, or at such other address(es) as a party may designate by ten (10) days’ advance written notice to each of the other parties hereto:



COMPANY:		Revance Therapeutics, Inc.
		Attn: Stock Administrator
		7555 Gateway Boulevard
		Newark, CA 94560

PARTICIPANT:		Your address as on file with the Company
		at the time notice is given

15.HEADINGS. The headings of the Sections in this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement or to affect the meaning of this Agreement.

16.MISCELLANEOUS.

(a) The rights and obligations of the Company under your Award shall be transferable by the Company to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company’s successors and assigns.

123768726 v1

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.

(c) You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award.

(d) This Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

(e) All obligations of the Company under the Plan and this Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.

17.GOVERNING PLAN DOCUMENT. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. Your Award (and any compensation paid or shares issued under your Award) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to voluntarily terminate employment upon a resignation for “good reason,” or for a “constructive termination” or any similar term under any plan of or agreement with the Company.

18.EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of the Award subject to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating benefits under any employee benefit plan (other than the Plan) sponsored by the Company or any Affiliate except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any or all of the employee benefit plans of the Company or any Affiliate.

19.CHOICE OF LAW. The interpretation, performance and enforcement of this Agreement shall be governed by the law of the State of Delaware without regard to that state’s conflicts of laws rules.

20.SEVERABILITY. If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

123768726 v1

21.OTHER DOCUMENTS. You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act. In addition, you acknowledge receipt of the Company’s Insider Trading and Trading Window Policy.

22.AMENDMENT. This Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Agreement, so long as a copy of such amendment is delivered to you, and provided that, except as otherwise expressly provided in the Plan, no such amendment materially adversely affecting your rights hereunder may be made without your written consent. Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the Award as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.

23.COMPLIANCE WITH SECTION 409A OF THE CODE. This Award is intended to comply with the “short-term deferral” rule set forth in Treasury Regulation Section 1.409A-1(b)(4). Notwithstanding the foregoing, if it is determined that the Award fails to satisfy the requirements of the short-term deferral rule and is otherwise deferred compensation subject to Section 409A, and if you are a “Specified Employee” (within the meaning set forth in Section 409A(a)(2)(B)(i) of the Code) as of the date of your “separation from service” (within the meaning of Treasury Regulation Section 1.409A-1(h) and without regard to any alternative definition thereunder), then the issuance of any shares that would otherwise be made upon the date of the separation from service or within the first six (6) months thereafter will not be made on the originally scheduled date(s) and will instead be issued in a lump sum on the date that is six (6) months and one day after the date of the separation from service, with the balance of the shares issued thereafter in accordance with the original vesting and issuance schedule set forth above, but if and only if such delay in the issuance of the shares is necessary to avoid the imposition of adverse taxation on you in respect of the shares under Section 409A of the Code. Each installment of shares that vests is intended to constitute a “separate payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2).

* * * * *

This Restricted Stock Unit Award Agreement shall be deemed to be signed by the Company and the Participant upon the acceptance by the Participant of the Restricted Stock Unit Grant Notice.

123768726 v1

EX-10.3 4 rvnc-q315exhibit103.htm EXHIBIT 10.3 Exhibit

REVANCE THERAPEUTICS, INC.
STOCK OPTION GRANT NOTICE
(2014 EQUITY INCENTIVE PLAN)

Revance Therapeutics, Inc. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this notice and the Plan, the terms of the Plan will control.



Optionholder:
Date of Grant:
Vesting Commencement Date:
Number of Shares Subject to Option:
Exercise Price (Per Share):
Total Exercise Price:
Expiration Date:
Type of Grant
Vesting Schedule

[Vesting Acceleration: Notwithstanding the foregoing, upon the termination without Cause (as such term is defined in the Company’s Employee Equity Vesting Policy) by the Company (or a successor, if appropriate) of Optionholder’s service as an Employee in connection with or within twelve (12) months following the consummation of a Change in Control, the vesting of this option award shall accelerate in full, effective upon such termination of employment. In the event of a Change in Control, if the Company’s successor does not agree to assume this option award, or to substitute an equivalent award or right for this option award, then the vesting of this option award shall accelerate in full, effective immediately prior to the consummation of such Change in Control.]

Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) options previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable

123768602 v1

law and (iii) any written employment or severance arrangement that would provide for vesting acceleration of this option upon the terms and conditions set forth therein.

By accepting this option, Optionholder consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.



REVANCE THERAPEUTICS, INC. By:_____________________________ Title:___________________________ Date:____________________________

ATTACHMENTS: Option Agreement, 2014 Equity Incentive Plan and Notice of Exercise

123768602 v1

REVANCE THERAPEUTICS, INC.
2014 EQUITY INCENTIVE PLAN

OPTION AGREEMENT
(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Revance Therapeutics, Inc. (the “Company”) has granted you an option under its 2014 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

1.VESTING. Subject to the provisions contained herein, your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

2.NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.

3.EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit plans).

4.EXERCISE PRIOR TO VESTING (“EARLY EXERCISE”). You may not exercise your option prior to vesting.

5.METHOD OF PAYMENT. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in one of the following manners:

(a)By cash or by check, bank draft, electronic transfer or money order payable to the Company.

123768602 v1

(b)Pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.

(c)By delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock.

(d)If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

6.WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

7.SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).

8.TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:

(a) immediately upon the termination of your Continuous Service for Cause;

123768602 v1

is not exercisable solely because of the condition set forth in the section above relating to “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the Company’s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company’s insider trading policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date;

(c) twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 8(d)) below;

(d) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;

(e) the Expiration Date indicated in your Grant Notice; or

(f) the day before the tenth (10th) anniversary of the Date of Grant.

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates.

9.EXERCISE.

(a) You may exercise the vested portion of your option during its term by (i) delivering a notice of exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.

123768602 v1

(b) By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the Date of Grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.

(d) By accepting your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 9(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.

10.TRANSFERABILITY. Except as otherwise provided in this Section 10, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

123768602 v1

information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.

11.OPTION NOT A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

12.WITHHOLDING OBLIGATIONS.

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.

(b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding

123768602 v1

obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.

13.TAX CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option.

14.NOTICES. Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

15.GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.

16.OTHER DOCUMENTS. You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell shares only during certain “window” periods and the Company’s insider trading policy, in effect from time to time.

123768602 v1

17.EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

18.VOTING RIGHTS. You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.

19.SEVERABILITY. If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

20.MISCELLANEOUS.

(a) The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.

(c) You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option.

(d) This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

(e) All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.

* * *

123768602 v1

This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.

123768602 v1

EX-10.4 5 rvnc-q315exhibit104.htm EXHIBIT 10.4 Exhibit

REVANCE THERAPEUTICS, INC.

RESTRICTED STOCK BONUS GRANT NOTICE

(2014 EQUITY INCENTIVE PLAN)

Revance Therapeutics, Inc. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby awards to Participant as a bonus the number of shares of the Company’s Common Stock set forth below (“Award”). This Award is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Bonus Agreement, the Plan, the form of Assignment Separate from Certificate and the form of Joint Escrow Instructions, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Restricted Stock Bonus Agreement. In the event of any conflict between the terms in the Award and the Plan, the terms of the Plan shall control.




Participant:
Date of Grant:
Vesting Commencement Date:
Number of Shares Subject to Award:
Consideration:		Participant’s Services

Vesting Schedule: [___________________]

Additional Terms/Acknowledgements: The undersigned Participant acknowledges receipt of, and understands and agrees to, this Restricted Stock Bonus Grant Notice, the Restricted Stock Bonus Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Restricted Stock Bonus Grant Notice, the Restricted Stock Bonus Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of the Common Stock pursuant to the Award specified above and supersede all prior oral and written agreements on that subject with the exception, if applicable, of (i) the written employment agreement or offer letter agreement entered into between the Company and Participant specifying the terms that should govern this specific Award, and (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law.

123768225 v1

Participant consents to receive Plan documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.




REVANCE THERAPEUTICS, INC.

By:
		Signature

Title:

Date:

123768225 v1

REVANCE THERAPEUTICS, INC.

2014 EQUITY INCENTIVE PLAN

RESTRICTED STOCK BONUS AGREEMENT

Pursuant to the Restricted Stock Bonus Grant Notice (“Grant Notice”) and this Restricted Stock Bonus Agreement (collectively, the “Award”) and in consideration of your services, Revance Therapeutics, Inc. (the “Company”) has awarded you (“Participant”) a stock bonus under its 2014 Equity Incentive Plan (the “Plan”) for the number of shares of the Company’s Common Stock subject to the Award as indicated in the Grant Notice. Capitalized terms not explicitly defined in this Restricted Stock Bonus Agreement but defined in the Plan shall have the same definitions as in the Plan. The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.

The details of your Award are as follows:

1.VESTING. Subject to the limitations contained herein, your Award will vest as provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.

2. NUMBER OF SHARES. The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan.

3. SECURITIES LAW COMPLIANCE. You may not be issued any shares under your Award unless the shares are either (i) then registered under the Securities Act or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Your Award must also comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.

4. RIGHT OF REACQUISITION.

(a) The Company shall have the right to reacquire all or any part of the shares received pursuant to your Award (a “Reacquisition Right”) as to the shares you received pursuant to your Award that have not as yet vested in accordance with the Vesting Schedule on the Grant Notice (“Unvested Shares”) on the following terms and conditions:

(i) The Company, shall simultaneously with termination of your Continuous Service automatically reacquire for no consideration (that is, for zero dollars ($0)) all of the Unvested Shares, unless the Company agrees to waive its Reacquisition Right as to some or all of the Unvested Shares. Any such waiver shall be exercised by the Company by written notice to you or your representative (with a copy to the Escrow Holder as defined below) within ninety (90) days after the termination of your Continuous Service, and the Escrow Holder may then release to you the number of Unvested Shares not being reacquired by the Company. If the Company does not waive its Reacquisition Right as to all of the Unvested Shares, then upon such termination of

123768225 v1

your Continuous Service, the Escrow Holder shall transfer to the Company the number of shares the Company is reacquiring.

(ii) The shares issued under your Award shall be held in escrow pursuant to the terms of the Joint Escrow Instructions attached to the Grant Notice as Attachment IV. You agree to execute two (2) Assignment Separate From Certificate forms (with date and number of shares blank) substantially in the form attached to the Grant Notice as Attachment III and deliver the same, along with the certificate or certificates evidencing the shares, for use by the escrow agent pursuant to the terms of the Joint Escrow Instructions.

(iii) Subject to the provisions of your Award, you shall, during the term of your Award, exercise all rights and privileges of a stockholder of the Company with respect to the shares deposited in escrow. You shall be deemed to be the holder of the shares for purposes of receiving any dividends which may be paid with respect to such shares (which shall be subject to the same vesting and forfeiture restrictions as apply to the shares to which they relate) and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company’s Reacquisition Right.

(iv) If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the outstanding stock of the corporation the stock of which is subject to the provisions of your Award, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares acquired under your Award shall be immediately subject to the Reacquisition Right with the same force and effect as the shares subject to this Reacquisition Right immediately before such event.

(v) In addition to any other limitation on transfer created by applicable securities laws, you shall not sell, assign, hypothecate, donate, encumber, or otherwise dispose of any interest in the Common Stock while such shares of Common Stock are subject to the Reacquisition Right or continue to be held in the Joint Escrow; provided, however, that an interest in such shares may be transferred pursuant to a qualified domestic relations order as defined in the Code or Title I of the Employee Retirement Income Security Act.

5. RESTRICTIVE LEGENDS. The shares issued under your Award shall be endorsed with appropriate legends determined by the Company.

6. AWARD NOT A SERVICE CONTRACT. Your Award is not an employment or service contract, and nothing in your Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or on the part of the Company or an Affiliate to continue your employment. In addition, nothing in your Award shall obligate the Company or an Affiliate, their respective stockholders, boards of directors, Officers or Employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

123768225 v1

7. WITHHOLDING OBLIGATIONS.

(a) At the time your Award is made, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with your Award.

(b) Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to issue a certificate for such shares or release such shares from any escrow provided for herein.

8. TAX CONSEQUENCES. The acquisition and vesting of the shares may have adverse tax consequences to you that may avoided or mitigated by filing an election under Section 83(b) of the Code. Such election must be filed within thirty (30) days after the date of your Award. YOU ACKNOWLEDGE THAT IT IS YOUR OWN RESPONSIBILITY, AND NOT THE COMPANY’S, TO FILE A TIMELY ELECTION UNDER CODE SECTION 83(b), EVEN IF YOU REQUEST THE COMPANY TO MAKE THE FILING ON YOUR BEHALF.

9. NOTICES. Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.

10. MISCELLANEOUS.

(a) The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company’s successors and assigns. Your rights and obligations under your Award may only be assigned with the prior written consent of the Board in its sole discretion.

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.

11. GOVERNING PLAN DOCUMENT. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.

123768225 v1

*****

This Restricted Stock Bonus Agreement shall be deemed to be signed by the Company and Participant upon the acceptance by the Participant of the Restricted Stock Bonus Grant Notice.

123768225 v1

JOINT ESCROW INSTRUCTIONS

[Date]

Corporate Secretary

Revance Therapeutics, Inc.

7555 Gateway Boulevard

Newark, California 94560

Dear Sir/Madam:

As Escrow Agent for both Revance Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned recipient of stock of the Company (“Recipient”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock Bonus Grant Notice (the “Grant Notice”), dated _______________ to which a copy of these Joint Escrow Instructions is attached as Attachment IV, and pursuant to the terms of that certain Restricted Stock Bonus Agreement (“Agreement”), which is Attachment I to the Grant Notice, in accordance with the following instructions. Capitalized terms not explicitly defined in these instructions but defined in the Company’s 2014 Equity Incentive Plan (“Plan”), the Grant Notice, or the Agreement shall have the same definitions as provided therein.

1. In the event Recipient ceases to render services to the Company or an affiliate of the Company during the vesting period set forth in the Grant Notice, the Company or its assignee will give to Recipient and you a written notice specifying that the shares of Common Stock shall be transferred to the Company. Recipient and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice.

2. At the closing you are directed (a) to date any stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver same, together with the certificate evidencing the shares of Common Stock to be transferred, to the Company.

3. Recipient irrevocably authorizes the Company to deposit with you any certificates evidencing shares of Common Stock to be held by you hereunder and any additions and substitutions to said shares as specified in the Grant Notice. Recipient does hereby irrevocably constitute and appoint you as Recipient’s attorney‑in‑fact and agent for the term of this escrow to execute with respect to such securities and other property all documents of assignment and/or transfer and all stock certificates necessary or appropriate to make all securities negotiable and complete any transaction herein contemplated.

4. This escrow shall terminate upon vesting of the shares or upon the earlier return of the shares to the Company pursuant to the Company’s Reacquisition Right or other forfeiture condition under the Plan.

123768225 v1

5. If at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to Recipient, you shall deliver all of same to any pledgee entitled thereto or, if none, to Recipient and shall be discharged of all further obligations hereunder.

6. Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto.

7. You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties or their assignees. You shall not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney‑in‑fact for Recipient while acting in good faith and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith.

8. You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree of any court, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction.

9. You shall not be liable in any respect on account of the identity, authority or rights of the parties executing or delivering or purporting to execute or deliver the Grant Notice or any documents or papers deposited or called for hereunder.

10. You shall not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow Instructions or any documents deposited with you.

11. You shall be entitled to employ such legal counsel, including but not limited to Cooley LLP, and other experts as you may deem necessary properly to advise you in connection with your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor.

12. Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be Secretary of the Company or if you shall resign by written notice to each party. In the event of any such termination, the Company may appoint any officer or assistant officer of the Company as successor Escrow Agent and Recipient hereby confirms the appointment of such successor or successors as his attorney‑in‑fact and agent to the full extent of your appointment.

13. If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments.

123768225 v1

14. It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the securities, you may (but are not obligated to) retain in your possession without liability to anyone all or any part of said securities until such dispute shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings.

15. Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or upon deposit in any United States Post Box, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties hereunto entitled at the following addresses, or at such other addresses as a party may designate by ten (10) days’ written notice to each of the other parties hereto:



COMPANY:		Revance Therapeutics, Inc.
		7555 Gateway Boulevard
		Newark, California 94560
		Attn: [General Counsel]

RECIPIENT:




ESCROW AGENT:		Revance Therapeutics, Inc.
		7555 Gateway Boulevard
		Newark, California 94560
		Attn: Corporate Secretary

16. By signing these Joint Escrow Instructions you become a party hereto only for the purpose of said Joint Escrow Instructions; you do not become a party to the Grant Notice.

17. This instrument shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns. It is understood and agreed that references to “you” or “your” herein refer to the original Escrow Agent and to any and all successor Escrow Agents. It is understood and agreed that the Company may at any time or from time to time assign its rights under the Grant Notice and these Joint Escrow Instructions in whole or in part.

18. This Agreement shall be governed by and interpreted and determined in accordance with the laws of the State of California, as such laws are applied by California courts to contracts made and to be performed entirely in California by residents of that state.

123768225 v1



Very truly yours,

REVANCE THERAPEUTICS, INC.


By:


RECIPIENT



Name:

ESCROW AGENT:

123768225 v1

ASSIGNMENT SEPARATE FROM CERTIFICATE

FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Bonus Grant Notice and Restricted Stock Bonus Agreement (the “Award”), [Participant’s Name] hereby sells, assigns and transfers unto Revance Therapeutics, Inc., a Delaware corporation (“Assignee”) ________________________ (__________) shares of the common stock of the Assignee, standing in the undersigned’s name on the books of said corporation represented by Certificate No. _____ herewith and do hereby irrevocably constitute and appoint _____________________ as attorney-in-fact to transfer the said stock on the books of the within named Company with full power of substitution in the premises. This Assignment may be used only in accordance with and subject to the terms and conditions of the Award, in connection with the reacquisition of shares of Common Stock of the Corporation issued to the undersigned pursuant to the Award, and only to the extent that such shares remain subject to the Corporation’s Reacquisition Right under the Award.



Dated:

	Signature:
		[Participant's Name], Recipient

[INSTRUCTION: Please do not fill in any blanks other than the signature line. The purpose of this Assignment is to enable the Company to exercise its Reacquisition Right set forth in the Award without requiring additional signatures on your part.]

123768225 v1

EX-10.5 6 rvnc-q315exhibit105.htm EXHIBIT 10.5 Exhibit

REVANCE THERAPEUTICS, INC.

2014 INDUCEMENT PLAN

STOCK OPTION GRANT NOTICE

Revance Therapeutics, Inc. (the “Company”), pursuant to its 2014 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this notice and the Plan, the terms of the Plan will control.



Optionholder:
Date of Grant:
Vesting Commencement Date:
Number of Shares Subject to Option:
Exercise Price (Per Share):
Total Exercise Price:
Expiration Date:
Type of Grant	Nonstatutory Stock Option
Vesting Schedule

[Vesting Acceleration: Notwithstanding the foregoing, upon the termination without Cause (as such term is defined in the Company’s Employee Equity Vesting Policy) by the Company (or a successor, if appropriate) of Optionholder’s service as an Employee in connection with or within twelve (12) months following the consummation of a Change in Control, the vesting of this option award shall accelerate in full, effective upon such termination of employment. In the event of a Change in Control, if the Company’s successor does not agree to assume this option award, or to substitute an equivalent award or right for this option award, then the vesting of this option award shall accelerate in full, effective immediately prior to the consummation of such Change in Control.]

109779885 v3

law and (iii) any written employment or severance arrangement that would provide for vesting acceleration of this option upon the terms and conditions set forth therein.



REVANCE THERAPEUTICS, INC. By:_______________________________ Title:_____________________________ Date:______________________________	OPTIONHOLDER: [NAME] ___________________________________ Signature Date:_______________________________

ATTACHMENTS: Option Agreement, 2014 Inducement Plan and Notice of Exercise

109779885 v3

REVANCE THERAPEUTICS, INC.
2014 INDUCEMENT PLAN
OPTION AGREEMENT

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Revance Therapeutics, Inc. (the “Company”) has granted you a nonstatutory stock option under its 2014 Inducement Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

1.VESTING. Subject to the provisions contained herein, your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

4.EXERCISE PRIOR TO VESTING (“EARLY EXERCISE”). You may not exercise your option prior to vesting.

5.METHOD OF PAYMENT. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in one of the following manners:

(a)By cash or by check, bank draft, electronic transfer or money order payable to the Company.

(b)Pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of

109779885 v3

cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.

(d)Subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

6.WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

(a) immediately upon the termination of your Continuous Service for Cause;

(b) three (3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above relating to “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has

109779885 v3

been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the Company’s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company’s insider trading policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date;

(c) twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 8(d)) below;

(d) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;

(e) the Expiration Date indicated in your Grant Notice; or

(f) the day before the tenth (10th) anniversary of the Date of Grant.

9.EXERCISE.

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the

109779885 v3

sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

(b) Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement.

11.OPTION NOT A CONTRACT FOR EMPLOYMENT. Your option is not an employment contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment.

12.WITHHOLDING OBLIGATIONS.

(b) Because this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise

109779885 v3

of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.

109779885 v3

20.MISCELLANEOUS.

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.

(d) This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

(e) All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the

109779885 v3

result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.

* * *

This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.

109779885 v3

NOTICE OF EXERCISE

UNDER THE REVANCE THERAPEUTICS, INC.

2014 INDUCEMENT PLAN

REVANCE THERAPEUTICS, INC.

7555 GATEWAY BOULEVARD

NEWARK, CA 94560

Date of Exercise: _______________

This constitutes notice to Revance Therapeutics, Inc. (the “Company”) under my nonstatutory stock option described below (the “Option”) granted pursuant to the Company’s 2014 Inducement Plan (as it may be amended from time to time) as evidenced by the Stock Option Grant Notice and Option Agreement thereunder, that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.



Option Grant Date:
Number of Shares as to which the Option is exercised:
Certificates to be issued in name of:
Total exercise price:	$	$
Cash payment delivered herewith:	$	$
[Value of ____ Shares delivered herewith:]	$	$
[Value of ____ Shares pursuant to net exercise]	$	$
Regulation T Program (cashless exercise):	$	$

By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Company’s 2014 Inducement Plan (as it may be amended from time to time), and (ii) to provide for the payment by me to the Company (in the manner designated by the Company) of the Company’s withholding obligation relating to the exercise of the Option.

Very truly yours,

Signature

Print Name

109779885 v3

EX-10.6 7 rvnc-q315exhibit106.htm EXHIBIT 10.6 Exhibit

REVANCE THERAPEUTICS, INC.
2014 INDUCEMENT PLAN

RESTRICTED STOCK GRANT NOTICE

Revance Therapeutics, Inc. (the “Company”), pursuant to its 2014 Inducement Plan (the “Plan”), hereby awards to Participant as an inducement material to the Participant’s entering into employment with the Company, the number of shares of the Company’s Common Stock set forth below (“Award”). This Award is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Agreement, the Plan, the form of Assignment Separate from Certificate and the form of Joint Escrow Instructions, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Restricted Stock Agreement. In the event of any conflict between the terms in the Award and the Plan, the terms of the Plan shall control.



Participant:
Date of Grant:
Vesting Commencement Date:
Number of Shares Subject to Award:
Consideration:		Participant’s Future Services


Vesting Schedule:	[____________]

Additional Terms/Acknowledgements: The undersigned Participant acknowledges receipt of, and understands and agrees to, this Restricted Stock Grant Notice, the Restricted Stock Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Restricted Stock Grant Notice, the Restricted Stock Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of the Common Stock pursuant to the Award specified above and supersede all prior oral and written agreements on that subject with the exception, if applicable, of (i) the written employment agreement or offer letter agreement entered into between the Company and Participant specifying the terms that should govern this specific Award, and (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law.

109782575 v3



REVANCE THERAPEUTICS, INC.		PARTICIPANT

By:		[NAME]
	Signature
Title:
		Signature
Date:		Date:

109782575 v3

REVANCE THERAPEUTICS, INC.

2014 INDUCEMENT PLAN

RESTRICTED STOCK AGREEMENT

Pursuant to the Restricted Stock Grant Notice (“Grant Notice”) and this Restricted Stock Agreement (collectively, the “Award”) and in consideration of your future services, Revance Therapeutics, Inc. (the “Company”) has awarded you (“Participant”) a stock award under its 2014 Inducement Plan (the “Plan”) for the number of shares of the Company’s Common Stock subject to the Award as indicated in the Grant Notice. Capitalized terms not explicitly defined in this Restricted Stock Agreement but defined in the Plan shall have the same definitions as in the Plan. The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.

The details of your Award are as follows:

1.VESTING. Subject to the limitations contained herein, your Award will vest as provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.

2. NUMBER OF SHARES. The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan.

4. RIGHT OF REACQUISITION.

109782575 v3

your Continuous Service, the Escrow Holder shall transfer to the Company the number of shares the Company is reacquiring.

5. RESTRICTIVE LEGENDS. The shares issued under your Award shall be endorsed with appropriate legends determined by the Company.

6. AWARD NOT AN EMPLOYMENT CONTRACT. Your Award is not an employment or service contract, and nothing in your Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or on the part of the Company or an Affiliate to continue your employment.

7. WITHHOLDING OBLIGATIONS.

109782575 v3

and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with your Award.

10. MISCELLANEOUS.

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.

*****

This Restricted Stock Agreement shall be deemed to be signed by the Company and Participant upon the acceptance by the Participant of the Restricted Stock Grant Notice.

109782575 v3

JOINT ESCROW INSTRUCTIONS

[Date]

Corporate Secretary

Revance Therapeutics, Inc.

7555 Gateway Boulevard

Newark, California 94560

Dear Sir/Madam:

As Escrow Agent for both Revance Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned recipient of stock of the Company (“Recipient”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock Grant Notice (the “Grant Notice”), dated _______________ to which a copy of these Joint Escrow Instructions is attached as Attachment IV, and pursuant to the terms of that certain Restricted Stock Agreement (“Agreement”), which is Attachment I to the Grant Notice, in accordance with the following instructions. Capitalized terms not explicitly defined in these instructions but defined in the Company’s 2014 Inducement Plan (“Plan”), the Grant Notice, or the Agreement shall have the same definitions as provided therein.

109782575 v3

6. Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto.

10. You shall not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow Instructions or any documents deposited with you.

109782575 v3



COMPANY:		Revance Therapeutics, Inc.
		7555 Gateway Boulevard
		Newark, California 94560
		Attn: [General Counsel]

RECIPIENT:




ESCROW AGENT:		Revance Therapeutics, Inc.
		7555 Gateway Boulevard
		Newark, California 94560
		Attn: Corporate Secretary

16. By signing these Joint Escrow Instructions you become a party hereto only for the purpose of said Joint Escrow Instructions; you do not become a party to the Grant Notice.

109782575 v3



Very truly yours,

REVANCE THERAPEUTICS, INC.


By:


RECIPIENT



Name:

ESCROW AGENT:

109782575 v3

ASSIGNMENT SEPARATE FROM CERTIFICATE

FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Grant Notice and Restricted Stock Agreement (the “Award”), [Participant’s Name] hereby sells, assigns and transfers unto Revance Therapeutics, Inc., a Delaware corporation (“Assignee”) ________________________ (__________) shares of the common stock of the Assignee, standing in the undersigned’s name on the books of said corporation represented by Certificate No. _____ herewith and do hereby irrevocably constitute and appoint _____________________ as attorney-in-fact to transfer the said stock on the books of the within named Company with full power of substitution in the premises. This Assignment may be used only in accordance with and subject to the terms and conditions of the Award, in connection with the reacquisition of shares of Common Stock of the Corporation issued to the undersigned pursuant to the Award, and only to the extent that such shares remain subject to the Corporation’s Reacquisition Right under the Award.



Dated:

	Signature:
		[Participant's Name], Recipient

109782575 v3

EX-31.1 8 rvnc-q315exhibit311.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATIONS

I, L. Daniel Browne, certify that:


1.	I have reviewed this Form 10-Q of Revance Therapeutics, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(c)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2015





	/s/ L. Daniel Browne
	L. Daniel Browne
	President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 9 rvnc-q315exhibit312.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATIONS

I, Lauren P. Silvernail, certify that:


1.	I have reviewed this Form 10-Q of Revance Therapeutics, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(c)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2015





	/s/ Lauren P. Silvernail
	Lauren P. Silvernail
	Chief Financial Officer and Executive Vice President of Corporate Development (Principal Financial Officer)

EX-32.1 10 rvnc-q315exhibit321.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), L. Daniel Browne, Chief Executive Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:


1.	The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2015, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and


2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 10, 2015

IN WITNESS WHEREOF, the undersigned has set his hands hereto as of the 10th day of November, 2015.

/s/ L. Daniel Browne

L. Daniel Browne

President and Chief Executive Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 11 rvnc-q315exhibit322.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Lauren P. Silvernail, Chief Financial Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of her knowledge:


1.	The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2015, to which this Certification is attached as Exhibit 32.2 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and


2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 10, 2015

IN WITNESS WHEREOF, the undersigned has set her hands hereto as of the 10th day of November, 2015.

/s/ Lauren P. Silvernail

Lauren P. Silvernail

Chief Financial Officer and Executive Vice President of Corporate Development

EX-101.INS 12 rvnc-20150930.xml XBRL INSTANCE DOCUMENT 0001479290 2015-01-01 2015-09-30 0001479290 2015-11-09 0001479290 2014-12-31 0001479290 2015-09-30 0001479290 2015-07-01 2015-09-30 0001479290 2014-01-01 2014-09-30 0001479290 2014-07-01 2014-09-30 0001479290 2014-09-30 0001479290 2013-12-31 0001479290 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2015-11-01 2015-11-30 0001479290 us-gaap:SubsequentEventMember 2015-11-30 0001479290 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2015-11-01 2015-11-30 0001479290 us-gaap:SubsequentEventMember 2015-11-01 2015-11-30 0001479290 us-gaap:CreditRiskContractMember rvnc:MedicisPharmaceuticalCorporationMember 2012-10-31 0001479290 us-gaap:CreditRiskContractMember rvnc:MedicisPharmaceuticalCorporationMember 2015-01-01 2015-09-30 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2014-01-01 2014-12-31 0001479290 rvnc:MedicisPharmaceuticalCorporationMember 2012-10-01 2012-10-31 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2012-10-31 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2013-01-01 2013-12-31 0001479290 us-gaap:OtherNoncurrentAssetsMember 2015-09-30 0001479290 us-gaap:MoneyMarketFundsMember 2014-12-31 0001479290 us-gaap:MoneyMarketFundsMember 2015-09-30 0001479290 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001479290 us-gaap:CashEquivalentsMember 2015-09-30 0001479290 us-gaap:OtherCurrentAssetsMember 2014-12-31 0001479290 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0001479290 us-gaap:OtherCurrentAssetsMember 2015-09-30 0001479290 us-gaap:OtherNoncurrentAssetsMember 2014-12-31 0001479290 us-gaap:CashEquivalentsMember 2014-12-31 0001479290 us-gaap:FairValueInputsLevel2Member 2015-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel1Member 2015-09-30 0001479290 us-gaap:FairValueInputsLevel3Member 2015-09-30 0001479290 us-gaap:FairValueInputsLevel3Member rvnc:DerivativeLiabilitySettlementMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel2Member rvnc:DerivativeLiabilitySettlementMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel1Member rvnc:DerivativeLiabilitySettlementMember 2015-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2015-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2015-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001479290 us-gaap:FairValueInputsLevel3Member 2014-12-31 0001479290 us-gaap:FairValueInputsLevel2Member 2014-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2014-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2014-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2014-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001479290 us-gaap:FairValueInputsLevel3Member rvnc:DerivativeLiabilitySettlementMember 2014-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2014-12-31 0001479290 us-gaap:FairValueInputsLevel1Member 2014-12-31 0001479290 us-gaap:FairValueInputsLevel1Member rvnc:DerivativeLiabilitySettlementMember 2014-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2014-12-31 0001479290 us-gaap:FairValueInputsLevel2Member rvnc:DerivativeLiabilitySettlementMember 2014-12-31 0001479290 rvnc:DerivativeLiabilitySettlementMember 2015-09-30 0001479290 rvnc:DerivativeLiabilitySettlementMember 2014-12-31 0001479290 rvnc:DerivativeLiabilitySettlementMember 2015-01-01 2015-09-30 0001479290 rvnc:HerculesNotesPayableMember us-gaap:PrimeRateMember 2015-01-01 2015-03-31 0001479290 rvnc:HerculesNotesPayableMember 2015-01-01 2015-03-31 0001479290 rvnc:HerculesNotesPayableMember 2015-01-01 2015-09-30 0001479290 rvnc:HerculesNotesPayableMember 2015-07-01 2015-09-30 0001479290 rvnc:EssexNotesMember 2014-07-01 2014-09-30 0001479290 rvnc:HerculesNotesPayableMember 2015-03-31 0001479290 rvnc:EssexNotesMember 2015-06-30 0001479290 rvnc:EssexNotesMember 2015-04-01 2015-04-30 0001479290 rvnc:EssexNotesMember 2014-01-31 0001479290 rvnc:EssexNotesMember 2014-12-17 0001479290 rvnc:EssexNotesMember 2015-06-01 2015-06-30 0001479290 rvnc:EssexNotesMember 2014-05-01 2014-05-31 0001479290 rvnc:EssexNotesMember 2014-01-01 2014-09-30 0001479290 rvnc:HerculesNotesPayableMember 2014-07-01 2014-09-30 0001479290 rvnc:EssexNotesMember 2013-12-20 0001479290 rvnc:HerculesNotesPayableMember 2014-01-01 2014-09-30 0001479290 rvnc:EssexNotesMember 2015-02-01 2015-02-28 0001479290 rvnc:EssexNotesMember 2014-02-28 0001479290 rvnc:HerculesNotesPayableMember 2011-09-01 2011-09-30 0001479290 rvnc:TwoThousandThirteenConvertibleNotesMember 2014-02-01 2014-02-28 0001479290 rvnc:TwoThousandThirteenConvertibleNotesMember us-gaap:ConvertibleDebtMember 2014-02-28 0001479290 rvnc:A2013NotesWarrantMember 2014-01-01 2014-03-31 0001479290 rvnc:A2013NotesEmbeddedDerivativeLiabilityMember 2014-01-01 2014-03-31 0001479290 rvnc:TwoThousandThirteenConvertibleNotesMember 2014-01-01 2014-03-31 0001479290 rvnc:TwoThousandThirteenConvertibleNotesMember us-gaap:ConvertibleDebtMember 2014-02-01 2014-02-28 0001479290 rvnc:TwoThousandThirteenConvertibleNotesMember 2014-02-28 0001479290 rvnc:TwoThousandThirteenConvertibleNotesMember 2013-10-31 0001479290 2014-02-01 2014-02-28 0001479290 us-gaap:WarrantMember 2015-09-30 0001479290 us-gaap:CommonStockMember 2015-09-30 0001479290 us-gaap:EmployeeStockMember rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2015-01-01 2015-09-30 0001479290 us-gaap:EmployeeStockMember rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-07-01 2014-09-30 0001479290 us-gaap:EmployeeStockMember rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2015-07-01 2015-09-30 0001479290 us-gaap:EmployeeStockMember rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-01-01 2014-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-07-01 2014-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001479290 rvnc:NonEmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2015-07-01 2015-09-30 0001479290 rvnc:NonEmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2015-01-01 2015-09-30 0001479290 rvnc:NonEmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2014-01-01 2014-09-30 0001479290 rvnc:NonEmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2014-07-01 2014-09-30 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2015-01-01 2015-09-30 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2015-07-01 2015-09-30 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2014-07-01 2014-09-30 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2014-01-01 2014-09-30 0001479290 rvnc:TwoThousandFifteenAtTheMarketIssuanceSalesAgreementMember 2015-09-30 0001479290 rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2015-01-01 2015-01-01 0001479290 us-gaap:EmployeeStockMember rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2015-09-30 0001479290 rvnc:TwoThousandAndFourteenInducementPlanMember us-gaap:CommonStockMember 2015-09-30 0001479290 rvnc:TwoThousandAndFourteenEquityIncentivePlanMember us-gaap:CommonStockMember 2015-09-30 0001479290 us-gaap:RestrictedStockMember rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2015-01-01 2015-09-30 0001479290 us-gaap:EmployeeStockMember rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2015-01-01 2015-01-01 0001479290 rvnc:TwoThousandAndFourteenEquityIncentivePlanMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001479290 us-gaap:EmployeeStockMember rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2015-01-01 0001479290 rvnc:TwoThousandFifteenAtTheMarketIssuanceSalesAgreementMember 2015-01-01 2015-09-30 0001479290 rvnc:TwoThousandAndFourteenEquityIncentivePlanMember us-gaap:CommonStockMember 2015-01-01 0001479290 2015-03-31 0001479290 rvnc:TwoThousandAndFourteenEquityIncentivePlanMember us-gaap:CommonStockMember us-gaap:DirectorMember 2015-01-01 2015-09-30 0001479290 rvnc:CommonStockWarrantsMember 2015-01-01 2015-09-30 0001479290 us-gaap:EquityUnitPurchaseAgreementsMember 2014-01-01 2014-09-30 0001479290 rvnc:UnvestedRestrictedStockAwardsMember 2014-01-01 2014-09-30 0001479290 us-gaap:StockOptionMember 2015-01-01 2015-09-30 0001479290 us-gaap:EquityUnitPurchaseAgreementsMember 2015-01-01 2015-09-30 0001479290 rvnc:CommonStockWarrantsMember 2014-01-01 2014-09-30 0001479290 rvnc:UnvestedRestrictedStockAwardsMember 2015-01-01 2015-09-30 0001479290 us-gaap:StockOptionMember 2014-01-01 2014-09-30 0001479290 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-10-31 2015-10-31 0001479290 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2015-10-31 2015-10-31 0001479290 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-10-31 2015-10-31 0001479290 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2015-10-31 2015-10-31 rvnc:monthly_payment iso4217:USD xbrli:shares xbrli:pure xbrli:shares iso4217:USD false --12-31 Q3 2015 2015-09-30 10-Q 0001479290 28062233 Non-accelerated Filer 1999-08-10 2005-04-19 Revance Therapeutics, Inc. 4000000 7000000 100000 144200000 P12M 0 -210000 0 0 237744 950978 39200000 1441000 0 400000 33 9800000 100000 66.75 1356000 0 598000 6176000 307000 3018000 10191000 949000 3971000 4217000 1054000 0 -1356000 0 0 67000 -426000 13000 60000 238000 649000 0 0 0 1250000 0 0 48000 148000 0 39000 76000 219000 0 5000 6490000 0 981000 0 80000 0 P3Y P3Y 500000 0.03 4574000 84000 -48000 9365000 126000 270000 0.1 131882000 0 50000000 210000 0 25000000 405594 58000 0 17977 131800000 0 28000

3149000

2731000

-364000

4145000

5990000

10000

435142000

452501000

2285000

557000

1728000

4611000

1644000

2967000

2590000

1182000

1408000

7314000

2879000

4435000

600000

400000

1198000

5000

148000

39000

153909

253625

6426

1877949

198662

308193

7945

2374055

192469000

165514000

172731000

143497000

166038000

126175000

72454000

51364000

2357000

72454000

53721000

12000

2000

166038000

126165000

72454000

53711000

22000

10000

3914000

187486000

171032000

90494000

183572000

-80538000

198662

409450

44753

0.001

95000000

23774465

24313222

23774465

24313222

24000

-13977000

-48705000

-19153000

-51372000

123982000

26200000

1095000

1637846

26206000

0.0325

2012-07-31

23700000

0.0985

0.115

0.10375

2015-03-31

2300000

6900000

800000

2600000

500000

3725000

3762000

1561000

1586000

1541000

1481000

-0.60

-2.70

-0.81

-2.17

-0.60

-2.70

-0.81

-2.17

1900000

1100000

2151000

P3Y9M

0.0109

0.0725

166038000

72454000

53721000

126175000

72454000

53721000

-60000

1541000

1481000

66000

126000

226000

4032000

-29000

-8300000

-8331000

-3524000

-477000

1178000

3096000

-83000

-7073000

1238000

-24000

2654000

134000

-500000

-152000

-75000

228000

10336000

390000

834000

9600000

271000

300000

276000

971000

264000

564000

100000

971000

300000

564000

14000

18000

68000

144000

P36M

16100000

23158000

192469000

165514000

10236000

11739000

1541000

1481000

2357000

14000000

234892000

15541000

-5369000

-56861000

-45951000

-39218000

-13977000

-48705000

-19175000

-51382000

-13977000

-48705000

-19175000

-51382000

-13977000

-48705000

-19175000

-51382000

832000

95000

1050000

3900000

2635000

13900000

38511000

18843000

50756000

-13825000

-38203000

-18768000

-50531000

49817000

1269000

5578000

5394000

5222000

32354000

1300000

3900000

1300000

3900000

2002-06-30

29000

6000

10000

-5000

-73000

-98000

-221000

6900000

7100000

1438000

762000

1100000

54087000

5444000

2849000

1624000

1604000

102672000

134600000

10154000

10100000

22000000

6750000

1402000

738000

19274000

19254000

22400000

146000

1768000

6230000

2652000

8600000

24261000

13016000

32573000

75000

35000

435000

400000

-258797000

-310179000

75000

308000

75000

225000

9831000

10800000

5300000

14250000

5827000

18183000

4611000

7314000

157286

0.572

0.425

0.615

0.575

0.464

0.574

0.735

0.508

0.613

0.724

0.505

0.627

0.025

0.001

0.016

0.025

0.001

0.019

0.020

0.001

0.017

0.020

0.001

0.015

404073

286984

145571

725838

90000

0.01

0.04

76286

114428

23740

35610

P8Y11M

P6M

P6Y2M

P9Y1M

P6M

P6Y1M

P8Y2M

P6M

P6Y1M

P8Y5M

P6M

P6Y3M

30.76

36.00

2500000

51364000

3737500

487500

352544

176369000

142356000

23331104

18009537

23755199

23625869

23331104

18009537

23755199

23625869

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gain and loss, and fair value (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td width="27%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,711</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,357</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Facility Lease</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2010, the Company entered into a non-cancelable facility lease that requires monthly payments through January 2022. This facility will be used for research, manufacturing, and administrative functions. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the Company extended the term of the Lease by thirty-six (</font><font style="font-family:inherit;font-size:10pt;">36</font><font style="font-family:inherit;font-size:10pt;">) months to January 2025. Under the terms of the lease agreement, the payments escalate over the term of the lease with the exception of a decrease in payments at the beginning of 2022; however, the Company recognizes the expense on a straight-line basis over the life of the lease.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense was </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,222</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Milestone-Based Commitments</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has one remaining obligation to make a future milestone payment to List Laboratories that becomes due and payable on the achievement of a certain regulatory milestone. The Company is obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.  The Company also has one remaining future milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> due and payable to Valeant Pharmaceuticals International, Inc. upon the achievement of regulatory approval for RT001 or RT002 (Note 3). </font></div><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain commitments from outstanding purchase orders primarily related to clinical trial development and other costs related to the Company’s manufacturing facility. These agreements, which total </font><font style="font-family:inherit;font-size:10pt;">$22.4 million</font><font style="font-family:inherit;font-size:10pt;">, are cancellable at any time with the Company required to pay all costs incurred through the cancellation date.</font></div><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. As of May 2015, the Company became subject to a securities class action complaint, captioned City of Warren Police and Fire Retirement System v. Revance Therapeutics Inc., et al, CIV 533635, which was filed on behalf of City of Warren Police and Fire Retirement System in the Superior Court for San Mateo County, California against the Company and certain of its directors and executive officers at the time of the June 2014 follow-on public offering, and the investment banking firms that acted as the underwriters in the follow-on public offering. In general, the complaint alleges that the defendants misrepresented the then-present status of the RT001 clinical program and made false and misleading statements regarding the formulation, manufacturing and efficacy of its drug candidate, RT001, for the treatment of lateral canthal lines at the time of the follow-on public offering. The complaint has been brought as a purported class action on behalf of those who purchased common stock in the follow-on public offering and seeks unspecified monetary damages and other relief.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. At this time, neither the outcome of this matter, nor an estimate of the maximum potential exposure or the range of possible loss can be determined. The Company believes that the class action lawsuit is without merit and intends to vigorously defend the action. Nevertheless, this litigation, as any other litigation, is subject to uncertainty and there can be no assurance that this litigation will not have a material adverse effect on the Company's business, results of operations, financial position or cash flows.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No amounts associated with such indemnifications have been recorded to date.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Outstanding</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">24,313,222</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding. In March 2015, the Company entered into an At-The-Market Issuance Sales Agreement, or the ATM agreement, with Cowen and Company, LLC, or Cowen, under which the Company may offer and sell our common stock having aggregate proceeds of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> from time to time through Cowen as our sales agent. Sales of common stock through Cowen will be made by means of ordinary brokers’ transactions on the NASDAQ Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by the Company and Cowen. Cowen will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions we may impose). The Company agreed to pay Cowen a commission of up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any common stock sold through Cowen under the ATM agreement. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">352,544</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the ATM agreement at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$30.76</font><font style="font-family:inherit;font-size:10pt;"> per share resulting in net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$10.1 million</font><font style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions, and other offering expenses. As of September 30, 2015, common stock for aggregate gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$39.2 million</font><font style="font-family:inherit;font-size:10pt;"> remained available under this facility, subject to certain conditions as specified in the ATM agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2014 Equity Incentive Plan </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Equity Incentive Plan, or 2014 EIP, automatically increased by </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of the Company’s common stock outstanding on December 31, 2014, or </font><font style="font-family:inherit;font-size:10pt;">950,978</font><font style="font-family:inherit;font-size:10pt;"> shares. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company granted stock options for </font><font style="font-family:inherit;font-size:10pt;">725,838</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">157,286</font><font style="font-family:inherit;font-size:10pt;"> restricted stock awards under the 2014 EIP, including a stock option grants for </font><font style="font-family:inherit;font-size:10pt;">90,000</font><font style="font-family:inherit;font-size:10pt;"> shares to non-employee directors. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">286,984</font><font style="font-family:inherit;font-size:10pt;"> shares available for issuance under the 2014 EIP. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2014 Inducement Plan </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">145,571</font><font style="font-family:inherit;font-size:10pt;"> shares available for issuance under the 2014 Inducement Plan, or 2014 IN.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.3170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the shares of common stock is based on the Company's stock price as quoted by the NASDAQ. Prior to the IPO, the fair value of the shares of common stock underlying the stock options had historically been determined by the Board of Directors. Because there was no public market for the Company’s common stock, the Board of Directors had determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, amongst other factors. </font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font><font style="font-family:inherit;font-size:10pt;">. The expected term for employees and directors is based on the simplified method, as the Company’s stock options have the following characteristics: (i) granted at-the-money; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable, or “plain vanilla” options, and the Company has limited history of exercise data. The expected term for non-employees is based on the remaining contractual term.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;">. Since the Company was a private entity until February 2014 with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;">. The risk-free interest rate is based on U.S. Treasury constant maturity rates with remaining terms similar to the expected term of the options.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Rate</font><font style="font-family:inherit;font-size:10pt;">. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend rate of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> in the valuation model.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Forfeitures.</font><font style="font-family:inherit;font-size:10pt;"> The Company is required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.8780487804878%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="51%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:66px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2014 Employee Stock Purchase Plan </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Employee Stock Purchase Plan, or 2014 ESPP, automatically increased by </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of the Company’s capital stock outstanding on December 31, 2014, or </font><font style="font-family:inherit;font-size:10pt;">237,744</font><font style="font-family:inherit;font-size:10pt;"> shares. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">404,073</font><font style="font-family:inherit;font-size:10pt;"> shares available for issuance under the 2014 ESPP. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.09756097560975%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the shares of common stock is based on the Company’s stock price as quoted by the NASDAQ. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font><font style="font-family:inherit;font-size:10pt;">. The expected term is based on the term of the purchase period under the 2014 ESPP. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;">. Since the Company was a private entity until February 2014 with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;">. The risk-free interest rate is based on U.S. Treasury constant maturity treasury rates with remaining terms similar to the expected term. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Rate</font><font style="font-family:inherit;font-size:10pt;">. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend rate of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> in the valuation model.</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense related to options and restricted stock awards granted to employees and nonemployees and the employee stock purchase plan was allocated as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.1219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.65853658536585%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="75%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains and Losses on Available-for-Sale Securities</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassifications from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="77%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="21%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Liability Associated with the Medicis Settlement</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. These liabilities, consisting of the Medicis settlement, are considered Level 3 instruments, while the assets, consisting of money market funds and U.S. government agency obligations, are considered Level 1 and Level 2 instruments, respectively. The fair value of these instruments was as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liabilities associated with the Medicis settlement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liabilities associated with the Medicis settlement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the U.S. government agency obligations are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. The Company did not transfer any assets or liabilities measured at fair value on a recurring basis to or from Level 1 and Level 2 during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="77%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="21%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Liability Associated with the Medicis Settlement</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the derivative liability resulting from the Medicis litigation settlement, specifically the derivative related to the Product Approval Payment (Note 3), was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment. The significant unobservable inputs used in the fair value measurement of the Product Approval Payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses fair value measurements to record fair value adjustments to certain financial and non-financial assets and liabilities to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="9%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="71%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest expense by cash and non-cash components is as follows (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash related interest expense (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(971</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense — debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense — warrant and derivative related debt discounts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense — convertible notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of 2013 Notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,331</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective interest on financing obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash capitalized interest expense (2)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total interest expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash related interest expense includes interest payments to Hercules Notes Payable, Essex Notes, and Financing Obligations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Expense</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, includes cash and non-cash components with the non-cash components consisting of (i) interest recognized from the amortization of debt issuance costs, which were capitalized on the Condensed Consolidated Balance Sheets and are generally derived from cash payments related to the issuance of convertible notes and notes payable, (ii) interest recognized from the amortization of debt discounts, which were capitalized on the Condensed Consolidated Balance Sheets and derived from the issuance of warrants and derivatives issued in conjunction with convertible notes and notes payable, (iii) interest recognized on the 2013 convertible notes, or 2013 Notes, which was not paid but rather converted into shares of common stock, (iv) interest capitalized for assets constructed for use in operations, (v) interest related to the extinguishment of debt, which is classified as a loss on debt extinguishments, and (vi) effective interest recognized on the financing obligation. The capitalized amounts related to the debt issuance costs and debt discounts are generally amortized to interest expense over the term of the related debt instruments.</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest expense by cash and non-cash components is as follows (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash related interest expense (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(276</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(971</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense — debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense — warrant and derivative related debt discounts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense — convertible notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of 2013 Notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,331</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective interest on financing obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash capitalized interest expense (2)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total interest expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash related interest expense includes interest payments to Hercules Notes Payable, Essex Notes, and Financing Obligations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Short-term investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. All of its investments are classified as available-for-sale and carried at fair value, with the change in unrealized gains and losses reported as a separate component of other comprehensive income (loss) on the Condensed Consolidated Statements of Operations and Comprehensive Loss and accumulated as a separate component of stockholders' equity on the Condensed Consolidated Balance Sheets. Interest income, net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of investments, if any. The cost of securities sold is based on the specific-identification method. The Company monitors its investment portfolio for potential impairment on a quarterly basis. If the carrying amount of an investment in debt securities exceeds its fair value and the decline in value is determined to be other-than-temporary, the carrying amount of the security is reduced to fair value and a loss is recognized in operating results for the amount of such decline. In order to determine whether a decline in value is other-than-temporary, the Company evaluates, among other factors, the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, and its intent and ability to hold the security to maturity or forecasted recovery. The Company mitigates its credit risk by investing in money market funds and U.S. government agency obligations which limits the amount of investment exposure as to credit quality and maturity. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents and Investments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's cash equivalents and investments consist of money market funds and U.S. government agency obligations, which are classified as available-for-sale securities.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gain and loss, and fair value (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td width="27%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,711</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,357</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the remaining contractual maturities of available-for-sale securities were less than two years. </font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no significant realized gains or losses on available-for-sale securities for the periods presented. No significant available-for-sale securities held as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> have been in a continuous unrealized loss position for more than 12 months. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the cost basis of the investment will be recovered. The Company believes it has no other-than-temporary impairments on its securities as it does not intend to sell these securities and believes it is not more likely than not that it will be required to sell these securities before the recovery of their amortized cost basis. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in fair value.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standard Update No. 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40)</font><font style="font-family:inherit;font-size:10pt;">, which will require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year of the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The guidance defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. The guidance is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Company’s financial statements. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.65853658536585%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="75%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains and Losses on Available-for-Sale Securities</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassifications from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</font><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.35477582846003%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="69%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,374,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,877,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares expected to be purchased on December 31 under the 2014 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,945</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,426</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> (in thousands, except for share and per share amounts):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended <br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders, basic</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share attributable to common stockholders</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to common stockholders:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,755,199</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,331,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,625,869</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,009,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,755,199</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,331,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,625,869</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,009,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense related to options and restricted stock awards granted to employees and nonemployees and the employee stock purchase plan was allocated as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.1219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of these instruments was as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,721</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liabilities associated with the Medicis settlement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liabilities associated with the Medicis settlement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,222</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.3170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.8780487804878%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="51%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.09756097560975%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant accounting policies are described in Note 2 to the consolidated financial statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">. There have been no changes to the Company’s significant accounting policies during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, except as described below.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div><div style="line-height:120%;padding-top:24px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investment securities with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents may include cash on deposit, money market funds, and debt securities.</font></div><div style="line-height:120%;padding-top:24px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Short-term investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. All of its investments are classified as available-for-sale and carried at fair value, with the change in unrealized gains and losses reported as a separate component of other comprehensive income (loss) on the Condensed Consolidated Statements of Operations and Comprehensive Loss and accumulated as a separate component of stockholders' equity on the Condensed Consolidated Balance Sheets. Interest income, net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of investments, if any. The cost of securities sold is based on the specific-identification method. The Company monitors its investment portfolio for potential impairment on a quarterly basis. If the carrying amount of an investment in debt securities exceeds its fair value and the decline in value is determined to be other-than-temporary, the carrying amount of the security is reduced to fair value and a loss is recognized in operating results for the amount of such decline. In order to determine whether a decline in value is other-than-temporary, the Company evaluates, among other factors, the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, and its intent and ability to hold the security to maturity or forecasted recovery. The Company mitigates its credit risk by investing in money market funds and U.S. government agency obligations which limits the amount of investment exposure as to credit quality and maturity. </font></div><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses fair value measurements to record fair value adjustments to certain financial and non-financial assets and liabilities to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="9%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="71%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standard Update No. 2014-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40)</font><font style="font-family:inherit;font-size:10pt;">, which will require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year of the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The guidance defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. The guidance is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Company’s financial statements.</font></div></div>

EX-101.SCH 13 rvnc-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Cash Equivalents and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - The Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - The Company and Basis of Presentation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Convertible Notes, Warrants, and Related Derivatives link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Convertible Notes, Warrants, and Related Derivatives - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Equity - Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Equity - Schedule of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Interest Expense link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Interest Expense - Summary of Interest Expense by Cash and Non-Cash Components (Detail) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Interest Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Medicis Settlement link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Medicis Settlement - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Notes Payable and Financing Obligation link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Notes Payable and Financing Obligation - Essex Capital Notes (Detail) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Notes Payable and Financing Obligation - Hercules Notes Payable (Detail) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Notes Payable and Financing Obligation - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Notes Payable and Financing Obligation (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Warrants - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 rvnc-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 15 rvnc-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 16 rvnc-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Investments, Debt and Equity Securities [Abstract] Cash Equivalents and Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Other Income and Expenses [Abstract] Cash related interest expense Interest Expense, Debt, Excluding Amortization Non-cash interest expense Interest Expense, Debt [Abstract] Non-cash interest expense — debt issuance costs Interest Expense, Debt Issuance Costs Interest Expense, Debt Issuance Costs Non-cash interest expense — warrant and derivative related debt discounts Interest Expense, Warrant and Derivative Related Debt Discounts Interest Expense, Warrant and Derivative Related Debt Discounts Non-cash interest expense — convertible notes Interest Expense, Convertible Notes Interest Expense, Convertible Notes Loss on extinguishment of 2013 Notes Gains (Losses) on Extinguishment of Debt Effective interest on financing obligation Financing Interest Expense Non-cash capitalized interest expense Interest Expense Capitalized Interest Expense Capitalized Total non-cash interest expense Noncash Interest Expense Noncash Interest Expense Total interest expense Interest Expense Earnings Per Share [Abstract] Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Restricted cash, current portion Restricted Cash and Cash Equivalents, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Long-term investments Long-term Investments Restricted cash, net of current portion Restricted Cash and Cash Equivalents, Noncurrent Other non-current assets Other Assets, Noncurrent TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] CURRENT LIABILITIES Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accruals and other current liabilities Accrued Liabilities, Current Financing obligation, current portion Financing Obligation, Current Financing Obligation, Current Notes payable, current portion and net of discount Notes Payable, Current Total current liabilities Liabilities, Current Financing obligation, net of current portion Financing Lease Obligation Noncurrent, Net of Current Portion Financing Lease Obligation Noncurrent Derivative liabilities associated with Medicis settlement Derivative Liability, Noncurrent Deferred rent Deferred Rent Credit, Noncurrent TOTAL LIABILITIES Liabilities Commitments and Contingencies (Note 9) Commitments and Contingencies STOCKHOLDERS’ EQUITY Stockholders' Equity Attributable to Parent [Abstract] Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of September 30, 2015 and December 31, 2014, respectively; 24,313,222 and 23,774,465 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) TOTAL STOCKHOLDERS’ EQUITY Stockholders' Equity Attributable to Parent TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity Fair Value Disclosures [Abstract] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Money market funds Money Market Funds [Member] U.S. government agency obligations US Government Agencies Debt Securities [Member] Derivative liabilities associated with the Medicis settlement Derivative Liability Settlement [Member] Derivative Liability Settlement [Member] Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total assets measured at fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Total liabilities measured at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Equity Option [Member] Common stock warrants Common Stock Warrants [Member] Common Stock Warrants [Member] Unvested restricted stock awards Unvested Restricted Stock Awards [Member] Unvested Restricted Stock Awards [Member] Shares expected to be purchased on December 31 under the 2014 ESPP Equity Unit Purchase Agreements [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock equivalents excluded from computation of diluted net income (loss) per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Income Statement [Abstract] Revenue Revenues Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative Selling, General and Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Interest income Investment Income, Nonoperating Interest expense Change in fair value of derivative liabilities associated with the convertible notes Gain (Loss) on Derivative Instruments, Net, Pretax Changes in fair value of derivative liabilities associated with Medicis settlement Gain (Loss) on Derivative Instruments, Contract, Net, Pretax Gain (Loss) on Derivative Instruments, Contract, Net, Pretax Change in fair value of common stock warrant liability Fair Value Adjustment of Warrants Change in fair value of convertible preferred stock warrant liability Change in Fair Value of Convertible Preferred Stock Warrant Change in Fair Value of Convertible Preferred Stock Warrant Loss on settlement of preferred stock warrant Gain (Loss) On Settlement In Exchange Of Preferred Stock Warrants Gain or Loss on settlement of warrants to purchase preferred stock upon exercise of put option. Other expense, net Other Nonoperating Income (Expense) Net loss Net Income (Loss) Attributable to Parent Unrealized gain on available for sale securities Available-for-sale Securities, Gross Unrealized Gain Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net loss attributable to common stockholders (Note 12): Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Basic Net Income (Loss) Available to Common Stockholders, Basic Diluted Net Income (Loss) Available to Common Stockholders, Diluted Net loss per share attributable to common stockholders: Earnings Per Share, Basic and Diluted [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted-average number of shares used in computing net loss per share attributable to common stockholders: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Warrants and Rights Note Disclosure [Abstract] Warrants Warrants [Text Block] Warrants [Text Block] Debt Disclosure [Abstract] Notes Payable and Financing Obligation Debt Disclosure [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Hercules Notes Payable Hercules Notes Payable [Member] Hercules Notes Payable [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Prime Rate Prime Rate [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Proceeds from notes payable Proceeds from Notes Payable Notes payable maturity Debt Instrument, Maturity Date Interest rate, percentage Debt Instrument, Interest Rate, Stated Percentage Plus (minus) difference from the prime rate (percent) Debt Instrument, Basis Spread on Variable Rate Notes payable repayment start date Debt Instrument, Date of First Required Payment Notes payable repayment terms (payments) Debt Instrument, Number of Monthly Payments Debt Instrument, Number of Monthly Payments Payment of notes payable principal and interest Debt Instrument, Periodic Payment Prepayment charge on end of term payment Long Term Debt Prepayment Long Term Debt Prepayment End of term payment Debt Instrument Final Payment Amount Debt Instrument Final Payment Amount Warrants issued to purchase shares Warrants Issued For Purchase Of Stock Shares Warrants Issued For Purchase Of Stock Shares Exercise price per share (usd per share) Exercise Price Per Share Exercise Price Per Share Debt discount amortized Amortization Of Debt Discount Amortization Of Debt Discount Debt issuance costs Debt Issuance Cost Convertible Notes, Warrants, and Related Derivatives Convertible Notes [Text Block] Convertible Notes Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Net Loss per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Total stock based compensation expense Allocated Share-based Compensation Expense Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Debt Convertible Debt [Member] 2013 Notes Two Thousand Thirteen Convertible Notes [Member] Two Thousand Thirteen Convertible Notes [Member] 2013 Notes, Warrant 2013 Notes, Warrant [Member] 2013 Notes, Warrant [Member] 2013 Notes, Embedded Derivative Liability 2013 Notes, Embedded Derivative Liability [Member] 2013 Notes, Embedded Derivative Liability [Member] Principal amount Debt Instrument, Face Amount Convertible debt Convertible Debt Shares issued upon debt conversion Debt Conversion, Converted Instrument, Shares Issued Shares available for purchase under common stock warrants Class of Warrant or Right, Outstanding Shares issued upon exercise of warrant Stock Issued During Period, Shares, Exercise of Warrants Stock Issued During Period, Shares, Exercise of Warrants Fair value of embedded derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability Gain (loss) on debt extinguishment Interest expense Interest Expense, Debt Amortization of debt discount Amortization of Debt Discount (Premium) Interest expense, excluding amortization of debt discount Commitments and Contingencies Disclosure [Abstract] Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Amortization of premium on investment Accretion (Amortization) of Discounts and Premiums, Investments Amortization of discount on debt and capital leases Amortization of debt issuance cost Amortization of Financing Costs Change in fair value of derivative liabilities associated with the convertible notes Changes in fair value of derivative liabilities associated with Medicis settlement Change in fair value of common stock warrant liability Change in fair value of convertible preferred stock warrant liability Revaluation Of Convertible Redeemable Preferred Stock Warrants Revaluation Of Convertible Redeemable Preferred Stock Warrants Loss on settlement of preferred stock warrant Extinguishment of Warrant Liability Upon Exercise of Put Option Extinguishment of Warrant Liability Upon Exercise of Put Option Loss on extinguishment of 2013 Notes Stock-based compensation expense Share-based Compensation Interest for 2013 Notes and Essex Notes upon issuance, non-cash Capitalized interest Effective interest on financing obligation Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other non-current assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable, Trade Accruals and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Payments against Medicis liabilities Increase (Decrease) in Derivative Liabilities Deferred rent Increase (Decrease) in Prepaid Rent Deferred revenue Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of investments Payments to Acquire Investments Change in restricted cash Increase (Decrease) in Restricted Cash Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from issuance of common stock, net of deferred follow-on public offering costs Proceeds From Issuance of Follow-On Offering Proceeds From Issuance of Follow-On Offering Proceeds from issuance of common stock, net of deferred initial public offering costs Proceeds from Issuance Initial Public Offering EX-101.PRE 17 rvnc-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 18 R39.htm IDEA: XBRL DOCUMENT

Warrants - Additional Information (Detail)	Sep. 30, 2015 shares
Common Stock
Class of Warrant or Right [Line Items]
Common stock warrants	198,662
Convertible preferred stock warrants
Class of Warrant or Right [Line Items]
Number of shares underlying warrants	0

EXCEL 19 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`,6):D^Q4T!0%<2K MTMWDT3N>>Y-QSJ:G=T^.PFAENCY,BS9&=\)8J%LR*I3649^4F?5&Q73KY\RI M>J'FQ,1DA&^7BE3&K!5AT;A/61EUEG_V,8G"?5A)8HFJX, M\:FCL,U_K;PZ7]!,/73Q1\8O[Z[TU`TUH=7NQ>IRE;J$]-NT2&KXEL/FPJ^2 M:9.'YOKYAQ7Y_I?/LO$2EZ:[\.I1;Q@L=S:F?"Z-TOVV43U:O[BW=O&?VX3R M4S74C)U/A3[J+;LD%=\D-;#4^D_>KSNEMIZ^99@+=_A1M,I3YRY+D.UY\-?1`#&TX[A,2/<@B0'!(D1P628Q\DQP%(CD.0'$<@.8Y![% M````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^#*G*_=IT MJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26 MM#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O] MC^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P"4$L#!!0` M```(`,6):D=Z'EWBQ0$``&<<```:````>&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'/%V%707F`.C-C:(N`53=LV[Y`!(8@R$6QJ[9OWY1%12\^ MZ@+I;!(ED<;_ZI/E+-I8SA_#J4J'KHWUH8^3M^;4QOGX?EG4*?5SY^*F#DT5 M;[H^M./773G93ESP^6<8K7X.7NRWBZ+8;V58O)<#?N0 MEL5K-QQC'4**[GR3FW&!\?-['_ZS?+?;'3;AH=N\-*%-?U2XKP4*EP_2?)!2 M@BP?9)0@GP_RE*!I/FA*"9KE@V:4H-M\T"TEZ"X?=$<)NL\'W5."I`0REIPD MA#5':P%<"\=K`6`+1VP!9`O';`%H"T=M`6P+QVT!<`M';@%T"\=N`7@+1V\% M>BM';P5Z*VFOC3;;'+T5Z*TBM'+T5Z*TBM'+T5 MZ*TAM'+T-Z&VDLQ)T6,+1VX#>QM';@-[&T=N`WL;1VX#>QM'; M@-[&T=N`WL;1VP.]/4=O#_3V'+T]T-MS]/9`;T\ZZT:'W1R]/=#;<_3V0&_/ MT=M?Z!WK:@C;IS0&ULO5??;]HP$/Y7+)XZ:30TL&Y#-!*E5$-J5R18^VR2`ZPF=FI? M4-E?OW,":2A)1'A87^J<[[M?W]TE#*3I]*=:Q:!1@&'O42A-GX0WK35BW'<< MXZ\AXN:25"3=+I6..-*C7CEJN10^W"D_B4"BXW8ZUPZ\(\@`@G:<&VUY`^ME M&,>A\#D*);U'X6MEU!+9^-V'<.!\5D@19'D&?J(%;KU.IE,4I3HSGX MDH<&,JT/8:HS4E',Y=;)GAZ$?#5_XKFZXPA%U.%%9GW--03D],!Z+DQU?FTI MS]!B1VLN5Q`4=8\O][5X!FULIE?N98?^\A+LY9EMX(&0JRD7VGB##?8WX*/2 M.YHV>"Y+@?(MZ>9Y3O&9%EMP`_9XT]IP+;C$%C/B+SVZKR]* MOYHU`)J!DPO38U&W>!8]KW>=:M#I4-/),_-V93O(VTKF`D,P3\LIU_B?2I'F MM"]$[[I5R'YO@G$9L+%$:D`5(+V+C*4Z`XV?@M$1N:?1N[C6DB M-V"P$G-/_<6>>9@`>P1N$IVE7:K[6R'MQRG?\D4(J?%[(8D%:E/VM`BKRKJQ M.]`B4OQ7]L*UII3IQ,M+-)$(5$"[&6-+8X7A*!(8Y7F2(Z1`@,*!\O#W?DLO M;=EP6YXV('M0QC#:8RS=?&R(J,4B05N("I87!MX2.Q_C365!:WOAZF=SDMU. M$Y+9Q=PF<`;9KGL2<7L'7YHSR"YJ:*JW6\N7>]U\DMWO)TXE:[-A$`B[_WC% M.-2R5\YX%7MM-J,]'S3%V)YKSGBWG/%Z3/EVKL?TFJ^1[K?3NG&7?#9PDS-Z MLMTBG8_=/@$``&D#```1````9&]C4')O<',O8V]R92YX M;6S-DTU/PS`,AO\*ZKU+LP&3HJX'0)R8A,00B%N6>%M8\Z'$4]=_3Y9U+0,N MNW&K:[^/7\=)*1P3UL.SMPX\*@A7>UV;P(2;91M$QP@)8@.:AU&L,#&YLEYS MC*%?$\?%EJ^!C(OBEFA`+CER<@#FKB=F52D%$QXX6M_AI>CQ;N?K!)."0`T: M#`9"1Y1DU:O9&MN8D@SZJHR.:QYP;J5:*9!W[5#V.Q4[(W@=CG*0??OT]T\/ M*4.RKG(?5%_5-,VHF:2Z.#`E[_.GEW0VN3(!N1$054$Q;!W,LE/GM\G]P^(Q MJ\8%O.5367(1+F&_B!`N[Y2<(O!S4"=-EVT+;6"]#E>[7$!U>3ES9VOKVF/H1 MG;VJZ@M02P,$%`````@`QHEJ1YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B- M;'EDD81_OTV23;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6 MN[!3+UES@6QHO M(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF( MM/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22("" MR7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2 M`Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]! MMHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$ M^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+- ME`L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9-AIRM1:! MMG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X M2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F] MA%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E M[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I M4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y"M-2D&_# M^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^8 M9Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H M<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;05 M3L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X M$G:V#P(RN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3 M:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ= M+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^ MP7V*BH`1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(& M8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4 M#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04````"`#&B6I' MMSFNXV<"``#,"P``#0```'AL+W-T>6QED<,U0-18FY7LF%9$CIJ2R\JI089979Q*@W M\OV)QQ#A,`YYS:9,52`5-5<1'&\@X/;?B0Q'\/GB\^]:J-M/P(V#+X.!_WQY MV\&V&NN-0YSP=O;'4$'Q&'U`A:(:O_`N*>""@F4+A^MP"(< M,>P\[A`EB20&S!$C=.7@D0%LQ35^C'`A;6P7H1]GZ+>19)%$T&]^;P^7M.QV M,,JJ6!OF>]2 M>.R1WU/3Z;/6JM$E^-'I.3JXA1YJEF`YM7^+ATOZ>K7_RNS7"7LR/[9JCI!P M@N28=GRVTB;G*^U]:NHDTJ[/5]K-?TKSFJ;5Z8Q;?7&#@J0F5!&^UH#,2^;! MZ*9;+:OMB9HS6[;MT*XJE.BG]58439;A'-54/9*%4'8Q@JU];^0'DXW7;$,1 MP=;^B3-2,_NM%V($VB+AI%ZH;M(TTZUJ3K/ M)C'%JF-G;(>6^?5SG$![4CP1/)&$^,OQ\>?+^6(GK]J\++1^(6^E5'9BIM'* MN6HR&-A\Q4MF_]$55_#?4IN2.;@USP.]7(J&2^:$5G8E M*AMM:?80FJT,9X5=<>Y*V<)*)E3T]8N=+(7D3]Q8`!-65?>LY-/H349$,NMF MA7"\F$8IW.I7WGE@ZNJJ%M+?C(:C:.!ANZX^&)+K@K>PQY6P/[9_1*3@2U9+ M]PC![KX[C6*:4CIN&?ZU)\%?+0;Z!X3E3JSY(UM,HV%$6.WTK9".FQOF^+]& MUY50S\"*R%(8ZS+?W>;-4BA1BE\^;KBS*_WZGS;BEU:.R2PW6LJFE?^C:01? ML.]/($8G\LZ+CBW^]R,QC<9#`*Z%%0LAA=M,H^9:N-.G_N"*J2QE!53FR;?5\R*!O-@N.U$-$:@\3XHJ\N2F8UOFHEG)6"R,AC#RSS7 M-8PA`ITAT-D^Z(X7(H<8,NZ<;+J%VIZCMN>!M$#?R>QG+=9,-OGP79JK-4S3 M3Z`+!+K8!]TR8<@3DS4G=YS9VK3YQ>X-L7S#?<2]=MR2![9A8'\3R*U0X`O, M2/)](3&JXW%8Y+6?ZN\B;@M MEC<.VEN6PI7OB86P'/2&0Y]X)S58WCA@[RYXW`9[&@=$]:/J-K@%%C(.&'D/ M5]^TM:3BAF0K9CBY=,Z(1>W\D&`45C(..)G5"\M_UGY1FJT_BX"=C`-2]LZ, M^`*CL)5Q0,M>O^D0KVA83QK0\P^&DY-'GQS<08KUI`$]>TVG%*,Z"^T!>N[" M^0M#L*?T6$_)"49A4VG`U-:Z8!186!H0ME<_V-D1"IM,`R;W+M+T#*.PR?2@ MU96X`F^PV.OD"*\!Y>=])1EA%+8]"=B^ M-W&W^6[7O3E&8=N3@.W]T_<4H[#M2<#V7E1RCE'8]B1@^RXQG>GR<2[%*&Q[ M$K!]NZB$09T#;HIM3P.VOZ.0]I?6UF75E$48A6U/`[:_HYHI5X,2?L-R.G\Y M7;#.02'%MJ,T\@4>U'*UE-?P[+OZIEE3!K7D767X]3=02P,$%`````@`QHEJ1V"` MRNE``@``C@<``!@```!X;"]W;W)KZUDS@!U6#6=D+W[=^%NPWH-(2;3B=XU[/AE[JO@#I>]J\O.T\4-5`R;X*%0*)!\W MO,>$J$R2_-*/]"[8] M)"KAD1*N?[WCE0O:#!;?:]"'>=:M?O;F31Q9F]L`K0&.!IC-&B)KB$8#B'6G MIC+=UP\D4%DPVGN\0^K?!FLI9RJ)S.QQG4VVQ'5PJZ*W,BR"FTIC%7"BV!D% M&!6!S.T$0-]EA]H.OP?LC2):!D0#()IV$&E[O&R/!WL\M[5ZK63U`@6Z*V9\@G_ED5@,?6+T@K90GU\?LK+HD,7_`NQ2]UR[T"%/(3UB7FF5&!9 M1/@D2ZKDY3A."#X+-0JE0.V3,SEL=4P'B!&2?_/D!++)Z(-A?SX:?% M*UD\%FRO=?.C/1G3!3^K\MP^;DY==WD(P_;Y9*J\_5!?S+G_YE@W5=[UA\U+ MV%X:DQ_&HJH,48@HK/+BO-EMQW-?F]VV?NW*XFR^-D'[6E5Y\VMOROKZN(&- M._&M>#EUPXEPMPVGND-1F7-;U.>@,6NR MNORW.'2G/JW8!`=SS%_+[EM]_=O8/NBAP>>Z;,?/X/FU[>K*E6R"*O])V^(\ M;J_T32)LF;\`;0%.!:#8`FD+Y+N"D)*-_?J4=_ENV]37H+WDPZ\-#SW>#(WT M+0?MV%K?I78\^7$X^[9#W(9O0SL6P1FRM\@RD5E"3DC87]\;`ET(.0^!5*_N MUTM7K^;UDNKU;<1X1,[4"4)2H5*U3&5$00Q"XOTPRAM&49CH]C)Z'H80#3)2 MRU1&E+B?0WMS:,H1,SD(D9H)04BL[Z>(O"DB2I$P*0B!2'"#X:`UDR3V)HDI M2-,D-/2"24,(I*BY@9FH>,7(I-XL*64!)DMJ M[W#-C4NZ=L*"\.883_=!D`EB&268D9$*SS.G)8!E7`WE*.T6O'7AGYW(EC]AD&1;$BG\Y]"]6D?2IWJVZYLS>,=$RD_W)+">9 M-'R[["9YJA5^0+\ZT0J/&;2]99!;=__)+"?Q:Q-)=HHSE6,T:L'>`Y%;/H!: M\1B`?G\ATY_J;E@1.FE."/9"R"5-3&*_ MVTHU&C;PO0IJZ>+5)Q-%M]CY-V-;6?'P7U)L]&V M;,"C`=\,8;QIB$9#],F`')GMZQM1I,@%'SS9$_.SP[V6"Q.BDSUITW1+TA8? M3/5:)'&.KB9GE."9Y-%)\+JB'!7138+T_HL0>(*(YA#8023_]T>3/Y[[(^=/ M/R+>64GGFG"28!<$X;JJ7%*MLL2+++%CR3[NDLQ9G.0^">RS+BQ7A*M$R2)1 MXHCN-HBC)&7X2 M<6X[Z1VYTJ?+'H6:K<%A5J9::;GPMT#;J%X/]UJMZNU^`M0 M2P,$%`````@`QHEJ1]!4IUR>!```;1@``!@```!X;"]W;W)K6#9K*(0?[.D7Y)T2\IJU/=_&AW6G?!KZH\M$^+7=<='\.P?=WI MJF@?ZJ,^]-^\U4U5=/UK\QZVQT87VS&H*D-&2!Q6Q?ZP6*_&LJ_->E5_=.7^ MH+\V0?M1547SST:7]>EI01>VX-O^?=<-!>%Z%4YQVWVE#^V^/@2-?GM:/-/' MG"4#,A)_[_6IO7@.AL:_U/6/X>7/[=."#&W0I7[MAA1%__&I4UV60Z:^YI\F MZ;G.(?#RV6;_,LKMF_]2M#JMR^_[;;?K6TL6P5:_%1]E]ZT^_:&-!C$D?*W+ M=OP=O'ZT75W9D$50%;_@>RXJN6*^:^A2TQV*83_2QQYLA29\Y:,=L?:>U8^'S4/JY MCLDJ_!SR&(1=(!N#T/M(!LB9"/OZG8U@"U<-;`QG]RM(@8@1))M-DO^6Y&XS MN6TFO^PK#O%\/CZR\=%E?`3QT743Y8@(^DLXC&2",(4P.#"=J7HUP M]H8`-6(^/G;V1@SQ\74;Q65O`$(YH0B5`J5B0NY#&4"<"E7*J4J!*(:J4:8N*D+:DAN() MJ@LH0:1`!CX'BBM!/48K<>I*0%>"Z`)D297$Y*<6X^KVS^Y*F<$$$9PBT@S6 M)R,>RPTE3G%C<;]4(#V],0PJS3`T0G1-#`+E%O)8P2\K=@L`P ML15W8QB*K1F&P=;4S#*H)F"6_?+NH:1W"!+1H7' M"DB%6Y%P;BBN%8EY1;-(-H_D!ND5>5@5=6\L*+BXQ'86AD$%S2+9/)(;I/<% MX3/IW'L*"@XNL4V%898)NI(;"',HRS"&&92EI(\]N?<4%/Q;8IL*PRQI0K$) MFDX<3[!>RBPG!I_&Y!DN4I)X['"I>W=!P<8EMKTP#$-:DQH&G8J`4'0NWJ:Y M?TQS;R@8^+?"-A2&&49,8(OZQ,V,F.7Z$<.<,;>'V8G[7>'5 MB=9R#H57IUK+^2J,W+,`?%5%'AG4/O1^4GH/B M^U1F*?9`Y7TL/V/20ZG;;9D]?F-*X_^C-/92&OLIC?^+4NF>%6!YRB>#V_$8 MN(K"',\PC$LA:((X1SJ1G%-*L,/91,9,*.RPFS-[BBG4LWO5?1?.^/[3!2]UU=35>U[[5=:?[1I.'7L).%]OII=1O MW?`HA]&`VW!XZ>JCO=R?_L.P_A=02P,$%`````@`QHEJ1^IT)"D@!@``AB,` M`!@```!X;"]W;W)K^GK:;YJW;[X[UU].B?3LADO M?-L]OW3#A?5VLY[*/>X.];'=-K\?(O5W_I>"?MQS*'C^/4;_?:QN;_^^ M:NNRV?^S>^Q>>K=JN7BLGZJW??>M>?^CICK8(>!#LV_'OXN'M[9K#K'(1%.T;KJ]2.%^^&JS^VN=JL?PQQ2`)GDB)(]*18]\'9.\"2 M*PYC<;A^@S(H',S?`>,=\+P.&.J0X-#$\N:\O!G+9_ZSQ6R4'$,E@F1E-7JX M+BM)9GRF[+P;R];&AMHDM(9C:^-">?QLTY[7)DBT]>ZZJ(PBE]"N&>LD"TZ, MX"1(T`F:,FC4O`O/NO#!A153Z6 MMT)9,G>.%QJXF42DM>@@A`F@=)Y!*Z+O#(!45> M).:2""3ZPR67KSN9@/LIMP#*Y10FA.`Y"00XJ?.39J51ZOQ1!9&*DG,8M$*_!&0G"466,2!B;R#$4@0]*<3:+^3LI+J,#+I/2Z&QZAB#2X MI6D;YW/2\E?-=2L\0)$212W-VA@7X\X[05=..G0)>03RJW&,Y$O9G>#!AP0^ M+<$&Y\$7XZ#V/L4-3SXDJDEY:8'S^6*,H\!E*6YX]F%<6$OLPWGVD<1E-F4< M\/!#@I^6X(=37FFE=()D"68,GS,:%6=&![$A@(($ MXBBRUHC/*<@`C4_9JC4\C`U!5%J:%"1:>67EYT7!/-H4(AN>R(:(#!*1HRC3 MY]M_C*6@PUPG)$N&Q[(AXDJ+]()$N3+2=G,98_G,^`066CXEM<1F2$A)+8]3 M2S@5E]$DLN+N.(GRE'T;"WQ]B*>0D"99GH"6"(@2`4DD;<67I/$IN\J6)Z"- MNXT2`4DDM7]I+W)?M(8*>P\_6(.%I9XE0XAX2 MB;S(A:`Q-DM`K^.34$>@$W>0W/S+HAC'F`1(.9Z8CH@I38&%NTPM&2]Q,R!/ M6*8Z/@%U!$SI55WAYE\6D<0FI#2.YZ[#F*-)3N;?%;F8G*8\(!Z[+J:+%]C] M]![=L2^+/KU#)XF_'$/KL^,-A_KT/![[:!>IF.WFS_!U!+`P04````"`#&B6I'KCFUTI\!``"Q M`P``&````'AL+W=O<.3!0C&C?7`?@ MR;M6QAUIYWU_8,Q5'6CA[K`'$_XT:+7P(;4M<[T%42>25HQGV0/30AI:%JGV M8LL"!Z^D@1=+W*"UL/_.H'`\TAU="J^R[7PLL+)@*Z^6&HR3:(B%YDA/N\,Y MCX@$^"UA=)N81.\7Q+>8_*R/-(L60$'EHX((RQ4>0:DH%!K_G34_6D;B-E[4 M?Z3=!O<7X>`1U1]9^RZ8S2BIH1&#\J\X/L.\A?LH6*%RZ4NJP7G4"X42+=ZG M59JTCM.?[]E,NTW@,X%_(K"I4;+Y)+PH"XLC<;V(L]L=`MQ&D:!,7%(+#ETJ MGF+U6NYR7K!K%)HQ?(,YSY@5P8+ZS1:! M?"N0W][B%G->,/FG)FQSIAILFZZ.(Q4.QD]'NE;7VWGB:28?\++H10N_A&VE M<>2"/DPVC:%!]!#:9W?WE'3A_:R)@L;'\%N([72EIL1COSR0]966_P%02P,$ M%`````@`QHEJ1U@_)&NB`0``L0,``!@```!X;"]W;W)K:>M<=V#,EBTH;A^P`^W_U&@4=SXU M#;.=`5Y%DI(L39(]4UQH6N2Q]FJ*''LGA8970VRO%#=_SR!Q.-(-G0MOHFE= M*+`B9PNO$@JT%:B)@?I(3YO#.0N("/@M8+"KF`3O5\3WD+Q41YH$"R"A=$&! M^^4&%Y`R"/G&'Y/F5\M`7,>S^E/;$))!37OI7O#X1FF M+>R"8(G2QB\I>^M0S11*%/\<5Z'C.HQ_LNU$NT]()T*Z$'XDT?C8*-K\R1TO M<(L".;5[[9( MZ3UZ&NGI]_3M3-^N'6XGA_OO!;)9(%L+9/>WN,:<9\SC?TW8ZDP5F"9>'4M* M[+4;CW2I+K?SE,:9?,&+O.,-_.*F$=J2*SH_V3B&&M&!;Y\\["AI_?M9$@FU M"^&CC\UXI<;$83<_D.65%O\`4$L#!!0````(`,:):D>5HMLZH@$``+$#```8 M````>&PO=V]R:W-H965T&ULA5/;;N,@$/T5Q`<4QW%VNY%C M*6FUVGVH5/6A^TSLL8T*C!=PW/Y]`5]J59'R8F;&YYPY,)`/:-YL"^#(NY+: M'FCK7+=GS)8M*&[OL`/M_]1H%'<^-0VSG0%>19*2+$V2'TQQH6F1Q]JS*7+L MG10:G@VQO5+.E0SA1+%W\=5Z+@. MXY]=.M&N$]*)D"Z$^R0:'QM%FX_<\2(W.!#;\3"[S=[#31#QRL1&->_0QN(Q M5"_%)KO/V24(39ATA3E-F`7!O/K5%BF]1D\C/;U-W\[T[=KA=G+XZ[9`-@MD M:X'L^A;7F-.$V27?FK#5F2HP3;PZEI38:S<>Z5)=;N/S7BEQL1A-S^0Y946GU!+`P04 M````"`#&B6I'N]7N?*$!``"Q`P``&````'AL+W=OT^K%3UH7TF]MA&`<8%'+=_OX`O MM:I(W1!5)2K(L27XPQ86F11YK3Z;(L7=2:'@RQ/9*0_*D.-`D60$+I@@+W MRQ4>0,H@Y!N_39J?+0-Q'<_JCW&WWOV96WA`^2HJUWJS"245U+R7[AF'WS!M M81<$2Y0V?DG96X=JIE"B^/NX"AW78?RS2R?:;4(V$;*%\#.)QL=&T>8O[GB1 M&QR([7B87;KW[2G%V#T(3)5IC3A%D0S*O?;)'1 M6_0LTK/OZ9N9OED[W$P._T-@.PMLUP+;VUM<8TXS9O.E"5N=J0+3Q*MC28F] M=N.1+M7E=AZS.)-/>)%WO(&_W#1"6W)&YR<;QU`C.O#MD[L=):U_/TLBH78A MO/>Q&:_4F#CLY@>RO-+B'U!+`P04````"`#&B6I',G5-4Z$!``"Q`P``&0`` M`'AL+W=O M:>M<=V#,EBTH;A^P`^W_U&@4=SXU#;.=`5Y%DI(L39(]4UQH6N2Q]F**''LG MA8870VRO%#?_SB!Q.-(-G0NOHFE=*+`B9PNO$@JT%:B)@?I(3YO#.0N("/@C M8+"KF`3O5\2WD#Q51YH$"R"A=$&!^^4&%Y`R"/G&[Y/F9\M`7,>S^J^X6^_^ MRBU<4/X5E6N]V822"FK>2_>*PV^8MK`+@B5*&[^D[*U#-5,H4?QC7(6.ZS#^ MV683[3XAG0CI0OB91.-CHVCSD3M>Y`8'8CL>9K+@)(EZ9V*CF'=I8/(7J MK=CLLIS=@M"$25>8\X19$,RKWVV1TGOT--+3[^G;F;Y=.]Q.#G??"V2S0+86 MR.YO<8TYSYC]ER9L=:8*3!.OCB4E]MJ-1[I4E]MY2N-,/N%%WO$&GKEIA+;D MBLY/-HZA1G3@VR&ULA5/;;N,@$/T5Q`<4QTEZB1Q+25=5^U"IZL/N,[''-BHP+N"X_?L"OM1: M1)"TSR+M3>39]@Y*32\&6([I;CY/H+$?D]7="J\B[IQH<#R MC,V\4BC05J`F!JH]/:QVQTU`1,!?`;U=Q"1X/R%^A.2EW-,D6``)A0L*W"]G M>`0I@Y!O_#EJ_K8,Q&4\J3_%W7KW)V[A$>4_4;K&FTTH*:'BG73OV#_#N(5M M$"Q0VO@E16<=JHE"B>)?PRIT7/OAS_IAI%TFI",AG0GW230^-(HV_W#'\\Q@ M3VS+P^Q6.P\W0<0K$QO5O$,;BX=0/>>K[5W&SD%HQ*0+S''$S`CFU2^V2.DE M>AKIZ77Z>J*OEP[7H\/[ZP*;26"S%-A'4L*;#3 M;CC2N3K?SD,:9_(+S[.6U_#*32VT)2=T?K)Q#!6B`]\^N=E2TOCW,R<2*A?" M.Q^;X4H-B<-V>B#S*\U_`%!+`P04````"`#&B6I'A.E40)\!``"Q`P``&0`` M`'AL+W=OYF9G;6CZQ'\V$;`$>^E-1V3QOG MVAUCMFA`<7N%+6C_IT*CN/.IJ9EM#?`RDI1D:9)<,\6%IGD6:R\FS[!S4FAX M,<1V2G'S?02)_9ZNZ%1X%77C0H'E&9MYI5"@K4!-#%1[>ECMCIN`B(`W`;U= MQ"1X/R%^A.2IW-,D6``)A0L*W"]GN`,I@Y!O_#EJ_K8,Q&4\J3_$:;W[$[=P MA_)=E*[Q9A-*2JAX)]TK]H\PCK`-@@5*&[^DZ*Q#-5$H4?QK6(6.:S_\V:Y' MVF5".A+2F7";1.-#HVCSGCN>9P9[8EL>SFZU\W`31+PRL5'-.[2Q>`C5<[ZZ M3C)V#D(C)EU@CB-F1C"O?K%%2B_1TTA/_Z>O)_IZZ7`]=-_>_B^PF00V2X'- MY1&7F..$^3LD6^RI`E/'JV-)@9UVPY;.U?EV'M)X)K_P/&MY#<_0X7HP+=/KK:4-/[]S(F$RH7PQL=FN%)#XK"='LC\2O,?4$L#!!0````( M`,:):D<_\,1YH0$``+$#```9````>&PO=V]R:W-H965T+V!GO0_D^#1G'G4],RVQO@ M=20IR=(DN6.*"TW+(M9>35G@X*30\&J('93BYM\))(X'NJ-+X4VTG0L%5A9L MY=5"@;8"-3'0'.AQMS_E`1$!?P2,=A.3X/V,^!Z2E_I`DV`!)%0N*'"_7.`1 MI`Q"OO''K/G=,A"W\:+^%'?KW9^YA4>4?T7M.F\VH:2&A@_2O>'X#/,6;H-@ MA=+&+ZD&ZU`M%$H4_YQ6H>,Z3G^R^YEVG9#.A'0E/"31^-0HVOS%'2\+@R.Q M/0^SV^T]W`01KTQL5/,.;2P>0_52[N[2@EV"T(Q)-YC3C%D1S*M?;9'2:_0T MTM.?Z=E"S[8.L]EA]K-`O@CD6X'\^A:WF-."R?]KPC9GJL"T\>I84N&@W72D M:W6]G<:>M< M=V#,EBTH;N^P`^W_U&@4=SXU#;.=`5Y%DI(L39(]4UQH6N2Q]FR*''LGA89G M0VRO%#Y`R"/G&;Y/F5\M`7,>S^D/2_>"PR-,6]@%P1*EC5]2]M:AFBF4*/X^KD+'=1C_[-*) M=IN03H1T(?Q,HO&Q4;3YFSM>Y`8'8CL>9K+@)(EZ9V*CF'=I8/(7JM=CL M=SF[!J$)DZXPYPFS()A7O]DBI;?H::2GW].W,WV[=K@=NV>_OA?(9H%L+9#= MWN(:1I"1+D^2.*2XT+?)8>S%%CKV30L.+(;97BIM_)Y`X'.B&SH57T;0N%%B1 MLX57"07:"M3$0'V@Q\W^E`5$!+P)&.PJ)L'[&?$]),_5@2;!`D@H75#@?KG` M`T@9A'SCCTGSNV4@KN-9_3'NUKL_;$))!37OI7O%X0FF+=P& MP1*EC5]2]M:AFBF4*/XYKD+'=1C_9+N)=IV03H1T(=PGT?C8*-K\S1TO$K\R#O>P!]N&J$M.:/SDXUCJ!$=^/;)S2TEK7\_2R*A=B'< M^=B,5VI,'';S`UE>:?$%4$L#!!0````(`,:):D&PO=V]R:W-H965TVRC`.,"CMN_7\"76E6DW1!5)2K(T27XPQ86F11YKKZ;(L7=2 M:'@UQ/9*M"@14Y6WB54*"M0$T,U`=ZW.Q/64!$P&\! M@UW%)'@_(UY"\JLZT"18``FE"PK<+U=X`"F#D&_\/FE^M0S$=3RK/\7=>O=G M;N$!Y1]1N=:;32BIH.:]=&\X/,.TA?L@6**T\4O*WCI4,X42Q3_&5>BX#N.? M73;1;A/2B9`NA)])-#XVBC8?N>-%;G`@MN-A=IN]AYL@XI6)C6K>H8W%8ZA> MB\TNR=DU"$V8=(4Y39@%P;SZS18IO45/(SW]-WT[T[=KA]O)X7_TSV:!;"V0 MW=[B&G.:,=]=LM69*C!-O#J6E-AK-Q[I4EUNYS&-,_F"%WG'&WCAIA':DC,Z M/]DXAAK1@6^?W-U3TOKWLR02:A?"G8_->*7&Q&$W/Y#EE19_`5!+`P04```` M"`#&B6I'DE/M7J$!``"Q`P``&0```'AL+W=O:>M<=V#,EBTH;A^P`^W_U&@4=SXU#;.= M`5Y%DI(L39)'IKC0M,AC[=44.?9."@VOAMA>*6[^G4'B<*0;.A?>1-.Z4&!% MSA9>)11H*U`3`_61GC:'KXCO(7FICC0)%D!"Z8("]\L- M+B!E$/*-_TZ:GRT#<1W/ZD]QM][]E5NXH/PC*M=ZLPDE%=2\E^X-AV>8MK`+ M@B5*&[^D[*U#-5,H4?QC7(6.ZS#^V()L%LK5`=G^+:\QYQNR^-&&K,U5@FGAU+"FQUVX\ MTJ6ZW,Y3&F?R"2_RCC?PBYM&:$NNZ/QDXQAJ1`>^??*PHZ3U[V=))-0NA'L? MF_%*C8G#;GX@RRLM_@-02P,$%`````@`QHEJ1RC39KZB`0``L0,``!D```!X M;"]W;W)K&ULA5/;;N,@$/T5Q`<4AZ1--W(L)5U5 MNP\K57W8?2;VV$8%Q@4<=_]^`5]JK2+UQ`3@2^$QRP9'QLEF]^%%T5N<2"N$W%VFT.`VR@2E(E+:L&A2\53K%Z+ MS?XA9],`N"!?6;+3B]1>>)SK^F;V?Z=NUP.SG<9\_A?$[8Z4PVV25?'D1)[X\)%WHH%?PC;2.')! M'R:;QE`C>@CML[M[2MKP?I9$0>UCN`^Q':_4F'CLY@>RO-+B'U!+`P04```` M"`#&B6I'0@D(ZMT!``!%!0``&0```'AL+W=OOEF:V]B#SCO:)-"R\"R9XQ(OZ<@?+AZ.T\5WAMJEJ9 M`LXS//NN#8-6-KQ%`LJC=]H=SJE16,&O!@:YF"/3^X7S-[/X<3UZOFD!*!3* M)!`]W.`)*#5!&OP^97XBC7$Y=^G?[&YU]QDT]YGG6D@I]$5$TKT84K?=KLT2@Y5Z#Q M_D/DH5K?:?."0JG,--%S,1[S<:%XYRZM^>;,_P)02P,$%`````@`QHEJ1\[. MYG"E`0``L0,``!D```!X;"]W;W)K&ULC5/+;MLP M$/P5@A\02K+=)H8LP$Y1M(<"00[)F996$F&2JY*4E?Y]2>H1)3#07L3=U3)%C[Z30\&2([97BYL\))`X'FM*Y\"R:UH4"*W*V\"JA0%N! MFABH#_28[D_;@(B`%P<4D>#\C7D+RLSK0)%@`":4+"MPO5W@$*8.0;_Q[ MTGQO&8CK>%;_'J?U[L__0QN(Q5*]%^I#D[!J$)DRVPIPFS()@7OUFBXS>HF>1GOV;OIGI MF[7#S=A]]Q\"VUE@NQ;83B.F'T=<8TXSYG,3MMI3!::)5\>2$GOMQBU=JLOM M/&;Q3-[A1=[Q!GYQTPAMR1F=/]EX##6B`]\^N=M1TOKWLR02:A?"KSXVXY4: M$X?=_$"65UK\!5!+`P04````"`#&B6I'QW(E@;$!```6!```&0```'AL+W=O M*UMT8.'Q_Z(#S`5-2VP-MG>OVC-FR M!<7M#7:@_4Z-1G'GEZ9AMC/`JTA2DJ5):P]F2+'WDFAX\32!P.=$/GPK-H6A<*K,C9PJN$`FT%:F*@/M#C9G_*`B("?@H8[&I.0O8S MXDM8?*\.-`D10$+I@@+WPP4>0,H@Y(U?)\UWRT![GVC7">E$ M2!?"?1*#CT8QYE?N>)$;'(CM>.C=9N_A)HAX96*CFD]H8_$8JI=B\V6;LTL0 MFC#I"G.:,`N">?6K%BF]1D\C/?VB>99\+[&:!W5I@-QUQ]_&( M:\QIQOR'27;5))L$;O]A,F/N_C)AJ\8I,$V\GY:4V&LW]FVI+D_@F,;&O\.+ MO.,-_."F$=J2,SI_?6*O:T0'WCZYR2AI_2-=%A)J%Z9W?F[&>SLN'';S*UQ^ M!<4?4$L#!!0````(`,:):D<=6=7#I0$``+$#```9````>&PO=V]R:W-H965T M=?4S+8&>!E)2K(T2>Z9XD+3/(NQ9Y-GV#DI-#P;8CNEN/EW`HG] M@:[H%'@1=>-"@.49FWFE4*"M0$T,5`=Z7.U/FX"(@%4;Z)TC6^V(22 M$BK>2?>"_2\86]@&P0*EC5]2=-:AFBB4*/XQG$+'LQ_^[)*1=IN0CH3TBL"& M1+',G]SQ/#/8$]OR,+O5WL--$/'*Q$8U7Z&-P6.(7O+5PRYCER`T8M(%YC1B M9@3SZC=3I/06/8WT]'OZ>J*OEQ6NA^S;W?<"FTE@LQ38C"T^?&UQB3D-&+^V M5TG8XDX5F#JNCB4%=MH-5SI'Y^T\IG$FG_`\:WD-?[BIA;;DC,Y/-HZA0G3@ MTR=W6TH:_WYF1T+E@OG#VV98J<%QV$X/9'ZE^7]02P,$%`````@`QHEJ1QH) MG-"C`0``L0,``!D```!X;"]W;W)K&ULA5/;CILP M$/T5RQ^P)B2;5A%!2G95M0^55OO0/CLP@+6VA[5-V/Y]?0%"JTC[@F>&*0;.A=>1=NY4&!EP19>+11H*U`3 M`\V1GC:'\RX@(N"7@-&N8A)ZOR"^A>1'?:19:`$D5"XH<+]^'W2 MO%D&XCJ>U;_%:7WW%V[A">5O4;O.-YM14D/#!^E>.75(-U MJ&8*)8I_I%7HN([ISSZ;:/<)^43(%\+72&#)*+;YS!TO"X,CL3T/9[+@) M(EZ9V*CF.[2Q>`K5:YEGFX)=@]"$R5>8<\+<$,RKW[7(Z3UZGBP^IV]G^G;= MX3:Y[[>?"^QF@=U:8#>-F/\[XAISGC'_F[#5GBHP;;PZEE0X:)>V=*DNM_.4 MQS.YP/GMXI*3S[V=))#0NA%]\;-*52HG# M?GX@RRLM_P)02P,$%`````@`QHEJ1U,5KF"C`0``L0,``!D```!X;"]W;W)K M&ULA5/;;J,P$/T5RQ]0$T*ZNQ%!2KJJVH>5JC[L M/CLP@%7;0VT3VK^O;2YEJTA]P3/#N:.M*6[> M3R!Q.-`-G0O/HFE=*+`B9PNO$@JT%:B)@?I`CYO]*0N("/@K8+"KF(3>SX@O M(7FL#C0)+8"$T@4%[I<+W(&40<@;OTZ:GY:!N(YG]?LXK>_^S"W?6K%BF]1D]'B^_IVYF^77>X'=VS7]\+9+-`MA;(IA%W_X^XQIQF MS.T7$[;:4P6FB5?'DA)[[<8M7:K+[3RF\4P^X47>\0;^<-,(;`PU MH@-OG]SL*&G]^UD2";4+X0\?F_%*C8G#;GX@RRLM/@!02P,$%`````@`QHEJ M1^LQWWG!`0``>P0``!D```!X;"]W;W)K&ULC53; M;MP@$/T5Q`<$F[VE*Z^EW515^U`IRD/[S-KCBP+&!;Q._[Y59W(PO.W@42$]",'4WPMP.9YPBF/BJ:T;XQ(DS\C,*UL! MG6YEAQ14)WQ.CY>]0WC`KQ9&O=@C5_M5RF<7_"A/.'$E`(?".`5FEQL\`.=. MR!K_F31?+1UQN8_JWWRWMOHKT_`@^>^V-(TM-L&HA(H-W#S)\3M,+>R<8"&Y M]E]4#-I($2D8"?82UK;SZQA.#MN)MDZ@$X'.A/O$%QZ,?)E?F6%YIN2(=,_< MOTN/%JZ(U.@\7' M]$VD;Y85;H+[X1/^VRBP70ILIQ;OW[:XQ%PBYLO')KM5DUT02)-W3"+F$YWL M5TWVDP!]QR1B-O^9D,5T"%"UOP0:%7+H3!B..3O?LS/UT_4*S[.>U?"3J;KM M-+I*8V?4#U0EI0%KG]SM,&KL2S`''"KCM@>[5^%RA,#(/E[U^;W)_P%02P,$ M%`````@`QHEJ1TQK;0*P`0``%@0``!D```!X;"]W;W)K&ULA53;CILP$/T5RQ^P!@*;5420DJVJ]J'2:A_:9P<&L-87:INP_?OZ M`BQ=1P*)WP:4YXM[:X4"(J7L0U#RH`:0[:946U+I0 M=\0,&F@32(*3+$D>B:!,XJH,N1==E6JTG$EXT M^@2I2K+R&B9`&J8DTM`>\2D]G`N/"("?#":SV2-?^T6I-Q]\;XXX\24`A]IZ M!>J6*SP#YU[(&?^>-3\L/7&[7]2_AFY=]1=JX%GQ7ZRQO2LVP:B!EH[[3=PM]MZUP%]WW^7V!?!'(MP+YW&+Q;XM;S'G!/-XW*6Z:%+/`_C\F M"^;IDPG9#$Z`[L+]-*A6H[1Q;FMV?0*G+`S^`UZ5`^W@!]4=DP9=E'77)\RZ M5"HQZ]TC7@$-K_7;O]CK>VQA8-2RO00,```L.```9````>&PO=V]R:W-H965TA,GQJ3S4>2E6+@G*<\SSQ.[$RM2\<#/K*S_.?"J2&7=K(Z> M.%D(O>P[T=>D6:ENYPW?2_5(WF(J8O?=J&^;=&O[KZE@:Y[_RO;R5+OU M76?/#NDEES_X]2N#'$(EN..Y:'Z=W45(7AB*ZQ3IAWYF9?.\ZG]B'VAV`@8" M;@EM'#N!`(%,)01`"&Z$8)`0`B&\$:)!0@2$:&H$"@3ZB>#IT6WFYBF5Z7)> M\:LCSJE:L6A6PRLE4BL[HE&KIT4TG8^J]WV)43+WWI408'`'LP(,]OLQ:XV) M4#]DHR$WA%>;M#K%KLT%!A<#(=:`Z4<\:40T`-F,BFS'19Y!A(QG2TRVI#LO M!++%XP*!$0BZ`@$(D'N37CMAH5A$DX80LG5C,)S%+2'V:=P/BAV/<'/%MA MO7:0;_73=*MI&/`#F"\$^8@.&-\,`;NS^FR`.(QI0B>81W;S4):)/[!F`82" M`'\>SKOU:,?U6\)V2Z;JH8&MVH(FE#9$['&@.A(RE!*!I8_"8&"/`6Q*TO9" MBZ"*D@E5%+5E]*[8(U,CIPR)O4@BJ(!DH#:M`$0FE&)D+Y.(CH_\"ID:&$23 M%I.](K`/+FC_UE\!B%!"PRD98_N.QF9'3_B*86S- M&./_R-B^N3"9DC$QGZ9_$_8ZY]""5FZ.N@?.):LM^P]U`J?Z9M8V M&PO=V]R:W-H965T_O9YIC0R!!V$\#Y_LX1!SN[\N9#'!F3 MWF=5UF+A'Z4\/0>!V!Y91<43/[%:_;/G346E>FP.@3@UC.X,J2J#*`R3H*)% M[>>967MM\HR?95G4[+7QQ+FJ:/-WR4I^7?C(MPMOQ>$H]4*09T''VQ45JT7! M:Z]A^X7_@IXW:*8A!O&K8%?1N_=T^'?./_3#C]W"#W4&5K*MU!)472YLQB[E&[]^9U`#T8); M7@KSZVW/0O+*4GROHI_MM:C-]=K^D\Z`YB9$0(@Z0N?C)L1`B&^$=)2`@8!O MA&240(!`;@1L>MG6;CJWII+F6<.OGCA1_3ZA9P5OM(A2]H114TT39O%%KU[R M*)YGP44+`2;J89:`B<)AS*K%H&'$&E3P3250*9U1(]\5(P*!$9,58$9B`"(> MAFRL4?0X:6R3QOVFQB`0/Q;`5@#W!;`1P'=UI`92MY6V$(1G:!BT!A#I]6PP M"7$F(5`*?BR0.'N13.]%ZDR0@@`9KG,)&!*&$]ZNF=-F!C;)5QO2MVDQZ227 MN=-E#B[I8P$4.OMIEB$(CM^>,S'@L@$'_>((IA1DHSY6-#]B`6][;%BS<$<3(2WY>=:MEM. MM]H=?EXBO;W>K:_UH9/#O1`_M)FT-1"^^=2[5YFYUVS[ED*E?XI$H[ MJF-;]U"RO=2WJ:ZY/&ULE9=1;YLP$,>_ M"N)]!=O8D"J)U#)-V\.DJ@_;LYLX"2K@##M-]^UG@\E(>W&:;V_3Q*UVHF&JSNY%ZWY92.[AFOSV&T3M>\$7_=& M39W@-&5)PZLV7L[[M:=N.9<'75>M>.HB=6@:WOU]%+4\+F(4CPO/U7:G[4*R MG"F=HTSA:BPT_ MU/I9'K\+MP=J':YDK?J_T>J@M&Q&DSAJ^/MPK=K^>AQ^884S@PVP,\`G`Y1Y M#8@S(!\,DH&LW]=7KOERWLECI/;(]5[,UM2_>*#77U;8EK, MDS?KR&GP1//H-)<5I5.0DR0Q`"`%'BG(E`([BMEU!V1TD$T=D,$!2\\A\U[3 M#ML8-`@SQ.AE6>EDC*6DN(Z3@3B9PT'G[Z%3G,SA7):4@R2]3D%!"NHH/*]X M'#1??!0TE(*!%,Q1$`\%.QU-3CTD[*:CR4&*`4Q.F7+4^`!P1&!*'PD"`,0^"`H#@1183YHN)D`0F+X&:" MAA9`4("'#(Y(=D-$X.)%-"0B3D1H[@M(<`4CN(316,,TP$4.1R2_(2(%3%'` M3?X$D50Y3A9<.G`E8S&4O;U>2?R0)>?))?_?<(UC,<:]K5Z)_*!?))Z=D9.%GI&&.XL>.PL`?T-$S!W,0G/70P/!#@+R%TGHB1'GH0J&PO=V]R:W-H965T2"'*=O7PX2!7LQRXT-^-_EUZX_)+2\J.*C/$JIG:\L MS]3Z].AYY?8HL[A\4">95[_L59'%NCHM#EYY*F2\:X*RU*.^'WA9G.3N M>ME<>RW62W76:9++U\(ISUD6%W^?9:HN*Y>X]L);\=.;?Y=J8_ZY,=NY?JU!YG*K:Y3Q-77I]S( M-*TS57?^8Y+^OV<=V#^VV;\UPZWLO\>EW*CT=[+3Q\JM[SH[N8_/J7Y3E^_2 MC$'4";3-]Z7])?)-&!Q`30#M`@B_&\!,`+L* M\%IGS;A>8AVOEX6Z..4IKKM-'BMY42>I,CMEDZT:4MEYMEHQA4;HV"=Q*L,@"YHY$O$N2M#=HD(-/QS,:S_BB8&44TG8#;!+R? M@)L$B^$@PY['YU834B[XN&K3JD@0^`SA1H!N1.LF](?W$7TWK>:.8G.M) M@"8"8P+1E!!L2HAO2@0ZB."F#,H0C35E4(IH5E,6H)N%J0>=3D!\L"#-961% M"`%-$(*HB1$A.D\H?!=JQHH`FL!$DAE($IA)PA$8&-$]#FXDXT8Z'(=/)R*N MGH#C&0*X&L&,:H1P-4),YUN18"$E]RH2HBL"DTDB3&NBZ=9<2\:-P%`22R5' M3#TPE70&E12FDF*HI-=4WI;C1C)N!`:76G`%(@4,+IT!+H7!I2.SZ;`<'/BK MCM\)GBBIG2D#1`H833H#30JC24,$#?2:.:#]:"QIA^75,JKE";,.6\#56."K MP7RP&LQ'=-^([E7C1C)N!*:2$41;C(CPZ-X#TZH$QRQ183:993-$I!A9YLY@ MD\%L,@R;;'I2O9&,&X'1919=S%A@=-D,=!F,+L/,J@S-)8.G2V:GRP4B!0PF MFP$FA\'D/H('(YK@P:I0/'`83V[PC!!UY10L"J`PU'P&U`*&6F!F6R-"KK4$S*NPO")6%P+F5ID=T.[+=GU/U!+`P04````"`#&B6I'.@&&&:&F%VP_ONV)9_)1R!?5`FCT MRBA7IZ#5NC]BK,H6&%$/H@=NWM1",J+-4398]1)(Y4B,XC@,,\Q(QX,B=[4G M6>1BT+3C\"21&A@C\L\%J!A/013,A>>N:;4MX"+'"Z_J&'#5"8XDU*?@'!TO MF44XP,\.1K7:(YO]*L2+/7RO3D%H(P"%4EL%8I8;/`*E5L@8_YXTWRPM<;V? MU;^Z;DWZ*U'P*.BOKM*M"1L&J(*:#%0_B_$;3"VD5K`45+DG*@>E!9LI`6+D MU:\==^OHWQS"B;9-B"="O!!B']P;N9A?B"9%+L6(5$_LMXN.!BZMB%%&RJF9 MA,H5S[9Z*^)#DN.;%9HP\0IS\9AH06"COFD1!UOT>+)([POL9H'=.N-N$LCN M"R2S0+(62":!_?LF]P[#?4J/B=+D/_I,-UW2R>7PWB5=NWC,IRR\;Y)MFF23 MR>=_M.(Q47+XV`I>30@#V;B+H%`I!J[]@"S5Y:Z=8S=A;_`B[TD#/XAL.J[0 M56@SIVZH:B$T&/_PP;3&PO=V]R:W-H965T;Z=S#W3/5J$R!>"36WK>_D"P4 M;<1<'PK$WY_=)2Q+=N;-FS@P)KV/JJS%S#](>9P&@=@<6)6+!WYDM?IEQYLJ ME^JRV0?BV+!\JTE5&>`P)$&5%[4_S_3:2S//^$F61&D^!3UO6U2L%@6OO8;M9OXCFJZQAFC$KX*=Q>#<:X-_Y?RM MO?B^G?EA&P,KV4:V$KDZO+,%*\M623G_`=%/SY8X/._45SI=%?YK+MB"E[^+ MK3RH:$/?V[)=?BKE3W[^QB"'I!7<\%+H_][F)"2O.HKO5?F'.1:U/I[-+S0" MFIV`@8![@JG$34($A,B5$`,A[@D)'B4D0$A<'0@0B"N!`H%>$0)377UOEKG, MYUG#SYXXYNV.15,%;UH1I>P)K:9NB]"+C^WJ^QRG81:\MT*`P0/,$V#P"&9A M,`3=AJP,Y!,1J""MD6+?%@6&2$(.X%X*!"#P%645&-JDXG!A+<1:X,@-`G5W_U0$FLH"81" M[@L0:S&(>S&H-0)ZOQA/M-OLH5NN$ZO3!)SHI=,0L^PPD_LFJ=4D!8%TQ,1@ M(I=,4&AUT#N+#N0PP.%L-T&@TU\>Q,L`#3R M2"P!,KG<)E]PSX##T1W@J@.2.\`U`$GJN$-19"]$!(5(QNIM0(FKE;T)H1BL MR%A!#2AVM;(W&92`%1W+RH`032EU<")V)P).DTNG],+)@`AYH(F#D[UM(0I. MZ5CY#`BYEL_>MY!I2A$:W?J3_]L4]NZ%H#4AEXF@;TT7+P0,0,``$8.```9````>&PO M=V]R:W-H965TUKE_`<[T+K]9JRIN_J_%-=B[J[GM0OHQ!D9@$&`>X%O8]90$!`SH)H4!"!('(5Q""( M704)"!+7/J0@2%T%(Q",7"-E(,A#H>L0# M-1>[F7R;BWPV:=C)XX=Z+)"!HB'[XL\ZBR9G7D"9FB(GC4S,$8_(7`TD&>EZV"'D21Z),GEI"/* M)8L<*D2Z0G19(8(,Y&O.M&-JU1?%X#@,'6QBHTVLIBP>V6WN%1,GD9UY4$R6 MNDS^Q)@D@0Z[O++4^-+3_WCI(V.&$62([3U=*0:%(Z>WGAE],DAZ->$OF:<, MLB1V9J69U"$)"HU1NN9O)MHS0(XS#2&S$^S$0W-M"1!";D[8[*07<&9W>M10 MYN9$S$YJH1-RM2W%7YP4%$5I3%RLS!L"BKY?JG<:"L.!M0H0<>NX>=]`,70< MV8UN`7(<2_.V@&!?(-ANM``H!$["MNT4.1'5H:H($TYJT(P5Y$ M8KO1O(<2%R/S7H1@$R&I_07/`3(LR^#BHZRBS:X[GG!OS8ZU4/\=^];^"'2# MY4?=5?L&ULA93-CILP M%(5?!?$`8WX#1`1IF*IJ%Y5&LVC73K@$-#:FMA.F;U__8,I4*&QB^W+N^8YE MQ^7$^+OH`*3W0^)&*>9_:B!L.OFA[PIO_;63NH"J$BU]34]A M$#T;/`[MR7\.CW6F%4;PLX=)K.:>SGYF[%TOOCLACN\`"': M2(%_SY[_D+IQ/7?N7\UN5?HS%O#"R*^^D9T*&_A>`RV^$?G&IF\P;R'5AA=& MA/GU+CP,4F,P6(/8)@C"]'/,;"6JK2@,TF0?DVQB$H3S2<3 M%O]O!JWN[(BO\`/S:S\([\RDNO[FKK:,25`NP9,*WJE'9ED0:*6>9FK.[?_. M+B0;W2NR/&757U!+`P04````"`#&B6I'A=@*Q%4#```W#P``&0```'AL+W=O MVS.QXT[_V79C30^\^I-'!B3WD>1EV+B'Z0\ MCH)`;`ZL2,4#/[)2_;+C59%*]5CM`W&L6+IMC(H\0`"$09%FI3\=-VO/U73, M3S+/2O9<>>)4%&GU;\9R?I[XT&\77K+]0=8+P70<7.RV6<%*D?'2J]ANXC_" MT1J%-=(0OS-V%IU[KQ;_ROE;_?!S._%!K8'E;"-K%ZFZO+,YR_/:DXK\USB] MQJP-N_>M]V63KI+_F@HVY_F?;"L/2BWPO2W;I:=S_B4&QLQN@(P!NAADUH,:` MNAJ$QB!TE109@\@U0FP,XD\&@2Y'4\RG5*;3<<7/GCBF]2<.1PJO:B?*LR<: M;ZJ.HEE\K%??IYB`.S(,ZC`SS2#4P\PU$\+[R%(C5R)0(JU*D6]3@;32 M7A6:0?>))TV$/!T/`KP>TKP=WB8:TB(<,.2.N`=!T0 MHP#?JHP:IM3O5#/@/O$T2"P'B94F?L080P#`<#[4F@]MO$2?*D>[4JA-2I=8 M:0)%;D)"JY#0O%C2HT0SM!OEJQ@-09C$3FHBJYK(J*$]9=8,"LD7/3>U-E@4 M]F)+C=$!;RN-)8ZO.K8F%YODPF$'B;6+$ORAVOD4WZ_@S$`P`<"IAA#;8V'[)+I-"[=#PC68 M?>I!8AT3W;P6ADE"UU#V@02IO?7H32P#N8:RCQS8SIS$P45D[008?:,5[-T( MVW;LF7P+`Q'7A!-[*-VXV*6;$+`FC(![PLC>D`C:$[[YF@SD^C$A>T,BTY#4 M90]EWS&@;VP9D+U[D-DT4-33J@9".')-V=X_R+0&[=FAS`R$0N0:S-Y!R'00 M[?EV9P:"(8[B+_]S@LX6OOCF/"6_#3Z74F[C+ZN7,]XCJ+?RG]3D<+:!E M?0E'*WVBN[J?CH_IGOU*JWU6"N^52W5P:';Y.\XE4YK!@\K@H$ZQEX><[61] M&ZG[2I_K](/DQ_:8>CDK3_\#4$L#!!0````(`,:):D<`&J?:]`(``$P,```9 M````>&PO=V]R:W-H965T=V=F+]AHU*K-`+(GK]M\W7RC:$+P1",]Y<]X3(,?%A70?](@Q<[Z: MNJ5+]\C8:>YY='O$34E?R`FW_,Z>=$W)^&5W\.BIP^5.!C6U!WT_\IJR:MW5 M0HZ]=:L%.;.Z:O%;Y]!STY3=WS6NR67I`K*\.1R8&O-7"N\;MJ@:WM"*M MT^']TGT%\P(@@4CB5X4O='#NB.0WA'R(BQ^[I>N+''"-MTQ(E/SPB3-D_EWMV)%GZ[O.#N_+<\W>R>4[UAY"(;@E M-96_SO9,&6GZ$-=IRB]UK%IYO*@[B:_#S`%0!\!KP'4>@6$%@#`AT0 M/#M#J`/"AQD\Y5U6+B]9N5ITY.+04RF>)S#G>"=$N+)#I1HO&I6#KV+TR)+M.)NU,$ODD421Z M:6#H3YM)C692*9'&%B_II)=)(I\D"D7,$H2>>/&`;S0CA_D'R0<6.QKB5;,\ M25E/1;;'K8>@3:HP2(T;`V9C>EMZW'/NC8')A=((1+:/PK1.H9$H>.(E`M!L M"6I+T&8)/K56BK)^Z7HE&%M]:2I%4?B$,V1VAK0S=#_3W:ZF(?[I]<>IK*<@ M3,:IO*<29-O8>@KX"#T^B=Z@56IP=Y!-*G6VY-PRM?E?1Z^-\"L4K=;#^!K, M,V`8ST7C+%NSF_QJ<2H/^&?9':J6.AO">(,GN[$](0SSE/T77N M,W$:BP50S:ZZ8.34]^[7/Q"K?U!+`P04````"`#&B6I'/+VHR%8"```4"``` M&0```'AL+W=O?<34'@!TSA"&;D`J5XLF94`RY6-(+8!5%\*1(N`">XT0`P[RTTT3%WFB: MD"LO\A*]48M=,8;T[PH5I%[8KMT$WO-+QF4`I`EH>:<"_Y.ZA_(E!!*P2,IF/JUCE?&"6XH MMH7AEQ[S4HVU?C)U#*V?X!F"UQ+://T$WQ#\L83`$(([(1@DA(80CLT0&4(T M-D-L"/$#`>BWJ_9F`SE,$TIJBU50'EAW+N!4B@AEBRDUL2U,!9DO]*$C` M30H9C-?!K#3&\YSGF+7&1.YSR%9#[@@@3/8Z]>P^%YYV.NA"8[SGB(U&1`.0 M[4N1W6N1O1$)1I3K-^7ZW8WQ]=L*9J\%@D8@Z`H$9F?#[RZ[F%6#B5XG"7N3 MA$8@_I[$U6>LU+NB0>[$'P!MQH"V)MUD-@#:_0]Z6E346U1DBIH.%169CV(2 M#!GN03TU$_>:B;5"Z+P6F/8>I*FI9L3KF/4ZF&F!^.'#BSMU[C7FL4C0N9$P MHA?5;9AU)->2ZW/?1MN&MO3DC?807[OSC=L3W[KSG>Y7=_DTJ>`%_8+TDI?, M.A`N[E%UZ9T)X4B8=2;BALY$BVX7!3IS.8W%G.JNI1><5$T/;O$I/\`4$L# M!!0````(`,:):D?QH<]$XP$``#X%```9````>&PO=V]R:W-H965TIB9NT$$U!M3&TG=-Y^ M_(,9*J&DF]B^G'N^XX!=3ER\RXX0%7PR.LA#V"DU[@&0IXXP+!_X2`;]I.6" M8:67X@SD*`AN;!.C`$91!ACNA[`J;>U55"6_*-H/Y%4$\L(8%G]K0OET"./0 M%][Z"*7&2(,_9L__2-.XGGOW%[M;G?Z()7GB]$_?J$Z'C<*@ M(2V^4/7&IQ]DW@(RAB=.I?T-3A>I./,M8<#PIQO[P8Z3>U)$<]MV`YP;X-(` M77`'LC&?L<)5*?@4R!&;=Q?OM5P8$^T<2.NF$TI;?#35:Y7D<0FNQFC6P)6F M=AI8H$4#M/\F!'I(LH9`:Q"GN_L&B3=`UF!P!HE+$,7H:\Q$:J=*(;9-S#I M)B;UF.PK9BVJG0A!".]CT"8&>4Q^`^-$*-FE]S'9)B;SF.(&QHD0RHO[F-QC MTO7+S>B99S1;1+]*"C=_HR6Q:4M,I,*COZV6*[/Z!U!+`P04 M````"`#&B6I'<8VU$;(!``!B!```&0```'AL+W=OK%3UHGOMA"%8]8':3NB^?6UC M6+I"F[W!GN&?[Y\1-M4@U;ON``SZY$SH7=09TV\QUL<..-$WL@=AW[12<6)L MJ$Y8]PI(XXLXPTD<%Y@3*J*Z\KD755?R;!@5\**0/G-.U.\],#GLHDTT)5[I MJ3,N@>L*SW4-Y2`TE0(I:'?1_6:[+YW""]XH#'JQ1Z[W@Y3O+GAN=E'L6@`& M1^,(Q"X7>`#&',@:?P3F'TM7N-Q/]$<_K>W^0#0\2/:+-J:SS<81:J`E9V9> MY?`$883<`8^2:?]$Q[,VDD\E$>+DD(2"9"Y(8M_X:.3; M_$$,J2LE!Z1[XK[=9FOERD$L&6E/LQUJG[QWV4N=EFF%+PX4-,E"LY\TV:S! MEK]JDDPFV=(D"8#\.B"=`.D2D`9`<1V0K7:0!4#Y?G)^>G.`G42ME`8L(;ZQO,Y>^#E@T!JW+>U>C7=@#(SLIQL]_U;J+U!+`P04````"`#& MB6I'OMRUKSX#``"+#P``&0```'AL+W=OR9VXFD?.I/)0_M,;-EF`L@%'*=_7P&+2](UEO,0 M0#Z[9\]*!Z3IR99OU=Z8.OC(LZ*:3?9U?;@/PVJ]-WE2W=F#*=PO6UOF2>T> MRUU8'4J3;-J@/`L9(5&8)VDQF4_;L>=R/K7'.DL+\UP&U3'/D_+/PF3V-)O0 M23_PDN[V=3,0SJ?A.6Z3YJ:H4EL$I=G.)@_T?L5%`VD1/U-SJ@;W05/\J[5O MSS-%G69'+,OR'I/\XF<'C?9U^UTI MJ`Y)LP#IO8.731*7.:C:;*[+53OXT(R^SWE,IN%[DP@P;(!9]!AZ&;/L,.PR MXK%#1".0IYYH!+,"(GZ&A$XK*ICU@OE0,`,.CP2\3R"&"7A7P)=FR!92=,T` MB."4,\8N`U<`Y$H)$X8"I;1;2/LM`XW.H_>>0X=9AQ*.W`-*2:!5[4%&<"BRFU4AO`:28C+D/ M%6Y%QCRF$4#.ASKV6#$,MR+KK>A3+6Y%=H,5&6Y%)GUZVX&TWS>4X69DO1D] M7M=,X7K5#7IQ\[#89X([$!52*NI!A7_"F`:W>_2,$U0P)S=LVW#S<`I5C.[< MP&&229]W(,?-PQE0?=G[Z4]4X#!RISS>7_S"9I1[;)9Z$*&>FS^.[S.Y`%E\ MC$ST'U:,+!R<40[)SOQ(REU:5,&KK=UQISV;;*VMCZAMH?^Z'L^?\__`E!+`P04````"`#&B6I'(S=`4B8#``#B#P`` M&0```'AL+W=O]Z,S.7K37J%&9!6))7+=O7Q*2:&LXF]X(Q-_YDB_F<#S+*^W?V(D0 M[GVT3<=6_HGS\R((V.Y$VHH]T3/IAF\.M&\K/CSVQX"=>U+M95#;!#@,TZ"M MZLY?+^782[]>T@MOZHZ\]!Z[M&W5_]Z0AEY7/O+UP&M]/'$Q$*R7@8G;URWI M6$T[KR>'E?^,%B4.!2*)'S6YLKM[3RQ^2^F;>/BV7_FA6`-IR(X+B6JXO).< M-(U0&F;^I41OMU_":;JS![`%8!V`2@#`R(5$!T"YB! M`;$*B%UG2%1`<@M(Y5Z.WN7.%16OULN>7CUVKL1Y0HL![X7(H.PQJ39L&I.# MSV+T?1V'\3)X%T**P7?,9F12-(T4(W(C@F$!UE5@WS8#EN%X>H)\)%(`*3X5 M*1]$)I<9Z67&]YL5R?AH[B`0:X'H7B`>!6;1YP*)=06)^KF2OUW>,QO-I--, M[L`4#DSYR$P:2JV&4B60`88T,P,,:68.&%(,"@%#FG$XRIG54#:>PB0&#&5J M$@P8ZO2B@N4N&J](1@>]C#8'O8P>ETJ(T M_;\ZM-K"H4.&&PC*H<(%*"S3:"NX:F);T1]DZ,F]'+QT?_Y*;4=.>/F/1 M`/TSOD&+'%G&BZ&='9O/F_QZ>:Z.Y'O5'^N.>5O*A[9+]D@'2CD9UAL^#3M\ M&AIN\]"0`Q>WF=CZL04='S@]ZX[:M/7K/U!+`P04````"`#&B6I',+PR0E\" M```A"```&0```'AL+W=O0EQH>9.>.)8R?N2/M. M+-BU&9TFJ2@O:MF]5 MJ*C-)):UUS:)R8V518U?6X/>J@JU?_>X)-W6!&9?>"NN.1,%*XFM@7E M4.*=_VC11T]!'#_WZM_D7OXLQR[M8VC3.^H%O)WDCW'>LU>$+P M1$HJ/XW3C3)2]133J-"'&HM:CIUZ$]J:-DV`F@`'PM!GFN!H@O,@N(L$5Q/< M9SMXFN!]ZF"IMD,VB#Q'X"&PYOA0A7-JA4XZ%16=R)ZCUQG3"V M[D)(8^`(LU<8'\Q#,@5Y("QN8-(%-*JO\_W)5/WG4PTF#033J7KC5!4&@!#.@U(%\KQ@'I,I#`R# M:!YTT-U\UUU?4SBYIE"%&JSSH\E0H^=#!?:D`UE>VZP:!%P[7-BM/2J`"ZAL M:.@L;.J#1L'H2S;6Z/RK<'N5-P\U3N16,_6+'JK#[;:#XOS\5-^#30HFZIFX M#>5Y^Y!/X@9=\4_47HN:&D?"^*DMC]@+(0QSP_8+3SGG]_4P*?&%B<=`Q*]N M,#5AI.DOY.%?0?(/4$L#!!0````(`,:):D?<+T^)V@$``$`%```9````>&PO M=V]R:W-H965TS7<%U/C'^(5H`B3XIZ<71:Z4<#KXO MRA8H%B]L@%Z]J1FG6*HC;WPQ<,"5(5'BAT&0^!1WO5?DIO;&BYR-DG0]O'$D M1DHQ_W<&PJ:CM_/FPGO7M%(7_"+W%U[54>A%QWK$H3YZI]WAG&F$`?SN8!*K M/=+9+XQ]Z,//ZN@%.@(0**56P&JYPBL0HH64\5^G>;/4Q/5^5O]NNE7I+UC` M*R-_NDJV*FS@H0IJ/!+YSJ8?X%J(M6#)B#!/5(Y",CI3/$3QIUV[WJR3?9,% MCK9-"!TA7`BA#6Z-3,QO6.(BYVQ"8L#ZV^T."LZUB%)&PJBIA,(43[IZ+:)H ME_M7+>0PX0ISMI@;PE?JFQ:AMT4/#3W,XL<"^UE@O\ZX=QG#QP+1+!"M!2(G ML/_:9&HPO4UI,<%CBWC3(G86T5>+>&UA,;LG/))-C\1YQ'<\DF?;2#1 MW+%(GVXCV_3(G$=ZYVMDVQ[^ZA>GP!LSR0*5;.RE_<.7ZG)9G$(S(C=XD0^X M@5^8-UTOT(5)-6AF*FK&)"CWX$7UVZKK;#D0J*7>IFK/[83;@V3#?%\MEV;Q M'U!+`P04````"`#&B6I'ZA'/'+$"``!S"@``&0```'AL+W=O$ID#8YA#P\-Z;>8.%)[G2YHV=".'61U76;&6?.#\O'8?M3J3";$'/ MI!9/#K2I,!?+YNBP"V.)RX#3IHX'6]?5*1F!:VMAAQ6]C-8;H""*,2/@EQ9[]Z2 MQ6\I?9.+;_N5[8X31IZM=@9 MR_T$E@+>2!&A;#&E)IK&5/!91M_3($")\RZ%#,;K8=8:$X)Q2*XA-X0C"ABL MPK.',GB*[HTGR#0BG(#D#T4V_XB,ENFW9?K]9OG:910\%@A:@:`O$)ANQW\7 M&2E,K7NA,4\@!A$Y$2@#=N8[[S=&0)W>!@-O_@7%.UG'" M<5!N0-X"1..H38>*'GM$@QZ1]CA1RAK]ATB5J0YJEF&63MZJ;D^([IH-R\] M>_)$OHNOP3(#`_%(_5OPU6$LX4B63VN&:3+7$=W*CHM8QB5`17160Q<(;9&@R8 M$(%D=Y:`OBL=ZG3X[P([@TC@XPIHK!#-FT"VB>@Q0302H#E!9`GBQP2Q4T%L M"9(_NXPUIC,^&`Q$:13."OV%VQD&%E@#@%`'``E,L"(49 MR-$=5RP.QBB!2R1!MR1H)64+*)#;&/0?QD1N%=$28PQ(?A;W/A^+2B*8?)(3 MS`9D2]A9+P[N'>BE$V9X3=%I.6V@&K"?XENUM/3@O=&418_/Y#MFY[KCWIX* M.;[UK#U1*H@4%CY)F95ACJD\,[-HS$70?MR;T_(N?P-02P,$%``` M``@`QHEJ1VPBA.":`@``2`L``!D```!X;"]W;W)K&ULE5;;LV?WH`5-3Z)_DSO.5?+>-IVO6=-(9)=_[C23]ZFL+Q_<#^S=K5\E^9Y`O1_*[7 M:J?5YFFRYAMV:-2+.'WGWH-5N!*-M)_)ZB"5:(>2-&G9N[O6G;V>W)MRXLO" M!<@7H',!D/\68%^`8PN(+R"Q!=07T"\%F?-N)_?$%)M/>W%*Y)Z9_03W&MX; M$LV<2,NFAR;MXH-9/?*8RXBE0Q0? MD$P;";I!@QL\=H.\B@@"/!"0,0%V!!A_%EE:3.=L.`SD0,EEU-*A\NM"2%`( M\4+(=0(:'`6-'T415%!X!?2RR87#X.)ZCS+8H[P^[H7#`-;[+V*:5;!/Y7

XML 21 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Payable and Financing Obligation - Essex Capital Notes (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended

Jun. 30, 2015

Apr. 30, 2015

Feb. 28, 2015

May. 31, 2014

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 17, 2014

Feb. 28, 2014

Jan. 31, 2014

Dec. 31, 2013

Dec. 20, 2013

Debt Instrument [Line Items]

Short-term notes $ 2,500

Cash paid for interest $ 564 $ 971

Essex Notes

Debt Instrument [Line Items]

Secured promissory notes, able to borrow, maximum $ 10,800

Interest rate, percentage 10.375% 11.50%

Short-term notes $ 2,500

Settlement of outstanding loan balance $ 1,100

Notes payable $ 3,900

Shares available for purchase under common stock warrants 44,753

Cash paid for interest $ 100 $ 300

Equipment purchased by third party, increase during period $ 100

Equipment purchased by third party $ 9,800

Lease period 3 years 3 years

Percentage of original purchase amount of asset at end of lease 10.00%

Purchase of equipment sold and leased back $ 1,100

X

- Definition
Equipment Purchased by Third Party
+ References
No definition available.
+ Details

Name: rvnc_EquipmentPurchasedbyThirdParty

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equipment Purchased by Third Party, Increse During Period
+ References
No definition available.
+ Details

Name: rvnc_EquipmentPurchasedbyThirdPartyIncreaseDuringPeriod

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Lease Maturity Term
+ References
No definition available.
+ Details

Name: rvnc_LeaseMaturityTerm

Namespace Prefix: rvnc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage Of Original Purchase Amount Of Leased Asset At End Of Lease
+ References
No definition available.
+ Details

Name: rvnc_PercentageOfOriginalPurchaseAmountOfLeasedAssetAtEndOfLease

Namespace Prefix: rvnc_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross amount of debt extinguished.
+ References
No definition available.
+ Details

Name: us-gaap_ExtinguishmentOfDebtAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow for payments to acquire rented equipment which is recorded as an asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireEquipmentOnLease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_SecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount at the balance sheet date of borrowings from a bank, not elsewhere enumerated in the taxonomy, with a maturity within one year (or within one operating cycle if longer) from the date of borrowing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ShortTermBankLoansAndNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=rvnc_EssexNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Equity (Tables)
9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Fair Value Assumptions
The fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Three Months Ended
September 30,

Nine Months Ended September 30,

2015

2014

2015

2014
Expected term (in years)
6.1

6.2

6.3

6.1

Expected volatility
61.3
%

61.5
%

62.7
%

57.4
%
Risk-free interest rate
1.7
%

1.6
%

1.5
%

1.9
%
Expected dividend rate
—
%

—
%

—
%

—
%
The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions:

Three Months Ended
September 30,

Nine Months Ended September 30,

2015

2014

2015

2014
Expected term (in years)
8.2

8.9

8.4

9.1

Expected volatility
73.5
%

57.2
%

72.4
%

57.5
%
Risk-free interest rate
2.0
%

2.5
%

2.0
%

2.5
%
Expected dividend rate
—
%

—
%

—
%

—
%
The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Three Months Ended
September 30,

Nine Months Ended September 30,

2015

2014

2015

2014
Expected term (in years)
0.5

0.5

0.5

0.5

Expected volatility
50.8
%

42.5
%

50.5
%

46.4
%
Risk-free interest rate
0.1
%

0.1
%

0.1
%

0.1
%
Expected dividend rate
—
%

—
%

—
%

—
%

Schedule of Stock-based Compensation Expense
Total stock-based compensation expense related to options and restricted stock awards granted to employees and nonemployees and the employee stock purchase plan was allocated as follows (in thousands):

Three Months Ended
September 30,

Nine Months Ended September 30,
2015

2014

2015

2014
Research and development
$
1,182

$
557

$
2,879

$
1,644

General and administrative
1,408

1,728

4,435

2,967

Total stock based compensation expense
$
2,590

$
2,285

$
7,314

$
4,611

Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):

Unrealized Gains and Losses on Available-for-Sale Securities
Balance at December 31, 2014
$
—

Other comprehensive income (loss) before reclassifications
10

Reclassifications from accumulated other comprehensive income (loss)
—

Net current period other comprehensive income (loss)
10

Balance at September 30, 2015
$
10

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814

Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock based compensation expense $ 2,590 $ 2,285 $ 7,314 $ 4,611

Research and development

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock based compensation expense 1,182 557 2,879 1,644

General and administrative

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock based compensation expense $ 1,408 $ 1,728 $ 4,435 $ 2,967

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 25 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended

Feb. 28, 2014

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Oct. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

Extended term of lease 36 months

Rent expense $ 1.3 $ 1.3 $ 3.9 $ 3.9

Purchase commitments $ 22.4 $ 22.4

Medicis Pharmaceutical Corporation | Product Approval Payment Derivative

Related Party Transaction [Line Items]

Accrued Milestone Obligations $ 4.0

X

- Definition
Accrued Milestone Obligations
+ References
No definition available.
+ Details

Name: rvnc_AccruedMilestoneObligations

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.
+ References
No definition available.
+ Details

Name: us-gaap_PurchaseObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rvnc_MedicisPharmaceuticalCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CreditRiskContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Equivalents and Investments
9 Months Ended

Sep. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Cash Equivalents and Investments
Cash Equivalents and Investments

The Company's cash equivalents and investments consist of money market funds and U.S. government agency obligations, which are classified as available-for-sale securities.

The following table is a summary of amortized cost, unrealized gain and loss, and fair value (in thousands):

September 30, 2015

December 31, 2014

Gross Unrealized

Gross Unrealized

Cost

Gains

Losses

Fair Value

Cost

Gains

Losses

Fair Value
Money market funds
$
72,454

$
—

$
—

$
72,454

$
166,038

$
—

$
—

$
166,038

U.S. government agency obligations
53,711

12

(2
)

53,721

—

—

—

—

Total cash equivalents and available-for-sale securities
$
126,165

$
12

$
(2
)

$
126,175

$
166,038

$
—

$
—

$
166,038

Classified as:

Cash equivalents

$
72,454

$
166,038

Short-term investments

51,364

—

Long-term investments

2,357

—

Total cash equivalents and available-for-sale securities

$
126,175

$
166,038

As of September 30, 2015 and December 31, 2014, the remaining contractual maturities of available-for-sale securities were less than two years.

There have been no significant realized gains or losses on available-for-sale securities for the periods presented. No significant available-for-sale securities held as of September 30, 2015 have been in a continuous unrealized loss position for more than 12 months. As of September 30, 2015, unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the cost basis of the investment will be recovered. The Company believes it has no other-than-temporary impairments on its securities as it does not intend to sell these securities and believes it is not more likely than not that it will be required to sell these securities before the recovery of their amortized cost basis. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in fair value.

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814

Equity - Schedule of Accumulated Other Comprehensive Income (Details)
$ in Thousands
9 Months Ended

Sep. 30, 2015

USD ($)

Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]

Balance at December 31, 2014 $ 0

Other comprehensive income (loss) before reclassifications 10

Reclassifications from accumulated other comprehensive income (loss) 0

Net current period other comprehensive income (loss) 10

Balance at September 30, 2015 $ 10

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 55

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51821188&loc=d3e1436-108581

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax of reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Equivalents and Investments (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Schedule of Available-for-sale Securities [Line Items]

Amortized cost $ 126,165 $ 166,038

Gross unrealized gain 12 0

Gross unrealized loss (2) 0

Available-for-sale securities, fair value 126,175 166,038

Cash equivalents

Schedule of Available-for-sale Securities [Line Items]

Available-for-sale securities, fair value 72,454 166,038

Short-term investments

Schedule of Available-for-sale Securities [Line Items]

Available-for-sale securities, fair value 51,364 0

Long-term investments

Schedule of Available-for-sale Securities [Line Items]

Available-for-sale securities, fair value 2,357 0

Money market funds

Schedule of Available-for-sale Securities [Line Items]

Amortized cost 72,454 166,038

Gross unrealized gain 0 0

Gross unrealized loss 0 0

Available-for-sale securities, fair value 72,454 166,038

U.S. government agency obligations

Schedule of Available-for-sale Securities [Line Items]

Amortized cost 53,711 0

Gross unrealized gain 12 0

Gross unrealized loss (2) 0

Available-for-sale securities, fair value $ 53,721 $ 0

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Medicis Settlement - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended

Oct. 31, 2012

Sep. 30, 2015

Dec. 31, 2014

Dec. 31, 2013

Settlement And Termination [Line Items]

Derivative liabilities associated with Medicis settlement $ 1,481 $ 1,541

Medicis Pharmaceutical Corporation

Settlement And Termination [Line Items]

Settlement consideration payable $ 25,000

Upfront payment paid 7,000

Medicis Pharmaceutical Corporation | Proceeds Sharing Arrangement

Settlement And Termination [Line Items]

Settlement agreement, payable 14,000

Settlement payment $ 7,100 $ 6,900

Medicis Pharmaceutical Corporation | Product Approval Payment Derivative

Settlement And Termination [Line Items]

Accrued milestone obligations $ 4,000

Remaining contractual term (in years) 3 years 9 months

Risk-free interest rate 1.09%

Fair value assumptions, credit risk adjustment (percent) 7.25%

X

- Definition
Accrued Milestone Obligations
+ References
No definition available.
+ Details

Name: rvnc_AccruedMilestoneObligations

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Agreement Settlement Upfront Payment
+ References
No definition available.
+ Details

Name: rvnc_AgreementSettlementUpfrontPayment

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Settlement Agreement Amount
+ References
No definition available.
+ Details

Name: rvnc_SettlementAgreementAmount

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Settlement And Termination [Line Items]
+ References
No definition available.
+ Details

Name: rvnc_SettlementAndTerminationLineItems

Namespace Prefix: rvnc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Risk-free interest rate assumption used in valuing an instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Risk associated with risk of default, credit spread risk and downgrade risk, expressed as a percentage, used as an input to measure fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsEntityCreditRisk

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss contingency liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_LossContingencyAccrualAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of cash paid for the settlement of litigation or for other legal issues during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_PaymentsForLegalSettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rvnc_MedicisPharmaceuticalCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=rvnc_ProceedsSharingArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CreditRiskContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Earnings Per Share [Abstract]

Net loss attributable to common stockholders, basic $ (19,175) $ (13,977) $ (51,382) $ (48,705)

Net loss attributable to common stockholders, diluted $ (19,175) $ (13,977) $ (51,382) $ (48,705)

Net income (loss) per share attributable to common stockholders

Basic (in dollars per share) $ (0.81) $ (0.60) $ (2.17) $ (2.70)

Diluted (in dollars per share) $ (0.81) $ (0.60) $ (2.17) $ (2.70)

Weighted-average shares used in computing net income (loss) per share attributable to common stockholders:

Basic (in shares) 23,755,199 23,331,104 23,625,869 18,009,537

Diluted (in shares) 23,755,199 23,331,104 23,625,869 18,009,537

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 31 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Level 1

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value $ 72,454 $ 166,038

Total liabilities measured at fair value 0 0

Level 1 | Money market funds

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 72,454 166,038

Level 1 | U.S. government agency obligations

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 0

Level 1 | Derivative liabilities associated with the Medicis settlement

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total liabilities measured at fair value 0 0

Level 2

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 53,721 0

Total liabilities measured at fair value 0 0

Level 2 | Money market funds

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 0 0

Level 2 | U.S. government agency obligations

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 53,721

Level 2 | Derivative liabilities associated with the Medicis settlement

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total liabilities measured at fair value 0 0

Level 3

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 0 0

Total liabilities measured at fair value 1,481 1,541

Level 3 | Money market funds

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 0 0

Level 3 | U.S. government agency obligations

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 0

Level 3 | Derivative liabilities associated with the Medicis settlement

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total liabilities measured at fair value 1,481 1,541

Recurring

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 126,175 166,038

Total liabilities measured at fair value 1,481 1,541

Recurring | Money market funds

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 72,454 166,038

Recurring | U.S. government agency obligations

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total assets measured at fair value 53,721

Recurring | Derivative liabilities associated with the Medicis settlement

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Total liabilities measured at fair value $ 1,481 $ 1,541

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=rvnc_DerivativeLiabilitySettlementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) - Derivative liabilities associated with the Medicis settlement
$ in Thousands
9 Months Ended

Sep. 30, 2015

USD ($)

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Fair value as of December 31, 2014 $ 1,541

Change in fair value (60)

Fair value as of September 30, 2015 $ 1,481

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=rvnc_DerivativeLiabilitySettlementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Medicis Settlement
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Medicis Settlement
Medicis Settlement
In October 2012, the Company entered into a settlement and termination agreement with Medicis Pharmaceutical Corporation, or Medicis. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to $25.0 million, comprised of (i) an upfront payment of $7.0 million, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of $14.0 million due upon specified capital raising achievements by the Company, of which $6.9 million was paid in 2013 and the remaining $7.1 million was paid in 2014, and (iii) $4.0 million to be paid upon the achievement of regulatory approval for RT001 or RT002 by the Company, or Product Approval Payment.
As of September 30, 2015, the Company determined the fair value of its liability for the Product Approval Payment was $1.5 million, which was measured by assuming a term of 3.75 years, a risk-free rate of 1.09% and a credit risk adjustment of 7.25%. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2019. The Company did not make any payments under the Product Approval Payment during the nine months ended September 30, 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Name: us-gaap_LossContingencyDisclosures

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Payable and Financing Obligation - Hercules Notes Payable (Detail)
1 Months Ended 3 Months Ended 9 Months Ended

Sep. 30, 2011

USD ($)

Sep. 30, 2015

USD ($)

Mar. 31, 2015

USD ($)

monthly_payment

$ / shares

shares

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Debt Instrument [Line Items]

Proceeds from notes payable $ 0 $ 6,750,000

Hercules Notes Payable

Debt Instrument [Line Items]

Proceeds from notes payable $ 22,000,000

Notes payable maturity Mar. 31, 2015

Interest rate, percentage 9.85%

Notes payable repayment start date Jul. 31, 2012

Notes payable repayment terms (payments) | monthly_payment 33

Payment of notes payable principal and interest $ 0 $ 800,000 $ 2,300,000 $ 2,600,000 $ 6,900,000

Prepayment charge on end of term payment 500,000

End of term payment $ 400,000

Warrants issued to purchase shares | shares 17,977

Exercise price per share (usd per share) | $ / shares $ 66.75

Debt discount amortized $ 100,000

Debt issuance costs $ 500,000

Hercules Notes Payable | Prime Rate

Debt Instrument [Line Items]

Plus (minus) difference from the prime rate (percent) 3.25%

X

- Definition
Amortization Of Debt Discount
+ References
No definition available.
+ Details

Name: rvnc_AmortizationOfDebtDiscount

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Debt Instrument Final Payment Amount
+ References
No definition available.
+ Details

Name: rvnc_DebtInstrumentFinalPaymentAmount

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Debt Instrument, Number of Monthly Payments
+ References
No definition available.
+ Details

Name: rvnc_DebtInstrumentNumberofMonthlyPayments

Namespace Prefix: rvnc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise Price Per Share
+ References
No definition available.
+ Details

Name: rvnc_ExercisePricePerShare

Namespace Prefix: rvnc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Long Term Debt Prepayment
+ References
No definition available.
+ Details

Name: rvnc_LongTermDebtPrepayment

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Warrants Issued For Purchase Of Stock Shares
+ References
No definition available.
+ Details

Name: rvnc_WarrantsIssuedForPurchaseOfStockShares

Namespace Prefix: rvnc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentDateOfFirstRequiredPayment1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).
+ References
No definition available.
+ Details

Name: us-gaap_DebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=rvnc_HerculesNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

Equity - Additional Information (Detail) - USD ($)
9 Months Ended

Jan. 01, 2015

Sep. 30, 2015

Sep. 30, 2014

Mar. 31, 2015

Dec. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock outstanding 24,313,222 23,774,465

Proceeds from issuance of common stock, Maximum $ 50,000,000

Maximum commission based on gross sales of common stock (as a percent) 3.00%

Proceeds from issuance of common stock, net of deferred at-the-market offering costs $ 10,154,000 $ 0

2014 Equity Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of outstanding stock 4.00%

2014 Equity Incentive Plan | Restricted Stock Award

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted 157,286

2014 Employee Stock Purchase Plan | Employee Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of outstanding stock 1.00%

Common stock shares outstanding increase during period 237,744

Shares available for issuance 404,073

Common Stock | 2014 Equity Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock shares outstanding increase during period 950,978

Shares underlying stock options granted 725,838

Shares available for issuance 286,984

Common Stock | 2014 Equity Incentive Plan | Board Member

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares underlying stock options granted 90,000

Common Stock | 2014 Inducement Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares available for issuance 145,571

2015 ATM Agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock issued in connection with ATM Agreement (in shares) 352,544

Stock issued in connection with ATM Agreement , Weighted average price per share (in usd per share) $ 30.76

Proceeds from issuance of common stock, net of deferred at-the-market offering costs $ 10,100,000

Common stock remaining amount available to be sold $ 39,200,000

X

- Definition
Common Stock, Capital Shares Reserved for Future Issuance, Percentage Increase
+ References
No definition available.
+ Details

Name: rvnc_CommonStockCapitalSharesReservedforFutureIssuancePercentageIncrease

Namespace Prefix: rvnc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Common Stock, Value, Remaining Amount Available to be Sold
+ References
No definition available.
+ Details

Name: rvnc_CommonStockValueRemainingAmountAvailabletobeSold

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum Commission Based on Gross Sales of Secondary Offering
+ References
No definition available.
+ Details

Name: rvnc_MaximumCommissionBasedonGrossSalesofSecondaryOffering

Namespace Prefix: rvnc_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Proceeds from Issuance of Common Stock, Maximum Proceeds Allowed on Secondary Offering
+ References
No definition available.
+ Details

Name: rvnc_ProceedsfromIssuanceofCommonStockMaximumProceedsAllowedonSecondaryOffering

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenInducementPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=rvnc_TwoThousandFifteenAtTheMarketIssuanceSalesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

CURRENT ASSETS

Cash and cash equivalents $ 90,494 $ 171,032

Short-term investments 51,364 0

Restricted cash, current portion 35 75

Prepaid expenses and other current assets 1,604 1,624

Total current assets 143,497 172,731

Property and equipment, net 19,254 19,274

Long-term investments 2,357 0

Restricted cash, net of current portion 400 435

Other non-current assets 6 29

TOTAL ASSETS 165,514 192,469

CURRENT LIABILITIES

Accounts payable 2,731 3,149

Accruals and other current liabilities 5,990 4,145

Financing obligation, current portion 3,018 307

Notes payable, current portion and net of discount 0 2,635

Total current liabilities 11,739 10,236

Financing obligation, net of current portion 6,176 598

Derivative liabilities associated with Medicis settlement 1,481 1,541

Deferred rent 3,762 3,725

TOTAL LIABILITIES $ 23,158 $ 16,100

Commitments and Contingencies (Note 9)

STOCKHOLDERS’ EQUITY

Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of September 30, 2015 and December 31, 2014, respectively; 24,313,222 and 23,774,465 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively $ 24 $ 24

Additional paid-in capital 452,501 435,142

Accumulated other comprehensive income 10 0

Accumulated deficit (310,179) (258,797)

TOTAL STOCKHOLDERS’ EQUITY 142,356 176,369

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 165,514 $ 192,469

X

- Definition
Financing Lease Obligation Noncurrent
+ References
No definition available.
+ Details

Name: rvnc_FinancingLeaseObligationNoncurrentNetofCurrentPortion

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Financing Obligation, Current
+ References
No definition available.
+ Details

Name: rvnc_FinancingObligationCurrent

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share Attributable to Common Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) - shares
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Stock options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Common stock equivalents excluded from computation of diluted net income (loss) per share 2,374,055 1,877,949

Common stock warrants

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Common stock equivalents excluded from computation of diluted net income (loss) per share 198,662 153,909

Unvested restricted stock awards

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Common stock equivalents excluded from computation of diluted net income (loss) per share 308,193 253,625

Shares expected to be purchased on December 31 under the 2014 ESPP

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Common stock equivalents excluded from computation of diluted net income (loss) per share 7,945 6,426

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvnc_CommonStockWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvnc_UnvestedRestrictedStockAwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

The Company and Basis of Presentation
9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company and Basis of Presentation
The Company and Basis of Presentation
Revance Therapeutics, Inc., or the Company, was incorporated in Delaware on August 10, 1999 under the name Essentia Biosystems, Inc. The Company commenced operations in June 2002 and on April 19, 2005, changed its name to Revance Therapeutics, Inc. The Company is a clinical-stage specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The Company is leveraging its proprietary portfolio of botulinum toxin type A compounds, combined with its patented TransMTS® peptide delivery system to address unmet needs in large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin type A through two investigational drug product candidates, RT001, also referred to as RTT150 (Botulinum Toxin Type A) Topical Gel, and RT002, or RTT150 (Botulinum Toxin Type A) for Injection. The Company is pursuing clinical development for RT001 and RT002 in a broad spectrum of aesthetic and therapeutic indications. The Company holds worldwide rights for all indications of RT001, RT002, and its TransMTS technology platform.
Since commencing operations in 2002, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, and raising capital. The Company has devoted predominantly all of its resources to preclinical, clinical, and manufacturing development of RT001 and RT002. The Company has never been profitable and has not commenced commercial operations.
Since the Company's inception, the Company has incurred losses and negative cash flows from operations. The Company has not generated significant revenue from product sales to date and will continue to incur significant research and development and other expenses related to its ongoing operations. For the three and nine months ended September 30, 2015, the Company had a net loss of $19.2 million and $51.4 million and used $39.2 million of cash for operating activities during the nine months ended September 30, 2015. As of September 30, 2015, the Company had a working capital surplus of $131.8 million and an accumulated deficit of $310.2 million. The Company has funded its operations primarily through the sale and issuance of common stock, convertible preferred stock, notes payable, and convertible notes. As of September 30, 2015, the Company had capital resources consisting of cash, cash equivalents, and investments of $144.2 million. The Company believes that its existing cash, cash equivalents, and investments will allow the Company to fund its operations for at least the next 12 months.

Follow-on Public Offering
In November 2015, the Company completed a public offering, pursuant to which the Company issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million.

Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements, in the opinion of management, include all adjustments which the Company considers necessary for the fair statement of the Condensed Consolidated Results of Operations and Comprehensive Loss and Cash Flows for the interim periods covered and the Condensed Consolidated Financial Position of the Company at the date of the balance sheets. The December 31, 2014 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America, or US GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2015, or any other future period.
The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission, or SEC, on March 4, 2015.
The Condensed Consolidated Financial Statements of the Company include the Company’s accounts and those of the Company’s wholly-owned subsidiary and have been prepared in conformity with US GAAP.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes, Warrants, and Related Derivatives - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Feb. 28, 2014

Sep. 30, 2015

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2015

Sep. 30, 2014

Oct. 31, 2013

Debt Instrument [Line Items]

Gain (loss) on debt extinguishment $ 0 $ 0 $ 0 $ (8,331,000)

Interest expense 0 271,000

Amortization of debt discount 5,000 1,198,000

Interest expense, excluding amortization of debt discount $ 264,000 $ 276,000 $ 564,000 $ 971,000

2013 Notes

Debt Instrument [Line Items]

Shares available for purchase under common stock warrants 409,450

Shares issued upon exercise of warrant 405,594

Fair value of embedded derivative liability $ 1,900,000

Gain (loss) on debt extinguishment (8,300,000)

Interest expense $ 9,600,000

Interest expense, excluding amortization of debt discount 300,000

2013 Notes, Warrant

Debt Instrument [Line Items]

Amortization of debt discount 400,000

2013 Notes, Embedded Derivative Liability

Debt Instrument [Line Items]

Amortization of debt discount $ 600,000

Convertible Debt | 2013 Notes

Debt Instrument [Line Items]

Principal amount 23,700,000

Convertible debt $ 26,200,000

Shares issued upon debt conversion 1,637,846

X

- Definition
Stock Issued During Period, Shares, Exercise of Warrants
+ References
No definition available.
+ Details

Name: rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants

Namespace Prefix: rvnc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

+ Details

Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph 8

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=rvnc_TwoThousandThirteenConvertibleNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=rvnc_A2013NotesWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=rvnc_A2013NotesEmbeddedDerivativeLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Payable and Financing Obligation (Tables)
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation
As of September 30, 2015, the aggregate total future minimum lease payments under the financing obligation were as follows (in thousands):
Year Ending December 31,

2015
$
1,054

2016
4,217

2017
3,971

2018
949

Total payments
$
10,191

X

- Definition
Schedule of Future Minimum Lease Payments, Financing Obligation [Table Text Block]
+ References
No definition available.
+ Details

Name: rvnc_ScheduleofFutureMinimumLeasePaymentsFinancingObligationTableTextBlock

Namespace Prefix: rvnc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

Interest Expense - Summary of Interest Expense by Cash and Non-Cash Components (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Other Income and Expenses [Abstract]

Cash related interest expense $ (264) $ (276) $ (564) $ (971)

Non-cash interest expense

Non-cash interest expense — debt issuance costs 0 (48) (39) (148)

Non-cash interest expense — warrant and derivative related debt discounts 0 (76) (5) (219)

Non-cash interest expense — convertible notes 0 0 0 (1,250)

Loss on extinguishment of 2013 Notes 0 0 0 (8,331)

Effective interest on financing obligation (126) (66) (226) (66)

Non-cash capitalized interest expense 0 238 0 649

Total non-cash interest expense (126) 48 (270) (9,365)

Total interest expense $ (390) $ (228) $ (834) $ (10,336)

X

- Definition
Interest Expense Capitalized
+ References
No definition available.
+ Details

Name: rvnc_InterestExpenseCapitalized

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest Expense, Convertible Notes
+ References
No definition available.
+ Details

Name: rvnc_InterestExpenseConvertibleNotes

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest Expense, Debt Issuance Costs
+ References
No definition available.
+ Details

Name: rvnc_InterestExpenseDebtIssuanceCosts

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest Expense, Warrant and Derivative Related Debt Discounts
+ References
No definition available.
+ Details

Name: rvnc_InterestExpenseWarrantandDerivativeRelatedDebtDiscounts

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Noncash Interest Expense
+ References
No definition available.
+ Details

Name: rvnc_NoncashInterestExpense

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents interest incurred for borrowed money which was used to produce goods or render services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_FinancingInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InterestExpenseDebtAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph 8

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies (Tables)
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases
As of September 30, 2015, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands):

Year Ending December 31,

2015
$
1,269

2016
5,222

2017
5,394

2018
5,578

2019 and thereafter
32,354

Total payments
$
49,817

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 44 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
Summary of Significant Accounting Policies

Significant accounting policies are described in Note 2 to the consolidated financial statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. There have been no changes to the Company’s significant accounting policies during the three and nine months ended September 30, 2015, except as described below.

Use of Estimates
The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investment securities with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents may include cash on deposit, money market funds, and debt securities.
Investments
Short-term investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. All of its investments are classified as available-for-sale and carried at fair value, with the change in unrealized gains and losses reported as a separate component of other comprehensive income (loss) on the Condensed Consolidated Statements of Operations and Comprehensive Loss and accumulated as a separate component of stockholders' equity on the Condensed Consolidated Balance Sheets. Interest income, net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of investments, if any. The cost of securities sold is based on the specific-identification method. The Company monitors its investment portfolio for potential impairment on a quarterly basis. If the carrying amount of an investment in debt securities exceeds its fair value and the decline in value is determined to be other-than-temporary, the carrying amount of the security is reduced to fair value and a loss is recognized in operating results for the amount of such decline. In order to determine whether a decline in value is other-than-temporary, the Company evaluates, among other factors, the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, and its intent and ability to hold the security to maturity or forecasted recovery. The Company mitigates its credit risk by investing in money market funds and U.S. government agency obligations which limits the amount of investment exposure as to credit quality and maturity.
Fair Value of Financial Instruments
The Company uses fair value measurements to record fair value adjustments to certain financial and non-financial assets and liabilities to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
The three levels of inputs that may be used to measure fair value are as follows:

Level 1
—
Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

Level 2
—
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3
—
Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

Accounting Pronouncements
In August 2014, the FASB issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), which will require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year of the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The guidance defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. The guidance is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Company’s financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Sep. 30, 2015

Dec. 31, 2014

Statement of Financial Position [Abstract]

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 95,000,000 95,000,000

Common stock, shares issued (in shares) 24,313,222 23,774,465

Common stock, shares outstanding (in shares) 24,313,222 23,774,465

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share Attributable to Common Stockholders
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Net Loss per Share Attributable to Common Stockholders
Net Loss per Share Attributable to Common Stockholders
The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2015 and 2014 (in thousands, except for share and per share amounts):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2015

2014

2015

2014
Net loss attributable to common stockholders, basic
$
(19,175
)

$
(13,977
)

$
(51,382
)

$
(48,705
)
Net loss attributable to common stockholders, diluted
$
(19,175
)

$
(13,977
)

$
(51,382
)

$
(48,705
)
Net loss per share attributable to common stockholders

Basic
$
(0.81
)

$
(0.60
)

$
(2.17
)

$
(2.70
)
Diluted
$
(0.81
)

$
(0.60
)

$
(2.17
)

$
(2.70
)
Weighted-average shares used in computing net loss per share attributable to common stockholders:

Basic
23,755,199

23,331,104

23,625,869

18,009,537

Diluted
23,755,199

23,331,104

23,625,869

18,009,537

The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

As of September 30,

2015

2014
Stock options
2,374,055

1,877,949

Common stock warrants
198,662

153,909

Unvested restricted stock awards
308,193

253,625

Shares expected to be purchased on December 31 under the 2014 ESPP
7,945

6,426

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2015

Nov. 09, 2015

Document And Entity Information [Abstract]

Entity Registrant Name Revance Therapeutics, Inc.

Entity Central Index Key 0001479290

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Document Type 10-Q

Document Period End Date Sep. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Amendment Flag false

Common stock outstanding 28,062,233

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: rvnc_DocumentAndEntityInformationAbstract

Namespace Prefix: rvnc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events
9 Months Ended

Sep. 30, 2015

Subsequent Events [Abstract]

Subsequent Events
Subsequent Events
In November 2015, the Company completed a public offering, pursuant to which the Company issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million.
On October 31, 2015, we entered into a separation agreement with Arthur P. Bertolino, M.D., Ph.D., our Chief Medical Officer and Executive Vice President, pursuant to which he resigned his employment with the Company, effective as of December 31, 2015. Dr. Bertolino will not be entitled to cash severance payments in connection with his departure; however, the Company agreed to accelerate vesting for a portion of his outstanding stock options and restricted stock awards, such that if he remains employed with the Company through November 15, 2015, an aggregate of 76,286 stock options and 23,740 restricted stock awards will have vested. If he remains employed through December 31, 2015, an aggregate of 114,428 stock options and 35,610 restricted stock awards will have vested.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 49 0001479290-15-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001479290-15-000010-xbrl.zip M4$L#!!0````(`'.):D>-3PL%CO9L$?/G7Z\@_FY`H]L+@IW/P23@_(X$3NE[P\M/Y;X\][5&_O#S_U]?_ M_J\O_]/K_:?_<'5FA$XZ(D%RID?$3HA[]MU+AF=_N"3^=C:(PM'9'V'TS9O8 MO5XQ:OP9J]AQ,7AVH`2P2VSU&6-%>';M9X@5(I-_OGY6)9OV())@RQ!C"=@` MV]AQ"+)MXHAXD-_M]3GRO<_LWS-*>!!_=L(T2**WG\Z'23+^?''!FC[%Q/GT M$DXNBL8+*`#4$T`/@?-R6!I%E,]EXXI6-A#7![K$:QY#&QJZDU=GV-R?M;`! M8GV`%TQ(G#0/R=L:N/'B$$,@3T=]__[]4S8RC%YH=P%=%#W*`;X7?%O1FS4_ MVS$INP>VY\3--&5-C"10)RD(@R`=-<_A)M%%\C8F%[13C_8BD>=,QZT?5!\0 MD<%23J0+VCKM.`F<6L^(3.S`(9^<<)0I0E"14':./:>97]K0P&V0%75BZQU MVC5VFSK2VX*+_UQ?/3I#,K)GG;WUG7M3:JB!^L<7-MGG.&MY((.S;/+/PPRE M#(&]$FF?*"7G13-3Q$_GL3<:^Y2GB^P^N:5SPB`AK\F91ZFV##;V'OWY9&13 ME7VH*?:2M^Q*>8M55'D,"M]%=[2)A-Z$Y[E]=F4Y97 M"@DMD=EE)C)\$T[49-A:J>4(2G(9,%.A3N]:M/R(#"PF!'R/N\`^[@%(+='. MV:?+I@OLSZV`G;!?6(W[#ED-^8.M1B8SW"%+B[>TM'A_,NL,SO"6.-N'S'++ MW`G3A/=@FAC[J!N.">W>,1G3V.2O(NK_ZS&AD&*YM?EW2LG3P]$X#.A_8^W5 MBZ>]Z.51&#PFH?/MFHR>230;GS['Y.^4W6!"_WFB<65MY%Q[/OJ0XI^N1/+" MV,ROY1==.OGKV/<:6`SK^6W18D].6B<8KMYV\6\&SF M1@FOG'UJ@"HB^1'O";:,N6G_?<7<2$B&)X3-%F)C/K/8K0%OBP6KM7JN9T=O MC[9/;@?9#+7QMQ,2:;X?)HS&VW%"-=A!I!V?%=QR]D8ES^9?JN73LL1-ZY-; M8>ZAF8>&]_C621"8:MZ@-YG8B3W*'C:*_/PKD_GGS61^L!@$]H"PZ_+>K"K.HVY5DG;39P+A#R>"4\6 MOIW"3!8';(&9N;CA8V)@;CNY[>Q$-(QX0,!!_7'&'6T9$*#=!P3EF8\I<"MB/WO) M-!.:*O3:_M\P8NLFOAT8Y#G1`C>OEC\2RKJ7>*2^)7$=!N3MVHZ^D<1*`[># MNM^0XQD4FED^&`KV>-:+HZ`S*-B7+?@1%/SV^',X(5&0>=H7$CBT`QLWZWX" MN-A4"$>%E+5Q@F['0R:WB>VS#=?NX6!]A-#(8N>U7(T--HL&]9,(!1NX['P$ M\"-Q(+?];;3]AX@5N55HAU5HCP?@]8!NK^ZM-,XCNXYJN6K#+=N+?K?]E/3? MIC]_H0*V(V?X=D4FQ*_I?-KG,ABG29QU@-W3_&9W,'%N^PRO[RAM\`:GM8>RDSRAHQ`]0!C?8602T3^55/C_,S)%TY0W*(9PGX*?.NG#+O"!IX/G0,GO%(WZ>Q!.O\ MB0J>&;7V),5)K(6CM/X=70'DYF7V7:(:<7TCDI#Z) M;\*$Q'?VF_WLD[EHZW<[\MCE!TI7+52[BZCJV-7N(6Q1'`68ELMC5]'2O#AG MH=J M,X$=$1#FF3J@^O&6ZL=[4']>;P'<''R,.:C73-!^JFF0K^Q#:U+:>SWYRC1[>5>,M737>L:W."Z#@5SM`Z^TUU_]NJY8T=M^M;2[*V09Q@,RU M>?@:-)#W8)]_30/"S?/'F&=I2_,L[=@\YXD4O+;?N/8/GTB)6R92XCZJ;7BS M:AM7_\[5OU5E;1]Y]!9E%)Y*GT1IA05X*`OPH,!-PD$#/,0"/+C;XR=;V'>^ MP$_"YC-$2/?`(L\\Y/^8D!]N&?)3HZ#LH2+#$*!P_1^Z(E/5YJYR>'"/'LDX MJ1_AX7;^X^P\8'9[BU4.]F/G\U6^%A%/W\.G89C&=N`^#;TH(230PV!"HL2C MPCNVQ;\QMX>-"[;R"OB#O<+&,IS>Z2H,7A(2C=@=V2G/VJ'"REC6SL'V_I.& M37*N?-V]2=!=]GY%@@,VJ6!H+,?*1/Z''45V%P])+\79$M[:G=KLY>S@UF`P MJ416@X8%2BP.ECP;,/@)K'B:=>IAT&ND`!VM7`NMB'^C6 M2;CV6ZY]U`/"CH]YS7S<(776:8.Y\`Z`QX3>DBDW?XQ5#T?C,*#_K;^2I;.I MZ$KV9J[T@.GH@;]_LIE^Z>51&#PFH?/M:'6\P&.G]=SP`*+VW8[EZ8`YP#_.B>?N8A"@=X*TKL MA[#@EX$3CL@T([D*'3NAHJ[!_9'XOA>\_$P"$MD^E:[FCKS`BY,HV^[*CL.5M32[Y=:H"]:H+7'0.UP9MT8MM49==6_<&GVT-6J1 M*^/6Z!BL45LRM965_ZS.>1/6RVVW8R;E=Y9'+P,W=3)U'45--"M1KA+0P2NC M30(^P:AMY9$$#FL.ZVY:ZY7;6!S6'-9'D1)Q6'-8'V&RML&A`P[K-><-3AG6 M;0E"MC\LQF'-8=WZE''[0[X M'FV?W`XR)34"U?(&3(9:\C0D^3?%+^,XM0.'L)&Q]A*1CGX0=*D,%L&TG1#V MBZW]/IU6?##Q5SL`<;*U*Q"[U3ARV._/E'+L[*ND_D#B) M/"?;V8)?&XE\>]QY/5-=AN'GJTQZ9V M/O1HFTV_Y#:=V_1]1M=5@.\KNN9U_<[6];MA#WD(P$.`KMC'`L&M?<-LG7VT MXU?LMC*`G[8\>0FSS9>!ZTT\-[7]VCC#BXB3A!%?\BU;\EO,WZCAV;QU%9^6 M:VVLBU)&7,]/&1@>B9-&7N*1V'QU_-0EKA6%(Z;!-,D>V+P=F'84>,%+?$>B MQZ$=D?Y;\PUF*[VBZ.*=R1U\@'6/4BI6ZU(QG2!$YP_"[1&BT\PZ,U:_!5Y2 M)FO3()S#M0[7:9J]5F0G=MCMP-#-K.MOP83$"7'GMFFRR@@';H.=W4!@)PC; M`P8%LTA^[GPNQ^F<@=WN!/-QA@(?`$P>"G0[%&@+=`\="O!$JS.)U@FZ?1ZM M=C]:/4'+RJ/5+D2K+;"GN3EEWY5$6Y[C:'R(DVTFD[]35D:?T'\6[C#7/C?Z M=VHNJ`;K(S)5TM#,9AMT,$W5'[44Z!+%%19#TT:VM7L M%0579MQ&[@-&K]^=K,-/?T/>1K\ZC7YE3#?&V^\W$-[C-;_*A' M)]M%S=-E<9NF??7ILE.4]499F-NTA&)["2LJ7\VH1>'&`+Y\V^/1@,M M_ZA1,W>KRB0&"<*1%RR?IE`+(SI>.\_\W?3JFG4<2N>;%C^W\2.S+S M!;7![!+`.J1SRZ*"@2*H2`*PF%T2^H9U_K77`S!;JZMFFI)BA$XZFO:XRQ:Q M1:_%&]"B:A94(9)5`1MJ7])TT^I/:9&A>?[U'N5D+)UE"1V,TDVID$Q55(V^ M*+YUI@0[FP3:87A=D`PBF`A2CKP-%4311*J;7D671Z:GYOJ]/S&X] MG<_,/(A.+T>V?QFXY/7?Y&V#B2U3D$09`=-"NJ8JDBEIN)Q8-32]'F MCMF.5F:WX]LT8>>X7>I=:T3E!]/Q33A1D^'YF4L<;T37'FVXL2I4]C$4#*@+ M:A]KABQ;"&A60:6A(@.>GS&#D-VQM%A0$20($:H1O8*L.0XLSR>13C7Z$D:; MR!$:LM&7D4:5U8<`:5!`Y4HR)).MZILPZ-F.0WSF4HA[ELU0I:XVY1PY[',E MT3B,LMB#`8T=)ZYG)"(N.R`^`:T"ZJ)+159 M`*H4J-0R43N1TTY1:V@:6YT"79VX!]0Z[=L2,\=-WLBV9#>D5*:Z%U05"8IF MZJJ&D*&C0LHR)=4X__I`)NRQJK.G(07"F*2)Y\3_/*,B_52EO#YQ1E463FF. M$Z7$O:98B9,P(+?/OO>2,1@O+"Q8)$RSAPFHJ9IDGZZY#.C-,RORX,7?ZD\J M4$EXV64]9&OUDT9+K805\0H&1)A15$!@:"45GF6?B`A>S/EXMUHJG(KSP% M\DB2Q,]^_38>1)33NSQ`K4G1@$#(I1@>1@+45D!#P$#2^]054!-L]:<2L(!I MSDM`KDM@'7,5.8S"*/'^K]A?,\AS8E"/&J9S`BA`#JJ;FZSS##\SUG\AD9-2 MV=^$"8GIA/:S3]:P"Z&IBTI?@Y:E8+I`=*"55A-!&HS,LPMJW"YE8<:F;L=# M]I<=!YK8/CO]0\W]9;:'G9T%JG-;O&%H*;VF)FB6U*?&WM3[LB)"#9%,E>2UY-0IIVTK>]^.F2^ASHL],V.EF1][(M'HV@N\43K:).Z0L2KV M!6@IFB8`C4:_@E*&/2*0A/.O=P!>5ZC_09(J_&66V`LLVXM^M_V4A`-J;R:$ MJI3BYBXB`T(#7[=Z*F:1G_RURS5UH0IWP-0-;,DTL)5UI*@TVE?*H`[3=:7- MJVNJINUIVSUC?ZY@3(&JJ!L`*X9D04NDIJ'T,J@/-&%AW?0@J*+PP]D35^N- M8=&0-0%C213[DJC*R"CT)DI(TMNK-W&-WFA8@"U1D'49JA*B%@]II=X4&K#N MA[%9U*O;8R^Q_3SX91])C";$I2&2E28TP2Z?^*89#7L6SWZA88(3T>2;-,3L M[7D]Q-*L0;'HZE`1S;(-H)B&JEC"U+L@U%>;L@8DRQB74O]QP1U:"Q_^6.MR M;6!!E43#-"19LQ01*:8HEYDFI"M<;-"&*@JJK.Q9&]EZ>B`CVV-'C&A000,( M;6)[/HM?6-SW&/IN8YBP_W=-+(M#))K]F@`8FF52>T\3=UQFFTB731'/VQ&D MUL.0+;FORHU9G3B+N!K-3DQSK,7CK-L[.*Q#442:)JI0TRS-E.`T+K%H_M\0 M:($J?^^B<@]LKO$'B`8DFHH,13%$+*DTY5'-G$U1`')_(=S?&8/U&-[R`MLO M4H0<`DUX!_O(``"DT1D43"3A/C`5!2$,2X\H(=AO3OD*,:SC8AF_-UFU/!Q< MYWL3Q9A&]>TP\ZF;0UU4%:`@&3!S**A0D=2RZ(DTN1;C+.RUL*K6YFS-I,!, M>?8EY-*+NL]O3T,O4AU M#)$`D*XCPU3I[VD1#EDF%%OH3%"A0->E@ND]+HZ;^0K4-"7(##PM$O(_05=*655.39&@)@@%D MV11$$Y5@DFA&"18)!4UHVH[2/-DIZFJEKS=2LAWI"@+8-'0$-5DTH:)"($TC M4)$ZJT6'!%2PDO9E=+V+&2]@&2O;YMV@4ELST8*&)6J<#?K'-"Q-5852)9:` MU86M!!6K[^*J0N`[&7P:TISO'1Q:1M_L&WU@(?I._`G)PNXM602F@*&`L&`@FO[(EJ&5^SVB`!%:S',%$6_/XCR-,RY_IGG_ M51C'M\%LR^B2.FH5D+:U[OH^\ MO;"W*E`"IJ8"9*I8DF@ZTS<5PYP&$\RP+I3C_Y^])^UMZ]CNKSSD>]HY,W-F M*=`"LP8!FBHO:0KTHVI1L5I%"BCY->ZO?V=(SI#B7-[+393W%SGM?>Y%?<`!.N$3O(!F7L+Q";D+$9CE(Y2 MRI"M#@S(^#7$(O9%9O%NT!KCET^E:RLPJ2R9;^.#"BUG[?!%-6;Y#-DYT/K^ MH;3V/#VG/TKK]FQ5.;C[O]G-P7)DR>-"93!J$R@`5BGE6.5(QNT$1JDE;3CY MN^$X&M8Q8I--)4*3!BO))IZB%K)64)4(IH__-MW?<\,Z95>`M*W)V7B;P7'K M/5LWH;K=:897`'.,I-&@1>:YD$YQ;^B_6%E=M6!$%U&<`N:ZMKO(L!W\5+E, MGI=^,VX`.,.,4C53'>W.`OH$'*GXX('33*I,A4<%19.$:O`2O$"@.8+@C]3:,7H5BS> M[$0\_+T;BV2RZ:$[E7,$GL';JKHIFNQ4]V;>]D@87P?),99I"QD0==`:C$D. MC*^UH&A4_\HX[.;9&V(Y(4NE8,)LS@&YB$X$KF/-7\L,8E_'YFT1'`W!@*RP M<(DTA8\B"!4Y5F41==^GA^=DXDI,KVXW&AU*98F"@%I6=&9RSHG-\ M3Q!JIE+@SJJL4VE_C0UZ2P:@;QR`"8Z<#/$$O>DSSGI!`4YD$06]D5C=PRB$ MZT+>$X`=;P8]PG_A.@N?@!Z^,Q3O:@$5])"M[P)(L^/U3\!U)F0F^%!&";)W MFGS?'$S)A?&:G^4NZ]WAT#&(+&JF/UP_EY5DGTOK>]=8(O_*?[C^?$13R3KN M*/.CAAF#0=MD%`6@M9`>F(+T+K1S>>$"GV$8%D4 MBAY3;260:$3>%^#'Y31!@8#X\/O`R,XK3ZSD6,(F22](!F32. MX&8#SS#X:_1^N/ZCE&V*T-\]E>Z^Q=J!QX?OYH]/3XL&T$[5TN%.-9%8=]N!KS#,!P%XQAEF9$QH*-@(Y!G#D%ET4;O">#.(;=" MX?F!G(@:@!N7HP,MI3((EN):4U^R',C=P699XXPPCM;*G$X9I%4V.Q\=\;XZ M_K*TFG<]G%RS_6%<]^U?W5[-[WY=M/76)=Z+OMZKVX6-N'%D<)[=42J6/7.>$/;S-C_?WC_][]3!L$_8)=S22&^%)'K@#AY)9V_8/Z-!'!B`H;N=KGNX' MUNEH3-68C"/K9A-($,8!!-G00,?ZLL>IX-^^^/SF,,S23M;/N?*#BIW(#@(YY5H)SGSI0K6A(LA--(,1-^O9=#K<:UJ4>?;[3ZLIW`T_^:?9S6SV MV_7Y0A+4I+R!_O"H;.E)-:G6WUQ.KBOXOIAY/!;*U\!S*FKD,4AP206F1`J6 MC%93KI#[(>/SH;AN8&B#2`/C(!;7S3VUBDZR1!MG6D\$-,UB4K<4E94$;L>;S?VI/XT M^WUEPWZZ^_7C\\JX'RS;;D;GZ<5^=B-9"XY/%%9SZ4=:2JE8O2 M)$X/5)O6&$>N[(NR;GVMH*W6*TKLA]$&!1[G_U,"G-5XZ*?Y[_?;"ZBF-CQH MB8:3>,GL>1*V+)UIN\&09&S($=I4-H,@;$`XOWLF\;HEY^+NCY6C=[@E%!$$ MD\)9(:TQY'(;5VM$R?M^3TH#;NC;#P9N*LD<1)*!-;YW5,J6^3 MV9#DW0"VI90?EH6`U0,\:JX`,%I.D;1#;1.W.AA9>4SQ-NL<"0&K[IAQ((Z" M"*J*[J M:I#HU&#[\9%PG1>G,;Z(E`UWX"D8AT01&Y!0M/5.+G:F`#JN'(_7S$0FH^QP(YV9+-^T%UQE1:;[U\M&VU2K_6GYF4?=;V\MGU^3FNM(+ M\;?9_>-BY'OU#0.1\HO4`3.\5`W(!5/1.0]&5,=0B90ZSP91?T&4^7EV?T^^ M]7>SA]G\^I[HXVXH4%JL22S](JNO&AK!?V':DO9*>)",0A*RT.1(5].FM5)] MJE.O/-2W(=)H&IXDV@0='6,N1!)M:5J7=\R^8[=4`&^+RL4D`5PP.3"KE1-E M/M]+TS;&4H39F5-04GY!I#F/*'!@7A1O->085*+P0;=N8$B^3ZQ9]6;Z8JH3 M6Y@LP:9@*9;3F7B9*[^5,4,YPFT7\-*H7$P4G/9,22-$LMY8DSP1J"D\8?J4 M!AC^!9'F/*)0UC0'KT+*SN?HO4#96K6<@8&%4^S-K,)$&&K+&ATA>!F?-BP3 M*JY6N34%HAV_2>S?3/7A9:T"A;)"!@%E_MAQ2:1AV`PF,YU5X$;;+X@T9[(* M`H-07I-)X*0W,#O1:L'1N,Z_IO#A=/]ZYR[?5<)CR&K"7_=(6SOZJ%CDK!-A M?7,SV^@P;AMI)@I028'!8!TS.:(CNH14[:2(QG;M#HIMV98I["Y.BU5F?6K- MH##)!D6]BTA%P:&<,": MRR(PV<]`X`@+0E'0*[WTNJ9-9828^ZK8V:!OJR6.:\=#D)"Y,RRD`":E1=YA ME6P(5G5MDG7\:1]@3H!Z@MP4ZEE!D13W*20=3=D177-P09E^CX\]$NC3KA\/ MK6B\\!'JA3K9>;=^D\!L,W/#DR:W7&?.+>=<@P^MJ3QQMYFG;>5`)"+;#1J? M@W3_'YFQSR'['6Q!<)EQ2,8*@+XE2W['&I?+E#^ MA4C8NOUJ'\H$8Z('\E7+@IQ<5@PXA[$MX$-NAQ98*\G55[;LPY;NUN\N+A0? M+W(%90TQURJ*"(=AD0D*-C.9>O;VW!V?3=!0IQ.].Y"Y*CFF:D$S(I#,R'@`QS*517TFB7 M^W2#[CNV-K_]$+C&")4T$RIF+B/:&&64WK;!:9%5UT<&(<++KISEHUB^D`FO\3WANMZ`?9>Z!J>9:G&>.FEH^=L17`-W=CO!;TF?NL(" M=+W*[P'E`_6Q-)&#"CDYXZS,(7E=*YM1D*+N-WAN]\>]+M*OK)5#4_%W?G&E7-9-4FCLT*AH/84I,:[[`7*_Y0:%YG!>BFPT M.2^6:/SR,)\MUX.6I;=^=OLXGQW<3,ZT9T&%X&![^>AQ1^(!+G>RJ;]X/[I61SL332VAP" M5UGZD%5HPW&,]=L`_BQD/%DVK?#D&Y#5H-!-0I"*J2J;7D8VL(KYG;W1,A-T MI-VT(07'3=0&K4I.DJ#6UDF)&(;6(Y\-T@O@?3'9U&5+8(C`(@1FC$0OF_NA M\=QV\XLAX\FR*5(F[TU$P5AB:7'4NIV&4'GP?O@70]A1NQD2N5Y<"2<24'!N M,;=&/@VN[]L]625=&O6+B28*9;P.LHS':#!9M0U6&$WL6EG_+&0\632YI2>J M*-32%D,66;:+U>38.>R']=_FB2Y;%$M#]M.!U2WK&87'*I4'`$])XUM6Q5G]O]DDESLJ`H^N4=L^BD MSE$A6;&VX-Z$OM#W5D0:MT<8;)`8G!>,V)U-*U8*$_I%DB5%KO9-D;\.+I>2 M!5(*FB_65UJFGN`]ZRT&@C+#C]@X12I0<.XL=%IXS+*=GI8:LL[.[$7-D.0G1NIT4EK M")$B&A/*`%GI3P#5;G_I$(Z+:%X=J:E-L^7P6F#(-6%EF0(RY!6ID/J=%GQ? MG^42B(WN>_>"PO=8MB=)+L@E$XU;(6365S#9N1`KA4=2&UOU1_<R$D>0W<.]JGTA9MMSE\H7=:G+:"Z9S8"''[DQ; M'Q`$=Q`]/2..NFUF%8R"D(XE1DNCW@J/W=P(VO/2XAJ52LDX%G1H*Z2CM3T> M&HAE;X/'F`=C$UCN5<(Y)*<:]/)_[>&X59P<3QB]]=/3^VRR]5\N7ARL=GZZG:M%L/U_?WLQG^N M'?RK#TY4>]LL\]+)*LVKY&J6-[3I9.V<5-TZ:Z`\J?9RM&N^XU'$B4S8W-$X21I=:$3`GE23JB+#:P+<;P M@\-=V_,24Q@=C_[*]EU]>+[$[EPI6;0Z*I;+#$^*AK4=7BED-]2$+9F5./50 MSD8*,CPDAJ#/N+%>YTP*1)2+PC)&&TVKM,IR\6!H`RNYZ2B.1;D#P<"SNYIAC)2@[<**-"CLI"2FV'?%D1066G<,MSU2Q9'7!AL<'4:L-,1&3U$@RSK MB!"-=.B2-MFVX<9R8OD"B"S7![M/SQ\?Y_U)X$E.*.9XI(A<6Z=!6NVAF9PD MN&$#HF7;9O(]P#D>[%&ZLZ!09:Y="C8FS1#71^`T<^9UP5ZN-B\7#=BB<=\_DX$H^9B?T!'R5V)C4= M4@Y(QBQZ,G$/FV!*\W@?5]LA@3GUNE,M= M0C<07$U"-A8.&@HM#)IR$2P+1I(*!@ZR'0;:]MG5XG>P>R462()5) M`V`I^Z*F`$[6X@&'Q+I*R[=_9^_:FN.ZC?1_R3M3:#2N+UN%:\55=J15+EMY MY))C>Q*95&8H;[2_/HTA#V;FX,PYEL%RV9%+4=#>`1M_P?8!6Z[ZLN\0Y M2>RQ'$Z5HB$('46V5H?`8M?SP)`I-!\@QR+'?'FQIPAL(Y>T7[DQM$U9&9,7 ME=\503=0F3=@0>)5Q!X%G\ETKJQ3&8#^#3E7[DKTJ'-3_KN1@/U2P-YBEQ1D MN7IP^?Q6>O7*\B4SF=W#P5LE*$=Q9QE!,LPX0=M=K4=W*;!H6TMH35_X":%. M56'"_B*D4NB/A?;4<2U(I3JMD=$W-;(315\E@"53&LBG"BT+-^=++NO?5*@< MGUZH'$O+J)>>;\DU22EI66GXI.B%XU)36`RU-$H;MO&]BC?1V-;G;=FH?&%M MU6K(#2NL+'SX1A7<,TK3LD7AE>;)4-S0@25E9=I95F:W/=J^DIU)G2FV%M2E MH^N0"VT4A<18289B>0T[LFDOH\AFU+>MSB48A\ZTL;=C,Q36EH#7E9=D9$IA M0HUW1#*#M2>%V@AU@'&W[#1BXHYR;]79/7+/`Z2@D`(D;ARXX)S1%<`*&;;0 MXW14U9 M-DX[Z-N9BV=2&TYAL_&:!9=#!=T7<;MH^.+B1CU<3Y,3=3X?I^&6SCY"(8FC M[9FC#$B_K_.-48C0A(`K[*.KZ'Q6'L=MG9-ADO%L94R):1'S>MPU2]O,5ICK MJ7S&K;WMM)*)#E7@FMR60Y\RL[6(!#F-/06[I+H76F$.%-=&EP66LJ,18'6% M!I"0VM<+?8CS`W5^X9[>"=-\J9V,`3F4IIU5A2"!-.U&`-!S;9N11SFDYJ;P M/=6>Z94_D)B!?IT_K0$J#NL4>*VT=5$P$:5*W')KNO60D'GC65'S?G%EMR@G MR#Q*5VD"W>W<1,J,I`$9R;2U<>Y;M'C4BA\K,R50=_,5*,CA@V(F.*U]I`1. M*HO*KB?X8@PM%25(!3TQUY]^@%A34.]!.">SYH$)HZ.1]+&=6.2$VIE5:?J5 MA9UB]?D.YN7,'+EL')Q*(T&!]@##'2]Z@25+:?[=/MXMOAE>04$;GA"CP-,IS)6O7 MB//^T/EZ0N*&_5YMR#THRY'2_FVWM"QDL&"34V@P><&X8)UK+1G03FGY[_4E MI&U[6YO26@59EXE^DBPDYM&K3MH@?9\?;,NV!BXC[8AMZ7(22A4(:H]:8Z%[ MJ^U9YOL(55NV!7V*M+'@C?8'(*9WKE`!*$0`;XW6*2+RCGT-`Z`:L^[8SGV1 MYFB)1RQL60']8HY3HI958#*$BLQ!"4X\>)/'X#@;'CM" MF:!5V"WQ^`X^5>(1&PO*EYP&IAS7"C,7HL)OR2#ZU?.]=_&@Q`W73[Z=+U:S M">]^'"$"ND*Q<22SE,_M4K*D5SZY4%G=)054;>>WGUD>J_2VY?Y51B4_SY<_ M%_U>'L*UA=CG$\5_N/UR4J%HRP"RL(1#3)+^;IVYUA0@UHHIZ-8`T#?`3MFW M5*Q60Y`,H`$D3M79;;8 M23RU<78[K[`^P1_FRW]L-T!6.5GYJ:RC[[4=$!F8XS5HG.I M%$I"&N[$P";CTKZF&K;O=P^?/C\MT\-3> M(JL_`!,/WYD)L8"Z4\S*O4M6"%NGC6-P[2O*%C#CW#;Y)@Q^-239H"BETY[B M5`I2&2CIU\XYMF74M_6;6#\^!?SE'>-,)&_+BR3#;5:UMAIY.R/X9NAQ0U_K MH!16I/(`)%**X*01W*PG_BW8,<*#MW7;7#><,'1<$2K060A21$"E.78-$UY@ M\MX,?9BAKW5`?"Z#SY3=*VN9\]S3;VHD`&8,"?C;7+>-SZ,(^Y^?9P]W7X87 M;>-/+NO'3C*2V,RU5%)3[)IB+/A;%;A*XS[$'&]FWVGVJ]TJT3"A3"DY4?BL MDQ.Z/NJFF*R)!KZ]5=R$3+A"OA(S:@A:"S5%YX=!!\5S;,(N^#2?>V?.=,9:H;3D$H(3/C.,LN:WV;(FOWT[B*?5$[2T M7G./QG)F*$_BFE4(20:C3)5OAG[%>D),SB07`AT0G5!)2G6[=8ML`"WS;=TN MM&ZG`^H;^L>!B`5^*TMA>26:3D*KO7K]W]1*7K8R9*T)*HEBJJ%" MC.W[]P'6SS>SOWIE2#O+4N;2>\]$P*P-JVA(%#O\QQ8J7G<13X_^HA&&*>Z] M#3')6.ZU^FQ%]J>5O]+HK\XC%ECM0F[RWNA&_FR%+0)&=S&@ER*!J8\_+V'3`;Q2[P'KL8;*S+-1RQ\?N M46._VHJ`E=E`9%A`Z;30/%8$.PH!VQ5I7J9Y.M@G7FNF34ZWUS(_ M1MK.M;][&!J*7/YQ]O1^,7LZ`DL1.&96(`D],.^R1EV1,T4I,HTD6/O*=#Y% M1O'^"K40(#-:9D;A;T16Q]D=NN8XBCXCPY75F3@#`A-DF[1-J>#&*O*3%7-( MRU$DLNLK,KHNG"?'LT,Z)3'0_LJBUM"<%6-=FA,5*:PM[WY\OWC\-%L\?7G_ M\?893__3&%C$"*&14714T%COC3?6V@[H3F"VH[-W^TET%B4FUJ+09PK/N0'E M)$5)4?&*?6]%>T9NN-UQ1`[29%E^AF*/AZ&G.1<'M=OYTBC0W2=%HA!$6\XY M73&^&X/A=.K:Z-WTD4LFE3O!%/LX;R$+F(J2J8"2^1"EZ%Z$HL\PZ20N+?JH M6U",@\U9%QSFP%/46%^Z"]]R:9'Q$:YK_`D/'65YY*RDB#P@*,&SJ<19)2%\ M3>-/P5RFPI/B$_/<1"S@R+7,IU#)*6>VO^A]7IGO'MS=77F*UR%U_'EQ>W]X M-)L+=Z1A[\MR[SQO=R33CE.%OEZ:(/X(D&%&`]^A?DA& MUU!3;N)*3NFVCYP7474J&4]&E9'_0IBA4`:=Z@!13*9-``&OI^F'8])R[823 M,B;'C>1**!=\A:RC_VLBV9L^EMNH.*<(/GF>(+`H"QF?R22H5)5ZDYQ=B_-Q M`Y*?3?`/,\JGY^5-?&&#/!STWRH!*Z,S3,D8R,;5W`UY$\W=]$8$I@0Z4?H) MRQL0A?)82`;!4LJL,:ONN'/:[V>6_K0F@XXN.N/*BX/D'0.*G+LT68)K\$]K,+JE#0YBLKX3'M$-,T1VX<4'5#G&'7'TQ<7LF81 M&0GI$*R5O(N>0QSJX&@XOXQ3]P4H&1)`\)FIC.1X6?5:*'G3P#M-O/2O,D%` M.:3[Y9$6^_]W@FQ>:1L9IC`$0.FLL1PI3.O(A)#<8]NEZA=J]U7Q;'89=4V< M46;C-%V?VC-FM8Z\`OD9A"8*XWK4;5Y!F]'P.89@N`%+L9@D1U8.4K2VDQ<&^2JDM?&T]5A+.5C*:U!79+S`QC(HZ[Y"MJ,7C2.+CMM:8G( M65BPR"KQ+Y<4MC4C8^?4YCT%HT<#T>^-%P><*0!N.25E-J9L0]?%P8#8PI+W MX>(VI3U,C5%WS7/0:.ED9+KDHP`ZX%V(')1M[[T=A^(HJOG[W0#4F=K7C)9R@_Q@/1J,+:-:$-)3#[[NK!Z3Z=?8,L?;" M]O?X\-A54P_V\L:@\XG^&+,E".7(0JYG3\3V?79?R-VRG";T:*5:9>:-,Y:1 MWZ.,FN?8U:SH6Z*M6?73C8L(/>&SO8N)F6#!BZ"88(8YK,]T7-O(5=<2>G1L M*((.L>`">FFB\ECX,UYR`!=SBW,ICMP?W\_HM,^^IU2U..TU#-IRW2@H:>SR MP^QA]G^W'QNDP'5/?K.0Y)0N?'^*L\"-4.0.ZM!30!`%F$]MX/(=(<2V$KO* MR5-0Y=I;.H@^".$H[]>TARNBN@PZMYTGU;\@=I6-1T4:PR!W"97P*%%C<(C" M*MY-#:NH>7/&.((TAXKD'NY7U)D_/WZ\GRV6S^.>AYDNL1A]"EFXD!@:BB,J MIJFT3+4WJZ6XW.X2=%"@$Z4?LW*!.XPI%/97+J5D2<.Z.L';GAOE5[+G@H^5 M/AR#J2^,]@ED=A"5+--2251K:VB;'L!XKYK22G"P@&,PIIJ5%H+@^9!6C MZI[;1Q!M!P!`X\[=,"%@'0..\^7=Q\6:0*&O0W8=TIH`4CRV0+I6C* M)HE*!Q]K+J-S'.-,_NJ,%[,!, M/T*ZOHTO^ZR8KDHPGJ+O4&A@DI,AU/DGY]NBVK=BD%=XD2B\2J"\XYK\&Y36 MO[U6'O[.I!MUMU_ M4?O5F>(5'HTC*YC1WD?CT#.KH^@V&M?6-YG];\#&%P8(+EO.T\83D1=NQZ#2 M&G4GA6_6(*^!()&Y*8$:BL0YRE0)AH52>J![>8JE'Q]^*H7U=>?@P%HZ!JM` MNH#>(H\R"S1=&*\XBZ,.N?WLPV4;)?;,5JH0D=->]93'&JU']Q1N%XLO],46AJ&(S/];O+M[0MB/TV:UG=XO M'N]FL_MEH;7;;I9QTALJ6L6XNLN.)1.VW`!9/D MBGF0XP!#O2B(?YOZ["_=V92:Z!]BLA06&:5ST$*GHI)X4N?5 MZ?G#9RQ0HIF+*J/F,)`\!5-Q)[#:?]A3N;3E-]7D'+XTF7TDOW MR0D>UI,@239WZ8U41NVU4$BN4"TR4@[4/EJ4 M5NZEU(!T9U-JDJ0O"\5LI%0VH1<*_LW>U?:V<23I7Q2CN_K]RP']FO/B-MID MC5W<1X8:Q<1*I(^DLIM_?]4CS5"<'LZ00\JF(P6!8_U5-)-7389 M[P2<2-K@D?I@0_3&YV0SU58[UH(_Z+[Q#*X5$9GA8+5\6N8]>5[Y?R%,9^,F)I&.PP%#DOFG5]9:7:;>QVSA. MXL79&S11(N7.,_2`O<.X*'C5;/+DG`M9CKJ.W.BOS=X8]!(J0$ZX4!CZ:8+< MZ=2BZ#A3>A5CK^(;L#?H"1+TF7(-4`@!,>49FF;PP@?3`]@W\K)>C;T35JYW MDMXA&IK'`S@Z4MQ)85K583@O&3SG]?7MW+X,BX..KQ7*4AI,GJJ/.H]&M0I& M&U)JQW->X"NQ./(*-4#(RV6,%KJ>[D!/J^U=\K0BX/#8Z@M@S#( MJ#;HQ1-T$7:[#*4MS>\Y+[&7Q=5RCJ[:S?IOL_7V^0]V_G^/B\TB1\CXX?A% M_)QJ.UO_\33'6O_U>A]T(:_#K6[IZ3-'*3`=K4%CB8Z'C[$%<\4O>%<\5-U! M*[LL^5_U9,8"6RNT!R".&*TA,,5LBT$M@RE,D!%?[V"V9TB*SK.4ID=UH+0LGA.3].>74Z>Z3W(R*3&3L]D M)"Q0*5"@GBL*KNF;1(T&A:8#R;HWNJ#@=`J'HA!@(2Y5F>4Q3$=-V=C+I M8/0"#-#61K[/$T2G1[<$4*J),D&]QWB<2Z_:9Y-H*@M@A6@+&B90.*C*06H9 M,(`D>3@Q*4I4T[6'+G.97F1:4'I9"L=B7>F952DG;7+K5[+X2WN&@I9=(3H' MQI>F<%`Y1A%5WDPD@7F95U.V?2OH),0BXRR($G(*A6?D61@CW$K@E%+(FV&8 M8#N7)?0D,[+'(OJ)/!"<'TOFT%&"Y=8)A4]#)(P#\.GX-K$AN"YS<]FO.B#M M<\@F\UON7F3EK>8PY_H%IU!G;@0%3V16BP(F-=H#B- M,0W$8K"AQ/W\`;4\._"ZQ\A\&H%)C]O'=?77Q7+Q\/B`JK4N184#$-^'_6O- M4?)4FT"M\$XJ'?!6@"0I.M3P19\G-YJJ?K*'R9K"RB0K%4U2Q+J@4DYW!FXR M[E#-40K6E^V[%#JU@=.(F\+7QV5:/:[_MYJM3ZQ>>DI<)%Z+I(0G6H)*\"PM M'O$)%^I/J`-/X6@"I_'WZ?.ZJB8PB%I=:>E-KLJBA8S<8Y!3,QA,Y*7N%,SP M:0SN*)S(X;]7$_A3GAI)0T9E"=X1;;T)SYCI&RNZ4[U3Q(SIF$=VW12\(M1@XI+^T& MD[?8QL1$T^,0M"\CX\.>\*4)[['U>X03ZI/**#8A3XL&:]M-K5+Z,MGS]4Z\ MQ_KO714!.O&HT2/546A/I&FO"F&BO/AGG_AJNRB/<<8TI"X`]GF\WB;C%_$LK3ES]-0-S'N^!3%#;*O*>7 M.6G;7`B31)8C/J3D9B*M1S.-M__F;@IS0G!PWI-.>1=#DS=E29HBNCF! MN8:FDHF7L_5/_WXJGAMA>,V\S]B+E,201ZS;C5$QZGZ\P@[Y!ZDYE_#!-I8, M5"CS'`\$8,E2PAN4GPS26C89=/!E7Y'RD4`332;:&P],Y@J?T1Q8NTG#HGHO M*#?Z*U(^6"-A.J%F8@J]YCQGX52+N2H([ZE60F??VPFD-TY86JW_I_IM=K_K M8.V)F=G/?!]FYGOH:21>>4A**A85:.WYKC*:X4,+%=\UY0,G-/TD^7=XDB$I M?/O:XS.)Z"`YJYG<%6!9H8)5%U%CPDG^4GUY7,\_HP]U<_?/669J`M"O\2"Y M#419C`"`,.Y:F/*`VJT<0^0=0.81@LXC?D09@(0,34Y##:-I..C8@*Y*KV.A M#,XD^Y?J'IW!VT\K-(AY`5NNI.)]PX_(-Z]R^`FWV8ZB(ID&&Z<)3XD9;]!= M8=8KV;K6+&/C#8WG3:7QE1@=$5QD&*=EG8-QI\B]Z!9VVU@Q!"V>BX3>2W<1 M;C^MGHN=[;:>FV4=FA20/^)G^,OCLLJ_NUR9+B.>.N)R3U%,T1I.(&7]08R3 M4L0R]#ZD.@[R,!IH8',+T=1 M:HUL]%ZTK-1[@G>`LHZG[6(LC1:[%-#`0I[5-I8K?`#MXBFARI9PT-QC/9IF$4V@B`^.(X.:0R):M5&,U2I,B4O.UL!CJ#H?`X&\])2RL2T%T;G M\!%]0F@3/('TC/YE?+GS.'CRW])Z]?!QLWF<+>?XJA;;Q>S^;X^_WB_F-W=W MU7H*=)](N4"EM):,!`TBV';'#OJRY4.A!*3JF)ICB;L42V.+0)*B2070X!Q1 M.8)KT,\%1M%AJ#'A^MA?S[XZ^;>OIP&W_'7[(3OC>% MV/G[$7-I:*08_-'D?,;;2\$D'6(D0D$>ONOI?>!=_.Q1CL[@_[AN39>8C2RZ M$*U@>"?;(6YF*1_:DO;JI(^I:6'0/Y/6%.B[L,PVVWGSY7?YVM_U5MFY^8OW-C?UM7A\97 M]]JNI*\[J`%ES!V12D&;6R$62I`]4CATDX_H8(=9/ACZ,_M[]66['Q(?E'!`A/9YG1#?. M-B,=7+I83NVA7%2AI0_2<@;10VZG8]$0G:TB24KI/$'9`F*!2F45HX8WGT9T MD^]!I^>WG@Q&'ZDO-1W75N0V59T'2%S4.LC&QX_`0Y&^`.!=35=0L$=@MYJ4 M+Y"=SQ\?'NM\QZ&*S;-S_3=TXE:WTXMEU#$5**4I[_FSR6G2UDZ!)S^D:2Y* M>.=(OCQ'>#=W#2[!,PR%GWU9;'/*M,&A.'U?0]+2>8):28/.^!ZFU:TLX.]+ M3;5?[3R%N`MR-;K"T7/'\K8#0;+?AM'U;J6.E<7H..TV$UZ$K;-L-"1OT7Z8 M%!D0*:TRH>V!I;)\4R!+.)N4OAN0V5\+(-%3AT0`1>C?*1\JL@(;=3>,N" MHD$X?)A-WI0/9AZ33HX[)3R:/N6\U`W@,[['V#-3`J)3 M]#Z)\A-&$*C MA>FP,D;3V2P,+IU@/(]XL>!U2L3E\?XF80'@60FMPRBARIS'0KT`^_1!&U2U M#@(J7HSEK+`Z0;.Z@079@WE8Z*NGGWL\,8-5-(,1@C9:\8"!`A@G8SOU$_$+ MA9(A7;_R)&K&MEKR9`-XA7XB39Q:#PU,/LO+.HIPY;RC&5UK[VW>OA<$%YH' MH6V;5.(IJ'*R$8Z@)NC.Z-(E M6,U14U80G:67'Y_ZR$(U!W*Y!@-TT82Q0N<.?^1>"-X@UZ&?'$T9!M:O=8_E M';T=/N[OD[A0ZFH58-*AOR,I@_Y',22VK5)`6;#W\U]PP880J\SV::G8V M+Y=I$F-*Q4A2[@&QJ,4$#VWS!T8RMGC.7'8FJX]HC;I0FQ?J%Y:;BU'[X,77 M,>W0J@5`67Y7K+-M:C*I+WH\W1^[?_+<)&+_/5L_@]?N-.NF3DY^^CQ;/F?I M?ZP[`3\NG[*2HX7&^D.+XO;.6Z\+`)V&U)RI_FGV4/76(_%2Y52O_C3^FE$HU:\NP:>@P!07D2FD9IAA'A7I_`)I_/)L-A*M!R[/0O M?[27D6<+]5MC;S2%EB]5/ONPR-B#R]M?T"\_9(X."+*6"L94\>'+_>J/JGI1 MQYDHS(_+V\=YS.%L>8IEB$0<+>K->[`(\1X%=\ M?#KO10PA:.6()U9K2EO<)6[$N^P&+."W5IS1$^.H8]:XO#+#,R::TA'^E\2[ M[,:]EV^J.&,4C.?]JLK(8)(@3+30^L1)]2[`$P7X%1^?S1TE5@/ZGDJ1P+P, M;8=Z9=_1IQI30G**9$]J']MU)IMF[[*[+T>9[(64&B6>I.TUCYYV:2GD_=[P/5O5';7ZW$2$87E@;N< M9-$IY^.:?F>*4VL@D MJ'0$B);<4VK;Y9N1NS^_[/ZQNL>/R9O6OHLLY]Y,FTXVTJ2#X1J"XNAZMG4" MKVVOXOP@%+RR_/9/],HE^(T4Z!Y\062!$P\.N.8Q0TS3QOX%26)OQN4#!_$N MQF^I1O>Z5Q2&?."ME1ID`L.(:?.=RR.&#I&]0@M?DA>ZU%ML<-5@9@\4( M`@/YH-K*-B5[2,F[!*]+E8(65CJ47YZ)4D2!@J;JYRTW_0^12_XNQFM1 MI2Q/@D4=DO:"NN`\VZ$H$'I`E0KUUB1X99G0?9`\Z4#8D!P//CE'J&T16C.: M;Z\$%7MKJO0:\Z'[V^*M9REZG]`B1@=)TA:R@$?H%Z,@^EV,UZ)*0R").*>M MB"0!]32$W>IU1GJ+2>B5LKH8E,VHXX)PJ3+N M?V,,,QYPORH%]2>18,:-3>NJ^H@26U>;[?>7*25*I."8#2'DI>A$-9`J7/K8 MWY#V@;Q:BJWO/*]:>E>@1*4GD`=9G8M.TH!^BF@"0T6LY_TB)/1=A->@0+VA M@2IMDA26"N5=5$U0B"&&BOW2HY?HJO^.I'>M?J@BFB5""21+E6*6LEV%GBD& M[^KSZC.C!/6E8TD[XPU8EK@T33"HI$[]/NB;4Y_7ZG\2\-&3)`G&@T$&JUT+ M?I";LP_X+]2$>E=<4;4!IZB(1:#=Z\U==2*T#8XQ=1?7"+P6GT6WYWTKD!] M&FHQBE>H0DD&W!.6A#:$%Y8?>(!O2GU><2:4"D\M(7GMJG32)1U5,],2J:7^ M@/I\K?#]2J5WK=YG8*@GJ?/6*AX"1@L[7$4)EO17(MZ<^KQJ[]/Y"(P$5)36 M<9''VE,3O$LTB_)=?5YS]I-H&ZA1,5'@0(%H39KL65!"'?(^O[_P[Z>:^IN[ M^F\W]O?9XCZC2*;5NIZ\[X7)NJY'M]_04".QM%8@>6O\4KF(EZ^J>9B=6RRKA_+Z_""R3Z,<%Q M8C7U&KSG+AI+\_*^!FV)LT1Z!`=:&GV)RM^?1W!].N[U9(;"HE%X;J4PGCEI M3(/NEA<8I-0C,\J%4)S"9C=@4",TNT>AR^$3?);;;/KG8Y@4D^)CS7,CC['[O^$B7'A\Z-DU1/\R6]+-]IK=%Q.T4;G0#IIHH,FTD*_,,Z_#`;_S`B([ MXDBO27:OB(>E@HN*1YJ$]8XG+P)K' M_S1-50W-\2S*S[.#>'1EI;IVAOKFYF=MC@*.\2%C#';_:,`3F$:@^;;E\A)M MQ?350((QMG3=LQ5;WC:WH%15Y?6`YRT,\NYM"#MJQ(%AR3!-#'3/TB1J&ZX& MK&U1T_C!ARXU+5E3;:LP`Q4UPT"RL?7,DS5=PUS MFP$KFDZ[/[Z[2AWY&3JTHS6'C4F&3UW#]4W5<6A`53[%J,L,`T6]^/U/\QNE MGUH8B4=UUF\8KF`;1D&?X_%E"734P+9=K7Z8#?7E748%QT'Y>C9A>6D M0E%D6]:ROKU^XNI($K5Q8B),O17=40+X1$T+7`JMJ_8"SWX3Q/7R:='& M^^6>ZDJ&;CHFS)Y4A_J>6[\'HGF:(*Y7;B:=*+1;IC@5A4HR!,`^3&$<6Y+\ M>JMAP[<-681K=NRV5OH&(JQ/E<$M' M8NNR`?$6/XI6,Q15<_6@CK@@^'HCQ-6AB$MQ:2!;@>PYCJ('IJS:_J*H!B8K MGBN(2WO#(_(RQ.4JDB6IGBT'LJ)KCJFI]1$WGNU*VIL@K@Y%7(XD.49@J@:U M- M"OUM55$0#[EZ[/+KF'T*\^^LY`\+TXCQ.PM[E#,ASN9JH=STPX&FNK;DF';@ MN$#_5E`?.>CYNK5VKNE"!G[TX)6QGM79)NT3=%*I1/TCNU6D4LI M,%1)U7U9#0S;\0S?5SQ+AA\"2U?6CZIJ"*Y?;23]]Q`\RTN.$2=,OW_,PK0` M@#]\(O;\O+H'3YYS@7Q4U71\:FBFKKB.XB_+U2VZ<49H=?;92J\?Z<\S>E\= M<,HST`I=5F$\][`]639D33$L'_H3>[3JBU5=MZL%DU38] MZ)T//D][LPL$]W$6GFBOK MANRI)E4,JDNV*SN+'JJJXVT8K:[19R75@ M'UN7[]O#\FF>R8O3#%L+;,VT@:FU^F1M2ULY6;NN:3$ER8*0HR/R;1XBVY0/ MXE=#T[1`UJBGFZ8M`PYK$['M[>,'=U#+ZHY\.\;/`]-G3+68R)[RF6?_'[ M+TEY,XAO25'>)^S]Q1":O!R&DSBYO_X:3R!N@RB&_)5-PO1&_*V(_\.NJ30M M;RY^&94W:[E<]J`]Q0M500U5$Z*I'_A7FXDV"'@'EDK]8PJNQB`=MWH:\JKO@#W_' MFUOTY!W(\R31^%AD)ZODY`M*JCF,$3$5"?2 MA[FF#D5N3QWBO@\I"5@_G\%T@7#6[9%8G!R>LHC/E,A=7(Y).69<^&F8WO\2 M3J8W/YD0.]\4Y,.?GWOBCT)C0DO5#2&90A`?Q=,P(>$DFT&_LB'9T,A3.OP/ M6;DR"%R60/=::1%&,(IRF'F`Z-6KO2!3GLU&E>`#_MXT])Y_%@+G;!+&*0\W MZNL',U;?\SDJ,UX=:O3F"N7X&-2X($D<]L7FB:3,.`JAG984HU_)K2J&XX#; M0*69K)UNTIZN&#U3U=OI8N4E%N.S#:119;4%M]JK31FZ:I7;;#">3\\7XB[- MKM<47UP'@W8WIR@`&IG.LT_M#*(J63U5D]H>PN90]S8$8)LG] M!M^/P\&<)PJ.54YV.1NP*I-%ABPL9UPMC<$<,&#-"4@XX,#L,\*7EP8#UF3) M@M/LOV^R%`"SR'=WO9SU5[:?9H');B;XVVY]:VA<-CD"PLBBR*A?>O#35J!`]I MY1;#@NME%E52M\/X],IJV1/RSM="K[JW3$A"YHM)9)AGDVW^<<5W3OCH;+ MKPUL`X2*65)6L0=$60E_I[JUR,J\4EJ%TQ6Q:\^\`,!#)LCM0T2>$U"!\'%5 M()DD\-LM2X4?B],UU;;MST^%FVJ-6P@#YL+`4."B<4%8RFGP4PB^NHIAJ"[= M*'012385EK,H&Z70[`#L,KV,PF*\-%CV@Y<@L/:@85WI[8:6^7S"-&?F9B0# M$X=D)I;S8.H`)/J?BOE!EGE`<[FX><#Z0$YQ$2UF&&!`>?8CGE3+5HB#M%%J(IB:9:YR*4%%I6LDR[@ M'7W^:+<7%7QATU+D?QL.21(.26LQY@Q'HYR-N&&)11$R%&``M`LTD(3#@4SG M>"`S4%M>1>D+:)"LQD8URX!X8I@E2797D%]%W%#EO(O?KEL)&<2Z9"-FX'M& ML'S_46T\9]$L#SNNI35H\._-CJ19/@F3U:[P:^J&RZITBB7)_!JQ`,^_%],P M6GP_'.23,!_%:=7)<%9FBQ]RT2WQRUT\*,?7JGJEKOS[^::?Y3!@EQ&,1S@M MV/7BPT;0M90BKS_QZ27O>_K^0KT@.0RH^$SK:]^5@^7'?&L+HF?O+S3]YY46 MEBUO;6UY(WWB?:I\D@<^)/9\E`4'1V$RUW0_*\ML[)<837YN+^.(Y`XB/<\$'UX(NN!%5C_C&PISX5<+88]$Z MN='>;A>W,ERUP,K%R;6]1<,P4\J'P'G7XW@`]-&J3UFJ:%_]/`F6_3#Z/LHA MJAUPOLCRZY^BB+'A\/7@=9%CVO2?#^.L=6P]J.:N*.@?;6GG44#MT-(3E2'@ MUJHV:$_2-M>IV]9(5\:>W]?/201A7_[^(LU2=O&NEO-8Q//J^&4SP[:''Y./ MX,<>\UI'M1RU)U.C+B)J7T+(.B,T)G=(!) MF4M M]N*+)ROT+(#7(GV^$ZF#K=<_G.)K)7^W3`U9GJ+*FJ;(EJX'#K54 MQ:RW-#%U>MK4WO%K\Q5B:M=/G9KGF-&=#EN=L,.]XK?:&!`<506Q0VLK; M5LU#<_A;UU]8Q"LFX\->3](5Q[9]([!4C5(Y\!W-6&P+$026XAR=`H]JME]Y MHE_D\D71G$APQP4)23&;3/B+*[SRJRJ;8GSV6)0],DMS!BZ7_S`*XZI"A]?G M5*]C-(I[UXH#GEY0N%D,L(]E^?L#[L]+]LG'B=/^IGW?J^[0S MZ2?*M_T^\TSZB?;W-O'YVN4[C?V=2<*A6[5*S<"#;W77Y;S#(^%E*ZL,A\QO M3UBVA)![O9#;6HLIWGS:5Z/(?,^$(5:Q(HT]!S_&RU:/M9Y=J0XM_KM>2T+, M(.<@YW1"/X@?Q`_Z+/19R#D=T0].OHX,JF,L`1P.NF-2EYL5)=(5(NL(3C&, MT];J7Q%:"*WE?1\AW'IDMU?$%F+K2?KCAX,1<3H8X@OQA0$7(NM%B;G[*4W9.).%J.#$':%[7:SN\T@%L>->\SY)Z*>QX= MPN/G0CF=E!X_"Z2VECM'^D3Z1/KL M'GV*6;B!LW`,,I$ED261)4_S%@NR)+(DLF07L(HLV>D\-S(E,B4R92>PBDR) M3(E,B4R)3(E,B3/O;B+ON2QY)KM/K#/DF%7-2-#.B[-EW?5N'K#=*5TAKA!7 MB"O$U;GH"G&%N$)<(:[.15>(*\05X@IQ=2ZZ0EPAKEK7%;YC_+`VW20LBG@8 MLP$)B^MCH.^4BMP#EB]NMIU1UKEEH1!QB#A$W%DHKC/*0L0AXA!QB#A$7'<4 MAXA#Q"'BSD)QG5$6(NXM(.[YU6?T_!?DUK;[>ST+PB]NE!U/+KRX?A`_B!_$ M#^+GU>BG*SZ]M?=!CB=S^R]N&')/U=2V)._*4/+[G47K M0CY'/N^*XA!QB#A$W%DHKC/*.EO$O9V8]9\'^('\8/X0?QT2#][AXIG%Q'*/44SVD)*5\*58Z]5HD4@HR)^$#^('\1/ M1_6#^'FK$=T1UOA>2UR'NU4^K-NO61DF)%I[19Z$Z8"$MV&OG29-XA?'9.<8@X1!PB[BP4UQEEG1OB=BL.3Y`\VJM6>(+D M#97U'C6TE]?H62#OV,O2R)+HE]$O=T5QB#A$'"+N+!37&66=&^)P[H%SCU>R M>P3./?9-G;PK>2Y@Z_5;/O_SW:RX'(7A]-I>I!&"+/\2)NQ+G4/X"H([219] M__U__ON__KFXGF_7:Z<#_I^_S$C\">J-[NL[0*4IU]M?;/C^(O!DB6K_IWS[ MZEV0>``_A%%YZ;FZ*F3K_&$U:0 M/]@=^2N;A`]3;N/V)$[9Y?R(-BI+/Z^:G`H&)@8Z3H'"X0ISVMHA;M57?OEU M7`*0HNJ7NZHO_2P95$V+C9!Y9D=\\/?<$7E?$;@"'= M\^$O8C"_@H1)0L;0H^2>)#&(-&C4JC?R5>0N+L%^%R.<\;(!/HR+N!>DK"B(&5&^FPC8W9%:NUN)-,FX3UT M*DIF@_E]64H&;)H5<=GCK;-[N"3_SDHR!)HI>J*5`>LW^W^UVV(WK&XO*UJU MNVPRB:L2?WXC/`E&EJ41/-R+BRC)BEG.#C%`S?%5DP:NHUO44#W3MSU];H`> M]7UZ=`-LT[PVC6FIKLJFF@H[BD%1_?24`0,9)W%Y3SXRL(GSX(D/*?G?,)V% M^?TRN`5\2CUAYPL&@4>SG'&V`(,.";C&RRA,(R9<%1DNY$ZXW'`CL$3.;3H' M5`I"`+Z9AO?5^`-/9+/1>-MC9?F*?!W'Q;+%NQ@8"QAD5L#3A\`JT"1XYV@, M7`#WPW62%0O1*OR'(W"$'.N50FK@ MLP(":N$X;QLWK]XK'"__RGY$;,K!R_\>@H.+!)$U1ZI1"X*H'1::5!P5WM=$VYLMKM M&N=<%D;CQ?BWTFH5*G*I4PZWN955=/$%8,\F?8">`DZ(ATH=TS&GNE8:NB*V M8(Y6&JO5MB2O5O5744DX`FX;<0XK12G<<`;N%P80O.YD-IES6,U/,\&2:\%" M-F7@N'**WW6="[QG0RD\D$GF+ MHWZ6*ZX6+B(13NT3I:^L_DEK=,F_-Q^39ODD3%8IEE]3-RS6)`@,1#*_YOV% M="&^%U,(N.;?#Y]?P'P,/%#5R7!69HL?J@5<\'U*U+Z'M4LHJ^O+\PC9\?77A:71N;WTB?>M^3;SSH MON>_B__"=;KFTZS5W#;[%$^!X"GCG).EUX*2N-%43_@& MK%M'UTA7QK[%=,R>K//JR&5S0>0MONVE]619;LMLNC*ZI[>.M^.3#]GLX0WN MD*;U%`LW]44WM+<]'5*`\IK=D&;@02[HAO8V&TLL6I=P#0N')=N8-7+_(MD16NX.4I![SE43YZN;O?5E.>J5L\\:++QS.K<ZV(>M+2UW%8$!"% MY&P2QE6-3!]P*Y)!O*QG$GYG)%SFL>>B+]P"O^1C7)3D8]CG*:0LCT7U3%B2 M/HLRGA4=S*I*!KBCRF^G5:8\&L?L5I0!514\$=@L=`%Z,IHEO*7[Y>-XU=NR MS[STINHDKY[*>,M@F_=A(BIPM_8('CH7@>\\(ZH*@`9F,`ZS"=SQ@U<-Y=E@ M%O':VV7^IOG4,"FR+>IZ4#/_W]Z[-K>-(VW#GW>K]C^@4COO)E6T1N=#,C-5 M/NZ=^YE)LK%G[MJ/,`E9W%"DEB#M>'[]VPV0%*F#;!1_M M!HMGJX)JX]2=)O MS"A@N]WH&M5`B_$0D_EZA2A3.NPTT*6G"N;\>A M^B7)&<;;TN-"&:R$2NA:.7GQ1O7L"O4'C6P"&_X?S'I%+=S3/B]R&E> MTL6(>2Z_19QG-A643*>XXA-`^5P?4V[M(`[U%I/;6$)?I01JCMQ[O=4C2:+[ MC:LDY%[Q[6"D.;1,QK?_$;:RYCR_S<7V>/*P0%'"S(,61A9`3*7>HO.#2>CP M^/_C@$.?J2TAVKI<`6395Q'!_Y327S_*2$S9?0.^O$>(HNZ&?*9LC52FQ6(" M^@AVYOSC'ZS7Z?0[O52?,3EU##;605-^*R;<&^-K-WY](KOK>`8#!C;I'&07 M*3-US7T04B0"_,Z/'J$5`$3XQ7-C(HERG+ZM,G@<82'QOTNVU;VB`_!E@#@;$TPC)1AOI M1MRE"%2;F\18^`Y7FY%<&8H9[CGPHS25?2+\D^0KT!4>Q5GZM_8$,L,`/L)= MR*>J"0Z*,#3Y"30),SIX$F=EUE'6&B\#AM+\].[9*&E*( M;YAP*F?"=L^R*\?9FHU0^-3[-7)RL[\S?XK8= MQBCXC.@?%1QE#(0WY9'2W`=0)\`O3GI`7VZUPXZ:F$P\5/:^X^+?,ML-I+1) M#3L^JG`)0!JOP,T2X-/?@L\&A`+N&X`03`4B'-ZDS90O7`4'96SB"*=S&I"N M3)H'UT![X8GI,U*]F/+O*N%Y!KX^F#-0(6B$VO/'$GT+.=@XM44RD-+%7GGP M1]H\1^#6#Q@IISCUNT5DWN?)J*`X'G^0L186>E'0:#;%H5"R`#4$,:@)XKU[ M%X`>2NB])K-D/H,/:;!/N#4$OL`-FI;N+AKANX1J4'.A*5I5\C_`=3E#&ON) M<8@>Y\L4:?]\,+02Q*'L8-*7PFOT4/I!I)T#C@(7RI'F#K0.&`'X#=^4S,42 M`?U#9CZ`A5O!8B]2[)LDE0<^?#T&KP'\)R1@W#2J""?46TFQ+L0SFT,KHTG& M>6#^DATE@+Z40O?A:'^$5T]]%TUHM&K:4TE7.\\4:@N!U!LRU<05/`?F%GN5 MFS>^P*EN,)CFRYCKJ%>D)YZAXK%DZIGW#K-7"?AA`G*5#&,KFE/47DQ\MV*C M4+C36_4V[>*E-V*$)E1^.%H%I$>!#(-F'?W@<#[]4YL%EV\%'U9/*'QA)Z02 M3?1$,T0+(7'3'+KSP>Q1!>\MN"U2/E"8\!N2)OA_X%AIAPUX),+.C=&ST)XU M,+`[Q2:H!T_<,'FY?AN0T"QA1/3"(F%/_,`+[O3F_BGNE17A M3*@FJ77?9+N>\K;UAD"]%R>Y6;]IV23Q*3KZ>'EB2W-;18B$!@2Y&W4Q.F+#;.LV+L8(0N?.#=Z\F5FWKN.`O,[/:*N4;JXZEV M6@#)Q"[@BQY%I%U+O+MH+M'KQ$LRH.BP`70@,7N)P53U"*2((D^DS2K&9)X< MF[KL=ER43&'3]A/04SA>GMYED[IL!!.$%$8N]VBEI--L?)=F]_@(/<._?4P< MM`3+;IC-I'"E4!^#:(7#5LR@%>&%NI=4?I#.[Y#1V-\^=C M92LJ8VQ4YZ)0(N-"W$;;U<*XN+@8]LY:O>'91>=T,.JUANW3I!9&NWW6&^R^ M&(U)[V3)%\$%`\F^)*L5.KBC7%C`\N=LM:KZ6'VI[_4_(K1C7*4J=+SZ_4L< M1[9BJRV@N/5DQ0PO`++2@0H5?7R<$[!6Y$PH-YD'P?X9!@_PTSF?N5&RV&0L MXF]VS0TG8^"V)=Y#$J%;/P,OR/$M%G-766Q4*A#N5FXUK+V!C1)0%-1-`:Z?^-@B%\IG![8W2 M@.$=AA8%&FCVUGWWQ.1PFTZ,&L/>#T:>-&\8N-?0&UP:!XUZZ]:LS3,OUOKE MN&JJA"&69*QPH1)#3Y'0U;>,M*'3:)?8&[7*`-=R#(;!7_?"YWJ*,B\BY%CH M_V#N1N+X`0FHZ2@OSB(P"*R*G2&K*B\PT]^96@W!9=ML&0I#TR@I>X)37.WS MXK*^Z\P7JV*?QXZ+WM8\J@230]QHGTTX36E_UY#6._Q1YN>-RI77-3S^&\/$ M58G>29L^:N9O4%<]XJ9HN*W!KB.L%"&2P,#8*5HUEUC0;0[.9-8IZ,!RN M,:6"&\;S@9J-GME6N^,Y3M0R@\*)Q8RY4TW#^1/88@5EE8J45%]\5&N8L+'6E`';?!U4<5T=;'D(30KD-KXC!^7PY'K1VDAH"IEC+-Z%7+50:PL#\F( M$%L#:S183C;>"J!RPD.=9G@M,`%Q;MDO4``J/QEQ.,NF!7HM%PRV&83U^XT5 M1ZIL1VI@]U1_4K<^Z8">RZP>W'FOF7O,JB(+;/,I(DEB2FI-7Y5>M7!*%N"O`03^U#+,+%M: MBBV6*0T5Z\Y-130)G%SA.:1LI*B%!-DTW%M1@P/#IZ2"*JU60--LM@W((9<7 MI#)SGQ;H"HG5A#'SXZJ6!]8X17._R7]*:N8TQ]P4W%#,IM&O:M'!=G7K(?9- MUT-T=`86E4+$^XR50K32=53W7GB/AMP]X]5ZO1(W`.VAPOVEE.)[%EW6/&JL M+Z4:C<_^BFIM;:TCG:);+=T[#"QQ]FL:@=?UAT^S\#N6J`_",'@`3PX_F"&> MEO')=Y8'J3,*U,D0T+,O83`%1P.WI>@A5(&OPMA::5*:_E9=9F%7=5!+S!-B MA5X;5H97PIU)EGTQ%%S8N)#DO()##`89?=XQ]/G',9;AGJB\TNSE5_C#E?[A M5Q1N5N9#W";F7JU M&H9"J&P>.2WLB9@/7C)6,,U`Q!0*=)LC?D!W9U!B5'A>\T!%/5)E7Z'?3B@> MF!,\&`KZ@2]C>#*@LVCD!-SW$Q5M\1789L59I52]0&PZ!S0)4:MT,M1OE>F3 MAK22]-YL=Y>:(MUR+R430WQO>*:MQUWU'_]0M9)U&N]<'%BC8@7=JX7BL?M= M)\$O'+Z@SF-1@4$U9S03*3>#'UQWD,D!$!$PN$RRGAUH+&9Y81P=LXQ4#CGW MQ(D2BA("MU7X`8<7=W\^L=%.;S^*-6)4IIH296)<,]DVF-J^(^!="T8F>55R M'$6TV%@5$QEG^1NYW<;SH(=.;<:-,YFE42M1.OQ1EYE[S@ECK8&UZ@B(?`Z$ M=@%"Z.LI"-A)]?DI[M/&OX#M-46`X'R-ML-/,>GF/BQL$';$^S%/TSW3>:Y;66M$8J;GH1=-T M8"7;#;9)U$%;\KPGV5L\Z@53DQ/S!/.2`)[[8B6W$@\IV=>\<"K*_"`@3&C- MCI0)V.DL=#V&+='M27<09JH!O\\3(^8V$Y\#CGZH[>GM8U5!A&E46&7@N]IW MY)EJY\CPK%1!`TUBZ"@JS:9KA7-QUH\]Z+0>R654/>/[*2S70416FN.B9I=^ MY#VF4L(-51S7`1>3!9644EW-85=M;UCMVM72LU,K&^3>5=*]PX/ADJW;RW0? MVB[2I]I9,4MKZ634BTF$<]0NSF&>FK48"DX8BK6DD\?T',QY!Y4+HB);93!0 M"7/)9#-I@#D@,A44O'M7# M/<"HVVUT"_]5YSBC7G_'QQEUVW2<4>DE$=5'.M`(WXU>+6[@?S]Q':`/LTN[ M)1]I5$:QY4KB-4T+H%.-=E,J]S!.-6I2W>YRB>?@^(4.-E*1>ZMMKGQT549W M+PIR/):9SC9Z.N)IC08M,D9DC#90J5*.-RI6\U^NUU\[S1IUS1U=^8QLJH*- M"INR5NT5KT[GMZP;DEJ,YVMQXDOK:;5&IGS+[86:"V`9Y`^UQ\% M\W3]JS5%K(J%KK+?/X]QC53X4L5FO^H2<^>X^>\:\Z+4>2I?$L+:I"#6L-7M MC)I7_5:G?SJ\NNJ.SEN724&LB]YIJ[73@EBF=ZHL[TOY;^Q&CT\.\L:+D3F$ M%LW@7HK\J\RX:[5[^/,\*;&T'A<6[@QVN)[+L?,2B:9VP76M3JNS\HSI;1ZW M)HK77\_5+>JGY1R^_/$/:OM[4OS,\Z`?8;%C$WZORKAGR^2S M,``KY2@1F-R3U6N:/FIHO'CX1;8K)Q&95-W5AS+Q.Y5Y=)V>T%000O&^0J'S M6Q"CX+XN=)W6[[T-@V\BE+GDIWR>4I8_^^GT^N+T7^R?7G`+SG*"@;3Z[0/6 MXE2%.=77*F-2U4>YYZZGAJ1X(H!.5G-]=JOL5OY].A=&YI^+&$I*F"3U>_,G M2ZA^-O+=C9/""GH?F?Y[FXEL:"(O=JFPC]7[,BG0M5BQBKC M@:_SG"5[$`K\[G062/&N6,`@D4URWDT"%7TFD4RS>&1>5^%:$]SV\I,$UZCDL-#8GJI)F!ZK6M7M?,ENIU9F2-_-4134S[ M*KA?%B8P$E*0,2'88TG+A`&N!+I&M,WNKU3DO-4.C/6JT MS=I;?2ZAPB>8*&4:4CR[,MLL8.7/J286EXN\%^^+Q%1MH2YE_E+`-+=UUVK)R[K`?*P5`MV4U$>(13N%]DNB= M[2Z?T^.J]/+UTE,.D/[YXQ=0TAC]`Q6R\1Y+V'#2-6O0=6+J*I&M3[1?/35! MQW-EXEFR/]!4DO>HU[1&@^65EU>8R@:[,%S<96B@2:\A5D`3QS?^SC MI[ILN5M=%31CX:(Y7^8'9323+NO]TNG)A[G-B6<>M[^=7-N30$4AU<-.<):/ M%TP#1WCS/;QZCQ'^D,8%3M*X`)[N-]4MV7[/T?(6HP(/=1>WDC6/]MN`=K-WB$#]U%#Z]G0VFJ0LIO>NY^B7/WHD!7YJ5D5Q2F^1O(?^1YKWYWMJ=0G/?VT,):L<$-7,[2\G\$A2KP7H$18+B MCEAQ,P<09'(L6VDOO^-Y%9C%A^4JL0R3JG+WSIB.FQ1C/3;']!OE[[P]BHTO M-=KM7CG#04JYJ)3+VQI(*4DI22GWJI3+E7E)*4DI22G)?:V_4FX^YSS0J>5] M@`>P><_MABXY7EX=!6N9,WO+HU^>)(P#9#GYGY9/2K%B=5<7X^MLI"ZD+H>J M+NV&L5J:I"ZD+@>N+KU!P]C2^G&H"RVEK9'@5U=^.QECOF7AP*1*AB(JHW\M M<];J60$=MEY2#+`.,<`**=XFQ>=)\2J"'U*\^BN>N00Z4CQ2/%*\%RN>N;/[I)X;)B]3,\O&/BPG=A4F+W5@B?.5B(?ZH*1"=M.0MX MZ."C+^8E+,^$S?&P@:3V';3?#]@LOH512(]"&`?K:P#G&VFM>8EJ7ZXURYTN M5CLMGK.@*H2F%R950V^QLKXO8=*L2M3R7+'>0-6ZQD+$ZHR-./LXYKHQ\U*D MV`1U-E$B;3R]0)4W4_UTA;22JO[J9U^1%OX^"\58A&%6]Q0&-?9#?;X1UMZ& M[L.C(O6`8";P;'IUF@+TW/6YCP**G_@95C&44/J8%O&TFH)W!%/X(XL@+`KP'!'LGHZ1( M>B*$5Q3/G&O2JVLRF>:K'=-3%KZY`6`;9"11V$N+RI<6/91JU+/ZLTN4)%VX M4!=RGXIH$C@6\M$ZU5WDD'NQ4.?0!BH"O$!S)5AK^9Z]==]EY91Y=`)7GP"Z MQ.,'^`5^$M_QM!+);U62-K8N*S.?GCV"1<:1)M-3,/"%]UB9$4O\@_ZH)\&C M-%=DRIG>-DM)-+U'GW:`2HV"&@LWBD/UD/MW^I@2>''2+($ZYP9.KH.KW_)! M2?DM/"&5#9ZK@"6`U1DOH/J*)?`B_'(BG#N!W^ARWHF$V\T/,P\K[=\#DW@> MS[YO?4@?J_6Y>`B3S%JM^5RQ0-8!D!!?AY%\B>)E9.BC`M2@`NYP5&/@$+RY M!N5`G]._/]9O#-A."Z]=WQ:%D4&[R!%^]WA$!%:Z!X#'\#^/78G;4!7<5\5& M5;E0L*!S'A$J&3FN_Y5@8<7SQ,9]F.BN5]#W@JD%,8V^*#.!Y>$<\4 ME@%&'@]U4UTLY_[19R*Q>-"*Y'=U/D2^HZE9569:LXR,[0GR2&IMP"I&6/54 M&:LQF,M'&\$_MU5XN!"HH<8W"K=XWH\ZWPAAZ/JQ.J&(^]Q[_%,+/">WO%N5 MZR<^M`C_7/E5;.N(:+\<2'.-3XBM"AFW+`"(XGWB"UWLQ9"L=59B!.O.;BJ!<\ M0EG?4@"B7;$&^R3"7.TF=R61R M6>B%:J\=A.E<3].:G3O8-CUO"K@.9M[:SF"+DM,PH@F>)1;FV4N[K]#0E-8B M=>38<]W,=5+;;/VS0%\E/2)1MQ65#_T5.Y[&:#=Q,NS\!XRW*@B?8#WQAE7[ M"@]G^A@Q'"2G!AJ@[EL3R2G,<-*9R\)Y'LI9!FS8L9[`@S@$M]$8S8(PFY@\ M4S2>U;-H?'M+N;=?$!3/-;O0IOK7H!_T&\/!L-E-_ZE0#?K>UH7(FW6IF%Z; MAN[\A=5N:$V*)U,-^HK6\*8:]'5<`"?\'F<-^JK2*!7`I0KT5&MYCU`SODV> MH$90HPKS!,5*0Y$JS!O;+$45YDV)=$C%K%^1B48[B&NV@[@N2EG^]F)22E+* MB@BN+DII[N`T4DI22E)*`T(<485Y,TI)=3BHPORJ^P8=*IF]V=Y.BED?L;KT M!N;B*:0NI"X'KBZ#-I7,)G4A=7FY=2%G;"-UH:4TJC!O3FCM1G-G`CILO:08 M8!UB@!52/"IT38I'BD<6CQ2/%.\X%(\L'E68-[JRY5"%^95D1/5+*0I)44C2 M&M(:TAK2&M(:TAK2FMIK3?TJS"M\]K%*V/RU.ZH3\)+F%6N8Y8:WT/Y6L?V& MR_JI;U9N+627224S71N??8E#>\*E8%^PC*.1S@]7]+W4>FZ???:_W,>RNO-A M;%E88K>G:]_-"[ZO*9B/12K#>RQC&X3,E3+&4NNZC/[:0K#/2E.5>-9777_Y M8C$L"C;E45)UW_5M+'.JZ^TOR7T;,;26=7Z;QZ3U\*(`"_2N$MW:TKCY`O18 M5!Z+MR(LL++KA;!5^9+Y$'7T&'5U*6P336]W!M:@NYPHM)48='\;[%0:*T&: MU7#)":&I@6KD^59Z,`/^8^2)W6;7:@XZ)B4Z+Y:\3MLRG7G%R0.;$)(J?&B2 MD%87F$R*/V(Y4#"&\V,J$K',$NYP5DE"U11/BVXZS]27/-E3?G*M+S3E(,I,-D>#7C_[IT)U)KNC:A<;K$U51&JHZ1=2@32JT_ M4E&=R3J&P0B_5&>R2C1*9;"HSN1155Q[^4[Y"N#07#6/BLF60'P\(*Y9>4L" M<>4$70$0EU08LWJ)U50;LU;%A9H[R,$^BN)"-5+1RAD64DI2RD-4RL-U!4EC M26-)8TEC26./7F-KOX!"A35+J^74;`Q-"^*P4]JKIS?U,F2U5I>NP0WQI"ZD M+@>N+CV#+ARI"ZG+@:M+MT]U:#=3%UJ*H]J:AF,.Y9_D<1RJ62,MK)>)(\4C MQ:L,?DCQ2/%(\4CQ2/%(\>HU"SRLR1Z5UZ3B312+K);9(JTAK2&M(:TAK2&M M(:TAK:'RFKLOX:@_XN5I]4KUI"NLG_9'6C_M7%=K5%46EWJXC?@:;'61MC4% M(EW);E5M-OAF7?E#?2767L-Z:NR_<1#IZHYXPZ?3ZXO3?^VHH-T.AB>;S=Z( M<&IP1$1A=^*BV-67R4BE]?+8#!X9K*R:=X#B_F-]-,EJ[GX7N@'3&65(7+N/?XIQ9X3FYY[LCU M$Q]:U(A5:[%?`Q7Y'S+POBD'S.#X1NE/>*?4"A6**7=]I3TP MX#)#-X`G6B3(PQFOC.`NTNBHX>%*-1),!O,%N*1LQEV'X5=I0%8J?7,"&`D_ MB-@,*V*#U&<\?XGK)[54L6:TT&5LXXP"D@J\^*NE&0R>(59&?HU5%?Y3A(&1 M!Z5]2Y@3\*L*R#:VQE@>0R8+GI?C`)?5VF7$JV^6:PFJ@MO*Q3TY4PR"F!6^ M5&-A5M'+*L6N^Z"LRXEF03O7!Z4)/KALH?!4'6/0KB`U9J@60*)@Q_`7;:#X M`S@2$BP]L*:^7"0%U_4-..J%+Q1#IC79$Z.:^8FHS\JY\;S`5N^'#[HHLE2% M,*))$$MXC'RW?1%DDT6/<^\I/.0`RA7W&JUV:]1+_FD;K%;O]:[;HTM-H=7*>7V1.>JYAE*@)=SR*B@V.O94NUF.NX9D+XW5$M MYDS0G4H4'JR4Z*G:<#DZ35`KM:`P0:UJ4*M5.56J"4P@KCV(2ZH)#)VOTFZ0 M4GCKY4>F6\/!B`B,"(P(K$)0 M)`+;8`+9[YH[H:_6J'DM@6T>(3NL0-@_A2]"[JDX&'>FKN_**.21>[])E8:L M^?LXWVV#X&P9FMAM&JM4_IQTJH*9LIT&\@V.6J,&;=(HTBC2*%/BZEK=SLZ6 MO8]%HRC+D33NB0#3J&\N0GXD&E=:KD*S[G.TW`8SMGZ#63EXZP#>G"#&K5.O M4<>U0U45&9N+/CTGOM>$IRH3@6I;O5%S_R*K"GI*]S8HC$YD1F16&IFUAR5- MD(C,B,R(S(C,=D=F`ZMC;K,-D5GYH"*V([8CMMLZMMUOF3NOXNC9KCZ56U]2 M_!E*^V[J7>2XI MOQ"7JE&'I:U#KE(5PG59TL>\+].Z$JVO&<``(E`+L@`#<1@(<" MP)*V^#.,.[3+5-VLE=(I@/K%\CK@LEF#1K\W['6R?\S5S>J^LFS6H+?CJD3M MSEZK$E&.P=/>1<7V-%=JV_+O?BC@77\"V_Z3NTGQ0S0N6'G<9Z=I.=Z3<1"> M7'/@G&MA8\585\@MW!RDPD[+8ONNS5'O]&-*6M_G M<1KUQH[!R=J65KI5>U;[_+SCK@I3LU#8'I?2'8-(5/'=;!C.0U'CNI#OWYPA^Q^**\`:&<>8'][9>__?4O/Z7/NN0A'@TF MOXA0W9)=I0Z9@P]?Q?CG-U<72&7_ZOS[YN(-NLTVP.>LW> M9?^JU3D]O3CKM0;]RVYG=-7IO/EE85PV6,%:-:Q/+O&UNX:7>9?+J8,?AS%U M=.*8$A8[C:+0O8WU,EX4%$X5G<"-(GPZ%%+MU5T1X6E&8331J[N`-.BIVA63 MG)BYZCS`6RY=6U?^=+T89ZT^R,U+Y::.0P5+691;_A#!1&[9H8-+`MRF?Y$Z MRD&=\(1%\>%E6!1?+!?%7VVSMWFE>IN1)ZU<1=BJ286U=8N)[S;T74DZ&1=H M2TO8)T#6_%O-9L5.ANKMYLU]^,Y M.XKZ5XUV5KM_M8_*T[6RI"7R+;(` M:[]"_K8ULEJ#G9FJ9P4ZU_P]B=@X6#?)>JM+WE'E[#_M,:(]1ML28,<:#V@J8RL][@[9N-\D8.-ZVTDK8VHLBHP*\\7I%EN-0BM M%D:YXFQ7$]_0<(1O1U18"X`23Q)/5@"&Q),5C"`23Y;!D]M+E:*.Q++$LGMG M6<.12F+9_<0P#SS-<:.J!AN`^>6)NCL4>/VM5'7063G!$>*JLAI+P")@$941 MXG8L./,+UK4_'OZLO/TIM`*]WUEP=2:ZS<9PC^?LT?HSK:L0G1&=&:2S_AZK MR1*=$9T1G1&=&:.S=J-5NY28JH"L_JNYQ'?$=\?&=P-RW\KFN]+656L?<;NH MXZZ/JAW;58^C4:K#>?N-P+UJSUQ5(%>73<'DT!'5'3?5[3,Z1U1'N2'$:,1H MAQ.@(T8S*S_B0N)"XL)Z!N^.BPL/H[Y+L05XBF;^@+L3D^=JJOO^3U7=%LX) M!P'Q.Z$W3T@62^$PUT_.F806;7EPY-.G%9I*$SW*_%#*.=AI*C)AC#!&&"., M54-BA+%=[Z4XT`7>3;=49"UM;W1B3=FQAPU.KC$_SVMWK$&O9[5&H_U/]JJ" M*[QOY[,Y>T M$D1*;%*0K:'5;(ZL7J<"B[V'HL2TX]]`_G&)REH_+:W"S+0R6-KYE)1L)ZEC MY2:AI(ZDCJ2.E9F('H\ZTIYATM?ZSSD/1E]SD\T?50;7JNMWUK".Z&JUM-O8F+`Q6\XG,R=Q3"Z387,B_Q,_YU_I!..5>@3=;>$WV8)T: M:0O/2Z[Y^4WSC?H,K&&GGU>(ZL:="LD^B0?V-9CR)4,TY>&=Z^M&\C@*TB^T MU5/?/+A.-'D_[#Y@T!NVA]U^L]GY(>4\8"Z/SZ1XG_[Q89&MYKW(!Z,R MQNNOM`4O"&>IEL']HQ^>Y=(BE2;B6LPB,;T%&]%I6ELX$02] MLIUZ,]#;/)5OIV!L-UO&#AFA^2-![6FHO3@.2R>OK$'EM9J=!#.<=6QRH,KN MDOOJ<;Y2V^H,NE:S5_Y9\+4X$JGT:&1UM+-R-H-49X/ZSWP,.1^9,QROGHRNE=%&PVM?M_82:Y5&?"R;1F9K$/6B5[' M&C6-F9Y#T0F:CZT1[._^O9"XDA/"_T+7QC^UJ>%@:YQJ3M$JHVV=YM!JC3JE M"ZDJ:*%I5D5MUF&J5[NG,JY(O6BJ]++@HBY&)+[/A#)D4!6BO`>F_+1G\41_!SX MMNNY*LS:(W$>Y?A7CG]]<7>`*\K\Z_[ZY>,-/F+>A\H,`I1>< M!U/`]*-FD6&[-?@@V:_B7GBLP\:NSV%4N`>WPY0SGJH<12Z3%DCV5CTVB"7W M'?GNZ8J`+\L#W3K3\B7IAK5+!M29?J-18]1L=SOI/SUSF7[=5V;Z#08[3KQK M[R;3KR;93Y7S*UY>O*SR22FODJ#ZN)26<@&7WG/,K&:_NOP6S%WTR,!2!L"Q MN!4ZD_B#"UR.[/R;<%S;E>Q:1)$GD'\IC/I*7%_-32!7Z9'I/',N_D[+8IND M$)5!#/5>23973OP5U<+KDH/0ZYH[$ZO6J-EW4*WV-37.E;>/SO[C^7 M4EJ[_85OS9W%M#SZY85':EUS_TC25U M\4"Z53B5LQ:XJT`DUG",=77\]L*5MA?@@^5FT=C3UN6H==D[ZUX-^OW3J\O3 MOH[&=L[.!J>7.XW&FCQ29?6$7AD#)2^6#(,*D6X=!\VW?KB+4'(2_653W7K) MN(_Y1;,@C"2S0<$Y^I+KPL!<`5#=XR7Q#!>?$17BS#[C\,@$FNP6L=E@\'(I M\G=9B"[X29U(D\2FT^B'S*(?%L--[NI*X`KA9*'J7,LL]C!Q\=B:B4A:N/CL M*:@M])F'WP0T%9A(]^'WQG6#W6%,S<<',7XG?/N1!;=`)4IGY)K7M]3M^N]V ML2D@4USA=N&G1]7KY1"\VI,_E^L#+R7$_O)05^VBY"_>,E]B(+WUVCWSW=ZN MM[#O?,\\=9`Z6,4.TF+/*Q=[6G4KM%""*WAJ*AA`:*2EQW)F*G.Q_K%A8)BP M1]C;'GMJ8C27J[%0$P&/@+<)\(QM/R7@$?`V`=Z+=YUMY?L=_L+;DI#5>QQA M!Z&*R[U7VT,P%I7ZXACU*P7-.Y1U'6B@,L(Z7/XDQ!'B"'&$.$+<<2"N)O&_ M,I,L?EM:G]WGS*TJ4C&6\E2G[9R#MM7M&4O$K\I0XGVTPWE_5IMH@&B@`D-) M-$`T0#2P,02&[5;;&`:J,I[$!<0%Q`7$!2:X@):1GJBB^6R2]P%&N$I5Q%[' M&K3+W\%,!FR#(U]*JS%Y`"Q_\+4E2<4JD-="C$]P),8GQJ^NPU]`1JOVCOU- M$'$OW9*:[&=UBGM1C>&IE'H,==C^OKNR"WN26`G5%=I]JS7872V06N"(HIU[ M3ELB!B,&>ZG(S"Z^$H$1@1&!$8'5-UY!!$8$1@1&!%;OF!BQV+:!LPH'K)-2 M7*J2\=[YKRZKXY468F4$1T@D)%9#<(1$0F(U!$=(/&8D'O=.3?5Q@Z(]:7#&L54X^A!_"#^&'\$/XJ:!\ZAY]*S.RF3LKLG"V0G9:)%LZ M)%)N?$CD3@\NK(ID*W$V8666%LP>_E/UL7_M>D&-R*E:5$],<_1,0XG]Q#?$ M-\0WQ#?$-\0WQ#>'QCH7V+56>JH\DYW?&IT'5`4=G> M%3E1Q%_$7Q6>_A&+$8L1BQ&+$8OM'4O$8L1BQ&(U83&:2Y89/_LQXM#]E=?G M_L[U"Y.R3Y(\^E:[^8-.W79]8)WH?<=X8OTV/7VJM;F7M+=L7'M#8GQAK(:;V<+SDFM^?M-\HSX#ENWT\PI! MW+A3(=DG\<"^!E.^9&$>7">:O!^-&J-FN]M)_^G]D"H4*(O'9U*\3__XL*@@ M\R;F0[IS)>NOS$]\0518->WG-]W>#\_J;Y%)DAM;V]ZW]8UUN:\V#:4.[K6# MM=_L--S.5`Q?Y4+/&]O;PSG9%3L5^U2R8,PNA"VFMR*/;,K#;R)B8\#,)OZC<3E512I'>>!RJ]^WFIVAJ:Y7 M92SQ/DHDVY]-)QX@'JC"6!(/$`\0#^PW-;TJXTE<0%Q`7$!<8((+2ER\.I0* M"#4^M'G=.-5B#\+N=K*\IL!+3;:XF)T5;2_16B"O;`>+%@J()8DEB27KC3QB M26+)NF"56++2LVEB2F)*8LI*8)68DIBRODQ9DYRHZIX:6?U#H2HE*$5X8IP M1;BJBZP(5X2K/2>B@U"J-&&MR.['DL^?KM@IZ7O7[20*(THC2B-*(THC2B-*(THC2B- MIIS[)K,7'::]LX;EA/;BPZ8KT;A2CQ&_F8A<@`]/$L5$K]\;UPUVAPSO8Y87 MXW?"MQ]9<`M`4]L`)..A8$)&[E2EB-T^LHA_`[UFKA\%@%E?NH!^=:UZ=')7 MYH7,RXV'TR&:ABX=L,RG">]<6LL&P:8O?LCAR/>@!O,:) M910^0G^Y[_#0F;^%30-'>-*":VPO1K)AH(03_!A,Q0F#ZY/2^R>W7&*,.>QR3HE3L&W089N/XLCG2_@UML#R+:8L(%@87,<4-A M1Q[(*,2V)9\L!L)(I923L^J<%.DS=4,%"\4L"%&<4<@=HAL$W$?[H M".[!F_X;!Q'^YJN1DGPJ$W2A:'F\']AQZ&*X7Y@KI0QW&"'PG$!&+-0<`>^ MOH6QG*``"A?#KS/^B*,-+QKSV(O@J^`_T`TU<%I2\-*)*Z,@1+IC#H_X!]7" M0,E@+I:D8PW&SB?`SMR:-&UGDP!59]A(%SF!]$ M*')?CJ$7^&52.A'D^GQ0'(6B&AF'H<(:EZY4'0PURO6Q;"TE*/UWFSFQNA:; MN,0+VZBQ#TH%N/>CB60"J,)AUV(6J1.!6:>I#@+N&7F1ZH6Q9C\"1R;M30\P M9FO/+=[F!8VM63?OM[3ZP+H%&FZ70<.!!^ZT@H72(05!X".@+LYD/`65?4P) MVBZJU3*#)_#.)FF##S(!7X>-79_[M@L:[/K`H3$J/2;\)BV0[*UZ;!!+&&SY M[KT)L]K>4D+M%TP)/'-A5'#S_DV^D$XY5YQI/&:K)UZ'&SA>#C4ZQG]_8VO*^]K8W;G9? M3,)%0LR+H4*766ZQ^DZP\8BTT6 MJN9S=EP,T(M@N3H(%I,S8:LE"L][7'QN*#RU2A8%ZI#$=L1.<=T)VL*^ MZ(47]O93$`G6>6>Q!S!"CHA$.%6K9;>/Z2I2NFH`'_!/C,;#0V[3=B=]2E\8 MBKL8_@K"1[W(A2]3RU_8N9GWF#XM6?EA?`H*'*G5O`ET-?_DF0@QEL+!#\4G M<.:XTE97C[D-;TA6B&8AM#)T<2%,AZ;G:X1)DY,F9J]4#TO6J$)7?F/<^4\L M(_Q1K]3D%^%B?VF1B<7XWN5`>+):HUZ2O'.MX'-CA>M[JMW?84!SS5XCZ:0; M$M>$\/-\-V7O_WU+S\M7?EY?)5&^S_.@_U?@(3M1URF187[*L8_O[FZ0-?F7YU_ MWUR\8:X#7\"PGG0N^X.KLV&K,QQVAI?GIZ=7Y]VS7FO0O^P.+D_/>V]^65#Q M#:+@JSC^289H=Q<80E&&R=">NOR]&X&5L=<$^Y2C^$=*()EP64ZZ1NAPN`LV M3!=!087D&MU12YDAUO]S\E?,0:PN2%=AYTM+B'PP5R>Y;_2B*OZ07U6%NS.F MR[_!F6-<\P"W%=^H=(!DT1])`59X"&(/&!Q)V1;` M,$GN@Q2>IWE%"P:7BV?9#!M,>8#H*+K:!-*$&D<6L^2@"6 M"!ZA7IK`"7D>Z`$4`.SF&-<9?5NLA;&2;T[V&8(1A2MS&.;Y&-$D%"*7#Z&- MHA;XV`U!R-%#@#\D62U%R>6L:6JJ/"Z+=M;2@DP&&A'`0`A)%L>4?P?[^*>V MF2A1>-.RB58^!\!L\<1U5KY6#CY$%6DXA)5B0KDA5YD.1![MT)4'8^ MESM:?Q&1*[E[%/TQ+YV0K?BN6C1-UB)S-1!$-`F MUV=:OC"-ZJGDJ$(ZU4=$/O3IHRHA<>H[Z1>7WV?"E[E\K!ML4I:3]8(,J_.+ MSOEP-.IVN\W+?K]_T>V<#I(,JXM6;]#9:8;53I*.W$1V*L4.A(?3$9MCNDZ2 M,J0^@*!G@:^R3US:G+[S]>+AL#',_S%<'0IZ-VA*.N@]I41UN'R M)2&.$$>((\01XHX#<;6/$1HHDXEY`VGIHZ4L@[>M%U=)+$-L51&2L0I[Y?6Y MA#JA[;[QJL^'72BT>LQ1+;HEBC@XBACTB2*((H@BB"+6442/O`BB"*((HHCU M%#$:&"NY?1P44?>EJ34[%-NF#VH]JE!:I818&<$1$@F)U1`<(9&06`W!$1*/ M&8FTZ/7A4[IA=G'!JPP@'N/":O7@5#GY$'X(/X0?P@_AIX+R*3/`5ON3===Z M3RQ7FH@YXA9/_Y`QEJJ!ULIGSGC:\OA=HV[^7L_E+:&NTUKA5`5*>-]KCI"L M\:RZ.@;@>%3L;7>X,V0=]@H4*1XIWB:*UQF1XI'BD>+M7/%:9/+VF71QE%._ M!QZ&/#FF>L6)WFIFF)Z$7TOH.1ATI:7 M:HOQXF2D+*0LAZHL[9:QF,1QJ`LMBKUZ9F0'OA(35J'W@TC0DA@MB=&26/VL M':D8J1BI&*D8J1BI&*G8_E7L;O70$H\F`]>`0V,73G! M8^[P*.=VL]5AG\J:N]5.\VCEBL*+%%XDO2"](+T@O2"](+W8<@8SM#H=*H-4 MXD0%SX(_EM6HR_%8V"KI+EN.@LG,6!_<[=^QX!;>JTX9I[C"TW&%MK$$I"./ M*E!$CR)ZFVA>GQ2/%(\4;P]Y463R2/-(\\CDU5?Q-I\85F#^5VQ"%YZFKG!] MT,?H_8GZQJ0TLXQ%F\_<"!KRY\H3@-J;T-W+M7:_1][7(J[YG(RJHI84]ZR0 M-3PTO6IWS.U?)GTJ#2.D;P>B;V3'2.]([W:O=_VNN0HY1Z)OI2W_U7WU[R:` MZ1SS31:YWFD4)@$P7O$,>G<>HJGL>N#+95:'``Y%3BERNH&<=E#CJBHJ5+J3 M2II%FI5?#1S0MAJR::1YN]>\D=7I&ROH<^2Z5Y,SCZI[:-1&)V_M/LY5-UD2 M[@AWE<-=]>/3E9(EX9)P6459$BX-R9*V%SV]P/"*=84-<-D!7#I!C!7S7@/, MM4-3B\#YWW(@F)77Y_[.=8/1?WM#F<+^U+5-[G6MK?L97M# MBE+]8K;PO*2!/[]IOE&?873L]/.*=]^X4R'9)_'`O@93[G]@ZX9H5=#WP76B MB9;"LZ@H`OKE%V\<=]X$GTO#N]#[PFACH/J5>O]Z"XZ!]5?UL$R5/,<$^_1@ MRZ7-TZYO>[$#:,M^F?%'+"0L612P_Q&A'7N(1:PFS+[P1X2TQ2ZE%-_UEY8Z M0_,JJ]OU.:O;)1NO)@/2H#IHT$;[[VNH01\7E29?CF`6AS+&HV1!74YM=6`L MJL%U!&K!0T>R\\!QQ]!55`EV$\Q#J3CUG?2+2]V#"U?:7B#C4-S@@VY`>&=>8'_[Y6]__WH9-"Z[`Y[P]Z@WVX-SL\'G6&[>]9K M#?J7W8O35K__YI>%H7Y*K=>-\DN.+1+#HT)N=<3_]EHO4=T^OFB_IIS:V:VEV&!BK;:@98G@6^,G`/;C1AT42L M_!&0+%VI=#D8L[?NN[D4,E,9"CNX\Q4-C,-@JI[%IP$PVY]:W>%.=92T*Y$C M;&".0$9@,A\FKCUA#_"4`I?`'?B(\P`%)>$+^$L%@)7M/N.>>L;U1`AH(/:* MPP/NA"]"[GF/^B#KM"VJ/YDM3^T_D!2^(6L/-'#IP+=$7OC7+#7X;]W7"2`[ M2]MQ4J).85AZIL6" M,'=`0R8.+O%W>(_KL-L8GL?A&6%ZO_;<`B8G,.)2C]IT"B^2$;`NMNK^W=R# MRXMU#*_CX*TEB(["V(Z2KV/E_K%@!O!1_AH\)_^8!_`B M,'5P"_2&,R\YH$(!H'AWXC6^O7??,;%<"'99F*OJPC;8S:2((8!>O`+M*U0P MP44>F0O*E,!8/V7);<8`F'HV?#]%6>#?A=/C725LU=FG+?Q+;=7BM+;3-DRC M*,VECMX^/LVA,.XPV./`\\!W`QSB<`6QA,OEN_=;]WM'D_5<$Y9ZO3(9[P<1%->WG-]W.#QO.F9(;6]O>U][U"W=]7VT:2AW<*T1KLH-H_4Q] MN!W5#U^UBZV0--<[F3U9A(*P7Z#WR:278+MUSX)P7,$?P(O;;<`)M8]@AT@.T8QQDU-$2@1)('M M.;"5E`-&UKKZ8#15R*QNM$A():16@U.WTK(ZS# MY4M"'"&.$$>((\0=!^)J'R,L.PO91!+V*\16%2$9V[)3JXTW[;ZQ^--Q[)VI M'G-4BVZ)(@Z.(@;&-N8111!%$$4<'D7TR(L@BB"*((IXHES]H$44L0E%U'UI MJKJ%6VL<2JN4$"LC.$(B(;$:@B,D$A*K(3A"XC$CD1:]/GPR>;[M539H"M]D?XK/6>F!;TL-UJ?UA5W&4;=![/J:TY MX94^J:P*E/`^.I)\SP;@>%3L;=?K"F3*GN*173M@O7A+^PLH M>9BTY:7:8KPX&2D+*XU=P8NFN<=^D+7K\D9>#JNT#:6@'3D406*Z%%$;Q/-ZY/BD>*1XNTA+XI,'FD>:1Z9O/HJ MWN83PPK,_XI-Z,+3U!6N#_H8O3]1WYB49I:Q:/.9&T%#_EQY`E![$[I[N=;N M]\C[6L0UGY-15=22XIX5LH:'IE?MCKG]RZ1/I6&$].U`](WL&.D=Z=WN]:[? M-50>_.0S2570]\N0TPYJ7%5%A4IW4DFS2+/RJX$#VE9#-HTT;_>:-[(Z?6,%?8Y<]VIR MYE%U#XW:Z.2MW<>YZB9+PAWAKG*XJWY\NE*R)%P2+JLH2\*E(5G2]J*G%QA> ML:ZP`2X[@$LGB+%BWFN`N79H:A$X__O.9/LLA'>\!E'*623F0EJO%BI!H=7ARV.E61V*'O%L85^J^B;7VO:6O6QO2%&J7\P6GI\>X;=RHD^R0> MV-=@ROT/;-T0K0KZ/KA.--%2>!8514"__.*-X\Z;X'-I>!=Z7QAM#%2_4N]? M;\$QL/ZJ'I:IDN>88)\>;+FT>=KU;2]V`&W9+S/^B(6$)8L"]C\BM&,/L8C5 MA-D7_HB0MMBEE.*[_M)29VA>976[/F=UNV3CU61`&E0'#=IH_WT-->CCHM+D MRQ',XE#&>)0LJ,NIK0Z,136XCD`M>.A(=AXX[ABZBBK!;H*9:[-AIV>Q]*FO MUY+T^I]^C.7)'>>S]^FS/_IV,!6GOI-^<:E[<.%*VPMD'(H;D-N9%]C??OG; M7__RT_S^>[@8:>!+X+GV8W85'@^%HOXJQC^_N;IH-UN]?W7^?7/QAKD.?,'M MZ.3T_+PU'/9@9MD]O3CMC\[:@].S7FO0O^SVSWKM]IM?%L;R*;U=-XPO\0:4 MN[18I**UX`N\!ASZ(U[^7L'!UM\\Z+;5YM,%V5_:J3UT@:7_+75@ M&X6ZG@1A=`*(G(+9R63#[H0O0NYYCX@RZ4I5S%X*.X;GN`"+!S>:L`#\8C`V M'IOR*/WA+A1@W4(63;@/_X1"L"F\=B*5;0K%E+L^*F7N%G@RV#6I;PE\P1X% M#RWV,''!X'@!2GJKYJU\6:%]Z$KW7MQS+^9HOV5L3[(WZ:?! MK8+#M[?<`P,NF)P($3$'+F^P4\];^;9PWB8@0`[?W'/70T8Z&0?AB>2>?K7- MPU!=$;$Q=T.&[0#G0! MO&<\5%(!P8$H]8D'`3PN5%^%8@($I\N*(O>QM_B8=UA;-%+B1AJ0\#3X2\76 ME5L$;!T)W3MXVN<9C+/R8%0[S@N/5<(42^PFB&K0%^ASR$)%L>PK'KN[D?.@5 MF.9`LI@[AL<\:D6P@R6%`HF`QRH!FRBB1&9R)FQ4AA/L:C17BZF()H%35"H@ M`3<*0KD`88:`&H.X`W`+0_@4X9,P701NCZ.5Z`EV0ET&4G"C!QC_"6)4KA"4C$7Z4#^>WL*+BJB$MO," M8RGAS0+I(@ZMY''W0CU.:5D<9GJ(/R[?@-.&8<`YFHUOS>N&ZP.WRRKP#.P1C:C[DBS1)-)T#!) M9WPUNNKLP3,VZ44N^8PJ\(`"!?75C@.,K@E?V.AJ@[?%9M5G)Z+)9*-C.D,T MI]/_`#U&`8L%`><]M9R?NK5>6XEBO\CKF]/DT[/:O0FP?L,-?HH7/"C[I8)A MKG(UX^D4?2UT/+2G)QSE05F+KG3FR6DCD[/\;Y5_%L02OI?OWC_-MB\,O=@" MG=&7<--2""HO2/RBK50A;&8L3+K0FU'? MZ&!AJPF"2-9\;!@Q/I/B??K'4G!J=?1QGA7?7IF1_H+HH6K,SV_:@Q\V#%PF M-[:VO&_7[]OU?;V:M)/ZM_J^84W:2?IWG/@\]/[M1O]JNH5^[\E3\^;VJEW3 M\!GWTLBL]5K,(H%AG[DH.TT+S]0U5NF"($>0RT/N0MB+B&LIQ+TX-Y>8K^2- MR/O9:+QW^1!^7HB?P7X/^S2>\O+/$!$N&+\$4.%R&K+L@BAXN@10X78:MFV-KR5EIYM!'5+(-FV&ZURU>WJB"`^(;X MAOB&^(;XAOB&^.:P^8:F4D0U1#5$-3N@FE:_;S4[YDZ=J?KH$]<0UQ#7T#2* M^(;XAOB&^(;XAOB&^(;XAN92N^>:FNQ`*U.$SQAUK MT&J94JRJ#'[9MII,\@&K1*M-ZD#J0.J0W/?6F#HL#WEY/FAUC_4E93E@94%W MJDWN%*D$J42)L4+2"](+T@O2"](+T@O2"](+THOCU@O:>?S$D6%!Q+W5)\,] M>5Z;*8P5=\IW9M^9$\1X.-=KMLJO';OD;>I`L*5-^549$G-KN\_)]C6+OV6( MLHQ@?=]J]8V=Q+&]1&N!O+(=D`IQ:N4\$V))8LGZ+VD201)!$D%6`JM$D%5< MY'Z],#=:'J\%4HVMG1-]$GT2?5://M4L?$"S<'(RB26))8DE=[.+A5B26))8 ML@I8)9:L]#HW,24Q)3%E);!*3$E,24Q)3$E,24Q),^]J(N^U+%F3ZA.+##D1 M^C%->,[>V3)K>C4/V*Z4K`A7A"O"%>&J+K(B7!&N"%>$J[K(BG!%N")<$:[J M(BO"%>'*N*QHC_%Z:9Y[7$IW[`J'U;8RPJK;*A0ACA!' MB*N%X"HC+$(<(8X01X@CQ%5'<(0X0APAKA:"JXRP"'''@+C79Y^UZA^06RCW M=S@!X;TK9<47%_8N'$/X8?P0_@Y&/E4Q:8;VP]27I_-;]P8M*UNKVNJYU49 M2KR/ZL"3&3DDFB3\$'X(/X0?PD\UY5,5W^A*$T4DDPBES_7LAHVE9D5Q:/J`%*UJP(L01X@AQA+B7(NZY`P:-"G&_AYJW MK$[?6!!VK5RJXGB5'9TE[2(^)SZOBN`(<80X0EPM!%<98=46<95PB?E1,<(8X01XBKA>`J(ZRZ M(>YIP=$)DJ5MM:(3)#^TVGVK->CM7Z*U0%[986EB2;++9)>K(CA"'"&.$%<+ MP55&6'5#',T]:.YQ(-4C:.[QTJ63'R-<"UAU_O>^8/L[M5+)@S);:MLVCKL4L$M-;$<[-1*=IL7:SM3SYW^;Y M:IW)R),NA+W8T)9JZ/)6W6T>;[%H(E@HIMSU@39!H_THY'8490LBJ'< MGUPU8P\B%,P34L+SN,^BAX`]`JAD8UD*EC"(,5,B^0$H?-?V;8X#L%@!F\.G`DFX5"0@^$TV"? MBN]X^CD3X>&I@/71S[DL79"1@KWKQT$L6>QGXD0ILED@H8\@2935-(!Q4`AO MM>=-F\+=$X!ZC0C*6NSG6K3D=L@P#KWW`P!#%(7N;0PX85'`[%`X+J#0E=_T M^CI(HKE9!/ M//>;\!Y/4-8G^$K]>ZXM.&[^^M%Z<#T/WZN0&$BDQSZ4&$@F8PR.AC4@J&BV.2#T$/$G`@Y^7`[,G/+S3 M<)OR$M0[E>^(:'P>`*ME3)UA(WTJR`PAJ>R>^[%HO&TZY?\_=./L3RYXWSV M_N,<2Q_]"W$;G?K.;UE[+D%:T>-UUBCX\1S\;.#7FY#C!.,45":2%ZZT`7=Q M*&Z`_\^\P/[VR]_^^I>?TI?\"I@\5]QR)WS[<7ZY5)0#]WP5XY_?7%V@8O^K M\^^;BS?,=>`+,,$G5X/+06?8O6J-VA?=4;LU.#UMG_5:@_YE=]`\.VV^^67! M*.65_\:=PDL^B0?V-9CR]7/KIVQ:86[5-6?3U,<'_:+;P'/T@WX#%K$!TM.;QOT[5*U1+..^@\D$X#% MDYF4%:W@9DC7YXHZ^5TH1$*"T82EX_(%]';*;1&KV28\-T1]Q#LL9-3DLD9V M_0/P@(QO)1`//`NXB=L)!=T^LC_`M*!;47RH9!^QE;H=W+/@H]U`-4^]8"4< MS<38XHRX<[V9A<&]B[23^C9@(/#%B5U(;E#S]P+5<.1$$8(P@S!Q>;_>-)LM M)1[\J\W&83#-NH=?XRM22Z=E-^./BLYN'PO"A^>G]\%SXQE^862,_][N-9H, M+O/@[8908T.CP9B#6*"M;]UWX,I(!BYH]*W*8+:$P5# ML#T(?(4>"[KDO@,-^!(&MA#@]%X#!G'NM+UKTG`HE;];/5-=Q1 MYL0"A@7`)V?"U@=TVWSF8OYCR`'WT#5N3]!KT'Y($9L6#J$6E9D.]ALCL_U; M&,&.)JS"M-44!%NEMKQKJ:8#_O)*9:;MQE&EW7;5>@4N%'@.1HB:4-S%P)\! M^&1\AKP+B$-*U+R9_-%>QEN(NN?$=L1.T]L2?7M%N"!O\UO]LHU^K:9Z>4OD M"&WJA5:AN?^,_<'IB>?R6]?#:5)J0-<-EH*W(5)L]$HC_ZG@Z'$KMX-+&4\5 M(2K_P=@8=AHKLH:VBDME&%#A,R`,-:\^&8-+!FP>"6--;C6:HQ_,!3MY,0S@ M_"=.)M*FVCMHM'MFVMM@^:E\MK]D\$%J?,RR<`^B7WP'JZI\1%4O1.+<%UTC M%7[(?CQS`R^X\ZS7 M[?8ZR83\XKP]&I4^(<^;M-;0$1<7?X>W4;77C-%GPN4%25JQ&IW4Z.=6^TJ M>^9^&M\!427.&>K.U>GU&6BYC`'PN>Y>1T!R/'38[S.,>+%/04/==-+J6:_6 MMV7QJ^9]T<%XGLY;KV""[MLNZ#RT)DJ<^1/VSP`;"!IAP\R9O;V.;T&8K@W- MZYUTF^_,VE.,)B:A1*`IGR?3)9P_8PQ9*E($D44+O)JX%!@M5JH+_@:89L[N M@F35236>1PPFZQ-XB(\+4&A7,"8:NM-DA0*H^VLR91\'001D*8`UYT&UI6BG M.\:'.VKN+]F=>X]3?V!GC(+&MQ)&-4*!XMIX!*T,XNAU/<"("7![`-R)!CP+ M-XA9$$8*5S"$0D5-&^QCH7%.H,C_Z39:&&E^LL?))-#&VXMM0VU5(4P,:"9& M\"YV'=TB,58QU66IQ'H&J2/,[B0(T'.$5T^`%I1U3\34;GX`DW2K%M/3KUH? MF'0!72`):(X*NL=AB(B)I=#"@3%/*G&QWQO7#?;/T],OROBJ>+Z=$7T:`$_B M.V"4OL-;U`*%@W8V")?Z!,9:C,=@H%&D^$@]#-B==,$++)OJW1C:,(\RH5*# M=O?U?`W&$:-73J`=`WCJ#%WH2"V3%0PX_)3T#VX0Z%;S*#7*&`&WHQ00V=/4 M9[@O:W0RU5KEG8PS`I`9`3PS8UHVGYO:Q8)1_1S><=_]4U$2,([*#5$?3GTG M3U>?QQE9S;EJ1;#$5'P4?^BTQMTAIW+`5C;_L7PK)5&P4>=86^G47`UL31I M=)=,;!Y."+ZS='TJ+]YZ!,:_@@8@HG'UFL]4B%?JD*Z5+L%E,0&.$8I;$D-6ZEI$F_6\,9JC=;)I93E!P-#84L]#UC0N4CA,94%Q5$H=\.R=T":5>V#];]U@5EP&L9/[ MQH$=)_-"A(`C[H47S)#W+'24XC$FU:@9&HI1#7N(#TW(%#7<#^`>=AM$,;P^ MGD*COP,29GK"IW,UIK$7N6CTN)#P&FA"&@Q-^Y2:0P32LG7RH%DAO\-FH&S@ MV3`.(L)55;2,8^#S`)NRV(CH<08S6M59S!B4:I'@5D61U!J1>ACH+::.L)N0 M^_*WF^MD>`?=#V`PP=HY*!;/50O+6B.4W^@X(3J.L3\5$?-51![>Z.$BL>K< M71@\8(-]$8>!;HY>-X;^)8/ZCV)7T@:`8V%/?)R8X_(7.B9RWH+UO03O)HCO M)BJ)26<$N'?)BA1SPO@N'1)F0_/0_@F0AXIY@K_@R0#M M7I.]/=Z->=Z->]PX^S124_BD\:[[:9.D`ZM.W(B8^^O]!%R?PEX=[%H?YP\:J1G('_#P^9/ATWJ$ZH^-I%VDF('@>CR/1MU>'%!`H8 MIP!U*>>.HP\*H)WI`FK'!N&J]!/`F:%;K_*"Q.HNNQNL!V;2@ MMJNL6@G!]_F6,XM@S,.9%YO4R4ZK,30/?`Y.H&W'TUAS)X8&;==@JD^GU32L M#LN&:!PKC"K2G_M;,$4`=\95B;*)DX_98SSQ`K+X+&H7V'_,J8D"^QM.=WRU MSPK]A5GFWR<_8AA:IJE?5C+!FU^O?JY9=O@BF+.$HLQ/4WEO4K%.PD764KFU MQ)'/96V;@WZW6RJ&%A/3,=Z<=/>E?56N#/BXP<-B+B""DH M$OB'AI;ZVPEQ[V"]]BD7V*2#B_<9W<"SN!)IJ+'ZX_-+JUY`FT(9S-=+>"I%N6#DYPO7BH M5Q>C0O1"+<&:R>VZ1JB%=1M]LZ:HDDI?*N4NKD897VE[`0>7M]:V\]26&Y6M MFRQ.H-+'/@?M1RH^#_"=4O^5K.#"AU79)<@:BAXPFIBL4LRS/E).$2J0-T_Y MDROH/-TE@3$X\!XEANG32*3*08LZ>4U]E(MYL)8PS`X.MR7 M0F]5`H/%;N/"'L@YI/)Y+EE^R^UC$F!4`7$;0YHX=/-4+9CCP3MFGMX@B&/P MNZ_>KG"MD',ZA=;97"VQ_'ZM4D[TR*3("!.49?NA&>[`QL619`=LBF*<2J8K M&??9H(=SD.8\?#63F'*<6\P31S,EB*'#8^@P"$=E#B69*?O`BJE)),YH0"MT M2'8<1S"061Z76:.Q2UK=@#]!ZX/86RB@WW"-8=[*KE:-8T'N@F5+:7DM M6C7_RL2&!O.9Q:JK'R8PVWT\"1[\9(G3=5ST"/1*7%J9`0WT_EKA>2X:WLBG-@3G\>G\^CI9R2_@FORT0>W3*!_8@#W3Q68$TFBCRX&D8M8:XMC%QQ"5XF=O<55L7?H1:AD%A\]SK>*-X-8 M`O[DN_=E*+BMME^_7%ZYUQ3*RC47A(Z?\^WP04FX5UQLQFNR!VLQVL+SDFM^ M?M-\HS[+&;?3SYO#!T;ESO5U(WDD7NC*@^N;!=:+)^\&@T>\-`;WI/S^D M%U^[LY(6O/_+Y.,M!OKP`::'8WG+5O-W4(5VFF[DDAML)<+@V3_GW>>&= M?ZJJ4VB[?\T*"9T6"@E=XP+;]<9G[-#Y1NL!GI>5 M-%?0].#KE68.O;ESV>J-G:W"XT:M=*OVK/;Y><==5RG##%$.<_9QFD.\C5D_ MN+,26\L+:G1$8EDN1/VU[>NB$B71^DUFTF7HW7/NM%$7[]`.-]U:>%5!Y?[M M:.T5^Y.(LHW6>L&EFHJ\U03CQ;Y@?:WOLSI,_C#-_I/9_PNR\.G`D^K%!^C` MD[+HDLXZ64^DZ\\Z>7K=])5+F^N62?W(=5POQM29>73X\KM::G:N8"Z"3X_3 M)=E+'F*Q3_E%A%BR=:.54PR+=KJGHVZGW^ZT^MW39G.0K)SV3[L7ESLMW;6X M\M,H>5/K+?$F?YT9\>9UU@ZZWBS.H9Q=V7GC"SHIEVJ?.\CC<5=IAO]'I M=0>#WK`][/:;S8ZY5=K^*U=I^Z-M%TV[.U[>W?J^W32T]A/E5RQJ&E@4[NUA M\ENI)6"]H;$P_SB:&,U^H;>/N$O%\Q%,3GPI]86@]C347IQBL1G1@4R.)8)U MK68G>GOA)HNWNXO^U2.*TK8Z@Z[5[)F+^AUUK*1&\>7*V0Q2S84`IS4<#*Q1 M=[F^**EFZ>M!:$H/RV*>Y\-Z#QP/JWJF\'[)+F]U%&TTM/K]Y2JW1Y[[1-.< M8]:)7L<:-8V9GD/1"9J/K1'L[ZIPE7!P[WH4NFIO>E+7!FR-4\TI6F6TK=,< M6JU1IW0A504M-,VJJ,TZ3/5J@S'KM\L/<1R*>AW[5.E:5P&;']VGSS)-*IBI M0QIRF^9R)W=@:)==7G_Y0CXDW(?!"V-*5Q5LT*R*9E5;BZ-O==M]THBUUL9` M?J&AG,`U*8>+UV/)/_O4=RYTTMO&%5F:H]Y%>]@[ZW=[O>YY^_)JU+]*\PI; MP^[P""JR"'VH2U)D:2&9<%T%H%N4NS[`87VZ(8]@)GH;Z_>H@Q?G$5`\70;+ M"8YK?GB#N5,0S!7Y*]3#L3!C%/JN))V,"Q[#.!^EJ:K\](JZ.;E&;)L*6VX^ MZ`L4\\#R/UO-IKF,S]9K4SY[NZF3,[]OZQ33FMQ'_:M&.ZO=/\K2?%7JW.#8 M$X1OE#OUF_:B+M&+*@ITY:0CNV*KQ.+JH;-RLW/"9XK/3^CD[Q2>Q*A4AX_R MWNM`C@2U5^6];[P$1^`C\.V*Y_8@/H+B04&1]O^8*%&EPOTO"/);>KF@RNI? M[]3\DLK:;%&YK_:;/MZV1E9KL#-3]:Q`YYJ_)Q$;!^LFE>HHR7!+^V]\GD@$ M>21UP=^V.M9H,-B9P(C@*)Y#/$8\9IS'>BVK,S2VJ9!XK+*.FC%A$OM5&Y#$ M?B]GO^[0&C3+WW%#[&:+N#@5>?RM5'716 M3G"$N*JLQA*P"%A$982X'0O._()UL^YNWEEY^U-H!7J_L^#J3'2;C6&K`K*B M]6=:5R$Z(SI[/9WU]W@"/-$9T1G1&=&9,3IK-UJU2XFI"LCJOYI+?$=\=VQ\ M-R#WK6R^*VU=M?81MXLZ[OJHVCE#>R2[#7;,58?S]AN!>]6>N:I`KBZ;@LFA M(ZH[;JK;9W2.J(YR0XC1B-$.)T!'C&96?L2%Q(7$A?4,WAT7%QY&?9=B"[JS MX@%W)^H;D^+]/U5U6S@G'`3$[X3>/"%9C.B_%@2[P;KJE(FMI>Z,3:\J./6QP5Z[8PUZ/:LU&NU_LE<57.%]*T]V+,LJ4.2*=/1I'>UT6E:K:>YL/=)16E`C M5=Q*%?OMGC7LD[G8'][9>__?4O/ZUXQG3F!8]"7(OPWK5%^ASAG`?3F?`EC]S`/_7@ M">JOS^.OP@[N?)"*`Z]U`[A.1C)["PR-C_+_*L8_O[FZ:#=;O7]U_GUS\8:Y M#GS![>BD<]YL]JY:%Z/>H-L>=J_.3L^OSGJM0?^RV^YVAJ=O?ED8S_S8W+A3 M(=DG\<"^!E.^GBIRMWNN+TXF*N/N?:O=_*&@<,.%7+].VW"JWTT0<4\GYYW< MHEQ53 MRT4R@/H&1&3ABV@BLDN29\SBT)Y`4]C,XSY[X'"A'E]X('P8!_#I0;*WK@]W M![&$Q\AW3Z<4/B7NG#K:(&(1%BFPNS@$S2=&(/>>PD.:*YZ1;X@?A%/N%4:^ MA==D#];9E+;PO.2:G]\TWZC/0#1V^GES0$YY>.?ZNI$\CH+T"VTHU3HE_[1_2%D2N,[C,RG>IW]\6.2W>2?"53:LU5]I/EX0`5,M^_E- M=_##L_1;9/_DQM:6]XUV_+Y=WW?H_6NUZ]+0:G=PG5YF3WC./37ERF_K;PVW MLYY#,\[[8"/G??F@BI(]]<08&I&6^O2@;=UMX#F)[S$)P>C_!K]-)+L$R^@4 M!;K2D MM/L6/4[<3.D\Z31![6FH&5N8(:A5#6HO/PJL`C@LZ:"U_AK<=:BN1(6KZA048\C/UM6R^"Q MRK5&S=H8Q:[`=,1N)!$8$=AVHNKUS"4*U!HS1%]$7Q6!(M'7R],3K>'`7&9B MK5%#!$8$5A$H$H%M,('L=\WM=*@U:EY+8)M'R`XK$/9/X8N0>RH.QIVIZ[LR M"GGDWHMM8KF;)5/O?#V[#$WL-H>[6E*H"F;*=AK(-SAJC1JT2:-(HTBC3(FK M:W4[.UOV/A:-HBQ'TK@G`DRC?DE;Z0Y7XZB4Z`LVF+'U&\S*P1N=P&%:?`=Q M`D?;ZHTJ<`)'5=!3NK=!870B,R*STLBL/2QI@D1D1F1&9$9DMCLR&U@=>H[O[K\UO7M5>B'[&X&TH,/5Q:??XJ41SGA79F0NTT[38)O41"(T'4?>@8O!$;WXN M5N77FYK=$?8(>T]B[U6,RZDJ4C&6P5*G/)1!V^KV MC*7=564H\3[:EKP_JTTT0#10@:$D&B`:(!K8&`+#=JMM#`-5&4_B`N("X@+B M`A-<0,M(ZV7[>^.ZP>Z0FWS,MV;\3OCV(PMNX75J,>D0UXW*+5K>L09MY#9?&\%3*#OHZ5(7?W2[Z/4FLA+K+[;[5&NRP#%(=<$31 MSCVG+1&#$8.]5&1F%U^)P(C`B,"(P.H;KR`"(P(C`B,"JW=,C%ALV\!9A0/6 M22DN=33#WOFO+JOCE19B901'2"0D5D-PA$1"8C4$1T@\9B0>]TY-]7&#HARY MZL%EH'0_8-R[%E<,:Y63#^&'\$/X(?P0?BHHG[I'W\J,;%[`+_?@2-T+YLT] M)\QO"VR71P)K74<3/#^`_28^(;XAOB&^(;XAOB&^.32^H9G4)DQ# M6Q;3+8OY\`[M6ZPZ4QU-SJE9.J-LTY*\8 M3ZS?IJ=/M3;WDO:6C6MO2(PO;$ZAS[E["ER(\LT+'#_G'^H'X91[!>5OX379 M@]5P,UMX7G+-SV^:;]1GP+*=?EXAB!MW*B3[)![8UV#*ERS,@^M$D_>C46/4 M;'<[Z3^]'U*%`F7Q^$R*]^D?'Q859-[$?$AWKF3]E?F)+X@*JZ;]_*;;^^%9 M_2TR27)C:]O[MKZQ+O?5IJ'4P;UVL/:;G8;;F8KAJUSH>6-[>S@GNV*G8I]* M%HS9A;#%]%:$K MN!?>7*[&)LH$/`+>)L!K$_`(>+L#'NN4ZO!5*%6U(A483E5M_%)`7*ZL7Q[0 MK0,UU`6UE1,)9/NSZ<0#Q`-5&$OB`>(!XH'] MIJ9793R)"X@+B`N("TQP08F+5X=2`:'&AS:O&Z=:[$'8W4Z6UQ1XJU@T4(!L22Q)+%DO9%'+$DL61>L$DM6>C9-3$E,24Q9":P24Q)3 MUI=$=!!*E2:L%=G]6/+Y MTQ4[)7WONET98=4MG$*((\01XFHAN,H(BQ!W#(C;W`L\&&=/W5>)([%+K]-W M>"L3ZX54A]3FEM7KEE2[^G!7":H?"-F[#226(9;9X4(F<0UQ#7$-<0UQ#7$- M<0UQ#JLLRI2WW->L>`CJ,$[.K?K9[/3)4CX'C-A%95=!3MH]%"RM$9D1F MM9T<$J41I1&E$:41I1&E$:41I1&ET91SWV2V\6':Z=\__1C+DSO.9^^O[8EP M8D]\'N-1@NH`07W>SJGOY%+/?TO"59_]K\*.PQ``=L:E*V_PK3<@HC,OL+_] M\K>__N6G%4^.([CW-]=WI_'TJ_`C[GWACYC=)*^"\/-,8.:[?_WHI-D?G`[ZO5:G=S$8C=H7HU&W M>]9K#?J7G?.+TW[WS2\+(YH?G6>.EEX%B*6#M/,*V.K/BJ=D=]J&=V'HTTB7 M$++-HZ[%+%H\T[2ISC3M&7F^I7+:^-U=*.YX)%BDHJ!CA08VU7!@'HXZFR5X M8&KW`P-5.+&Y;PM/G1D>I!#15TOV(.`)7+)QX(&!E.RMZ\.[@EARWY'OWC^I M/T\-9:X753BB_>7'F^6>4K"SE3VT?1Q%*1?:%=)?://=6\UF^9. M8]U%YK]K-'2Q=E='=O78E*$V1L6W9WWJC+IDAL@,O52?-BFV?,AF MJ#>@(\O(#+U8;4:,^P[&74/!QY$(R2H]);!.V^KTR"SMRBP=2!YWNEAA##>E M+)W7H:KK[I;/]R0Q\Y35'5G#C28;KUQ#KP.,#/*:@77T[5>[UZR?7T]X*,[@ M*J_VW@A_730;@^:9Y>MBT%_T!Y= MMD>#5KJ0/FKV1@>VD'XS$;F=-[BHCJO58CKS@DST,6%4S8- M'.'-:[_HM6S\02]&">>$@]+R.USISD9U^[7MY<7D@EGI#E=6^Y6+S]W>MFO![5VO6E-#CZNAQYP_L'T^;=;8WG,3[K*WGS\M MJZ7<(Y/9%HDM#L'D_@:_323F5@BG*-"5SEUV19;'QCK-3;(O=B[S`\L')_RF M^/T$/DX!OFPK3-:$1JL+Q&YK)9(Z#V9J>1]X/,)Z M)X_[C)=71\%:YLS>\NB7)PGC`/EAGW`X)BM6=W4QOLY&ZD+J4PDHIK"\4 M1V]@+IY"ZD+J*1X9/%(\4CQCD/QR.)123`J"48%)ZJH4Q2%)*TAK2&M M(:TAK2&M(:TAK:F:UM2A)%A6F"HGK'Q5*%6YRJ3T5E<(2ZIWV<%T%OCPWJQR MV(2'T-]9'-H3+F$"!3-H$:J?<#IEQ5-RL5M4AFCM(HCN*ZA`U4M'*&1922E+*0U3* MPW4%26-)8TEC26-)8X]>8VN_@$*5T4HKQM%L#$T+XK!S$JNG-_4R9+56EZ[! M'8VD+J0N!ZXN/8,N'*D+JIDX4CQ2O,K@AQ2/%(\4CQ2/%(\4KUZSP,.:[%%]-*J^0;'(:IDMTAK2&M(: MTAK2&M(:TAK2F@K51_OIQUB>W'$^>W]M3X03>^+S^!HKA9UAC;`O_'$J_.CT M@8?.=138WS[KXEU_<"_F^-?IO*#7#;[V!H1QYL&%O_SMKW_Y*7LT",<=P]C` MHVP;9J<1R/M+X+FV*V1V"\C91V%^%>.?WUQ=X&[2?W7^?7/QAKD.?,'MZ*3; MZPY'%^<7@_-!KWG6'_6[@_99KS7H7W9[9[U^\\TO"X.3%[2)>F^&!E=]7-IZ M>!U/ISQ\Q()M.8FQN>8(:8?N+4R>79]]"B+!VBP*5%$[P*9*"59U\<:NSWW;Y1XT`KY`%9%XRT?X M>\[HK5Y:>N\\F`)_/&;L-O@@V:GOQ_"`KV(6A!$+?'85A%/6:I[\/S8.=%D^ MW##)A"J7LB33=2)X!N1)4"A-:\:G70A;%6*9-[S3LMC*;;#;R+W!;N!'P2;\ M7K!;(7SF!\R>K<"?(U&-96H5)5O&:R/J3_BY>_="(RSO89R M?Y>J;N9E4O)R>V+-.Q6+!2<[;S!B_@)+@)NF;K1HZ[6 M^?OU7.G_>7KZA87BO[&+54*!.OB=NA%U=,J_B:PLJ%1*DJOD"3K(`O;7NP(78*T4!45G@+J#+(`)\/2_SNY5250\?G0(B5%:^DN7WF46'$3 MA#T682@"_@)+\0&W:<.D[XB>5C$OZ,@1205 M2Z8\R+!QT*%(YKH'MTY<>'N(+BX0QPQ>(WQ;4Q;W9(!7+(V*&R&?N.(^L7"A MX#+PT5.SV"1X@.]#:*0=H2F"<8\]>"=PK>?D^==[9(X+PQNR<1A,X<&!S,%A M>ZHJ..+=!:79!QN< M"UU"=00X1$I]I+#!CD9H4!4C`+SN0!T]4+$H_8%KK49E1?2F!82UCKO`TO^,.$K7$[`C)ZJ0R!R[DMT)7X0`[P3M M4I6Z?@FB[X`&(U7[FOM%#".P0C'EKH\V)W<+/%F#&V\!1"KGW&(/$Q?,@Q>@ MI+=JWLJ7%=J7OJQH(AR![X-1E]KDSF9A,`M=U%';`S.@J#LU.*XR__.6)1H- M!%[4:-U[H8T5/%FBL4W?I)\&MPH.W]YRCZ/UD1,!:HG&J$3<$=.)+!`P@MAJ*Z(;:Z"KC47CLK_"XU)N)I[''GVF:VM.M.4O&XAK' M`HCV8YKEJ[MD,5]$*;_*+`?8RE:(D5"G(#/WSPPQ&22@)U,WGNHN.*Y4$S&X M8;W\T=/BGE:9'-KQ"B7V$T0U:`OT.<1HAR-L3^$X\1*+WE0.2!9SQ_"81ZT( M=K"D4"`1,&Z2:=\ND9F<"1N5X02[&LW58BK`CW&*2@4DX(*')1<@S!!08Q!W MH*;F,_!$X4E`*2["@QK9^ MU,+[N1IJ?8T=@)OXI_;Q`ZT'\-34E4PC&?.W))2B&H](96K;-;XD:SV0JE#Z MR5?VO0C[L7ZG%*R^+YM`Y_7+@UG59H MC"(4]:#!@P_3<;`V MN?"&"M<%_DGN&S6=UO;(U3KAZD#CG%]R;T"+YBF`)5/P7*A11O`4'CI(K./B M?19.?\&!<7%&`[-B/A7`$=\4W^ENX0/RUVO72D57\B\%M0WB:)U4&NQJ_H.; MMD.Y#Y$*`;FVT//\!S5GO\4)OBW`[7#T5%T*SU,L[VO!H/(#U2E2CT+NR[&B MV512CPE9*4X&*Z8N`=9$,KH5T0-&;Q-5!]#./;02&"B(9=I\Z*?FG[S= MT$),.ZW]UF0:C>]"+U\[HTMAEE5"T4]#*_.`4D@/RU%,EXY%)GA+&T:.E([A M291.R* M2Q_)"LEJG3$3\U`&KG0KL!I"J?H\HEK'4FMXTL.")=`>@#Y:ZA5G1^5:U]ZR M5_/[7I:[L0CY'90^0TJ=#M9I-<^=!=5]Y'-36IT$U=WWCX"`/$ZI) MVM3AG9#^J[(JK]]2LG?)+!7[KG2"V6&`Y_.BJS3W3/\;!Q@Q4+,.'=:P<94S M<7ZU_ZZ#;/9$I9SIP^+ M2=:]R(.L)A&3K$A6)"OR(,F#W+L3H.Q\;N-._45$KN3N493MYLRESJU:-$W6 M(N=[&70.7>`%=SH59YX[I?P\G=N07RQ_>IWFSKZX.KT^TTF(3GZC\'6:]/'[3.W;^!0T MU$TGK9[UZIS\9?&KYGT)A81^9[F+*_=UG;!_!MC`\P#&(O39V^OX%H3IVM"\ MWDFWN7P^Z#:2LI)$E`?7\[*TJ^*>-F07F/39'BN]_)J"@3SY4X9;L_"]&+V5>B4[W$01+B'K9#]I=JG$IJ2_"97[3MS M7$V7=[B\$KI`C="0W(R9.0%(+>77U_0@25U)]QBD4V^=0Z]PI3++=3;7QT+C MG`#WY#W31@MW^S[9XS0_&V\OM@VU527\J7D_4WE-=['KZ!:I5#BY0BJQ5!EO M8#6^"<^=!(&C_TT$FN:M\D1C146J^6-2:[ICGO\`[,LL>$;GB+,J8.YJ`'X5*?7+A([:)$ MD>(C]3"H;<\*3FH_LNK=&+>'I#NW&2HU:'=?YX7!.'I@CYU`&5U\Z@SS[R)` M8?+&-.$-?DKZYV59TZGUQ9QH.TL,SYZF/L-]6:.SK0G+6[A7;4-]Q@0O5Z5X M4>F(8K4)@`2@"]YV>8^OW*3`Q&EOV&\U>[W1>>_BM']U<=6[:%^,FH-V9]3N M-R_ZI1>86$I%-FDR5U2<2$7%M*Q>;1@3A[>_X!/WG[&57=-S[8]8P.%>JP<. M='&'`.ZX\83:B<-F\2V@"8`]%I@+:.'>%Z0]9266DT036VO$3'6L06=@]9I- M(T]C$NNVR,4=SVBEC#S_[YU^PU13@9%TU0YX*=A-(E#]J7!SL!+`8/D!Q;[K7'1L-B7B?I?`#^?3UPQ9K$1^7$?!Z# M)<.,>[#2E]^%'2M+_P=F\:/SK))G5O&/\L@P*Q@:AL97`'L%C_.VY/C)RKD0 M7&$I\Q+2?C;819AKM7;)T)6[%=J3]'0:KMJ)K78F*4,_T[6@TD(2OK"SY&?5 M*`=%%8&3]V%>62!/G$I^ZL'1ROU7^^P2)P.?"-ZM2E[76>Q( M9<%LOLTR38B?%V7`*E7I8I?.I1YKT4W5'D4M->$LR0S]PR"^F\PM1N)0]2RU M<^(.6GZ7['XWHD:#OM4>]@V1_I)@C#RW#;:I:X@&UXR4!IZJ"X0P4-[IQ]4C ME@[0$I9+&J`63*^[[>7S,*LT0IV>!:[JKD=H4_=]G2]>\-A_E^+S.*O!\P(W MO=4>G+>:[5ZK-;HZZXU:%ZW>**D#-^A>7IV5[J;O.[)%=8NH;A'5+7I5W:(- MF:S(48J^0)F^O4_C>K_"!_9=?14&J!23*)J]__''AX>'QO?;T&L$X=V/[6:S M\R/^_"->^":Y/GJ*K:W!OU[!^7'@Y?__0C/LE]C__"Q_\?4$L#!!0` M```(`'.):D=$Z%:#,!P``)H@`0`5`!P`&UL M550)``.::T)6FFM"5G5X"P`!!"4.```$.0$``.Q=6W,;MY)^WZK]#UJ?9T3` M`!@`J7A/^9I5E1.I;&=S]FD*EX8U&Y*C,T/:\OGUVZ"HJREQ-#?1R;[H0@(] MC:\;C>Y&`_/3W\_GLX//4#=EM7C^C/U`GQW`PE>A7'QZ_NRW#^3%AU='1\_^ M_I___F\__0#@O"E_;/PIS.V[RMOE^LFGR^79CX>'7[Y\^>'< MU;,?JOK3848I/[SJ=6^+]!^Y;$;21X1EA+,?SIOP[`#'MVA:T-^T_/$\?7"K M_1>^;LV,,8?K;Z^:-N6VADB6'?[CEW26HX34/_6ZO.RZ]G\/Q94\[/9@C!X=`\OH:E+6?]6+U# M8V2./UHW@WX,WR8Q`+_5?%Y>D,8'O:H62YR=.$O+%GSN[CHJ?R]"*-,$M[.C M1:SJ^7JV7PBT!^LMJ(XZJC2SPVH&Q_'M:KFJX9=R4`=N3$?EWW^6T1 MH/ZU6KQ*5&=)(X[/H+:)R+I=TQN%$;@8%;66,ZLM@4%X/;.+K_B8E[8IF^-X M4D.##UZK4PL^=W<>F<=^LZL7W2%&AKJY:"#)N*EF94B^Q$L[2ZT^G`*T6.!: M4YB"VQ-;(WZGL"R];0%_)W(CC>,#BAW2E#N.&_.`7ZYGW_RLAE-L7WZ&=U73 M32*/IC[(*+]]/"IY6K;?SJHO;0;2CL`@O*+_O2S1MOU:+:'YW=:UO;!^[]%D M(P.OH49'8XDHM>'[\<0F'D,OJS7L<_J/_#(80@[>X%*U_'KC6;M&TZ9O?PZ3 MF[K\NHN7VZV&>FH/4;=K>!%TZSF9VLKU3)\:4U@*%ZO7;\7 M'G5HM5;]8UPMZEM&]0@C^3D\:A!]*`\_N@_+RO^!#@JL%PM\]%K^;\[3GUW' M]1B:0XVHG>N[K6U_#J[4\A=T^#%,:)4[>+#32#S=B&;]GC81`NXG1HFM__HX62\`8 M:+FQ!+MXNJ?YX'QW.YR^_)E\478=U=-^<)F-6+=HKR<"/&7S<[33CP4[] M>?H%0NG+Y@,LE[.UUNWBY]X.(_#2P[GJ0JO_"'Z%90KS3J#^<(K1[8OELB[= M:IED]K%*>9]JL5Z<3ZM9@'JG[#N2FWPS58#PMJ[FMX;^T)#'$<'HC$Z. M?3M[WHOH`&-*2843^S61157?N$6+3\=N5GYJ%=.WIS`%MV^:!LY?V;-R:6?K MUBVUM2_A*<;V7U![M%+-S99##6\W[2E&>&4%7GSZ5`-^AG,`\=ZQV[.%T%"P MC,30%%BV-#^/I-.?\P\KU\`_5PC6F\]M`O/[V@_/20"*<+P%-9!CWF5NGY-6CUP_&1\\J?PO0S>/6 MU5+1-FY=V[1JR"=KSPX3T(/$9'YULYMNJ_H#, M?0"_JE$'F;$82]5 M,P5H8ZGF+=I%)K47S%J2.6J(R;@C(1I%O-,Y1*&CX;*;:F;7JOD7U,R^*#^M M9G92N<+FH'++!8E69#@)\TAL9@61.I<>3"9$[KKI$O\+Z%('^&XHR4^'=_R: M$9V=;0':<&Y6VW+:*9[8VJ^=@IG1BE$G\E/O<')K$)?\OU[!`[:G)84BSW0& MPE/BJ`O$>"V(BX(3+97U-'-&1_\T?FK+$;Q:U?6-G:WN4&P(%=K2W&1.X(HC M*6$`CK#T;XKEJ#%:,*=Z>Z`CFN91)%]-#.D4:WK+01PM/GZI_@=L_=!2_VA: MA?#H8E-$(B(T1+.8$2Z=)TQGD;'`<`T3^^Q-[I&:]4)UOS0-GPK#Z=H5M<)9 M`)ZA5^T<9`1LX(1%I8G5-$J16:-LML_^YGYI6Q]<]TK?WE:K>C!UNR)62.`B M\XP1H3!\$TQ1]-%51C!TL\''X$2^,_FU7=O$7T_;^L"Z1\KV\10PX(]+J/OK MVC6M(L>1.^D,B2Z7Q"@`HJUT)`.EJ6=*JTQW4S7Y5U.U7JB.&%\_[@C>D.%E MVR-UTSSS*2+LQQUIFVH7IVEN/'I;XFW=H(`8/1,ADAC02@)X32"`(;D`2A5S MAKDGBFTO&-P=NMYJ5W`#%ER>$9R/G$A).1$Z(GWMLQ`CE2#I/D>F7<1R-R?8 M$Y`I%L1-B?+=O.#RE:WKKVB[UK7C#PB]5?_"!RX">$%;TIEZ"3):AJ\IM`5M.]GM@R;@G$>6.H$ M.@Y6D2B-)49JRS0&Q0SR?HYUM*-[:HQ;;FA5** M4Q,LL3(8$J1U&#SP#.'SVIH\5\;O=09@.#T8")XI!/\>^:M+CUY7WT7ED90* M*G.5"ZU(\!DGT=I`8LPY\8%9R#R&!W:G[_24(?QPZC(^'B%N;];H3Q@*&@%R81$;\XJ37AN&>*;Y=387$FYURGL`?S1 M@?'9!YOR:[7P.SV/]D32?)!&9Y8PRH$$)=&\>J4(-RJ+%"%R'/9_X>FE):.B M-4F.[]I3:J4>6]L7QAD-N38$\N`(!^D(2,\)YYF(,3H!(>[_FM)+$X8"9@JA MOZL6G]H[G5M:%YD*3(#(B`T65]S,*P*IM$M1'[3,HV6QX]2?)CD[@,"'@642 M<9?6E;.+&JY%N'FN[?9M+-MDOZ-K(2QG(M)`/(Z.2!\S0ATP!"`HH40N;7RB M:N@;K+<;8"%`49&J9D'&G$"&X0+UZ$NJR'"^AN`\[5@&.DWB95AAW57W7D!- MK.:[$RS?-BY8P%@!>4?2%DU`+A6)FD<2&*ADIT-D>YUWZRRA^R7='9I)2G`DYQD.$7ARSX34/.-.JHX)E,D%WTE@=S/Q M0Z$TD0[4*PB/FOOW]BG`1I-%Q]`!R`+)?"Z)=%819G-N>6Y4%!TK!*>)>X?7 MA,&`FD(9;AZKW:T&6UH7TF9&4E"X0@+&]-(S`CS+"8N6AXP*+WC'G/HT(>W` M"C`,1`^+_ML#E>F38LN9Z/M%NJ-'$:,4QF:12*HTQM[:$F\8(TXRI;3(QWH"F549K1\]"618DIT!<2OB: M7.4D-UX0EXXIQ4P(P\)WLB3T"@N&QVD:O8B`_(7WR.(K_%TN6RK%_=T*S56, MS$D213*]&2Y^F3$)W3T8>8F8[G>Z=)%O05TMT2K?[X3)(FN*JP/;%E.%ILKA2[ MP?U#^8*=G0N-;K<7`H?)\0=(%=)?#FVI,]1YL-;MM3\YL%:,@MA$Z:1=EY&G M2PW0+SZ..VZE>!RE(H3>Z,!*,PIB4SDD.^Y[N,U^:,ZJ@."]R8!Z1ZO+UIW+-"'5^V--$YHBVK18LE^X%>12ZHQ&7$ M$*-QD/!",[VH=IPIC!9'5WQZ,G2I.>RVTE]RVM"PJ62AWWD; MS/8Z[OO[%;GEWE%I232>$IY%C,,S&HE-UA%=(`JPUZ5N/:7W;17WH%A-DLF& M&=+\]#,L$(D9E"[\1[N@/FLN;BQ@L34[ZJMCX5 MYYS4L-R:TNA$IP`FT:?ABM`L>F)RA]SE&$=OZK^8Y_E>'PWN+_FI<)O"!%R_ M)SC\[^K"?!W'NV_0V&(0'NQ7Y)DR%$Q.,A\#`2UP.>7,$V]%M-0+!+6C8R"_ M-_,P-%"=C,7%:U;+Z[>L5O'&V\M102]J=-89]`UO]]F+#J0*K3$,\F@(.4^% M@`*'2C6]+!G-,B]]1Y.1?T\F8QKH>JTFQXOKUW`>+=Z<^S7+ZXO(OF5NFWWH M0:V@)H_.>$>\<8%P)2A."PD78U48B&$8W4U-U/>D)I.A-]G1\9NN\`5"NSW. MASL6D@F=VW1(VL?TBH@HB.#>$AJXT50I:;L6W.KO1%=&`VH*M;C6\:W>TT-> MZV-)%-8RS]`I1P1D)$RPG%BC-4;T`HP`G7<^L6N^,U49$;))ZJ[N?2/(EI<= M=7LSRS9"!6,J.%PP268!TBT`J=HD0T\--.>29KEA>UVW-]8VZ.@PCEHT\6V5 M0G,J2-AZ/>:1ZM92$,XJ:O/)6+_\NMO#2#_5P>27GBT7[NN M;FA/I+"YTCZC(95Y,0(QMT13:HEP0>8Y53+HCD'K1-4.HXG]V_*'\3"=8B%! MSCU`:-(KRX^:9I5LP]$".;:SDY6;E?XXHH?]<%:\-0WTP%SD(4]V3QO"#'I@ M(4>^,ALU_A>*_@8,H5AZ*O;D,(%1HGU.<-P05CB/,3,1^!Q]PN^GGJC9@I5&AG420S0 M9@#O85W,_K%"__[WX\I0?L/8?F^Y(L,L3;*:5( MY(P3:VDD,8N4.)4I<,Y+Q_K?I?`G4+L)`9[:PK5<`^_KDA(=4?,\$FT$1J8, M@](L#XPHRKA$[S5PW3'#-]T>TM26JR>`DY2D85BRODK"6?_'Q]JB0OOU?1(I M^;19SA\5X74C6(`05AD6B<\0HI"O,^6:$BDD7Y?O*-VQ@F&R/:DIM&LR=*=V MT=>;)\=GZR,I;\ZA]F4#H:6OOK5O$9G3,EI&C/*!2.4]D9QI$IT.P:@<7-?\ MP63;5U,[[4,!.:5[A6LRFMQ5[4_3?3AM:B5V]"RH$%0[=")Q;@02!.!X@_U4HW/(Z=]LJW)2JJ^+::S:HOQXL'4D>/Z%T8EUG0WA&= M7B,@5$C7=RE[N9OKE-<=ZRHGV[0:4R7&A?*IDTB5 M)V"H2C%"("XBF,9J:G=G]>_).=(_@_Z,B>04VG,//%<%[7WV1K8021D/8#A5 M2,:B3==`46+3^6?JJ(20%!Y+;-_AP>'7<%:# M+W>E!F\V*T";H+,H";,2?WB&JRL.!:=-S/,(7/F]/P4RA?A[8C9)C8U'([B6 MP3Q=Y?FO-:_'\7797-SWC4;TI(9YN9HW[5X,THU@P2%R7+P#B49F)$>AD)QB M#,A55-()PZ#K#MC3[EL,K5*3P3N)\MT>`[CEY3@V8WA(SW;U+4($GSF6$V$% M)RK+!0'/`_)!E>NE*#QU!KW.G(O%:>1*%SX@*(6SR4T$BD!UC MIR?=-QA*::8&MY,RO3E/(UW]7WM7TN2VK81_$>IA)U&5RSAVZOG@I>S)(2<6 MEH;-JHF4IR7)_/O7D$2-I&BA*((JGGWQ.9IPV9FP)U MS[_^,9TT!QS3^'FY6!]ZG.)21W%5])&C#1%1K4L%2%+U0I^:UFWNEFK=-=1P ML*R8[%0:#MNA$FGFR9L`\T^3_5M;*V]GWF47KZU482RW5.'H3N`&;$IB@G:D M4$:EBO"F=!VW)G-75E@.)`<)QK@V(.Q$-%*0WABG#/%26OS'>B*H2=@%5/*< MP4^[ACB/>MS0-T]Z@V^$ZB`7-I,COZX$%2'8P(@W'`B^J4L"JS2R:`NKC0B4 M=_4*WY5;N!_L.BDN!T-O8EU3TM8IW>3T%963PJ%^S@DMC",F-3MWQM@F61TG MWM7\8?PNWA?]`SB(K=P8].WK!9VZI)*E*VPH40M7@1+/P)/@64&L"S)PK4'1 MKA09IN;T4"9R?P`.F\^=`@93C8*4CKYX_OR$JG4Z<5T52[R@BUX64$FM2\-" M22SG)>&Z="1592,(@V6L`(Y[8T?ZC!M8GD,CS8+G,)K'_HG\^PE:]W_8.C3- MI#:+X6&R[ONP;M1^5CGI(K`JJ#&4XC*+A:.X$RM*P((B`*E+C=!.Z(Z=7MFX M,>C]*S`#X3L.^YH2&YNV91WH=E1"94L.,HA(<+4I(@MGB+`22%E&-`B]+FG7 M1K),WSF_^@)T'$(==,]^G-EPOOIB&P%5&93BP`(1$!DQD)HK2HE:OU"%@V"= M"UVM\+OP)&>'ZK+?@*J M=0SWC0E>1X14JK3*H>60H):IY6DDFJ6D9K!WM$`8MCFN*:]D$J4FAL><4=6RA,JJ"%2*4LX8N^$44Z$CM53 M!VHJE^N)G\ANSP+I*,1JER!T[K**1C"%D)%((PU)J;JX30L@W`H;N*%.TML; MB]TC>6X#<1Q3[0O.>%;[!:RV\:LLM?U+J]*;8(("W-&-(!8H$*.\2`7:F!!. M,%UTC#(85U/JFS89@-RA3O\UFYNP[U6=JR;&&[?&3?FT%XWO5/WF'MI%I-%O7C>&3C3D.M.ZUF%#X_C M>MR7-)4YKMMUE:+UL+GHM1[WJ_\.89FB-AX\/L_EBE>KPX`CE=S/3VB`YAY' MYI3LKQ:MU-M<7D'!M/4NA4L72>'1DEBN"^*I-"PXR>GET.+A[_X-(%'A"_@G M.Y_7L?8K+FP^[H[*);&5%D:H$@I2LN0(T6"(EER1(#6C:-P(D.YF93MG1\[> M*7&L6\IPZ`ZA2!U..-6R:;%Q_+R.G%B;R&V(V>LXE;+.*0ZIYP0#8H5QQ%%: M$L=+H$XKZ61\U9I]=JJ.C7<^3>[P-;=*V?M'6L0V&C[_&_(BQ7H#>?KW-TDXZU=8YFE6G.CZUM-AFSY_BNC?>_/WDU4TQ*S=. M1-3G'64+^L'G;YXW7M2/TTGZ*RW&Z>0BZO?2H/I`JX^GO?'GV,F.'V?K MV'FIA-.6!&W%50I*9820A'-1$J$4$"&\;`XAE=6T8T!;W@)J0W`C(XB]I$P> MN`1;4N/PLDI8\"Q*?`?RPA#N/9"H-&\([P.%VRN>_:`4Z`&L?XLQM*I?EL-B M[ILA.2'[-Y]VF`IEN3@Q6-[LCYU/GSD];)!WPJO/FS^BX[[[VS\M4V>GW9)Y M[6W:DR(J+I70*22D@/0:%*4@@-L;L=0$SH.GT#55=9@*O'T8CP.`EL\G>C#I MK%ZG#Q!J7\^_PF+Q!+N17KG'&?XD]R,LDH;P&=:-U!X6BUGMEHM5EM]TI\Y_ M:K@&LUR`7SF+%X=M>T?T`RJGY9H_.P5$V\K^C6!_>+\??EJ M)WASO68AI'.//1S.W?]KNK^L:WBWU1MR8JOW?')/];><`1^7!WZ'&OG?F]?S MZM=Y'\K%^?P79B@9YKN_''E*6^H_?/LV`_P,"81H_;)<+&?PH9[4OR]_7[5= M:P+[?L6)S8X(ZN29/Z&['A&_-Z%F+F^/IE%=*Z(2#(&Y0\6M)_]\VVE]1.@>_X*G/^'#=++X?M*7TU5>%6-D$14DHABU!*"4Q"O7 M]")"W89VKBB2WUS+]G"GXT#;R<"[`H1Z\OC7]#>PLYMYM">LLD"9E3XF"ZHD MR15&C%+%YDX]Z!8+9S1G\:LBT:VX#L`@%`4]T*1"2SE$E\I/ M%JRQF;5FX?7ZFU\ABVY!-C^/?IDN9_W1:"NM,A&4-V"(B"X2$PM*8EH]FUVW M4``=DQ+S-M5XI2RZ!=A\OHG+^FQ64^?KTLWA?TL$Z=V?&6.G#H?)&WBVM0"^ MUM\FJQB_R6)3A@B1_3Q]JGV=$=$V@V>>Q&%#A4SB._JBN278G)KYO&';!*7RY9OR_+NEXN+ M[]^_OWWXFL_>9OG-A0<`NMC6.EC"_>]\4^S_.OCAZLE M&N=)6I1Q.C%O+%QG9[_FV_3B<4)8A`@X%#Z6ZW*Y>.= M>?>F2.9W,XO61=<\*E/&R:P=JR]H],SQE_CKS+1C^#F)#OC-YO-D1=HV)+.T MM!W9=NBD!I_557OECT^GB?,%\>Q]>IWE\Z5C6"FT!>LUJ/8JE>O9T\7,7%Z' MBW*1FX])FLP7\P_&NIQ/\>.RSN_IU.2_9:ET5&?.(B[O3!X[(LMR16L4>N"B M5]1J]JRZ!#KA]2Y.'VTS(BZ2XO+Z4VX*V_#2G&KP65VY9Q[;]:Y6=+N0S-IF M6ABGXR*;)5,7=HAXYDI=W1I38X"K36$(;C_%N<7OUI3))*X!?R-R/[O%Z[!_OCLO?-[W)S:\LG]^9#5C33R,G4.Y'RQ^:MD;MA.YQEW^L(4H]` M)[S:4+U,K&_[+2M-\4>.3MJJDJ5.W/8PZV9OG1!OQVFE!K[>!H MI9YX>C*?V?QL/R:IK9JX_E^4^>+)@D`C$1JVT9?$B_D\SA]M6'$;VTE.\3[M M4?)V;?6$0+V.4:-J>_[>IZ6Q#I0O',^MGI[\;UX=+&H#1V6L_OB MUCFS+*UO)!TWT[G<]2SC:*7V/'TTTV22%%>F+&=+JZOBYV"%'GAI$5PUH=5> M@M],Z:9YGTQ^=6MGM[PL\^3KHG0Z^Y*Y=9\L70[.M]EL:O)*W3ML?*[_":V(Z!NY^>K.+KA\EL M,373,,_FST0_)G(_*NB=T<&QK^?/6Q'M0":WJ/`I?G1DK:FOPZ+TYO+K++FI M-:>O3V$(;G51F`<9WR5E/%N6KFFM;0D/(=O_F'QBO53QM&17XE73'D+"K1?@ M-S>YL=_9/F#QKMCMV4.H*UAZ8F@(+&NZGQ/IM.?\:O&U,/]>6+#T?9V)^:'R MW7-28Y)Q`8B^_<3[9L+S^^)3K;0Y1DI87TV1^L2YS$<]><'8@ M2VF3>.22F_"2X2F,WF<9*VY_49F4Y9 M75(^GYOY5Y,WY7,?C2Z9O+6T;"SSU9QO(6G(ZA%*>QFV1F(C`M?7/M@RZY*. MIPY2WE8-FH?2V`!CVFN3>\>S;_>P$VM M=><\:2QQ2;B#:#4;!C,KHOUBZ6-^F_I`SI>%MZ)EL?V83>@73R5+S M^#'.OYDR7*33XN.SR<4^.]E;(1*^)EHIQ90OL8^U"!'=22:'BH'V3I$:6<2I M&GMI$UW`-(0!_'[UC^S>Y.ER8W>=.^\@V2%1:1)U24204AM-=CZ7BH1EA!O9AM6 M6`\.9!8C"VT[@NNUC*$RX#A<*9(ZX%`2'U'E$8%)X`5X(Z&683#>:+6]TFI8 M02N4?D9[&%W$.28S&%[]+Y9(*^.'O>4C`"0,_#`$'&/@"81#1#9R0<9'%E%V MH:"L>UB&4/`0>;:;T MWB+$'I3>$3*#Z?VW+)V1]M&?3?N= M@#.$`1R.?/D\R\OD_]RIF:(\8@PU*40$,\RT\#@."*Z5[69WC.P?>584OZ>YB6=.E']8X(6YSG+S)7YH9E'U:$W=9Z076L5NC2C?NRPF>THS"4P&?0$SJ@'O4D M#Y6_&^Y!.*ZA<+Q6V`;5U[7"1N8500@]7RE/,Z2A6Y8D3&ZC!#OC;&0W_L]J M-R?"]<0@?KUXGC_47T[1OB3BSI*9ZM[X-$"#M3,O!\JG6M\1\2G.R\9P6 M\60M;F4*5575R`Z%@'M`>513093P1*!79N=C7P2OGC5U0(!"/#[[I78&U0GT MHA!)1'7(2:!!($+;X_EZ[N3['L!#+?8=S:;J3L$'$ZCZ@VRTR51NK\V.!"X1 M^V9UT/3XAM+>\I$@GI):$2"!_:3"$"FQ`4-2X`]D/PUWDWI1>]8];H/$1CL. MB]6A\GCWS5-P*A>=3J04R5`@)'T;51`N*5:V)_L;+#0$;+P;4"UU^S)R&@2W MO[8MC6[S:MPF=(KI_'C,QWT3K2\T^'0;VRAS8A;+6_-DEM]EJ_OF#IK`";4C M+GU("))`*F#A"FB(O4T$H"#3XUJR[$U+6=_(#>$\=O?$[:Z\^9P4WRKBDV/5 MHA`'O@Q`J#0C$EHD-0XW4DHO]!K9QV!)+T.$*1W"-ZR1N&EM;@%QCK0R[>%8 MM0@3S$(?:&)=+[)NE@(2;*3T8*C&&X=TH[R#%M$95C^K98PNJAB?0;Q"8DQN M1\"EU!MVJW-C#E2)(`HAUB'#/.282>%CM!TE=<";+?3V%E]THZB7"3+=8-,H MAN232;XPTX_)S!1EEIK=I0_[(H*J*I$?>)!AGVK?4\P//45"NN$X!'IDT6+G MRU\=X]/;.OTKW*\_P,I[SSL,=6^^'Z3)L>TRO+@1I<[NPJ$JD=!V6L9]@"45 M4D(J&(=:"4258("1RCSZ022LW#384SRB5@YM9W_(%T)SQ8%/U5HR&B@@Q[`G MT%XM+_<"VB,QVJ5^)ULR3>+\T6W(KN]9KIA.'ZP3^;[6@C+F>4H)&S+8H=]S MH#`@[+]\J/2PT^;2K;2[QU2Z@&:((/@)A[_%<_OQ2011.2>JKAPI(845EP') M%2$V$H1JV=T8I`CZ8SX\TH$67]I%7W#]%0QE=%/H4=K'\'9Q>6]R/IMERV#V M\N[HBGUEG8@"J7RF,`\PH('&E,EP)5^HJ`R'NE>C;L)4API[F7O>$42#N(;- M*SNK`[F[>\:K0HAC]2*JI8">%C[BB`20>531Y>@;2?*=A1(?P M#&$&+]BL'!3VEH\H90&A6(7*UU(!&H:`K9PG0Q1[8,0!0S?ZROI#Z>>Q@O%% M`R-2_BLLI>^N]ZY>0W]9-@H4EX$$`<6A%8%"I"A>C6B0*:B&RA&K.>BWU,G+ M5?.6:`PROK\8U6S#-18']M2(;#2L?(@`D=JM0C,K*ECU`Q1`VS$::?KTX MQANA4E_;A9F\OG7_^)?NU7D5Z_7#K9)?TI&\6ZA\2>?+5' MV?4K6\24[R./,V['2Q8H2+#4R@I-$.0,#989TTCSS7>->D-HD"6][5//+CHU MZ<1,'>/P2+<_5"724&.*O`#I@&F?0^'N3%A+)Z`_LBM$.M\U[`B7_OK^;M=] M^23,ZH7)T'YI\@_F)IY=YI_-35*XI_JF;HVSPAN<2BZR@R97OI4;$J*1'5$) M]S8X$,*:)=[V=[*Z#__0,V9#>(QGKY8=<1//RD6`>-1.DNWTB84*,T*YYEO/ M1V2SC>+^3D=W[1O:@#&04MU1Z$]Y=I],S50\_EZ8Z?MTFR7%)V5R7W4XOCZ1 MB'F"*DHH9(*'6@KJT2T"RE?-LN[PG\D<^D&J44;E'UG^S3:Z?B?N:I'?S18' MB%H=C,U&;T^.T-DB#[^V>7:I6:JXSRU M_#Z]ND-9^"?)L?NBJBM'DDE/!E#;YJ&6R+>&NI68^`UM@([>!GI#J%%?7C[^ M_/Q2BWCOVSPO^W5EQ<@G,'3WGU$L,23"-KR;O&#@-;L8AXU>O[V@TUBWMM6C M?&R'D$^S.'7WG]N/7TP^7V=%']-^2](1#1@'%/@X<'\D]7T9;*,:J9MMX@=_ M'OL8%K]ADCVRR;?W1;&P+FR1.\Y-GF33Y9N_Q6_F^_*GXUD?=0A$0-OPQO.Y M\@AD4OM$<+V$7",/"=)PE1B,WG1ZA6D0`UERN.+\4YY,S.9%Z&,V<:A.1*50 M(1(`>11R02DEQ%_)%U@!9<-<\_$O(':-S!":MU.7B3'3PKUM[CAV!T&>O8-^ MQ`(JZT8>Y@)AJHB/`;#CIPI\;R5OR`00S:ZCA7^>I<2N$>KO6%8Z-6GA[CM- MBVR63%VT^_1VWM[.-E6U^REVU_C>FN5-!P,RLK0YMV_ZIM/UB<7=,=0QL#"V MLVCNZ9G=X>P/-8ZB':@185]B``-?(R&PG88$GEA=#^+K4$+OE>ZW>\YMU4&T M/:6C(!`>D]@C&&C![/A'*%[+I4E8?6_?$.?06NODAS/V;7$8[2FT#UEZ4]JY MCQ.Q1H[9ON(1QSQD`&C%:,A]R`3T]08*.XT:ZAS^20EFK52:=0[*$)'B2S8K MLXGV5X@@AA"%@D@$?.)1KHCT=I*Q$:>5M5-4A=9;H?,SZ7]TJ61C4/OPZGX2 MASE>:Z2([RD?!'//'VD`RAZN># M6>65;"\+1QAY5-MI+(`A!0IHGS.ZQC[UU>4`WAJ2X97LUWAJ=G\T&1C>,CT'U'6P>?OF> M?;G-%FY/ZLMMDI?&I"^73([?OEJ;0$1KP@ MK:U2L@%0:J1S;K]"3U?#CFOX0/$(A81!`2CRL(U<$04!WW`:*JY'\AYD7_!G MG2/44I?:-CF=/EW/_)#$7Y-94C[6U6\EB4AKJ2@*;=#I"^5!ZM'UC6V,2RO,`>O/_N."*)*!CY2TO.H\MS[IFHCB[7G9CE\O>V[=JWB M=F@,U9U77+K8=@/`TA^#8(9[3"$6:2B0D08@*H0,20@]LIKAA(%6S MU(S>CF[TT?5[`VL0AS"+B^+R>AVT7.:?DYO;\G)1%F6\3$,[YB$JJD8J]$(F M`R8"X99!-)!B,QD*[5_:R#1Z.]G1N'1]#']8/))4IALP^/!#.`3 MR400*8$D0X1RY%.$.8)R(UFH<;,0L;(IFI*,D">4[RDWR\82*4B9"'==I.%AH-X.CW3M00:";0BC<@\/%RZY MR127J7YPNSA?>H.LA:E?KASB7(5%K"G=!3X`?*T]CCQB"1V[J[@UL9#QIM=*=#; MF9.N==X>D2&TO'[T?IE#MS)%E103-S7^E)MYLO?02>VZD<`T"*1`RKU[Q5B@ M_`!NL2.BV74BO9TJZ=H"NL;GE7J]?IC,%BX0*]G1P9P$%T@5-?Z>(JFZPVT=+I#Q@JZS@U05^?=(> M6RKQ<@XBXF5:^MQ9Q>KQC=V;@N)Q5V3]/@K_'N?3#W4>P&A-/&(A9YX6E%-H M;1'848P1R=RU2)Z[-[-R):DGU+:/R%2*6!R2L?ZCW"W;B!`*&03"\RBFFMNN M'83!&D.A`C"*A[J'-)6#3WD/"_1HLZV[??.#B$!HXC$::$)]R0CR^084=S7> M0-;7\/W,P4RB]D,AI^$YR+'.GM]_"+47`$XY"Q%0OO0!]ND60RC\\>:!=:#% MTQ^":`;77\%01I%-$"L(Q M=@N?6FM".%*0;^7$HIF=#/;,]ZN%*1UB.L@^5B=/4+CK>A#T?.@S1AA"E!.X MD2NP?7+$`4DW^JKU%D4SE'X>*QA?M#$BY;]&EEN;ATB$YE1ABXFG&)%HN``@A3JC%34G'H(0BWH0W& M#0\>]/WDR*L/^2T@'-(0*IWZ\X)1$``!P\"WSHX&A,`0@/]G[\J6W,:5["]A M7QZQ^CK"6[C=TX\,6:)=FE:)'BV>KOGZ`:0BI;(ED:*X0':_.,I5!$&2,5&]"XY[EF]QN/898NS7]53`VB^TNPV*_(;T.1N8R M1B7%SVIL\#=Y3:8!AHP+!6+0'//A1U3M2)KHQ)(-VHKEC$G?`T(=RO[U@!4Z&GZZF]G\^WRVG2QJ]/:3SV=<.F^1\#P6R":2RF#&I8^>K?!ID4NLT?/E@!HD6RE/H M(6#``&P)J39=3W$[_;0WBZ0W.?V8&WD+2(.$I^\VV/H:DR^>RQ`EQ(:)(+&1 M0CFGC*GT;0?Q4,EM=Z:)W(+A("?-K7$YC&PY:^RQZJ.[S$'+.13I*OEI@/HO9;M!-SF5Z8Z9.CQ#/^;KS6H^W56<;W(6>_+Y M#"`@M4%>NZ"%*`.]EQ7(1M+$M*MQ1?O3S6.W`SI,SOF15ZN6)B>>SF)Q34H4 M1%0$_<0+XE7E8L.6M[M!MK]K05(BR>UP#AS3L2^FT+!(R85F&3=$*L,TYPH( M"YPC`I2CM!BWO-V\D^\*:U\3BT6 MQ?_FL_#'?%HL9Y/5T_LO7_+5::ITW$,6+%L54)58&R4$(-"JREZ64B12(&]$ M5HT+>"L"/G],_+SY.BJ*.SB*Y:M5L5[O@JF++XVYUNIE8912"0*`UE9Q`AG4 MWE;^$PG:U=KL[X[TD6@U!+;#1+X/<\$BU=!J[<)0*<4\S!<4_BFC3;@%K5C5 MW^WK(Z:.]H'G8&Z"SFYB9%3'2M;::RB#DNF`@97M(!!K9[#W=SW[B'SI",)! M`NUZO;+1P+""8F"EL%@"+1RLMF<;?I-8$:\1*=,UE*TTG:/N=I7&/N81MGW5 MD&T8ZO?)?!%/`C;%Y_R/8C$[I^1<^YZP!P,?!J:((AYQ:8+U69X/66)1.PN^ MOTOB1])O>H8U";_U.>C""AIC'2=?PZPX,D"/K85;_-VJ#?56C6SL;3$-*=RZ/)K)M_EFLMAO]!_S=;[ZGL^^%"N_W6Q7 M>;F`'[[[]7*ZRL.P&JR8;5^=24HP919RX#5!&AI'R^-9JV!+CU9O-=$26$0' M0CKI=?7]MUWDQZM=1=K7R[UALS.8^UA.S_>6266M--AJXJ3F`#+E3(DIM;AE M`%5O-=ON<1GM#/VD&5VF1I3U]-;O-P_YZM/#9'ER_'W0_,I/R*C4+"CV7B+H M-`2,!4V_1-\PW4[]A;_B842B(DEZ0KS;1G$^AW^M*RO!%ZO=F/N8`#5=9H2$ MC5-Q1Y`W#"-L775<:0EO2_A?Z9PD,1$<$;S3VI_[:5F5-E=!YWK"PUG'?$VIW52V3"245M9H+R162 M$!A68DB\9^TN*$FO6F9CJO16+?,ZH">I5LML4WG"`8DD3L@3+DR@8?,0>`0@19(*BD*ZD`Y$DD53C="NYU`+I8'1B]V#V)_<.P$DWQT_CP%1#XS7?(BC) M3@M;X20H:U=BYFXJA+95VF[!,`GOV1TD3%%-HJ=&ACT:Q>74(%6A&LO`I*M! MMF3'$)E3[4#]E[+=H)N<4GS'3!V>H2_TO_TYRG4)7,=M,FTUT]9K0C$&!@AD M@O98;CT<#.61&S.-J[&(+Z5QW0!J*Q7\7;&\A@BU;3)J!!+8$:$948):`E%E MBP83HITE?5_Y?-<2H6M0[R/QDSMFM')2&.^@=10C02IR0]5N=QDO+6:T%:,5 MG(.I0)_K#T`^_XC8J1/%>!UB3(?^E*\>89TBU$NGF8-8"""H=EQ@9*RVTI6G M,5`,5TM^L&/OUL=/J<@@"47_',Z7!OM?12SJ%*\$_SC9U.;[]-M[YCF'WABL M"`RHP[`1$5QB#H1H=TEWRN$>-_$^*6'EAHEM=305M1/.<,X">IW((I^X_T.QQ5J.MT^;L/VE,]V`;EQ M]*O\(3KKOL=\BR(8.A<#`3NYK?OH^"2:0S_)H;I(?;R0Q,I>RU??Y]/\#%\6 MNRD4?GK_Y6,^+;XNY_^7S_81S:98;]9O&L0G=MQ3AJUW-@R*26>P@UHRLS\$ MIM`I0$>_VKN;\38/7.RPO\QK*@WFE%M+B<,""U5B:RUQ[=;7CH,81^/3V8C& M\220;'3C?JFM;HY[\SSTFH/S"ZTR1J*?,6PSCCM&A%!0PQ(8(V6[6[<&BWT< MA2)%7^@.H^=K:8\>+[3+E&3/&2TP))B:FIST'E81Q,BP3#IKL1'K-&'$3 M5K\N-Y([6TZ/$L-3(:99AWX>U')F\^_YHO@6/_M9P6Y2)+:N=>8X)M@X0ER, M89),*E0MMP'2H8+N&]J<',TB"\D7X1W?GV5+_/59!&^7@RC6 MF]4D7G+V_/GK6I9<]9Y,8$@5D8PBAID*-C%UOM0GG<#MSF1Z\TWWPY<^$1LD MTG.OB>6STXK:\_=?"@%M]((LS!*!A+,2:RN$-AH[7HWT\^I\IE]S:?K+>K_='_@%T=K)SJS^''^3(TG4\61RGR>W_7*.ZN M8[=FOEF'%>G-?/(YGF'-XS*T&\SL_3(0=KN*!1G#`^^*Y:K\;^#8O)&SJ]-^ M,J&\T3I>N>F8M-0'L^_Y9,TQ;VBM.V80+$^,:C>,/Y?%YU@")S+_]?+;=A-7 M@T")Q7PW2^L<7!WVDE'&8#R5-Q0YPH&6V)EG'(FB9JA+?"^ZM49B3I$*ZLFZ MLBI(]-/1JN=7^?]L\^7TJ<:EU:!U!I66Q$FL`,3<<0.8!Q50V`P5U'R5:VL4 MHIPC:V?8#J%;GMI#JV^N=6$T:)U!)RSP*A[+>2X)%J:,X7-4*L'3=7)U*M%S M;.D$IYL-R@\H=1$YF8R=JI M'!MPY$:X!B6)/M1)^L\\7T7_WM.;Z-UKKM)<>$%F..*>0P`U4$X(20'UY<@- M]^UNV>XY[S4QK:8[>$=;?7X>0JO-ZNQ[,ALOE/6",0:KW>`0*;:T0_M\JT)4)HHCP+:[M$A!`@ MRC%"Y]O5=1A4$>I`?N=88W$"M>($*K6]&`%N,-%8,2@`$("5>S[UUK0+ M4NKM[&\\3K3#:RQ.X%:<>&Z58 M0W#B[>2_BU5,EUV__V+SSQNU?"[__$>T"G8.^AJ3J>$;,FX!09)YSF,RE:", M@FIWQLRTVU.NY\K=V4S]X)L(MVHUV\;OR(STGA#F.$-:264\!Z2:6U+H=(VE MSB5\/8-NPO#WXU)R%M+]4&@$ZA3+_.GM9/5WOO';Y:P^)NYT@XQIA"'6V!JI M,*%,<%'ZVRG@ON6M*WTI.SU([$=.=`'3$`3X\X]7Q?=\M=PE`G[-P\86&F11,>4J4!)3'W1YK7;HR MF#$MRQ7T[PX$67,#16(VBQ.>A0JG=L;QY%`LC'3PWG,<9`4-L$F0B+81DXI9G@E M.<:&\D*U\Y@/SIJ6;O/K0/[U7)T4$FDE]UHHZ$E8*;@RY?@-H0E7#>AOE]/%=I;/7B_=9+4,CS7RJ/7] M#9F$!$D/`@>D90I2#VW%!@5<8O5L?KW9T;?$!O61]UD'I:S,_4-UGEX[J7S^ M/_Q>/YG)^F%_0A)_BO5IBF6MT[_;C^L3[+?Y;#Z=KP\*^T#=J-EL]Y9XD/*E M6#WNJU6U.4@Y8P$>=;7EV%'-;1:8FNH M@W%?1\]K%A2.NZ&R:4X>/70MWK.%A/L#+-F3@NA>>/_EJ#!]S;G`R>2<_&E3J`/'_K,B M^>%A$G3&:;[=S*>3A2E6WXK5;AN_[-MOUCI#P'*$%3`$$>B!@894B[-AJ5W' MUYN4BKZ1&V+Q.)Q.'"*VXAU0-?K)I689):$THWP MSC*B,ZQ^568DIU6D1X@.-(D/JV*:Y[-U+#X=HZ`/>^9E':*N72:)%YB26!T# M6R0YYTR7WVZ)3BPYH1LQ%/T!-,0L-ZN@WNPH78)0:TJ<:Y))::TBP@BI$3>` MA[FA*LPT:N M0P4FU:2K+H\?,6?W\*XEYOGBR[/2;2V80:UD0SR MF(>).-9.0%7N65))WR[:N/,YVJ=DN\9HD/2N8KV."TK85':%8:?3U7:R4!L3 M[-VG\,NZJ)-&[3/O\:YLD4%8`L.$8Z""4P+?3COK/+6UY[.,/J`:@B+/Y%W[ M8O4F_SI9'!"Z9.Q?:)51+)A72BH;*^Q92CPN+6`)D6Y7_K3SJXI[ID-W`+7; M"2+]\MG;^2)?;XIE_O[S8OYU'W)T=@\XWR2#`#$/>1BPY3B8*V&EJU8V'U30 M5B*E=R+2CM$9U@8_"@9Z5RQC/,UI-:!ARPP*;F08JG/&.^^A-997^B@![9C` M[H0)_8`T:.#>B*%]Y?R8U3K\B4U%IS8)`2@&COF7*D&CUA[:Y8$+\`1SI` M:U"N[.,T7=!S-T\'IT43BIQNF3FE&;/("DH))-A!`W&U5E+=KG"LO%=F=`)2 M7W&M[_)-M'(^Y*O=]8-JLUG-/V\W\=CK4V&*Q\=B^<>FF/[]4"R"%'H*O[SR M(PZ'>#$0-3P7.WS_)4843^.=KO/%-JS0X:7[ZT"O>76?\:S7CK(JP''X4TQ8 M^SY91(O#_;./E/:!SR]@N#3\$6MTJ,#_6?RTH&$=,N[.CJ(,_RZ__$V#NAQ= M=9$%?5]3;YFS$"KLL'7V^0I78%0P],8.;;UQH,UC7KOH*$-*&ARL8$"(`Q0X M([@LT21M#,4P)Z@<+;RSF404 M,8(M4X@I@[C6M-*?'(2)9:]W)YX?U<$;@6EUP'1D:/ZU"Y[>G,\EN-P@T]!B M(JA@1!OJ!)!>B^IK%6_G&^PM_*=S,7:*3BM9_KG\GJ\W^>QC^'H MF/1=(]4&33/C#=`<`2ZQ4,9JAEQ9QL`(W/*ZA-XJ7_!-NQMU.X\4Z'T![QRI M\=3!QAK0V0C#3M^?64D!QUHPIIWEA#MK2_O1!DP3J^HTNF=I#-`3.:WHLV3$ MNV*3KS],GF(7:CE[KHB]_'H((AFK7[=>Y_^8R;?Y9K+8/3VBUS\6VCMD2S1Q MXI]ID7&DE1#$>$7[<+A>TQNO!7BHCLP!G%!1S,GG\5Q7W(^'Y[*E)8ZH,!YS-ZU M&G)!?#D&3V0[?^5``KU='VN/Q/`K[7%0Y1^;7:&&H*F$/TR^-E>]+[TD4\0Y M)HVP#$`MC=0:NH/J8ML=0?28NMJG;MXA4(-,_(=BM8E1G'JR_/M-,5GN2\$< M+.9+RT%=VPP0KHGU$%-'/0AKG#]L<5*I=D'QO3F].U\D.L9G$&?W/S%W;SM? M/T0,GNO^UWDISS?*D'""(8\4Q%(2)*@];)AA$B22!M<7`SH#9@C1-YSU+PCL MG/__]JZMN6W<"O^DXGZ9V1=<9S.35)F-VU>,(LD.IXJ4E>3=NK^^H"327D<2 M*9"$:+>/<0"*Y_L.@8.#KU,GFM^+AVV[RN-ONIJMYU,L+)#=-#=@!:`'P"&#'*&,(05ZK MKTML%==[!MQ0Q/<,3PYEJ.R2S]/B4HN1E\."8-Y)[`V/BY3R0FH.:W@D33QE M]Y[3-A3)':!(.UO__EC\*%^]NO^2+HJ99:KVGIO5-=1ZT!M"&-.8#!`QQ0+6D M\6AJA(MV1VUO6B_35NW>T\QNP/*5R"0Q^K%4HT_377F?_'0FW?CTP&`UB%HF M-&,<$4&90:XV%I&`:2$B$+P)XKJBD<35\YE]D]'[VW+C%O.0C-W M:S6+*])F4:]+D]4Y]6D]-T2CDTE-I5$^H@N5<;0^@VA+$@-]WHPGKF^`!@O* M:8Q(^;6\2UZ6Y32>1[Z+H!0,>/P9*L'*140Q4 M,#`,0E!*=NI[.*R=,I8NAZ>H>E\+R.BJ M<'>%?3T$+#F^W'].-T7Y@N5%>\,&_7IH<)XSY82@4B%IF<#T6*LP2B.=3OM2 M!V[$T>?VW!&0W/0V+LD_#PX$`FNW>9[2YIOX/?:1&#*-VS,F'PU,EA!."04<"T$L0S$S:;>R:#+5Q6AW8;< MA8S7WJQ.0.0A]="QHTR):QD]);Q"M$*`499VG5&]O#1?E2C1Z#RJTI9:'3[Y<=F,9U/5B^W M2-A:48,JO).6B-[GWQ28J M^6)_?3<_7NBUUY(+SPA:(V6UDXX"QA5'U&!4?R0HL;]:]EC5?M2D/YR2/':O MW%:/)13K^T_KU>[;\JFZQ3WGO&LU.0A(F2/..&D@`-(XI'0EA?,VC>WL`:K7 MLCT80/F7@T.H73$[W[2KU;RX["$5?]`SA^+.R+%GIH90,IO65R][$&L_GWTW M;-*BWM:KAS)JJWR1SYO%C\LMV$Z/#IHX20UA"E!&J?<:`UQ++\!(&B<,\C'W M@D@/B[3?QUT=?OUR8\2F>8%Q9(7P#"OEL8,"^-K1%5>AYF+AXXA"[6%I[HQ- M$J]5:;T/V^WC8N[7FRJ:;G*_+P6T+Q1T=O=M-SM0Q23E7E@B&;&>4EK?/Y7E M.Q.]=MDC5I-('@2BM"#R?\3FQ(,&;<73*,:0I0._/'[=+GY_C,*[/UZZ!H;]E0.>YWYLX+H, M?WV7CRU"KL]-"<3`^#&5E4D4@LQ0!A6QSCH,H([?66,P:A8)&UOLG!@>A``` M&@K=/^&O73N7LG(!H/)0KQXFP5%&"C*>VDH]@FG9M M,)C;HT_"UL-`E&5I*`,CRO<\-!,HR[2O5Z4IWV1"7)H7/"::&`4H9P(SBHGR MOOZ*B&LLI'V+:/%^S8@>XLW%3.#D^,(0\!EIK8S@VRG@/="47Y:,V M&/KAZV2#CGY0>C]:,#YK8$3DYR?]14N+QLW_I[%!4.\Q8M(*I;&T@!)1VTO" M\%Q9W"TW_8ZU% MVSB-U>L=X[?;O[O`D<5LVW>#+$NXE,HP(XV[,.A`91^>AY379B70CU+ MMII_7DY7K1)XA_BY@*E&TB/,G&2&1WCC5U=_=A2/V%I(U(Z?BMV.!M3_JVP_ MZ([.M'G#FGH#\_?[C^7Z:;&XIKOLV3G!^;CG1]D0``PP'8_]`M5G?2[=N"RC MVU+\VG3N"=0<2O.J,V>CPIP<'[],[!2->[10]LEZVHU*6/@#- MDJX=W[-8/3057G@>%;`P96"-$4P9B;@W6-#GDZ=224IQ?9;.[:SP=#`R$MJ< M>O]R7.`241_%T%XS:[7D\:A8R6&LY>.U>I/8.,UH)RS>+K>C,P_S4SJ:<\=^ M(XH;UNS;8K)JKK%PQ5."X]P#28``)AHH3#J$>86!DB!;88V6]1?2^&MW1.@! MGW'HR-V?ZQYTI'Y*8-:[:+QZ:D5IQ$:+UN`ZE$G97/641J8CJ?ADT9%7EDVS M3_7,C&"-4`19K(5WTG"%`:WU'P&25K_A^K3:VP99=0?F1J0W>Y[.S0E$&L>A M]H134^JT9+Z6SS!&QFO[=6:L60,Z8?3^=&%TMN)X5.#FU#=;`J?&Q^62*8P) M]!A!2;01%LA*+J83.[L-YQ'LSL]EQI-0R1,3M9[]ZY"*^+*'S2$)\>^+/_?_ M=3DXJLT#@I8`1[-&>A`!H%0*I>H3%R$XS;^32Q\^=H_*'P*E;*>%8ZYJ4YYH MXYS`N/9<0H\@$/%,I)'RH);/BK2,C.%*:H`.M1LH-I2;QJR. MC-(V)<2>GQ0PH]``+1T!&D6CDH-X%*FD=#)7+=V+:;%]$=6F,V\**N--D1TD MQR4>5RD@4GH*M/>,,^I0!8[P,,U<&SA5M@^NK\ITN0ZDMY/C0"DS6B#CA..< M<$<@$Y5:`EV8([NF2ZM.:D,=/E.C1RL'OV"1);O]92U,GG<;7?3U3P>)Z\U]5],#803K'$9MF"(L0IQ M8VF-&<0C:YZ1T_1/1^EF.G%POTSNORQF93.(8K$U\22UF.NGZK1^''CU.;C] MDP.56!#)K6400XP=J8J`ERLBMR/KRI%3HP8#\;('[9>_E4-+[UW\QW\!4$L# M!!0````(`'.):D>%<$!+8YL``.??!P`5`!P`&UL550)``.::T)6FFM"5G5X"P`!!"4.```$.0$``,Q=:W/;.);]OE7['[#I MK=GN*KL-OD"R'S,%OG9_'ZY6_/#TOPE!1EFF>_OM-^A.]`DLWS19I]^?7=Y^MS M?.U?7K[[VU__]5]^^;?S\W]XGZY`D,]7#TE6`;](XBI9@&]I=0]^7R3E5W!7 MY`_@][SXFC[%Y^?KWP+-3\LT^_H3_=]M7";@N4Q_*N?WR4-\E<_CJC9_7U6/ M/UUU'_:_?5,MWW1?)8[>(?OUU=UWZ>IUE9Q=D\ M>4?8`*#AH\B7R:?D#M`_/W^Z/`C/O:#?N,B2+Y3RCTF1YHOK*BZJJ_@V61(< M]=/NB^1N_R.61?'J"90BEU*D(4K1=T<>7+T\)K^^*].'QR7AYV*(`P*(J[=H ME<&K:7@O@K*/U]T'R@9\0WIP(A?RVT?*!MV\;&&V4/$.[SY6-GBYF-6^''D5 M+R6_'&\>>1CTDG[MBORT_B9]?(\,U];7XKKUY.2Y2K)%LFC$\]6S0;KX]1WY M:;8JS[_$\>/L,GM*RHJ.4660W%8X6X3_7*75RW4R7Q5IE28EOBVK(IY7,S-R M7-?6$3*@$6#-M0P'>99F8S-`CNGIL]K"+,G./U^W@.J/E%E\QT/3VQ8HDC)? M%?-F%"-0Z3C>H/_K%L@S0&&".%N`!BC8(`5_M%C_[Y>+C<.O><_G^UZE&N)= M7-[6.-?D$+R:=9$LJ[+]Y)Q^<@ZU]?C\'3^+NTV1SU4V1=&^W*]> M05S,05XLDH+$4.UOQ<7\2!NNOW$QSTE4\%B=OVI.&DJI]RQ7_AXWY!%7]Q+7 MUWK(KDANN$1 M$K_.'&S8D8L"TS*Q9X>6:3M6BS<,D3FKN@&/I[N/"Y)''*H#`WB/0OAQ>5\+ MPE.\I,[5`K'E[&$]F%A;3NF-^RY$K>1.[`D00\1!?6]J@NA,_SY:KN\@]Y4:5_UF7& MF4MZ=Z!9MN9'FN[K-M(LO;4?F(8YV\[)&6((26:9.F!/#8(MN"N295VS3=>P M0=+@YH[L9)'-&JF-R;)@Y+5F=(VQ2;'/0(<3;`,=/7QBXZ\W')+/F=KJJQ>_*<:$2I.>H-A5/V7R?O!IAXV#,0R.7OQ$.!9&=R%:_8@.'@][@H8O+B98L@*=(G M\@(^)9^:[)7BH?6[?)51+"8T-81#"VF0#$^AAT*WQ1(&2)OMK,'@ZEW24`@, M'?L7C0P:.+XU[M1EN$7G4%<5J,>51>O3``64UWC\(\VX329I`/I]JV$VL,$: M=R.?P:0:1GS$.DD#R1K()#64T!#'2ASCR">]'28X(,KWL6><5$2HT/#IY]E3 M4E3I[3)YGU=).3.@YUN6[0<8N[KO&!!Z9FO3"U$X:)CDMC:-X7"^@0TRBGN` MLO(3SC^TJ:%9TA"V!0Z\'YU,\>%(*:FRAAT.XF.%2(^](S M)`PDB+G(_Y]QFI57>5DFY8_IJ_?AC@X^,],T/-.R=%V/`L,( M-`SU=G9!-W67ZO\1X9=GBT_].66?(@-Y1L1^&QG([P#I!0:7-$EDEZWZ/Q*U M0HI?8P/?-^A^H`R';QBF$$>>"CA*6<^$@#RZ)S(M(-&A7-6;R:EL49K%V9R8 MVU'6F6/[CF48+O(,%UN:'QA.V-ISR6<W27S.MWL(EK2"^]: MT""_7:9?CBPOD,PQFZRIY55(S3I(8#?8&EF_#G'3(UN#Z9R(6@WW(Y?\G@U) MN./'M(J7Z9_)8J99AJ4A2PN0C_3(=;#C!JVY`!O1C,2$M[G(G"6/%9[.LPV( M/\&>;U")+K$83*E`-JV(RV&)--B"-19W`Y)G11S*R9O9N!1+F#=/9LV5!:B: M8IHLXD9?ABQ,"YM,$Y&B&K4[(OB:CP+'0Y&&(Z1%)C8"HS7EA%$W:[C9Z=K? M+P3-B`2.!_;>]O2+^E=`-G`5W"`Z&>19)85"TKP&Q!$ARN.+0Y)'X$U,COGY M8Y/B_0X?DN&!]$Q!@H>ZD,M[6X8M/IYY=N#JIFN:AJ&;$'N.$;3K"'7;M",. MV14U,:;DREUO?)P]MG1<"6-2@M_3+B/N2;E%*9M(IBT,OW^),"<-S*H1QD5& MLOCR8U)HP=0/CYZGI""PD0 M3*`&=;K5]8?HZ>D?@QF=2$<9[DP2:F'3B2P_ M?WA<->$N_6N-NUGSU2`'[Y.JW=-<3XG]L-5Q<545Z>VJ.6ZARNG#'LASKBOB MY'V^)*\P[P2DLE9ET\LI-"B?G&ZWY5MI/=O3H'_4V,'ICK@0)+E'E%4WVT0T M6[F;^;B]05CQ<5:E"VHZ?4HV!V`TFTV3142(VY*UM^@W2,G8Y$:Z#G$$L>V[ MIHM]LT7JZ(8G-AB,!D_U.+%Z>(B+E_4PT2G[JX.36J^:$U%W1A.&,41X?!CO M'>`=.B;9_.*CRK8[VXQ$C<$^ MQA'+2;/6:#W''R\_YF5*X6P.EG%LSW50Y.MA9"+/0*[O>9;G:+JJ`0MO?2: MCFM$]#!0Q\8&[*SX&C)XXD7.1RN.]?#U=7ASS1F-\;+#IDL*B>%3H`;(Z83F M-1$]DB+(V$3$0Q1]+N6U$1($?U441)`VZJ-KMH<,;&BAH06N;=+5=JWZV):` M+O!:4"P/_N=/G\+W-V"`3'!SQJ,6*ND2$8TSL$9T:O78(>:HB(@2.2DM$79B MKZ0,HX196>BQA?0,5_+'5H$%5WY<%"\D"?F?>+E*9H870A3ZD1-I/B::%J%0 M;XW;FNOR*(TH5-LL')*4*2Z&43I?&9Y1.ICM3=@]#/0%R! M%B6H88XL6TS4]B.\-\V*WC#">$654^$0-%.J^2!9NX80LA8L\Q3:1%CA=$ M'MTWU<`P;4OG$1S9MA5KT09N'6*=@?DZ7T8Y$\QFE[Q0&!45]]\"H]GMF! M$UJ^&T#=A[8?>58$@]:T%U@.CX3*L*=8-M<0VP7OS152>7T%2"N@<8V74S^E M4,VFF6.SS*>3+<'M%D?*;W/%RDZ);62-9&"M1Q=E.B>[?&219G$P)U/6EDC2HGG_* M(CYK\9Z9K8D(B"#XOF(])P4<@5#^F!35RT?RCK2WAC[23/9]0@\&I`8=0^LF!C3+YXN`!AA2'OHTV.HA.6F!G8$LZ>D>"NADC7)&8I(WO&E@ MG8$:6'=%\9K+]WU<*HIK#O/4&]!(H'Y%K2G'M;GR,Y'G*Q8E"FEH15V(-C854LT8G_ALR#I=.7T/ M(STR,X2_B:C+(!=R>:^3Y%(Z/6=A'71![.E^Y/H81H$?VC`(4;A74X)71'C*JKG&Z@3*Z!O@`VHG0LTQ$0D4(5GG!5S M8?+XKL%NLM%M8P%)0;%C>%H4.*[E14CK$E(OTDT>;12SH%@&F]IL??;6D&*2 M('ML$J>>.#XU>UW//IEJ[:6E1Z"&T3@1+1KHQ+Z[P`=2PEF:GD'7"VPJ+D9_N,%70Q:9'^>$I_HLE0Z1LO-)JLU'R\S, MM$RDI_.BWEM8YG2:O523QK?ILMZ&2H*5[:-3:-!2O73+SFW?-`WLZ*&C6SI& M$0Z<3DO(?P%7_4:64=5%G4OL75Y=WER&UP"_#\#US0?_O_[^X2H(/UW7=QO9 M/X/POS]?WOPO;Z5'&NN,Y9]3$,Y9$]I`[(K1U$/3FL3,/(84^VYLUEEA_C%WJ`3;O` MP-.1C7W="2W3"$Q3P\C;K#K2(RX=$C2A6(-:5."Q@<6;D`GRQIB@J:>,,V%K MV5HC.MF*H;W$].5TPYBW"%%,8%\4-+X. M[:>G7XH&4CH=-1KJR%M!DD(-VUTRW?UB'[J;]CISON/[H>5[.+1L%T%BIYLT M23H@V)'[9(/*I%&V&1ENY')?(<[`L;[C>2=&Q4A#NAV%,`J,R$*. M&Y%!86W*(HDP3\@H\GS%XEQ#:E/2-ZI+M*R#>,[`48A3MI!1-9U\ M"MTP>>)T=0\E/0'B$`(G$AH.BG"JWUQXGFH"'&B]7>IG`VONY^\V,Y59&9[B.'?HHTJ"%="<(NR,-D`N9XAF% MYD^2BPY:8:ZR+7BRU9,U@V@B6P/>RL"V%FS6&_;JBS+63?)Q,DTBD@.?K&F& MIL<]320M3>8AYV@&K83I2277:CS-OQ,]T6D,]3>MTL^)96]^"W9)'. MTQ*4254MZX/^.4/LP92SQ=MCLLTW1&T1W4)[.>%V@B-$]43ELBB>2(@NS9U< MS9O(+6UW"3&P^$1L^.3/M-JRB6%@>B[)%4C"@+`1&8YMM39=W;+X=&V`(>6B MUF`#'/,8<@AD5:F1N..5J#5M%!=H@)U4H@ZSU*M/$LB=C#C)\.6-,DDC2*0T M.;.TT+$A,C7#U!S?,#0+=;=^(`@#P9KDT>>J+D;6^Z*D+`8^3A%W]5$J.\)E MQ]-5&]G*C,PL340?A*`?+BQRNL]^;4;^\)`V)V#0S=YY5I%$,"'I(#6)(?(T M.XB@KR/#B>P`=TMC?#T(N2[+&&!'<4BR!:TY#V$;'/B>SA(!]P?>^S*&\,HF M(6-1RBCFL]#^Z@W1E$#W1+1*AB=OKCZ51`Y7.)5GM=WF1/E0TP,O<"++<`+/ M#'TG0MT)A:YF\UTXQOOP$0*G/`,E!70&'N,"/%%8X-_ACQ!JX#$I0%G?75Y+ MEOXS<*TS""']K_D'$B&LJON\2/],%N`VK^Y!7-)9P&ORNB0/M^3W#7@&:'>I M0XD@F:\_U>I/S3-`GO&8S&DI;_GR,]#-,T,SSG1=K[^O&V>V;9Z9R&K-I65) MU_?7&R5655F1'^BTUQ"K`G$AWPO"'@PJ>S?X(T#R6EPWKT6-Y@QF09,K_Y1@3K&:;A`">F;_>9J!>0.2=^N6!&;91&=D4OED M:(M/B@X0/M?XSL"V1(V]L>LH9STJ)9'PB>B63(]V]WS))HMG0^KJ8;6D<_3U MP6;$Y&.1W"=924*&RVR>/R17>5F^3ZH/=S?Q\\ST',OT7<.D\XN&;[F^ZW
?4QBW6FT,47V$%#5CP M/87[0[?Q[N/5B&-'(=J5W&:)8LP+C*2P)5; ML(+D+IVGU0Q!P]5M6[=L33=AJ.,0.ZWE*'(@WV':@\V-**.+!A+W@=G#*663 MR9'9Y%/&%AQHT8'OM[E=`^R9#5)T+O8QRGJD3R+?$U$[F1Z].?]:,ED#)CEF MKJ=#-PRA'CB>;GE0BS;748:Z:?$LQQ!X_"BK,A1.;1SG3W1*0RIURJ8R3CY_ MP35OP1J693ZSV'XH[L9-PV=:?#:-V(IHESQ_.$V\YB6+6LRA. MBWJ:(DC+^3(O5^1E[.9X(ZCYD>7:EF:[T+`-S;1(H*;9]/3Q2/=95S0,LJ&N M;U%8S>P:V`)VNN4+?33U=#$I[$ZD>\GQ)5?P^HEVJ^;P_M^2F)I=?,@^)70U M.DF,O+A,R\]9?ELFQ1,-.R^SQU5%_IDP182@WD!X0S^?60AI@1MZOJ6'I@T] MUPC]%B*V?*Z#]\?$I;ABL^F^9^L;;$#K#L@ST#D$:H_.P+9/H'8*O/8*_%'[ MU=/M3]_4G(([L586U>?1&EBMK@]O#99A8,0VG]JH,:;KAP:9T>GG'Y.\ES4\ MN@8Y*I)_KI)L_H*?TW*F8<\U0]?`4#/LT/8ABF!GVO"YBOXR["D>0[9P@0X8 MB0`)-.%A8`B[G/(^$K%\LBW&J5KE/4P4BZ)*H'EJ2BG#I4,**(TN?F7;9SC( M'^(TFVFA$\`(>U`/(MLU#&:4^=& MHED\/!5E6*WJ'::-1?4DD#XUU9/ATB'5DT;7(-4KNW#SMWK-_2QR,'0C/821 M9=G(#34<;6R;+M,G4US7E/(H1=A(AKU)N?]H4$Y!VG:9 MX]0V8>(G+&[B/C&HVT#"1-+5[L>_ITE!'G#_61-BR@>XMC'54&GFWYD8,0@J&GV5J(27:]!H$X#Q>1:WDT_=ON MI/*RV0&4#XC_1F%;>(*JZKFZ8)VSE]2PLCKB,#AMA1K(,U%J")*IX(<9SZII@S M\>"N`78&UA2>/)U]2Q2+A`V@=VJ"-<250_(TF)Y!8J2WV7%HXL`WS/_G[NQZ MX[:Y//Y5=-D";B&*%"7M'4E1W0!I;-3)]J(7@XDMV_,\MN2=&6>3_?1+ZFW& M]ECFJZ0L"@1-7>N<\Z?XX^&+#BDD&*1AF(:XW\R-BYP!6QBIVID$1I$#&"D+ M9PXC'YJY@E&T)!A%1C#2E7?!,-(.10%&9O)8P0AV)F&&*0!YGH4QB!!)BP@. M_).GB6UAI&IG$AA!!S!2%LX<1CXT?MV3ZKK]GN%2;B*TGSO(%;4D#U&4X2(1!@%/8QR'PXH: MQ$QKRN;*IN^S9]+-H/%3UH:0GAY]XA,FO!K9YA!=CW+N]/9"/$4! M1^CGN@D60D+G8=5^WUSWA.Q6TEA6%`AAGN"(DHRP(@G1@.@LU4K>W%E=#B7- M=@`;8#E$6TXZ5F0_P\Q-0-3)^91M*I4[.NRA]_KK?_+O?% M4W6]Z[)83",(((4YRPA$,4Z3M#]?'(=)H54'SM"$;QY*KX*'QJW@1OJERSM# MY13AYE\T39(U>K4>!8U+OSZ$E"1_?4WZ'9V8U0`Q"#'C'+&>`2C M)!H.RN5(Z7(99\8\9V:*MPWO[TKS&X?="3].QUDTUZ/BJ3N'@X-_"CCTI*S& M??=3*VQVN[V]TFH7W"NH<6(0<2[D$BZO=QI/[>F-LRN)0ZKKHYI7)^HEB/_A M4UUMGY5/^+BIR@_[\F&W2DG!*,5)&G&R>%^MY7MFGB;"]\*D`E&"2 MRY*S!244BEE7WON9P13:?IGCU3G/P]-G66563HHDP1YZ8JWWP8T$W#?IHH-/ M>/PVG^;(L\26,Q]\CDM=-!/:UV77=B_JKIV]KM76A-4^<@$?$MDTB\H`-/4; ML+0Q:/+X%;Y8FK`A3(J+GRA:NLI23(H8D2R,$[G7`2GMS^AAQIC6G,?2U"2C MQ/$RFI.APE9?-?!/**TFQC?56KS<;O:N+U(ZA>T7-V5UT_WY?D-J?:;Z\W]DUR(.FQ6\.]7]T_7 MY74A9)#W8CVU"Y7G-_U=,A?E]E+>0]R6R8R(F`"`#(0(\3`..4N3K/$R#AD" MF59=Y(E=\XS//AIY=NLXGN/MPCZB0+YTP5%,\I>&NYM$6$$3EV%QY*F;7(W0 M"VYM/:+/TM!^[KYQVB0CX\-,;;^0\62NZ%_>US-G(ZC?0FOG&_UQ^@'-:?(< MT1A%,4A)`3*4QWF,XM[E&!9:GP7/Z:?GD>PMJ!E]$C-K>ZJ-3#]+4^H-4Z:M MZ.=*7'\2CPP[2VC8A8Q!BY#BY;6\2_#)Q>CT:?U0]F5G61PA@&G.$`L+@F&" MHMYND@-L/\1H&)MGG#@+I(NFGP;9*VP#?4_B.B&WLJX3$OR@ES:&#:1>-$M- MXE$"HK%0>I?XGC]*S';'D;(HCC"".281)BQ**.V*+0I#'(!(:YE'^^F^5VJD M0T']:')4WD`JQ>41KRKI`:C[XK#U9JXS[J\$&5M?,!9O(4BQ".#4K;P64JB= M0Q>)V4-=-;;^7F^WZVK?GWJG((\=$Z M%NP:BOQ/YYK.B6<+\<99,J%N>D#I)&O!VWME=%K<0CN-,^+3:&AV,MQ42[7S MX&]&_M8I<'NIEG#VVT$4M=/W1P?&7ZIOY6Y?7O\E_MQNKL2_-9:)8-/PK28K M6$B3*$PRF!*64QQQTMM-H5H="V?&/`.Z=S'8#CYVM%XW7NKPQHFV"M2>6E8] M?@^*'MSK`-0Z:(1R)])J0'UJB\L4X&%B$!9,ZYHJ!^9\ MS_KEFO$N*+\_EDVGVM?!US)X[+QM/N#(RZO&U0""X*D2;USSX:CH.BC@EQ<7 MFDL%+EI`;>U@8O&-%A.D=T'O7G#P;Z[EA?WL[ISU+ M\''X"`8"0.,BQSP'@$`.#43*<$M(\^?33^^'&Z]IWD((&? MIG5S:L!/JR[QK,%'A:\<)V_HA8P2T\?M]LB`J?!3C3CDH7ZJ]JL\B\,$TA1C MRO,$)3S/^Z-UN1@JM0Y93^/1E$ONI<@GOJWOF^2Q?(:EJ^=8:L(6/ZO*?;"I MQ`_+X)?[>K?[-7@4G-K)\*8=<%2;=Y+1QD/+SC+4G`5M)#_7*-/Z[&^(T6S= M_Q_CBV[0;@<7(\F51Y8/#<`NA?%FYD2^[O;;]=5^!5G,(ESP@D*0IRQ"A(=4 MUF-,61%AR!1A8OIX?WAH/0H&EX)_>J>F3BC?T&:D\]JJN9#N:!U&[?8ET^PR M?Y7?RNJIW*UX0M.(H+A@E$:IT)D'[H9Y3HLX/S01&71(U;'A1 M0X\3O0L30Z$W.T(!;7$6TNWU_:XMWPK-CGTN\GW_/MC6>W*W4`2DD'. M*(9)SD'"4(XPH+U!&B.MGFYNQ7/7'QQK-C.D9_^AB0$+`=6X,(UV>J`XR-8[ M-5]*\:8^(SBQUW0A?'$02.WZ==-.+7:EO'"95->YO-&K?I0)36=]!<*T`#Q$ M>1Q#S#-`:`IZHR#4NPO9SI+W)*1UKJEM<7UP3SLKL5)3-5692DC=_.5(PR// M>DI-GM>,R#2:[+B0=R&$>'[ZMF."]T M*ICM?'#N2:#.Y$]9N(50QB*`]R9[FE+HLZ-=M_Y8[X0IG"!+,E!_=5M4OTJ%?YX+(01,5 MC!@HN#20F(3P%DJ,Y=#8OY6?`L@)7VOK4UT-P_2JB#%,TH3Q*(K#.$1)SO/> M9DR0UOE2*T.>YUP?*O%+PKON.(XF6>PD5-T'GT@]W3;XB_ M+=+HKK@#;1="(3>QO-H?=R:0!I?:+MG/PU(4BB>GL`@QSDC,092FO9DTXWA5 ME;?R8C55&.D]7:D'96T/.G9$GT#E+$L0+_08[2QFRBVF?QBZ_ZI+V,B@W`O^ M6&\J.?J?5X?+NCY4N_VV^8)S]ZG<7VS+_?K["E(8XSA.H)AR$$08H#@3,LA([NXZH]O[\Z M]2AZX_5IXZRNFKWY@Q-)`7&">`Y0#EB11#B-\+!^DS&E_7(_EBVNG[^4U?]FD5T3C-,&41R0I$D1A4>31,6"!/].;3=K:\ MSZ[?FBEB[D'3>43!OWN-J+Y%B5<^F^VZJP7)]PPX3=T'1FW*[[6H8=8ZL8@X8P1RR M-(Q)#%(6I[#W`]`D5*_WZ<'X3`LCQZL=C[WCEO3SUT`*2?O<;:/'R$.S'-%2 M-,N1R\'@\_-"FK,WADZ1TID;Q;!\J8_&4:QMJB_86^F[3^V7D,%[C:^>Z"4V M6;,ZKRZ'M90/%?]^U?AW?G/2D]V*YBA+"20,9#B'12KF$_%P:A%`KKURY=B^ MYP&P.2XD$_O!9]F5WQCR3)9$7#>'Q@+5C"UAODQU7@4'KX,/5=#['9S?O(55 MK7JXOAK&8,5JQ@:R6+>JM\'I7M-7DI>%*?NJE*^ZTM.C^+WR>[F]VNR:8?/Q M:=_=9/&[JZ4M/5W?6^#RU$I+&"1]AWAJL)+*\8VLU*W*B]16VG2G/`V#C77^6Y$Q6FM(]+6NII-IJUH0B MZHU=K7['G@V':3OG)C]/.RK5V-%:-QHO9$G+530O#]RZ%$D95Y_*_=$!7XHS M`<%0_!,1'A4DCC@:C$2R[+7Z$7Z])VO!2/_POG`FD/7M-!&DJ8X:^WFZ]/>WF)LMEM!G),T+N*(A8@F(4QQ MSFC&8$AE(5&N=Y&T6].>$YZ#.\%M,YVI@G4?0'`C)C<[$8*8V?0QZ!;8=-P. M:K":L0GT:#8X^IN0^K=&ZN/[01MO@Z,FDOY.71=32\L1]'EJE(6PT5=T+TM: M^A11F:ZR;.:VO!,I7G-$H_FTH=R?WWQ>?U]1@N.B@`PAGA.4%A1EPP'$&%.M M#RIM['C.S9ZY9I*E66FHAL&IY-/AU.Y?3)LIXT#1S_71S7YW];W0\L<@RE%4 MQ$7O#D%4JW2[+Q\\IXC]-#18O^B0QZ?`.L>#7S[5^S(`T:^Z)0R]-9#!_':F MMK&>"0^)NVB_+ZP6Y3I6="+7+YJL[KBJW MS<_)4_7P[#BJ*:,'?N;M%3NK)$_"K"A(FA"*BSQL+K;NCV1%3*ONMGOKGAG: MN>&-HLHBN^:H#WW]D_3=YIB9I9U_3FBJVT(_'4^U`S0FJIF4ZO@N&#AK M`#7*SJ&]'EM/7:763OB;2N3=Y7FS3?X5!1S!J.LF6`@\G8?U\KYF+[+9@7(% M44)Q3HHB`A"!)"V*C`\K!1S98_%="U-,Q(-?-E5P7=_?K[='-!PY`N=200NN M.17/$<66@"M=."GKN&04J0>A`AY-28PQTZ=_$2Y@$B%`."\RS")&`.G-X237 MVL`QM3'-?-4/;)1U-,.-#PGM@3//E/,-;32@HZOF0K&C'<8[X#&311D]?Y>; MVSN927TKM^O;\M/3P]=R>W[3F-Z=/^UW>Y&`"W^&3"N)8Q"E18;B(@$4$89I M/R4%68RUOJ=P;MPSK'I_?UNW#@=5X[$\]='P:A<\[03+!,JNFLMYY2<$U203 M2O?-J(;$65M0CY6]JT'G:_!I:+S6W>#(W[/YYYRZTHZ@UELK+83!_N*K)WK= M/5&[S5H9@2F!(^7I M'/-@+2D=\%.O27XR>&H&9TA.$PEML=D-]:]\61$:D8B$@%/*$8:88=(7^`:, MTL(!.(UM3S@O=PI/<[&M\#F)SE,DI,M`Z%MRZD/4NF&6C5'[\-1`ZDA&=91V M51U(=?V7=&@GST[GF]V5F.L^;>S-?9%,K(];; M_EQ^WU,1]+]780'2E"4%3$!:();Q(HE[*U&&H7*%,/U'^UZ9,R@?9:#/.*PF MD,:02?](;X+&G1'T.)%(HWB67ZG,ZF)I2J96S>I5H"=`:ZG($FI067A?.WDM M-'.8O/RZ/\%BDD`.$YI1DB(0L12&N+46(P`*J/HAO^'3_=%`.K2(;.2T,B/) MAZ64"\DU;*.HG;Y?5GWET#5!D219$:9%4:11EA:B;]+!7`JT[B`SM>'[2*B\ M(RRX6/]H]NMD>E]LJG5U)7?WSK_>;VZ;$49S=<183Q/X^)'2DCXFXZL/_HP- MRJ[D7"2!#,(819"I+%H,.ERJ\EEVQQ5/*8E@FO(HY0"G@GYIT:8&C$8YT5JB M-7F^9_9<7MV5UT_W37G5CW5U^YMXQD/0]*6CZV5$9Y+.JJ;V5GJJ\\>GE'KL M<:6B-QJ]D.H=$ID*NR`*&8=P@D!V*(-$2[Y%!<^6 M=70V16ST4]A`FD@Z/?*<5BWXIW5,:T_)1CZ-S:6)9#3;93*64VV_Z>W8W]IX M2AO$@PX6D:9R3*6=S[$TB'S.:7^GJI97]>I=)CKYY*7G*]EVJ,Y'C&PBTDMS/WOW;T M!ED0H\L:$0ASQGD>`12E.8)QR'AO*4R@UI4`!H^?EAIFLT<3U?3)X4$P*W;, M,U-\K8@B/S3E6R!!=",888B1&,H4N=AN'AHS77J3IR@!*`X3FJ8HQZ'(:(:) M)^``ZR!$]]F>^=&XTW0(369H:Z0&#)_RZ-'BH(S^5,0-*EYH,<()4]46`@EC M]VLW+X_5LO7'355^V):0S* MK6>!;-J@:A8,'[56K>VE5$UD)M!0-Z,Y%D]QR=]39G-:G-$4QU+/A1#(/HY7 M28\380RSGS_7>WEOV8]<9%VKA&"<\R*A"800T225IQVJ]ORQ5(,*4(A!Q$C($B+$@4]Q[@ M&&L5D'1HUC.M>M^"K?#K3!9>ZQRS`I:=T"8`FTQC2Z`->O_5Z-VZ&EPHR#X! MX\9$5&:>DY98)`/=1#;*1(?B&3)2%A7:73YNR_7U>76\I@Y61%A#89CGK``$ M4``!P[W]D*5:6V7.C/I>`+]_V@6_/&RJI]VOP?7FYD8TCWAUVCG2_JX,'IMU M8$G/X)>.GKK5?]PU@`DY)]+>DIN-ET'KIKR\_-EFW:S0?%L_960Z:()%`M-% M7*.X=":<(2QEZGI^4VRV@MCE?S]MMH+7ZQ_R)V!%:41RRC,>AS@A210S&`VT MCJC2^5#W5B>=_&[+Q]:O8+=?;_?!M?X^HD.]3>`XE=26=)1NR@_V&D>#WM.@ MS^JEPTTJ7.XTR<26)+&!Y* M0W9.]AS4JGCE2&"-4_C3"VUV(-^)X&J'\Y4D.3&,>-!S"4?V'4=4>WOYK)+J MBW*[J:\W5YU5D81*,($%I@-F^49SC/S1%K7DN^UAFY<$!WIV=:U M7&.HKC:/Z_NFHLZF6R.RRJ2U13;)GGWJ:SE(]*XM(D=^H9-R7FRJ[R)S8>-@ M1O-?.XG4SW+G9(*:>P$(NHA23H4?!Z*ZQQ\FD(P MC;1T`N',\E`#`=6RSM,1OY5F6NJSA+S2-H3:W>MBOM8@"PW>=Y@G#_63,/I_ MW%U="*`@@+N&Q15LX[H:3O?(4=3*I2C)AX*9A2""(8P*P$]JD^XJL2EU#K@\S M]%@RK,5837;5B10^1S#,H5)V6/>LW+#,T&K@C0')$R]"'HI\7V_:_J"_"J[%V[3KVC/L-!W+=?S&B:=B/G2XFQ'#\FTK%?E MF$/])Z!7+`9TS#8(K0JBQ3!:-P]6C;(=-C0%QQ*S`D;D6G&`@!+G8G,%ADDY M%R4T4SJ'6*';I5-C";32Q1#:@? M#S\"6P*B;IXU.0T79X]/KT_Z>TZ>UE!H>U)$M+9*_W?[_)_Z@;EY M8!WNZU<"W\8X]6*$7!RD$(0XL$EWWN,&7*VX5&T85MWZK7;=@K&6#10VI&X$Y/;8U`TR:MI9+C&(D]`>$8O(6E%(,M418H0-"_`X7,F<#$A[35=EG3;FGI=H%H7! M]*>?J%@\6,?0.WFOP5\U)UB_U_B[6O8)9\`J$3Z48HVSDG/)QT;R]GWR-B;) M^J4D.4;5*USBNC@B?A@"VTM`'%5_)0Q6:+MB1?F&L9B^??G[(-'@R33_FK5\ M!.K'%?,)1^JJ<:Y#SQ57\[]-T%7=E55T+31S2SI>[K;Y]K%D5SY'Z2A&/H+( M20/;"P(_)LAOYO/Y3I*F,181:WDKAF7X2[:W/A=E6=]WU]"L>+_?Y=\/^_HC MJGU!5>*YTH>Z!.&IV%2/I^@QH0+'?((\#KV"%^0MIOYR=TKY/,O0@#"JLSH3 MR=/@2*'[@1.4*39@^N8!/[]LBE]9]C7;O>:KK)?,8U&--S7I].%I$!J6Q^.YWLPMJ_7K M38IT[-J5U3M'_V#O7OL!99-C2M(WP@^MU#J@6?0@UX<`DAP@*$7AK1E&3.) MHDBHMZ**'<-1J(%F==@L!DYNHJ$2HWQQ8"PRQ=1ZJ!V)JJH MQ95"_Y.G1Z':<6HQ@1`A$@'?`QY*$P\[+C,*0234T5#-TG0J)3=!49%7):4R M0*DVK9IFQN(@4>)Z)4CPO!5+U!D^S9*BB%NU[K(RJ_[CIWB[3K/7;%.\4-OX M)TW[NA'4`?``PAX]8HV""$:L=W9ENE).H=DC.NP95C`&L:Y=6O<@!75+"[-\ MZC4VJ6(:]H;/(WQ6"W"J&9`FV:;ZW<<_LFVV M6VXJ`/'Z.=_FM$:`UB*V&,H61`@"JUS1CV;#L MM2CK7;I\@U/T:%(OWYQ'CI-1+7B4V."\LH[I?HN5Z6(YE3`*<3ETYF=D368B MEH:<>W]&9Y!"_LMQ+<>#G_L)GBG!:?7HP0@C@)TD@HCI/(YMOI+XJ;"9OFDZ M=,_XU47C`?3+;B9 M"@.]*S-4ES#1,S"3^#.9^^]K("9=!NX8UB+(UJ0.06X;NBWV5BY9USZ!&9%;'JI(U0`6# MAR[.^6+"!%R+27T'\&S)`,O\1]9L/N8&I%@S]3-16-U>%4:?5T$]I*UF]VVK MV?OJC]8W8[$?D]"V<1H&)/:<,'$\W!;7XL#VA"ZII`P8SJXIIM_WK.OQE45Q MR5V>R]'')V3&F1.3+2G2C.C4*6(&5$F)QYEHD)H/A<8'2U%?VELLQW<<0!*( M@.U!-XA3B-S>6BCTZ9.DB4DT1N[J6Y9$.9TQP)\.I9GFGOLT.0)J(\CF3/5& MU(L+BB-%"K?F''U33@VVAZ(1\&(;5JD3]"*`88R#U&/&L">6U,A9,*PXQQT. M*"I!D9%DC4]CS!,F)C'ON9KJBN4D+P/JHL;C3,1%T8E"YZ,ETMSG_D=Q_U0< MRN5V??^4[_99MGW?OJ*U#HD;>8EM^SBR,4(>CEW267<F64;8&F0-.P+M5> M`^=2(6!<[M7#@NH:B`:+B_Q<#B#Z*)Y74-'HU^E`HYLXL4[R_?"_Y2IKA_[% M?@``23T?NXD;`Y1$`3NE(KXC=@TF;<1P<+G=Y=M5_D)+W$6&@*ISQW/>/6U5K[ZNLR4U*675I+4KKNFO>7BO]_BIFPF MFB$-?_A.2Y`&H;RD,556^7-K-%OW(M7,F&PF4#JTC3)($`0@2!(<0>*XML]0 M1"@5^EY'LVG#^M*`80.##R_%MI89:]5Y()'5Z&2>/]>9B'2)#*A'>F5U6-_D M1>VR-'@GR(SXN;R0+QE8E)DHHBGO3N16QDCDS[@VR[*\>6@/-&]V=_GCT_[F ML"_WR^TZWSXN4N*2$$5A$B6)&R)LHR1@=JO_!4(IF*JQ<31S^;K,-W7SX(=B MUP]:/VRK!X]^7$*;"3??F_QHAP6))F_*I'-F46BTMR2[Y*B8KN%= M64<`QT[Z+O`UE`7JHGHF(JC/G_=YHEZB^&Y3ZM;?C9*FAUUEI?E^K]GO;'!N MP4"5"P>D"4`A@$$,O`#X,7`0PT"PSW^CHMOP^$ECQ@8]5WOUA_@=N';F.:Y5 MIB1=3`5KI&TR:#58VPZ[+%.\LO#1`OPE%F_,K(#`)Y;\O[>ARSSW;?EYE#W/#Y[*;0`;I)Z;AJ%$/L( MI$X0)J2/GJG8S`]3(`Q',8K2>J4PZ0[-V'7INK\NW0A6!YA?%KZ$?A8K(A;B M3MQ6T]NA:H6^L162K-\PU`1$CN&!5P/CBS:35P;S?G[HWS$*L=RB_<:L M345>!%R,W1BZ$$$OL5.GV^HDC-/%:[;[7O"W+Q>W(+++CL%P[S,&2K+5C11K M?.F*:;K$,I&.IQ;.U13WRB=BM\__:1M_ M44MT_".M?;G=9<_YX7F1^$$4H02D)`$@#*/4BQQF&,'$$U,6=7O&=>88(DW; MZX"^;E&*]M=2IY=/@L;E54R0WA-:7R$S>-:G%N!O8[?4NL38@%[I8WLFZJ71 MH?<]M#13I9(EX9^KS8%>OAR#6D"[,N6GD0?M!!`7!\#O+F+L,!6<^Z+)J.%W MEO>YU%7U#RU,6@LLHW]CI1$G^13++=269"9;5K]?E[,0'<0)%,D^/^?[>KAT MO%VC8DO?L++M*L_*?D1U_)TVVEY5[UIVFL9I&'@(0CHBRO5AU(!`F&#"&T?U M&C59-MKAK/O3OT%J'4V/_U\&=OS^*0),#M:=FEB1F6QB0\Y]J%DU1Z'$8&1R MV%?V_LRW^?/A^8Y>76[8%'E2[&Y>,MHY?_OX.5N663.RLI_:[,>1'U1O0(X= M(L]V_2C$-@,7!F+W/N,@,EW*<#3XMG'#:OVP:KBL%7G9UG5]*;:_HV7U<&[J MRJ_.M^:_%JWP&FE1^;1[?NLI6"5Q?BD;'_JUI`5[[Y>N'5-L33>[7LL"#(2" M<1=X)B%B9*?/3B`>CW+^D,(&\=T\H&7Y1#;%C[(+8['G)DD"?>#X!(:AZQ`" M49AB$*4X"3S>GN5*-DQ65+%QDY584&!6C6RZ=&^(IZ$MK8/>N>Q4+;Z\WX#Z M".+>5U^R/;5UNRM>\W6V3G[]NZ0%^]T>CU?[_#7?5^ECDTL>JE]K?[/8]NCH M?(@*2AA[$;)#`GP/)0R=ZQ*A6^"1(!E.UE#\]5\6^7SSUU>+W-W\:=W6/GVMZ.< MJ_?DRNI]L7IGII-B/8LP(-HCK_),Y'ULKXM)MY9XR&B&(]."B(4;.L"VO;3* M\&R0V)$'`I<9\3Q@B]T9BOULX_>#5")HM<_XN[IG87AS2K`UGSTF`_[C5I&F M@/_F?/U_A[(Y5+LOZ,2L[2K?9&],WQ><.[;;GL%WBYRYY!%E;=QR?KTN:ZWK'Y;,%N;+BTSL4I#-0I3/A0S"2?3 MW.\Z#D`0^[;OA4D`$@\YQ&$V2.P*-A<1^,&&@\DQ M%N$F(2+\\*FX,6K$U)>/%4.-.WK3`\HF1=1,%$D.^X>6&M($\*>WJ]4NJP?# MOBW@:NN`Z$5R6\!57F]?LU;8%J$3!#@)[8`@#WD)27&0,C3TJ\'%-GND$Q7O M!?)8,TBX=E#4[*`/H*5K'U\:I/1#D;P#*YJ*&EH:SF1SPN602R<98.O3,>3? MZE)4AKHNHF&XKZPCY&-GB5+T#N6!9M=K)KIJVLOWN=P8I&HLXB<@=9W81CAV M`A#B&#D0=(:KWQ$Z5U"V9OJ0X'T!*RLU9U_GT;V^6K[DM*1B>BU$EN2%)OEU6[WK;1U24E0BXD>_X-K11:CM!&,9NZ)'^!!YZ M\GM1T-#8VY!N/=IRAU:?6:L*HM+'-**LJG_+Z#7"PYM^*R?:K-#CY659%O35 M/%M;/_+]D[5_RMI>M$V/Y^WP($9C#0%XR![8N]K7:R;[6+]?)[H$&"".KQ\@ M,UZ<-DX+!>@I<@^"^':,8P`B@A/71B%P4K\#@1/(M\G-V!YIIY?26_W/;)VO M\M(JL_U^DPDU_CC3+4V4PQ,;V.Q:S*%?FCGGBC$>9\%XW;7^Z:^3;OHV;=7; M"_13@'U:Y6/;)+4CU!T&DT3H6U8U2Z8K*<]$Y5-MBWG:H!F)NX,,#@1;/MZ^:*'9@`01L@ M-XAB![FN0Z#G=F#H-Q'<37:-(9ALK_9I\0M#+KYUQURJX4.$^:R2V.G"$63K MYN'-4.T>M=7!MIKFL3)->LVMC$"WWEFLD%S;7E,KQ9>.RA)W+BTUOA!S2$_- M.UF,^6R+A,RW3?&Z;L)=@\I_OQ3;OM?P[6%_\U+O7M?UD4_""*7$<0,$L!W9 M7?A._)`[8IH"8#A@TO<,>EG5OTBVI0.G0J2(_!I;$(ZX.(>U$`N+;Q$?#_'H MQ]!2U&\:I5?`K0;Y+!9&("S.88'DHJ*QA>(+BY+$G8N*IM=A#D'1N(_%B`^V M]O;)$&''=1!.O81$081!`C`S;/L(2A31J1L=IUZ.A;[LPY;N1X/_OVJGS$O[ M3$YS-#HDW$Y9C"K^+A)TYD6R++,U*IYIJ[,F5L:1[\=.&H8)LKTXL4.(V7T, M"7'HBGW#*&E$)'9*?G'3+))LNR7/(59XQ`HEB&6`-JV3N& M-';OC9.\#,B2(I$ST2)5+]YWVM!!BE(3=VS'&#C$Q0#$?F0G*0C8E1%)`Y`J M=B*]^/,-O]9V34=I]ZH^G-?EF+C2_9_MO]?SV%BAV)6U+;:_T\\YIV\].K"C M5.B>R792XE1]H3WO[[EW5@T,S>&U5(<;A=X'1[0\@!4-OC.]B)S$ M=;";)H$#?.+8$(8>LQ,4 M"=HYPH9J`%0YGDE44??C_Q_W5;/7I[_/#1%1(X;!*A"TJ6)%23),QL-EL<]N%GGY4M1+C?TR.8A_UE%I665 MV@F/#M?%.M^+Y9A,2[UH-C/&/K,98VE-K,QXB$6N(F,M MRS`3!=3MU=D"8XVD";S&KG;T"[HT:_[_J%M%F^UTK2H"'V`<^[;ON$F$<1*G M<<`0)*YOB[W=:C,[2O%3^:X-42V)]8OO44&Q:$LBG=SSZ>1$M(MI)0-I?6(P M?Z/L]\V`6JC3=0+BIW'PQ$'[6LQ$,$UX]N%\PA!Y"L)YN\M>EODZ;:L\VK0V MWJYO]D_9+JXE8^$Y*'2!BQ(G`J%=3Y-T^M=&+Q3["LL0"..''BU*=DG1*&E! M$5JK0X6[2H*DLDY3BR*KKN.MADZE9:O3PJT7IP9LQ1<6922UY:%52'FUKM-L M55BOEQ<5V0"I*FDM-?JEHJ[1E]:\#Q$D+J'=`P)0Y=8P9?T#L`V]D/.06;=5 MX_K;[.;Z8D:OW$JR+)V]FJ-7:^I:T]WCG(N.GJ1/+&556H#9*J6B6Y>350VT M*6AAO&JZ'-TN?]5S7G;+=;8`($0`^;%-8CN!GH?L"';6(PS57N^E3!I^M6>8 MK)<&E++ZR?$J*W[&*=6B?1W)+[M#E2OU1W8L&^W'7_6_M\!IB-S0M3%*4>#8)`$!8;ALG`B6\Q@&8UXK=X?E MYM2;^M$)J`X%U;I""MHZU>+H4EV*W_I\W.ZB>XT_FCS(LW;C*;(`YZ):;6(Y MYZSB1OSET7=S1"LH?]_SX]@\1$&"0AQ$Q$6.0ZJH8Z?,//:QHL#+V32LX]T$ MTN4CK=??=TUO=*JX)-NR8FV>:"V:W,.R>9$](7=7XGZV(*KIU42MUT*9^ M744GP2[X_EAY/G,:)!$L:9;*2Y;Q@\_V8&TM1-OW:Y(H^(] MDC[^3%P7W8U?L33(E,P-D!##LU4N*6=X[W,D*%)*W)K->I>]9MM#MB"NZ\40 MAQ"!,+03$B([8H9)]6NJ*9N8-7:)V MM#3L#6.""9@1)'K1(Z;V'8<>3",,69="K`=@@`L M]L5^N>%3-(UFA:2M0\B]+;_PS'@T-DK[,NE\PC<1WV(**#$2>[8#KP=DT.!/K*ZGVQ>F>F*XG7LPCB\FYJE>B@*"461'3I72VWX<(Q)WIZJIAQ*Q`TZ-ALV7VE>__K2D M-?9U"\KV0T-Z%YQ=_LS0..U\"C\VWU(JWMVL[0NKA=E]V'G5?-EYU;1*F>CS M3GX6!V38P%+,1&I->%88?XY5)?-XNF7@>PAX880!'A:$K\0F\ MDCT);93X\/V-0.8\8^\Y`$:4`]Z9$L6V8J]ZMPQ722V[P2.%5(G MCJW8C$SLTG9=R_($[[M2MIQV;^YP%4?128:N#U?3!*QL94@'HBH+0P?YJIA\ M\KK0,5Z@LI`DU#,A,77ZO%L4&@24A@SGPB3$35PO"JCGV\2.7=^SNX"96%A! M34AFV;%K0EF7^5)=$Y("774Z4BG>VE..LTTH*DD:"MMB)NRH0S/IY!\0O*&, MV4V0$TP_FB1,8A9".PEU;,\((S/LG%,C)BIJ0JI%&KDFE-Q])!\C'34AY;8: M1,)3FDDI01_NC__GU82`1H#3NRXKSYOZM6DMMBWH!5ULFC23:96FZUW",+MK MYH_GSTF^V>3?[[?WS\]IP819>+[O8.)YF-_O:]HVI>U5:=2PF3#"UY,I6D\S MV;=2(OXH=7/93R_;O4';M*PORVXZ(Y\K/6[9!][V7S89>[(;A=B_V\&NC51E MF.OD/Y5-@-G2UAQ<0G37,T:AHLQ.`!Q8#O5-RW9B,_&3,"1= M@(1#SPDA(8BZ56>Z\62U,H.V'0TF$JS136(=R2WH^8@.&S%1+2><$!75[T0! MO%;,4VZ$F?C^&A0[+?-I@DZ*5*O[A)I9,0N')BQD2)($4Q=C[(>&WW:182LD MEBR'@A:9D#(/5X5ONVN7ZJ_>G5^E_47M8RCX7DK!/L/74$Z/*V_=`&`&>2[\ MOG&^+5=7"BXBP\.N$1@FGT@7N*X1D;!=V#5]T'TSPU>;J:>R+&_+E_3V=5G\ M7?U$L:,"M(B\@Z+/&$H<$P9Y+1^J!)R!0W($&-`1D0-[ALPW4"$!QV,(5,)< M^)B^-:U-]\\?\NW7I[1XY1?>D>VZF27_*5WMB[K2Y5@Q"4,/>]3PJ65ZV(G; M&9W85!3,Z.7-!;MN^](B[J3>_O[5T9'ZI6I_O.$KNZ%[W]\4&GD>\GF],=T4_5RYT_+'Y^S\N4EWZP9CR1Y<>&*7\L) M6.09QG80FSAQ2>SY;7H/FRX=TKBN7)9QFMIY^7B7EN4FY5IPBNCUBU;.+%I^ M7Q;KJF>[_B!*7]\V^<\T1>7R![C/2I_M!+W:2>TUK&V^D9F;@DF->F)7-RW/ MY))R680%>NZU&6TF#*Y?SPN]^IJ!E7*QC](;U+:-&)L6IB'V<6#;GF6VZQE6 M&,N[TZ!EIG2=!5-XBG&%.\/J`57@^-87SC],DO^\!(Z@FRJ%YTP(;;@>5]S/ M`<`($Q*_:K,*B;XL5W\_%4O&?RM.@,QOZO(0OS8T,6FHCTTF1&`8MH-C)SB4 M/.+$P9"DJ"811LV4[I@.]2V8K2*'L!](9;HL(D9T,S`&C`:YP*B3&/5$OD'< M^6^EOCG;*CHR4\JA>X5'-9MK)BRK6\M\U'=@0(6J2O_>OU5Y*_HC+589\UL7 M'G4-YI5A,W9L/W)<[)G=PL1QI.O!F]!MA2&6JD@XUXJ%.O@D+4V?Q$BQ,#<-Z)F2I M4*$KA2D54('SH2Q<9_YQ\P;?/W]>%HR"G@QNIL(^'#X;ZQ&)U?GYD66;X^'62R"(B7N%[""-L*XI"X88+; MZ]1PP)@(5,M%ID) MG>K1+1_AD59"J80Q?5'\9*3^YW+#+P;Q#-NS;=]U`I/:4>C&<3L$"ONNYRS> M*J$_E%*NP%6RX\A>OZ4L"R`]7]P+S" ME#6R@<=50]`2XRUM,,'(J14#<3E&GS9]@.`*PT@A-1,:D9/]EXG1T@"(E\>8 M/NQ5.4Q7W:Z[-/-=F;X>)N=A*[9,2BT69+E)8!LX"OVN/N?%)FB!,*32+8.UL$HL`2V>UC+TQT3S]>ZB857)..'=4 M%,)K93/E9I@)(6I0[+1HI@DZ*)7>%P_+HFS^4MU9LLN:?E;VS==\FY;+XB?9 M[5(6%M=7FJP_9,LOV::JZ+$?[%_3-5X$KH]]-_`L-[:L,$Y"PVU#9--W#"K! MMV.)IK\I]ZO-?ET/\U^N5OF>=QHU1YVJ?\2^6>R7F[IG-2]? MT@*M]D7!?\OFH*\<9X]F?Q"QS]'T*9RX66E6"0 MV<>2P%TG[I$P@Y'O$5R52`VUC@`78#*T?MCD!D%+P"V!`7HS&&F M\T`-OIIE\#P+R]^%36G!OC-[B&_:'R?^P^!]V?6WQK8/>BG;R87VL M+-N6^=&(1&A7W7!SB#G?XUH"1NDG1J@G3=;RH4[`L>OU[^%UK5:O#.N9.+`* M%3JMT2N&2I@'^6BOWN)%]C7;+C?5P*]*`KRP+#,*$QR[L6/%/C6(';2Y&2], M?-"H@^&KC_NPIQKM'_C6&YWZQY7TJ668&^\?9DOKVD/U;I;E=?N\#\R)=\5U:M9.R1RKZQ M%_A;VB\5\N1QOLJJ>:K5;O3+O2G@8B((<]%:H"ZXH:6\\E!^&[WZ5@H6SV2P MFHEC+2G\+Z4K>0C$'.:F'A8WZ;VS%SY%_%:3!75\AV*&!7%"SS8XIN*TZA3NP+UQ&AZ()P08XM].`+N?7 MBCW@=1,W;^3A98!O6;[?-6?)_FNHBRL,UB7O5CW:Z]:*?\IZOW;G6A$:!Z9+`\T),_<1Q0Z<]C^'Y?B3>#:%+@%%3U:<% MN2XOS`QMB( M0AQ$),$QC0W:U5&"?F`] MMY,2'<2<15GW,GS"U5T%%IA)+DJ]7E=KO=.BK2>)`J+U%Q[J:";,G[>G<>%0$]1P^9224K6HD.`F:%7W3"(0ZSQ4L M,U73T;66(G[?R:$KJ MO0>,VARV`D6:O-N\(PD.G.B[]I/SR:2%;5'3B:A'*+6L,,0>Z88@^)[CRM'^ MT$5'W00.#3J7RAFR5#48>R#_CPG[D-W@@/BE]/=DB$MN%6,BKV+C&&(!^#[R M#CHBNXHJ@.>VQRC3Z]*.HQ8X\0FLJY=TO=\P$HY'B>&1H-T@S3`.C``THW4TJ33O8*TB51*!BWG[ MA5[_O22[W=+/CCWN4S3+2F?7M+?E\7?:=FF%KAL._*U2"LO M[_?T]4M:+!PS\JE)3#>D3!POQH'?>G.1BUWQ00;Z1-#,=OR=0>3I=]3)!>JD MT(>\2$?++$`'-K=\SU$K-&JD1J2\97+?UH*C+O%9B7XP#/JKEEYT+])M(4C; MRRPL)=D!H]5B@@TQLOA=[(W1;I`YY*U'T#(?]2F'^O;L4:^6X1>:E3]YQB/? M5K>:\8`B"EWBL/^,A%+JNL2*,>D6=4*AS4_-2IKWN%HF=!!*,L,P#$U!=WXT M(&'[%AQ#/;[\-7BNN?%*8)V+!Z]&F5/G72%$P@QULE83)(1\^\.FC6W?=WW+ M\HB+V\4"%C5`F$ENA9$923;-(`F?&!7I1VX8!4V53SB+RQ7N&8;C3#AGH!*Y MRD<+/,.Z:V)KW*V0$H]/3\1F[),HL&(WZLB,6JX-NS\0_OLA[XC<)8*]1DOP MB&DP6F)THAV)X M%K-R?XS8L!S/HXX?1S'!IH5Q%Z`Y#@9-=P;]8LV.")<%<6'D0B(81F(\H0T> M&$6((Z.%'?HH7"$&*;!FP@ERLN<*GA9))FC`D,V,&:#27^`&*1#`I4=^ M;2=[<'C:MPYO[IBN6SYOE(C+)UG,4H,VK,@X.M`#2HN$%ZL:8<\#/[2"6*3 M&)A:5KN\'8="%S>K7G.,?>D@F*(=20Y=ZM^!6V#(CG,.'MAF,PC@^>XSP]1Z?XM1`-N@^.?U;9/_3-,J2_O03(OI2>)B MZD:&8Q`_#*/(B!-"ND)/&,7NT"AHX/*CQ$*-C$T-HI5254@TU`#R@=&(V"L+ MCZ[80F64--0HPV.E$8VC/&(:9J1!@=-UV(#ADR(;S'=S4Z:A0"BE%$SA@L!3 M5O*##FR7S;YEZ_UR4U4?O(`FL>DGGH$QM0,GP.W4?S/"C@4Z)B6W@N:-JQ** M'^5T6V;ESZ:^$9/06S,S M]27C5WG4LLE6,94#+TE<(V(.HS1IN,?AM>NX01A/D07FRH6JU'N/)97"*'X3 M1%:D*P9XXPMB._1)XN`$&ZX1&59LVYTOF#B64'9;\E=K9K\PYX-S:EF@MS4` M,1)C,HWPP(BJ%62J'L]C(*XPCR1B,R$66>E/[T,8`H(P+=3#?-B_J7PWT['M MF'EI@14%/J&41%&7%*78"B&L`/O-FDFAGJ;%I9&+T8`PB1&#/H1@O```1PLO M'.%PA1;D\)H)*T@*GZMX9*`'9:6G@AW$VZY/^LTHCCT/^Q[E#3K%-(J!FAFIZ8)JQ?Y)S=B8QG!C9S=YF,,X$FDO/\5\-D%ZAWTDM.!,6 MGQ:#TS/*TQM$>$]Y3'=ED:W*9GYQX]0:IA&$D9F$E$6\),))$G0;6!0XH"A4 M;@7MJ;A6J*925R$/I'5)[,1X63]LT&S:"6(3!:MG<;G"CL-PG`F]#50B5_EH M06B&"NBI';=*3$0G9S"Y0B9#$)P)E0Q2X71`PF`XU,6^EURJ#]DVO2O3U]W" M3XAOTM`C'G:-T'!-UW>[-@MLJHUTAXNCF:1$AN"_,P.?ZX(J990'Q`JLJ2C\ M'=>0,`H=RX;31,GO(C\D)E9GUIGP^I@:0^-=U6#+#-6I)-C=[\M=N=RNL^W7 MA1?9`8G!+P6AB"&C=IJ;H0^2R8_=D7.SXQM9;%C->H@ M/K/_3F7$.1S`F4+M?-IW!^(`-*MS>=C^Q-ZC*D[*M_\N\MVN&L2>/Y^3)""^ M;1AA&!//QBX.D[CK.PL,(KS7ZUE>\[;>,L.JDQK5Z0WVQ5WMKF(#`*6]M4,C<74/`;EP9MU9I, M`MB5IS>-W`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`(B!Q'$16'-HT"#T# MNX1&K:A.;/FP2HKR6^?^XN[;EMG4L^RMX[%/E MS(`D>$&_X4),N28G3B6>[NK*@TJ6Z%C5LI@F)2?Y^R%XD>0;#8``29^WQ+*U MUUX;6!N7#0!\EZ`SW?LH)@FFXYGI2%$._S3AL4V)IN6@N'^WS5/6=7[HMZ3%A>[>^RXOINN7O1B46(:00Y M%MCW4NK!*,*P*_3F+*+^2$G,-FSGF>WLFJ`FI2VE&Z-G-.OA=ISFIHSSZ+GO M^*SHT5M0NPOVE;^O9\;WDA(U8^DB3[IJ3N\]>3KCQ59&=1LX]VGVTT%>`G1U MVTQPCONM(B]JX`N$JNDKB5/D"Q8%?L#3XRV&',54Z^:OR4"Z+FQL)H>G,AZY MUM2=7!XK@0X.I..$.68,1T^0C7/UZ9NF+9!';:'V\+UDPS<"Y2+[V6H;[SW; M6>/!5G:S&QBM6X`V^SJ=DEV%>;??5$!WJTU6\DVYVN;EH`VN"K))NEH^ MF9!O_5W#5ZD&)ZS@FT0+:KACW]"F1V:/DCN*RDSTV95W+UQ,Y(Q$92W]E.TO M=ZO\/ON8ER<%O\[/]KCN\FW%>%FI_V:U$&$LY#%0[J&`)QZ!@E"*8TQ)@L(0 M$KUU--O6G2^'58#!5IZG7N[WQ>;FL.]JC\]O)6@A7\@K##:KD3NY)J4]O=Q5 M<&;2S9VYEX_3QIUU=+[9'O;9>H%%BI"/DH3Y@9\@%),(=T`J#?)<=755^S/K M[.L&]FR[>TNKE0ZO&Z)WU^6U'33N]&94NLKOY*;<%\O5?H$]B*F@G-!JWA:( M,.$4=G!\CZ5.\[PRBE$D8%,C!W^34O#'V?EB!568K1@\HMG>&$`[<.].&`S= M'#8F,*15622ZH_2D.4G_>%GGK.[\B".*4QISBD-.0T1I$'!RQ!$0%.BI@W7S MSF6A0_RANWN@K><^E-W=!?<_#G(^!W;#!.3O(RN(;BAZI,-95&>B&>[\RT?J M'IHJ<56UW*5LU!]E!6O9E+C^N=G55RTVJ\(E/V3L4!35/Q<\#1,O#6&%A04) M1BA*8+-@44UBN$ATEETMFW:\["K[EN;JJFUNU597)Z15;W7U"!0T2"^Z6OT6 M;+?A5@(NCXE_DDNLUS^S[4/U&_EN?S?V0$R/V!X1=12AF4BH*^_R49JY&_F\ MW%W_S/^5+8MR01/*0^JGF'&.N4](Y,4M$,^/4JU7&^U;=R^BD1L1U6'8JHXZ M(M>1E%Y(+96#V0HTJ%'/4T1/K`[748,(O2\I-7'03$V-J70@J%6KS!HH."6^ M)XB?I'Z2H#"%B/D=E`1%CB15W;Y[48V=B:H&R[9EU0W!SH55PIZYM!Z9M2*N M^G%Z=_)JX**QP)K2:5]B1=4K&B0LC%$L,(LC7W@^883QH]A[ON)>M[J>N35AKCJ!^F]::N!AZ;2:DJF;66]OLN*;'E; M*=$BA(E`)"*1P`1#%F&*3J-HBI4>@W-GW;VNXKJNE[Z:.&@FK\94VE;711J2`'(60(;3")(T1"'JS".* MP\4^WR^W5C7U39M:2GJ$I]S%K^6?@!\M(#$;$/.124I0GWT]##D&,8 M\9BPB"'E6VE-O]]=-SQ!`@TF\*U#-?8AF]?8Z>EF@PF=2;\:[L?3@XEVB#'N M.:?3-SY*0RZJKX^J[LI12+U0&HS]($GD^Z%:Y]R-K3B>9#WK1;J'T\WI,U,> M-\P-EI[I3OB]2I"&^NB3.E/Y,7#D#?TQI499@+YDJ^VR+#>WFU5]!EM43I+5 MZG!_V"[WV;J^/$2>T2ZRNVQ7;AZRIHJXK5QI[A#YE.VO;J^7OXYBR0./!"2& M/@GCI!I8L!`R&OK0CQ.&::15B#<)0,>R=X:_O;?HD0?@LBW?E;7:?\CBLKV\ MR:%R`'S[DF^W0.2%/`S?T]=G%&LUH9U]F/4TFERQ2QG&[:&^:?MS7C07>#RI MO_Y4Z4R^VU<&MO+7+G=58\K*O5'(G1[""$,:H`#&`6;5[+B!@8,T$G31W(?_=;\L]FJYRC8"'7UZ"E99 MJNAR*Z^%`LL]X-DJJ^\-"KP+4"D"&EEM-/GK$1)7D9B)1CAS+Q^G0>LNKO?8 MIMEM7F1/=:K]L<3$@E@@KQHXIX3[B1?%81)UF/P8":U=3)=`'`\ZFX'FZM%` M\_$YL9L:*BB>NJ"[9.\T6HKK^',)E.;B_MN3@39(S^`?/ZD\&'O9?P#9?7L! M8\1P)H(^CJ]/=PW&(WC4]8@3R"3&&*<84XC"(*"!QW#<@<18)(M=]EU^[?6X MZQ'J`)6D!C=2\\P79=EY%F8@6RA8GBU3Y&]ECPG6(C3B/-XBA.78&J61IWXT MX51;=;H`K3O'UR0FRRM6P^%XU4$_[#/)/!,Y[V"=P30$5J8AQRE02F0I/(N2 M,"9(T(0G_M&V"`.J5>!CPZ#CZAZY4KEJ%:-9@[">*^SP/GSBX(1RZQ.$T]+Q MC*8!"DLV5IF?B;C:]4EC^&Y(F+.U5D_@B$"24AJEGO"9GPC:P:!I$+9KK>EN M[6:E]2W[^BNM'523==:O5=-I%UIAO=#:0I)P$ M*(*4DIA%,4(!(T&@LMPZ(ASG!4[W]\OBMTS(Y/OWHIZA@Z8@^DG9 M;NW7J7BW?MA1GCT!1Q_!R4F=-WY'"FO_\&JF$=4LO&KQRVCV1N_BQ:"!;[4G M0*E8:[(X:KS6/+]XFKW7/&9CWJI\8S",V13%B;W,M4SH;'#\$RF+Y:BBJ?G'WZDNVRG\OM=5;<+V)"`Q13'(9>)9T^"R!JCSLA%&$> MZ2B8"_N.=2W]M<^J:<0:5'][+P!#5K0PCU_JZ^4 MC[4_/;79@@82]YE[5 M2YJW!RVV>J-JVO/ICYGJVYJRPO!,Q,R2,_TGT`=1I"Q0GZN6=U>9.\V;%R$) M_2"-O0#C6."4>CSR.TLXC;F.*AE\O6,IZA#5#S>T3_EI2I()9VHZY)@N/?$Y M,J6R:.Y$;)[3T:,P`[B;B:P,\2"WUI!TC]^WJW-7MU^R>O/M\[+8_[ZN!EWE M? MWDDP`J7*BGU=_?K5[=F\F/S:E-7XTNBXK%IS[&JMBC!8YC@#*=.\:$MCOM5<*BW!=UN_RR*?]=SPM$B!'#4/`TB9A79:PT%)U-Y@M?9T`^ MR)#C/''"!D[@S)8.AO&I-J`>C4J]G&#&HI,QRW"*$P$@FG$61H@%LZ`&G M2&@*E#F=:N(T"I-ZPM1``A+3F3+ISN;L*--K]/2HTF!&9Z)(P_W(+38*$SR,1=_8$3-6W,X88<;TSW$`# M1VQGU;RJ=<_#B538LQB+0\TMW5G0I[$?,1:-9IL0AG2J;3OTN/[:7H,-MN:P MP6#%C]QR,](M]WE8;K:R[E'DQ=?E-ON:K0[%9K\Y/QA-H`]CG_L0HX1&7IH0 MYK<'HU$48*VR<1OV7(MW!_'#;5Y\*"N0X(12MWK'!KUJ@\^QF=64]#Y2AUQ$ M8ZD^YVWR^FIR+%(_D_&H59>>UMY8ITO_XIB/F^7-9EL;;:].65_MOD@@Q6;W MG2[+3?E_N_RFS(H'B?1R]^.PKSZNR*O^ZG33S8)P09!`0<09A*$711@GC2S# M,(I2K@=JM"W#N&*@]`X]=,SR+,W[D MU61[UD'7T_BIXNWV&AY+<>E)'Y,U@9GDFNG\?^U^H&D",446.ZT#$0A)PBFA M$6$L"4D<$=AA%0BQB3*9.L!WFLW,E[6G:0:CIS4W+6`>J6VZM7<7`1HGQ^FW MA[]>GC/@P%VN,PW(%/F.+;5UY]<\O^7;;ODZ\2#`G$2)AD"0T)3`12$0= M<,1#K9*TZ=&^RTQX`^/01&#]+CM!4YI`RS5K)W#/HR\$;)YT.;#A_ MO=PZE!!WB=9*J/2S[MG=TO_<[.^>@2P?HRP?^]2Y_;O^K@5$$/H"(U:-$E@: M(1[%I`-;Q=W7?[Q\&IPZPFG\Q'FMH0_U[=3+4M[WH/'0^9QBJID-9QM(\PQX MYA+X6?GT0J8KGZ2Z^M[))_GQZ%OSO5-E/)L!4LERDS2(N66V:4AX+9M-&!+G M&>P5K/^SW.SD8U:7N]7VL,[6E[MT6>RJ7RL7V$,^%K!*O)A'Q`N%QX\IF,#4 M;/%TNPN$H#Y/?":82*&/99%'`](+*$=:Y8#C(G,\UG_T5.7IS37Y MO^81P>7V[`(2W3+KD8.H-M2?;_STAO,OA^X"-,[45RXJ[N],7^=M-28]66F: MV,\D&TWD_*NW?X\?`OWA
-&\6GDJY;&`_%XT>4LV%IQE&TWQYJNB]B2!T&.I1SV4^#ZB"1*$ISP- MH$<#E&I=1V)DP'FBZ#"!&I3IXS]&W"E.+5S3ICE#T&;,S>#^!5;ZQNA#2)R) MG@WSX>F(>3@AZD^T/F0%V6[S^BG`JQ]G=^;ZH1="DL8HX2$)437B#GEG$`5Z MCY296W&L,1+8AR,RT$#3?:/5G$(UE1F'/3VI>9&XJ6Y=>Y6@'M493NI,I,>" M(T^?8K5$C;((I?<_MOGO+/NZK\90CPRFPJ-)BJ.*F`A&M+*=^$>#,5:ZI&BX M%<G@B]2-Q4(O0J03TB-)S4F8B0!4=RV^U-4X3^ MD97R^>GZ-NX@88SY/DLBPK`?"Q8D86?"0X3HR([.]SH6FA:*V>7\6ORH:8HK M:O141)45)ZIQ1D&/3I@0-1-E,(*>#V\G9KV_O>LZQGXH*AM4T(ASBN.$T,X( MXSPVZ/^*WSR6`IA=?Z_)DI8*."#(4`>FN=3^$0UO:X$F7?-2`UWP+^N!$07J M:ZYWRR*CRS);L_S^1[8KZZ5>(D]ZR?M;5W?9U2[KAB1Q+"!&,(&L&HY$./6# MN(-`,/2TEF(MVAUGXK(&^[LB/WR_`Y_RAT?'HGJ*WMQSKKB$.Q'=FBN[$N6' M&PD3G.,$-=`+T$(%%=:IYC\:1/8M!CL(QTRTSXEK3Y>.G=%G43>O?^8MA(B+ MM)J^B9`GE8T$'@A&L]6FS3[MBZ>3Q.ZH6.=%.#'E+"'(YP%-1(I93`(8'F7:ATCK M'4E3&V/O]$M@9JM4QBR:;?B[('#@GK\2=Z/L^[?D:&S]Z](Y%X4:ZL8;!0!F MM`Q1GG9JC3!+8X\*%(=,*AV.Q-$@BR(T4'L4K4RC/F8K9`.X-%8@!S1:T:!I MUM%>)4A/AS1)G:\2Z3KRMA8946.J1NV@*TDB$@3($X'O8419PB'NC$74&Z)$ MBA9&5J%ANJ/*FI'F."!LH-Y,-75[B1=UF='D<9X2H^M$O[P846(J+1^/]Z4B MYF$?<^K%Q/0<J;+LCQD:WZ0!TP^-Y<2R@6H\E/VL_ZH7%`, M`Y\%6,!*",,0)X0=XU/N9"R_O\]WH*S+^38U MW@O0H!R[BRDQUM?A[%(^E^YGV:NGG=$%:7H[5V5C_G.Q6665]?IGBRBF(L:> M\#V8()A0GPAX-,B34+,W&MN9L`."'Q(I^-MF!P[E&OS("E#*G_\QQ7;)2^2] MM3DRB/"Y=+_ACKRT\6&!&N5.]KG(5UFV+D7EG#2[K!R_NFW:7=W]%SP4%$>" MHQ`2A@(>I.0X^*=^R/0ZVW![SCM=!Q'(@->]3H*4Y^!79]UQY'[V)F\]_ MYS/I=Q8=RETU3Y-D=_-LQ[,HY)4,\N`/_7WZE<_+W_)']7XH6:VR;5;(Q\S; M.KQ/AWK27J5C&B(1TX!1FOJ8810=!\PITUNB&QV=X]GW&2[PT!::+B7@\@+L M:H2RO^?U.8?F+I_F4Y-"D'&CJE$N,MN`VBHJ.;D#;GZ#\]]K7>KJ3LZ;0^O6 M!6@W>7'?8+TI]\5RM5\D/`P\1%/"0\8#5(4%\?:)8B]-Z5NGK.T9*^K7.-HO&V)?L^T;:V.T_+>^S!?8I1''@!4E`*"'RQ06O MLX-BGZH,DXV_W'5A<]-93J"`1*6H2>:,]0O\*&3IZ;DN3STCOS);_=?W_.&_ M*R_EH`_)?TBE06=CO=<8>$%:!I,UL9(,QY];:C7:.L$JA2J6V\O=.OOUO]GO M!0P(YP(ACT8I9'$0$#_L#$61IW0XPOS;QU&*%A6H88$*E[96:+.F*A8N"3-2 M"PVNK.G%$Q)Z!<.4L-DHAK$#SR1C&!5*FL$.15%9$9MRM=S^*UL6Z6[-JUG9 M@HE$)`E)$"5Q$D<"^81UMAC&2D\@#3+@6#E:7*`!!B2R:I"^!A*;AGJ8\_>V M@(Q"G9Z&F+%F04=>X^(5*1E,W0S49+@/N<6VI#T.$9MM5K#*Q/>\^+U@U4`' M$IRF'B$L#02AB>C,$!HHW61M^MWCC$%J3*`#I3T`T:1+=?CACBFCP8)Q3Y4P!X`7D(P@07:E*MUV= M]#D/>5`Q$FWSC$QZ1-F)Y^N'X$VR.Y(!$*"8IR1.PKWVVL#:N.\I-"BIP["* M(J\`K'P/!A0C""/,8H\VEKSQ^QY,/559T/JH8ST8U_TD&`T=T"/F?0%PQHGA MHO-Y.BST^&.'3W1U(TX6T,?-<%<3&X-!K[X9"I]U@XOF\RGT,$W\D&-"T\C# M@Z$`4^6U![.OS]7/.U0FLP=#UM3[OCO"#$5`F2N+>O"*A'>$P8RP!2F$H0,_ MD8HI5&AIQF%2(IJ?U*N`8QXSQFE"DSCQ4X;286D4$Y0H/8,UY?MSZ<;Q)+I% M9J`O'+YA`:8T;*`?F\(O)K:(O3/ M3!PN2G0WF:Z?]O4^*S=%>;$SV^ MME<=<.F?IIC$I^K>QFQ4&FUU]&2V\(;;Q^!:A51[QR[.$'3^#(8-9A<@0#:] M^?OI#'LD*5^WHNMU]53*X_(WU;98%WD]'CP5:81$BJ'`0<@I)R'L+08XI-@+ M%6_83+#@,"&/H,"`RN3XM)VK+J<9^DF?LDCK0BZ?V/"DLM[F-/O17W5^?9O6 M^^(AV^=U8T7X'HXQ)$&".0\2']+!"DM3K4(=FI]VG-(;-/)&X(A'\R*@+D]J M&N.0(CU=>EAOY M2_KOI^(YVS8SD[IK*H?BS2(0E(8H@F$L.(4D#OAH/":>5M4O.Q9=3QL:=.U= MX_8W1S@UQ<82O6H:-#^S>M)TDM0%:902AV>DRVX,%J)HEIVJ7#9;3?W[6,HW M!]J]X3<&FVD.A%&`DI!@C*,P;81W,(@#7^O1!G,KCG7N`$Q7V280IZ9F\W"F MIV`'3`N2K)-$G9&IZ>0N1)HL.%+9;G>:$B2R8O>_V?:I&>Z)HLS*=2'OQS23 MQ79+J!?"E8@3Z$$OCGT!.>8A#5)O,!YHSN?L6'0L31(D:%'*^5S6_7 M^9'AM]J,$2,(4Q;QB-/8BR!)PP%'0FBH(X_6C;O>[3Y:2GZ%5E,?[9.N)I47 MY5M/-1NHX"3="])+74K/2*>SZ"Q$1=WY5\W4S'67_+9975_?_E\FG[3:7^_^ M+.[N]U^R;]M\Y84!8C")4Q\FV/1R5%/CZUI M8Z!%![ZV^'3?_)]"J.+*WCQ<:B[GF=/H9NGN)$GGUNNF,[L0';/AR=N5.5OD M*&M3;ZHO=L*8B'GD(YPDQ&,>@A'B@Y$DH%K;#GI?=GXJJ7S.=_NB81(\-ET@ MW^WR37](Z7L'5'?PILF)[B9?PE#.?<8H)X\%@ M5R`OTBOW,-F<3I>;7F+E_6'0?!WM_!ECZP0ON;,9^:/2WZKV\_ MY^NG7;$O\IIEVVV^25[Z?U?W_[!>!;$7^3'A/$0>\KS49_U]\086(AQ;Z(\6 MT3COKG^,Q1GJ[B;`4]FTR.V+7!@UG,0XC]"$LZ[%AR/%4<2VGU`(]+LNB41IC.Z'D-GI], M/84]QZ/"^I0+0C7J3,Q*K%F-B8D$JY67>(^'GV03N_PMH:R$/60DAC$L=81!@FT!3K";^[U)Q2OWM<;@$^;?H M3>6DH1DF@+M=WOWF09ZU6<5AY&/"!4:1PL"8\H?3`S403\PE^$_>Z MV,@B=++3/&8O4)1T>=13>(<4FBO[``ITJ&8BSDS%'1(X7;V5B=16[-=N M*RBU(4\+4VA3+TXH\R12U!1YM'$P^]=CXV"Y[XMFKE#"XA`1GX0,$R])(T3Y M8)7&0JG>FR53CA6Z1R,%N>T5CUFQT1$7"UPJJ/.\-.JI]$%1CF1FH+6'-S.C M&K(]+[-F\CV-834=?Y>'4WINC\`EZ+I%;RHGK4QS8_535=>L:L^UY^7ZA:[7 MNZ=L2_S%D892&!2'C@"R\<3"*<:+T6,<7.?)+VJ#7HLL*A MFGK-19_FOF&/"MQ6.]#B.AIGS7W6X@Q%9_3*!K$+42DKKE3VVYW6!%N*7[[Y MO=CF];XJ\^MOV^*N'?/7*P1Q*!!)6#.A]SR$FH'?.-`3*.9J1]4FFW%^!JT' M!QX&=*`ZP)L\6SGM^%'9;D5F;ZK0NOZZ>&QM97^>,S7^[S= MEU@)'\A$#P*T3A,8)'6;=?)QAPG[C_SAZPHY7&*)OSM.Z3-N`DT M'WH`_RA*\))GN_I_3-]3,298+:'/RJU>5C]Z1>4(W!48X+5[F)=Z*^4$76L;4;C)$D(9)A&T$^$ M"&GJC_;]T.RYJ*E&76M<@^G#;0,*%#TJL%,O7FB?8G-U<\ZN'963,('$"0:@ MX$_3"HAV]>YG!&KJWJ08+%C_IOFEH(,6B-/7PX_EX].^3KLJ!KM\4^PEC%5* MDS#DF$=!X"/?2Q%#WF`V#-3J+MJRY5C]VD[ZW';2[+B3KEN$8"?[:K;Y_Z?N M;4/PC\>\^4ZY-Q[TF3*NJ8HSD&TLAAVV9K37ET?IF);X+B6!/V=+1?DF\KPT MP9OJSBF=LT*3VOI._^I>>7>8*XNG_=,N_[V9R#T\/0SK37_D/_9?ON?;Y_SW M9FIW7Z^PES`?13Z)(TY(2A&%/1@":4*5QGYN$3B60ME+=`X#N&-:X=3%(DC6 ME,`!,CA@O@(=:M##'HX,-/(HD8,..NBP+R,X&@+O,>?\J+\\KV2A9CK%0D3*'P_]GV(*4P)3P(\(.$, MV4]Z>N;=9[S0A:AJX5;5/3FUD,?J7<9NBA26*;0J:+K-8TM[S#XG%(A8>]",=>S&.."6%C MAO5#X2BOJ0-PG]F(.Q'5X-EZ;G-#\2S934)WG=\T0N,LP[D)T:PY3B54+K+< M2)V=/*K<$#Q'II/('2X%1(>#;UF4LG\-$:,BS!)QPS;M+[5OMIG6[MI[5VC M6KELQ*?562758?Z2LG@QRMUD*:O4SY":SH?`>BZR MD("4&?[%LHZZ7X:I1I,XC=K4W0&ZC^6Z>LAIN1E^($\:EW7.BWJ]K>H&TZ%F MF`^#!/+8(SY"PL8'2O>YS;[L6"%;/*`%I#-" MU"=(8>3ME!L]03NBQ>@59WU^-(;)3GDR&POK\:4VW'WKYJDQK3$=2QBXFH.O M;+0(S2%H^VQ_ON'YM_V*)G'"HH@0["4A3Q")?#&8$'ZL=:5,Y[N.!;&'`AZ; M.!5U7>U>0"F)O0+RF1ZPK\"W:K>KOE^!A^R''/EKCBFU*%0;*[IB3T\R!^(D MC)G'=$<$G!FKF="TD#&8$?1J>BO1E8?[:K>7]UV3K/S7IRHKZV8(U\K23??* MU0KZ)/&Y0%Z0!@(VDB1X,AB.*=6Z8S_=FFLID0`_M)?J2XT!ED4V%?5C5B(U M5>7`H40'6GCM_+(;;-R\]WR:&\%YC[%S,F2-[:6(DSV'WDJ69:J4A2S](9\4 M>RKJ>SD4OKZ5HMF_C8NC-`JQP!1Y<>SC*.`^&RR&$/EZ5=\F&-+IZ2VI3F%53LYDHU9Q/O@(E^92PKG3?P[:C7J<9 M.B-;%FA=B%[9\*2RWN8T%>J5"J:I@"2%G"*?PR0B@A,\SO90HO1RMM&''0^@ MNA1O]D*J'D%JTN*,&STQN>3(1W&08\340O3!#'MEH:EH+5'_^ZEXE&IST[22 M^ZS.-]]>OMP7N\U-MMN_?"S7N[SY(7^21;=N\EU1;58DQ4%*!8R#(.$PX+&7 MA@,,@I#2Y,N5;=?+W`-B\#A`EE5.]Q)T(S`-ZBM0]+C!I@4.'EOD6JN^#F*B MLFY^V7!HCH3&2-P<1Z+%"VZZ2`R008<9W"PB$CHK])>-B.$:OFIDU`.CN-"O MS=;)K0!WO"]BL\"A>]4\S==>BELA&&("@R0.$!(L2IO!]3CWYR*&EM+9NW8N MGKKL">/[G$Y.1U;IM)UZYF326CJQRJBKU.$V1YCE`V7BEJ_]ZJZHZ[PF/6J: M_DEFCM^SO:S^_M(^C;[A'.["Z_OKW>%7=%F6T';>[6DZ]O6R0;6M?YGN[31CWU(XHN03A6W`/T=LNJ!S\.G$'6PI=_ETGH(-N#O-S( M/V\E?!T-W8,`]CAK[_3#Y=QUVT(('=`\:^../%Q,G MC:RRE'B9Y1_7<5-+61,X/)7!@G0TZ M\K=L?>;Y:E<\J^W'SDNQ9J8;+G[N*]"C`X=EDJK45$2[A=Y.$G9F2]<>V0O9 MY[7HT(G2;[:H)CP;%`281AX*6!%]#NRBKV$ZKV7*IS$*Z/ MZSX]/&2[%RF'?[N[^.T%L*R^[P^>EA_:/[#JX;$J-=XS.7N&?ZBN,S"NP\;`L19O=^FE\[G4*L^CV*]7V^>=HV(^?/]]DN3^1` MK,\I]'NVVWS>-\:ONXHNL@Q%.Y<[*KGS!B6DU(]8TTX%H2C%01CZI$/II2F. MF-:EBWFA.9;\GU>RTKVG,7.TU#1^P8'24_[!$9F76U<^?&LG)KTSH/7F"K3^ M@.NAS-'HTG%@+Y\5[$;E3*ZX4/@7DD$NY?W;^RN7#()!MDD?'K?52YY_SG?/ MQ3H_@)8CW281=OBV;7B;WUW?_IFOJ[NR^$_C5KO+R:JZF?4<`/LQ(YQ1G,8T MCGQ&@B@9`&.1:"VG7`ZEZVG'L;[)!M'KV[$WAN_77#"RNDEJR4$USU>#5Z!W MZU4"._;L"AQ\D__QX%U_QA*T_BTI@5F.F%(NNU0K65Q:NQ@1)S/<94-CD.SH M>OWT\+3-]OGF>G^?[R3.77[?0"V>\VXF^*FJW^9@PA&*D1>F(0N\T$,I(?X` M2S`>F*4T-UAF3%Q'#H#6`_#*A6'5YA_2"]T2H\Y#IINK+A\M\XRD%:@EI1LC MTI62BMMP+BYU.';W9(*8@V:3-/"<%5MI4U2[S]DV;Y])*?9%WB%9,4@)@\1O M$A&E5(@40=0#B&*/4T/!GVAU3FD?H'ZXK78?Z@8L.*#M%4+U;30']&N+]XS, M3Y#I::2[UN+S'*JIKJ4X+$]?;3EV6DFM4J>LF7]]_JUZSG=ENWQUEY?KQJ!\ MZ.!@OG]\#A'"@Y2F(O'3*$BA0`D;[#.(E,JV6#?J6#'_^N?G?X*[$2K()-87 M4(VO1:M7HK#36U6).]-9K7._D+YJWZ_*<:/5[*E)]S3/Y_L\WW_J)]ST1U&O M4A:$`8]P`&E"F!/61%N6)I3!$+?8]P'"9! M&.,X&"RF3&B-#R:8N9`.=>AL*)$JG>9:Y(!).VKT+HFSZ5&'1%.1-'E=L";I M>J*@2D;D*.N2/+DIC^,^-Q.GX@$L0C#OH"\%T-,M-3%V(CK)>/# M0\U%^9S7>YU"?],95%.:6MDTM1=4O.#^"`>L&C:926N-532,O0:F>.IY5Q+:,24^V MQ`F2K"[F/N^@R.$94;0=A87(H76W*K>-UYX$'@Z<_K:KZOJO"#:8@-/(SAPUZ"S MIYZV0C)95R\0#;N*>W2.OXO9P04@?;@"WUHO0./&^N%5^/5!*6A-W M6O,W_.8)8-O\>88$H!D@=PG`05!F3P#2AU\L`;RBW7(",`OI+YP`#!VVD`"F M4&TA`:P00MCG'*>1EZ+$BT@8L7$9FS!+@_EWS3@>I?]$&^HC;;B5SQH]RV>- MK`GW^\1.562KG%J4VL5HIY$H*K.Z>+53]T19QC3)4=_T*N[*XK989^6^44KY MUK$LE%5M"WD1Y'"W->)A0(*$,M2(HQP9DW@XAN230.\VAB63KK>Y#D]L'@$& M!\1@@*R[M66)<341NP#9>H+V#KG@ZP5O]"MQ=V[ORB[Y"]$]VUZ]W:UR09KZ MV:3=7586_VE/=[.JK!N[F^X"2KFYD?4D^W($U[>B*+-R763;S\U/VMKS-?U6 M[W?9>K^"H8@PY4DB0I[$49#$D*>KQFUG`.#RH>YWPG7YUJ M#P-V3RWV!YX(9-R/>$#C`)(X#4C$1,J;02`2G#`!5\W__%8I'XLTMJ.C%,>0 MU`6C^5\?1FS]$ZES=_M3])SKRI,I74KWG.[(VRYGB1KU6U/5PT-5ML]3]H9B M3EG,8$P"$<&(((^3H#.$(HZX4KDQ\Z\[GJ=T@+KG..>^]/.6BS,]Q)RWA?2, M"0Z\O>@SD8IW>\(F_V]WU[;;-@Y$?X5OVP7<7=U%/5*B!!1HFR#I=A\--582 MH;9E2'9V_?=+4A<[WM@F)8IBVH.KC^;0Q8YC6P@B'#LPP*;G1DTJ,Q&TN=K>2C0W_ES9I.O];Q7(CV$! M4@/P/GZ4R>WE1_CCJ7CYDY!!=8IRAYM(*8RB;FI11P_TX75_((4:HJ'HLRE6G?-^*Z)D,,OK* M9I65G[.G='E3WF5/>44OYEE\35?9'&*$L$-LFYX7VZ%K>M$3++.D` MQE8N!I#=WE@7#&L"JF_9)9]]_D)L4N)[EF8=YJ8PVQ:@B4<-'##D9.J#`W9` MP2NIV$09O5+#C18@C:JZ\7Q\H\X;F5#NRN]KMCUT7IX;GN5#\JL8P02[T/-1 MC+KRTHO<'KLBQ0RHV>%(,%W9U#A*??**B@M%23_*-*E$>H(O9(P:\;%/N\/< MEL5+OL@6X?ZO*EM\6C>ES_H)/6SSEWJ;"+1"'_N>;\(0)7$4^I;?(<`.CMN) MP3TG9!GN,6'$Y\H#;8>THS?6Y.MV9;1^`FD'4_U$XN3O\BR3'01]IJ!TS_X_ M/\$]-6FOP(Q'WHG(4^>8=!N!;3#A/N_N&P(M@9N)A5B&!X6T@2(BK%343SKF MI?0RY*Z9TMSQS(2VA_'=R#6]D,3X\`3:-:R$6V2'FQK[Z0H!-ZMKGZ.VF3.V MQ4J\O90L>CG$6"VS8L)[U=P/(#)\PW$# M^B_R'2<*NN5Z%$.A%#$V&`5)A,V[JWED!K)_-]D#/3,23J%4CQKL7A=U=09Z+P`U`W0^`&H(S/0N*)=!`43H$Z1[)\B MU424/Y<.9/52ME45,%WRL3)_3S.V6J+5G+_!>?6P+*I=>70K)W8-(XB1$P;T M[ACL(>PV-\P9/O8BL8;"JL&-G/._/6>@V1/)Q(0U0Z-OZ8^=$=U6I#R`G-N1 M=(Z=X#8F&<>J#BY-><12=E0N[:"::@!H\K)E.O]E'L(:'@CN5$3?Z!)\-`?2 M"S(/ELF"%ILVCLP08VA%AFUXR(@;BW'HF9%(4AE@9N3T\"5;Y`\D(=QGV^V2 MT2^8"X8PR*?JBL@37(1U@.@!=CV$]CQ1%R13`KN:B)\,3PKI0Z__R;;;M+PI MF2HNOM/F.;=9>?^G;*$9^.]696/_WJ[\IYW1I(3W^]^E15.V(. MFF%DH#`A!B(C)"8\,VC-A9[#]<9QJ`VE)5FC43F#)E.?>`GMJ4TC<#E2F8QH6P33JE=$3N)8V.)J\SS.S3W**!3+]006B-]BC^-*4]DL"FRP4<9FOYTS0UCEVPMS MB8!SFURDD*;#[A4YCA2RQY-H_VN:('ZD%;WY:[7)UE7])K(LZ3%G.N;"_>$K MM^F>?H3^2_2%2`VWJK4N;O9%TGTRM`&%#:$!W3#VH6U%.,1-IJ&' M(:`C]))P0I@C9XX63+V'E!9C^RPMA=>'4\:1;XGY3D(HEKD8XH\,,CAV"QSY M!7[LP?'W&M\`@&QC41]6=OT>+U86Z7H,!HLFJ0`-').`-TF"=NP6N@$AUQD[ MG?"JRG4O'2SP89.1+Z^WO1+>U.$5R'SO*++ZI<"#L^!.?;LZ!?&[EA8U&3TZ MY4==*'DK4>J";<*,>9=7/Y,RRSZM:6NL:LN`&PER<.(8=N"&D8%C!V'4`H^L M0&AWUO1H1\Z6%-/'1P(*Y`TJ4/)W#-2'IBFRY.CQU"9'4D\!=16TOK[[%/E6 M\%0ER$$#YU=,C\,(&3,Y2@C5M(M)G-.>7.L%`^Z;M@,#%R/;"@T+VUYB.BUP M[$;NY$M)(;2J%I*+!M3DF;%?3"=)\7C"?"9_D0_;C\A_=$:23_X#4$L#!!0````(`'.):D=1 M(\/!\V```(F>!``5`!P`&UL550)``.::T)6 MFFM"5G5X"P`!!"4.```$.0$``.Q=6W/;.)9^WZK]#][,LV.`Q(7HZMXI7&== MY<2N.)F>?6(Q$FQS(Y$>DG+B^?4+Z.:[1%$DI2C3+W%3P.$Y'SX>'``'P.]_ M_3$>'=W9HDSS[(]W\#UX=V2S03Y,L^L_WGVY/.:7\O3TW5__^S__X_?_.C[^ MA_AT=J3RP61LL^I(%C:I[/#H>UK='/TYM.6WHZLB'Q_]F1??TKOD^'A>ZVCV MURC-OGU-2GOTHTQ_*P%'LV#\ZAL%Q"-__*(?OCIQ]65E#_KSD;S_\@R?EOX?3TI`Q M=C+]=5FT3%\KZ,3"DW]\.+N_M*IX;7Y[::P5W^\ M*^ZR@3,>8L!"X$W_2ZW*U?VM_>-=F8YO1PZ"D[9U5+9*TM%VJCZ3T;'&GY.O M([N=PD]%M*!O/AZG,]'N13+/*O=UNJ\TK:'G^JJ=ZL>'P]1_X,GH-+O*B_'T M:Y\UZ!:JUY#:J57^RQY.1O;\RDRJ26$_I%DZGHS/K/,C%\G]M,Z7;&B+CWDF MO=219\3YK2T2+V1:KMP:A0ZTZ!2UFE]670&MZ'J;9/?N-2(IT_+\ZJ*PI7OQ ME$XU]%Q?N6,=M_NZMI+;AF6.FUEI?1N7^2@=^EA")"-?ZO+&VAH=7&T)?6A[ MD10.OQM;I8.D!OR-Q'5DQZ5K=NL_N?.KN7MP/TZ_OO%M86]<^?3.GN5ELQ;9 M6'HK5KY\O2.Y[[;-*/]>QY!Z`EK1U<7?5>I\V\>\LN6?25$D,^_WR;ELIX"R MA0LT*H=2';TW%]:S#5MYK7;?L[WEB\&0TT"[KJJZ?_2N==;4J;N]ACY,K>[7 MZ?*T5%MOW:*I:PMH2U>3I,7?D]'$\K*3'=B,CMI'PV6M/S@`GXW3*@U=["R4D7;O:LC!.I]J;J_?:599-P:JYIY@ MG4YO%&]=CV6[/7LN[GTLZD*'Z>B^O/'.+,_JDZ3EU[1N=SUFK*RTO4X?[#`= MI.6EK:K1E'7K]'FS0@>Z;!%<-9&UO04?;>6'>1>VN+QQHUM>547Z=5+Y-ON< M^WF?/)MVSC?Y:&B+M6W?4%SO=CST.?[CF\>^GC_? M2F@+-OE)A8ODWHMU5)^'1=GU^==1>EUK3%]?0A_:ZK*T/V1RFU;):%JZ)ENW M%=R';?]CBX'S4N7CDFV9MUYV'Q8NO0"_OBZL>^:^`8?WFM6>5P2U!4M'"O6! M94WWLZ&<[36_G'PM[3\G#BQ]5V=@_E;Y]C6I.;VRIEH;>LU)=YE>9^E5.DA< MN#H8Y)/IRN!%/DKK+(1O)J4OK=O5OGTK%O/KZ_1[7JZ]-V\QR-E`Q,;Z/LXA M8C.-LZE#')XE7^TSU5ZK-RJ*)]5\WA+S>4N03)5_35J+6OHXJU5%GPML45<7 M#*;Y4&O?F7^>/X23;@U^F"Z6Q5QPXFA7/N MMN1?RZI(!LOYMI&'YX]W3IUX+S>;D;LSG3TW(PROTL M^F?7>,)I^JT>9JV^,HYX2`TC"F'$!=48T0@O$-::H'4(/R8W+P9'>>%&&G^\ M@^^.W"]7MBCF?>>*S-\IUZL77BDI!B\^D:<5YR5.;J#FW0T7-3V"=#= MTR[?RU9RN"R=S\ES[].E3WIUS'&@KBF@BJ`@Y!)"1;`.E`MXITWBR,(IC7;C MFAZE#=RYIO"T,WEQZ1KKP83IT'D%"+5EQ!)P*@%%/-"<H#/:?4C^+R\^N]>5YU=OX?,C+5>0KJ:$.#08$\"%=`Y:`XET M%*FE[3H"AT.Y#OB0]X'YGO!-Y6/7LV['N)F,F(@PHH!`;F@82"U!%(*%_20, MR>%PKG5&;,ZX1ICWPKD\L_>S:,Y,LF'YP8Z_VF(5P5ZM$`NDB59*10I)C+`6 M)J0/ELD#ZC0[:.WG?&H#XC[(\^7R;_F=+;)ICL=\&XV'Y`&)M72J*R*&E"JL MN38.A@AK8*"0"^LE@*PAP8)?D6`=@=X'Y1[O8EGL[UT3A+U5)=82$ZRB`#N? M3V6()<1B89T+<>'A4*K[J*LED'=%H;5QU=N58JD9AY*@D*J`"$Q8P/#"0BU- M4\^TAUW?]HU<@S6-4.V#-\\FB=9V;:^6CP&0D"%C`,<8!"+$)B0+NV#$#RA0 M:J-Q\_8A[8,JLRTMD\+#-)O_7,N6MZK$KGL'"+@!"6`AI)@90H*Y=0P$M"EA M]K"7ZH`P+:':&V<^YME@<]J\7BN6`D(:&J()D])P+@*YF+-CTIG;D#GAK\.< M5H#M@SQU`KRS-+.GE1VOBI4WDA.;(`IQJ`,<0>/&"910NNCV&908'P[!N@^@ MNT2^#P:^K34?YT65_LOOB"Q7+5/5E!`3'.%(BX!C1C@5+$1T,4W'**!-6;=Y M!/4BA6,7K&O`B;P/W'?,N8?MQ7\K\K+\DA4V&7E3_N8Z!6&O\L)^3GXT8V,] MV3$#86`@<]T,5B:BF$1T&6)PA,/#"=QVSM-.6F1?&>RWL'3%X">R8V,D0!$, MA&8TH('D1J&'(!F8SOOW=6F#OPZ1MVF8W1*Y$4-C"&&`E`IT%&KHI[E))):!FL]`(L0Q7CMJZP:+,UN6UOK]VWY/@-\[>3T_]O+I MD<&?;&:_)R,WUANO0*2!M)AR$2(J&,80"!'($""TP(4PM9.$Q[US)[7)D_?= M(+VLP;U0=G'VTT>[Z@-=62\6!&!@:.3';893+H'0"SNAIDVSN[>:"#P8XK4) M?1\4NY@4@QNGZ8X"#6%+CJGAFD!U6+A&B&FJ3J<-;=^^+,U MQ/TN[\X/(KY(BNK^L_.RI;/='P4K[I_\4GLSU`;R8A/*D&K#"=.`"1/BD.,% M+@'`38?G>S@GUP_U^FB%/MCIW8[;/6\?[5Y6$!X%C;,309.')X_!69L3M:&D6!H1AA(Q*`F7%*L` MJ&4:-*#$,#L381YH;C2`J$PZ7KU8PW3<;8:^9LT\C/EUK: MP;4/UKSABL]JI(ZOJQH'!@+N(H*`:BJ($H%@B[DXC`0[R&SQ/KJVEH%O%'?S MP:"8V.&'=&3+*L\>S::]1IEU56+$`AAA1#4*5(1,H(BA"XT-T`<48;?7>'DG MV.YH);>SVTN77\``'E'%JA/2[V`(#YJ$-!E`$:Q,F>EE4>]*@B[94$SO? MI5=_E6V-H%AI'+G@#FB_)3EB")$(+-#@RNQD6F?OEMUJ4V;ULEN[;;&#I=ZW M##C-/G_/_]X+/5@O2O1]&F[;%'#/U\8PN; M7%6KCUK85%:,0600)YP8QAF0A`GTT*T(UO0`!OQO?O;0''M$S^U)&6O,0Z!D M""33!'`]G3V8V[[%Y!O99M/\KT;%#1MA1U,O.]QGMZ---T`IKB**)"&2,1C@ M^;0^DMIHLS;QJ.N4OR=T\OFMR6A!*I,7S[@W;;TZ>W%:D1]CSC`-B(0@D@@$ MF$4:++"+J-K)1.W>N97:!'LS/["_)NK8Z=PFV;U#S-_V6IY?73R2M!.'W2'^:5[,D^(6>^(6I$?"Q=6:VPT"Y"&BDD? MQ,RZ#4`%"]:>`+>'V&VV;[#M5\4*`^"&T[[/)5@IPA6&"T05D4T#\WUW6SW3 M\7F4M-M6W)EGV[==B3^'TP/$1`%70ABB!(NP8$!IQ34C(6"`K=VMUU%4]O0^ MTK7[+%XI'E.HE498A4@(S14'R/7"2H14"=#P8S)V?S[*&UF;(;J^'N9A;RS!1^-\NF`]OQVY3Z)M75B"J1"D?+#3D"9QC22 M9F:?452:WNZR<@I^S;LF4(O-_3Q:;@G@7CS2HM.>'6+DH^$\F_;A:[JQ5?5B MJJ6`@18HY"%A,`JHHE-?;CC5@C3-W]G'K1"M=F4M@MH'>9ZIN;8'>[5\3&G$ M",7***2E`M08$,T<=A12'!S2#7KMM&_>/JJ];&O(Q^,\FWK<]?L9GI>-F>*2 M2>`/47,F4!@JBF>N$T8*J@/:8[QE>[YR6-0V2/8UCGKL1-V+:XRB7JD1NX!/ M(1@"(K5/MXZ&FK%E[/F$:8[H`S:SN?5\O'``6$<*'>Q3KK')AV6DV>#C>0+EP M_OSJR:-7F%*_LON^%$)AP"/NL(N8@@3+^7PYY%&XDWW>/2QN;M_F><=0]YA1 MF&>EC]EM-K!#KSAJA)KJ#$-`Q9J%FG$H?!77LVM$Q#MY.:YGXE(+0/< MG3=Z6)5V:GW.Y8T_XL6XA[8XL]?)Z+SX9*_3TK6#'?IYSC7^:5-QL0L8N4+. M;DB(#ETT27BPP(&0J.FA)_N^U:03C]4Q^'WXL(^V\FYV;/VE)RLZE,;M,J&5U.BMO1Y,UC*EXM'&.-D<$0:+\3+PJ)5'X, M.],R,*#I6>*;;Z?X2;U,:]#V#MG0T;2/;F!?NK2OU6':(%Z,D,Y-LZ/[T M5R7,=WZL8LZ6HF/*(@XH0)CY_R1%2+)EA"=UTVP+]BMPJU_L^\GHR0??3LMR MXESGI/":6]+39ZL8]5:=F$JA3"A`&%#(!:64 M$#2SCSD#9>.$^OU,.6R=1"WAV@=OW`!R8.VP-`X6K['?A7-^]2@[905_UM:- M`\Q%B*DB"+MV@5@Q%,SL-9$`HO&NL(TGO']*'K6-;[?[M;*AOR)H^+`KQ0Y% M,O*E+F^LK7:S_WV9VO=H0\Q%7DYWC]78>%6G>DPB*EA$C`RT<3U!2)@4`@L! M?:L0N*-]5;PL;:W-94\+QA@@PE#$0A."4$64AV!IC81D)R<3]S%T;K6EGU_K ML`W$??0",P7G1PO6YLRS\C$)G&\C(0^A#J%B%`4!6\)#\:%2IVGKODJ2[3#M M)5_8C5'YX?SJ.;Y5Q6.C0QH`*24/N?9'J`$7?E72-@N8;:!M*<)NUM;5/=^X:-R?/9.\];WTJOOTUY5+4;(GSG$`..4*:(U MB$*XQ`KBIM.]^YZ6VM+`K45H^R#063Y;*JL76[]2.J8AE#0T/*(:"1P@%0CS M_^Q=:X_;N)+]2WP_/O(Y"'"1;F1R,1\)QZU.>]=M9_W()O?7+V5;>C&-L)JO(X1<+\0QF-0?EXOIQ1NI^20! M*(U,]"44\-8X#JQC]0GM@!ND^?7[.75Z$W26FHJC$=8(56]^/@`;KV,EL(;> M"DFU9["^G+5'J:5_8R<#[PA`7<@TGRU\T0@.0&K+E9>20BH4<43A.HQEI4]- MY1H['W>GT>>60LQBKLPF7V;S729S/.1VSYY/RWE4S7I/R-#@M:+I%($;0K`2 MR`E$D6)>65&#/_Z;6NOGH2?&7K-G\9.#PI2.1`WZ3E5)4T]DK!, MC#P$L0A+/:'&_J;1/0).0^PZD6>YSJ;3Y3;:9_>3GV5!=H,8SYL#@D:,*X.$ MHP1;0J!B^ABT0LG7W3L"4[*N?[WZNA!P)NB4/4A_%\%Y]+P])C!"I+,.*(\0 M%T0#3NHW'6'`K=8B]P.@3F2X=\!;["D3TD=T'_9$HY1N M-';3P^%QO72',85;F%C1_7)U@G0G?;(`M,92<&>8AX`R)*RK4P"8!*E'SCNR M5[KUGK*I(L?Y9(O5['M<^??BA;P:A98OC`Q,8@@$4]X('7>*HQ-P?$>6)/5M M=.SI/KT[[=W*/0_&]NHJNX69^.=LTQ!@IX<%!2S1,I[:\>AF"GLL.*UV*1'M MGV+E9M'5F=`SFU?-[*I`H1,<,`(Q@<)@#"FKP[$,@-10]3LRJ'J/);:4<9;< M^]-=$L]EW)\>%:@"3$-N/3"(8>&Y576$PJ!D$IZQTZ[TCJ/N9)ZM.+WML]H9 MJ4E*)470$\VH41YB9E6U0\QTJKLW=OZ5WE'5F#^9/7Q8'.BKFA6A7QX< M*)860Z@@4=8[CYAGQP(G0%+ON+%'#GH`4^?"SO1L5I%6[7*>RA8>J^*I6*RC M\WED9/Q8;.X>/T]^G'],:S-3(%I08B0FI]("USH4]C-'>RE@/4B,@G0/( M"HVH!M`?:^H<(JFQI[&'$'J`S]7"'4,BY14)E,$QRDW9K@H"J#!`3L$Z6%NV MQDJ$4GL:Q=N-1G4A^&$)@.YW,GTJ-K/I9)@^[3G8@"2W#%LI,88&.TPX+5AYU#V(`HKL'HH!4E%E*/%9-<2$N9A-6^`.^^R9\-1V\Q3U\)_BH1G&?AT5L&3>`6TD0_'HY)I# MBJH]EKPEN1SXURQR-X2N*R4^"*KV_(IM$+4?$034!BCMXVX,T'$_K+PS]WO3 MC`SBE=\V>`5^$L%ZVXLEJ!>]C9_4:&QB^)T8$;*A!\:+P&D,K M#"(JWAE282*,1PQ?S(WJ*^SVO5B%GSUCSHP+$`@/'2"64LRI'W(#=?FQLO$$P@#*-DT>:`RY'';+_,C\O%LEKX63?R]+#@:?QI"6X<0A30 M0UOZPRZI(JDM^\8>0^D:0!W*.`^2RK;)ZP;F]"^?#(*`N'R!/6!,*NH@$J+: MBY`N%2]7=H]]EXBY1K`Y0/+79+8H3\*[Q;%H[,,B;GN[RZ__6&SN5\7F;.9> MTRD"UI@R2CF.=[0BRD#-0'W8NN1ROZOJ(=X'CGH2<5*Y M0T[2/(%[S#AQ%A(+C>>("<1JTTZ:5+?^JL*'<<,GAYQS'%)^,EOM7N;5PW]M M]S?PW>,_D]5JR/(QPOI[L=K,OLR+^TH;NP>OP[I.G4H)4X5XCQO%'#8B M6GH4"D,%KG8(-4]]HAQA,]I.#Z;^17W5_7:W^+O8;.;%WMYW/Z:[Y=X]OKFP MDVVRTV8+VA(I%(X7N&06>Q$/8%I'O"!.+:MIWVGVG;IL^62?)814UFB\]#;W M8KKLV)T?&(2U5'/#'?0N6HS.<\^KG4IO4TM)V[>B?:?%W,=VN=HGR?ZWBBO^]6!63>9G*6!ZP9]G#6TT4RI(003U%!I!XEV/!K-'2 M8*"Q==;!5'R-L*:O:TCU*NE,J8._5B`V*!H],RIHQ:CWV)#HRBHBO":R#H50 MIE-?36#[J/>+T^I]H*D[L6:_S.H?PN?EBRS'0V&/GJQGTP8Y2HDS!N2H%TI" MBXG!Q!+DJ:]DHXA.)0Z"8^^:T>L%V9O\1XC-[C`9G&144^8)LF5W"AF-C-KH MU`S>:LU0[]"Y#JHMU3(NB-K9?+LY6Q;2>J[`+8\^4-FJ2VGF+1#QO^J`#C*W MFO0Y7IBF*28'4"L"@:H\;R^9Q<-AQ0WN]88S!*&]A%P#"504M`9X1VIXL'&X M3"VYAF-G;NOZ'N]'WH-AK2VR`B9<1T_+>U32''+ARU*:ZM?JDIGPA0'3Y_CPQ(L0?'^:(0.6-OU7L-+L&V4P5.*43"2T(]AYHHPW1E"4!)6?(K MP=@9)[N^#7L6_)A@>.FZ;#5/,`H+A0&6Q!C('3=>F5H.#*:2*8W]&NT/+XG` M3-'&@*@\G.9M*M%;SA241@HI`)W6CC#,#%-5/BC35/L@!*>F);:&5G9FI]PX.)O>T4X+6=([ZBS=]>?EIV*Z7$QG\^+5JC\O M&PJPP4'9Q]<%3*##"-KHEB/N4'3&?"U5QGAJJLC8#:^!D3T"5>;X@=@B@F`Z MFYSHL_?6QP*$V#!'`25"M\66RT>[E?%\VS[O#X6EY[-J$N:,`C(N=,"<&^( M(=I;5[*V[R6#J4HE'&A^7+XN=?G\9X$TB]*RP/GU^HLOFVH/A_6?0^ZEL<%C MBZ`"QBG(L7#*0(;K_<:_203IV+DCQP75CK64'Y5UUU6S7)\_2L\,"TA22`$# MQ@+(A5!($'^TD-BM]N`>,1:O4M"M5=(C@IC!''I)D<%*&@[K"(GR.#5KZDJ" MAC\`DSUIZ'T5XGL*E%,82^\T`D9@:&F]-Z=3Z4&:9T?]:>C+H:;W6\GC`*9/:AH:3#\%/Q/7[]P59X44;^J7@HBN?) MJ8+RDW7;J?,%;AC`!G&IH$$(>D90O==X):1&)MNWZ_DS?.R:]X>$)2D5$$K MA#:`*`T$A[X]/!1:<,0X\%=ZN5TR2+?C+UQXZ?)]HWG9A1%!,$P\98SZNDS+, M%*@BH!XKG-SEH/E[R5#\=:.`4K?JR1)]J2+HS8F!3PT)$FH$';*:0TP]!(P) M4NV.P^2RW01RC3_+5NM((7G?0TI"FI)MK:3'VOR\GT.^A6FJV)27O[[/U^(YW". M-^O>UG"2P"EV3E%`(=+2.:VLXI4$-**IZ;AC3V\8.&6Q-P4-`]'[5?%M,GNP M!X4?3G^U>-A1$*KHPY]]2$F;,!!H!,+(:"BQ`+;L!@F/MDQR5]?F3O*`3,F= MH^;,P3*#//(EPE(',<;A=DJ!N?I MS5'&?H\/@KT.%#`8]%;;J,C#4T]I:!_.[UIJ+_ZN+2A;3!U<25$@$'#&&@Z! MUYC[2EK`)7,2CCV3<2BX]J>:88!\S#5*Q>N;,P1F>+3?'9?1RX2P9%D!MMJ[ MHRX5EN^`*3,_++O0P*#NSJ?S@:*SXP+2$%$JM0;0$4BHD(16^RRI%X?)5KQ5 MK*5+?JCS;:_"0Y?UEB?;J['!(Q0-82>8P4(`[46T3*K]^OC_ADA$O"%H72?N M3'7Z#6-=9W#6?)(@)8(RRA4`)0D3RKDJ4<@!$?VR;+9=WGX,P]?W]Z.@`2&Z MKSOLD1>EY1<$RR3F`#`BD3+02,8)KR2GD$R-EH\]2R(G+TJ_*LD!YOO)S\,K MF)K^SW:V*EX]/D7?J\DS8_-)@N3>&0DDC+<+H$H9KVJ3V<;3XV;CX+D1M,RD MHD%`VJS2_]RP:%25]-]".FQ@E*?#B*DZ!.98:MKB>.OYQP;`=&4,X^9\BJM= MS:915Z486WDYKX<&3P25%&M'K<46&029JW:+,>\__/V'GH$=*V9U/0@!"MT^SZVC8#ZLU]N28G;YZ)?S*(>[ MQ=UC5-S;?,8M1@].S79HI:Y%;_L6QE9W)C`+WWT#$(H=!`5%8/Q#J9&6_L%^N(T'>%.H8Z M_TJ2@;IO6LMS[]788`"'#$B`REPZR1@P2E?[94BD7KXC+*,9$>*Z4$4.Z'TJ MOAWB3G>/_UHNOGXN5L]EJ:):/!Q>68]MGL^@L,TT@6*KM.:0.R`<1AQ26^5U M0LYDJ@]]);/8[9^(/2HI9Y#[4S'?!827GR<__IEMGLJFDE%095?RMA7[J5,& M3&4T4+0ETI:4+LIR4=G0$#&7&AQ/3?@9+#B>[6C-HZC<)VY#R_+4D.`(`18B M#)V&`DI".$;5[@!.3KQMG@WT_R?I-0K)PF(RF1?_*H/Y7R;3__Z\FL0?QK04 MPH[#[V"O_"ZU,V!,FS!*Q@F(HD`D`(1"2^71Q;.>WA!GV<#8S**?W%[1SGS> M4U>M*SJKK*$UURJ\B*[O]@[-KO>2T.Z.1 M$<_][6KZ%']2&7NV?:D;QP)T+F+UI*`=&RY7O8@CK MIS))[GLT0,IZRB)J[>'7E)(S*&TS39"*>\9]_(%B:;5BVL.JKBV:W>Q6\S!Z M>:SN4?##P4_%']1J]3/^=G:]4VZ*S<;(:@N',0<\$\%G'C M&I(7A@4TJ46L8^]QT`O:^I%YGKSN/>G?_61V+L#R\F/!>")0R>UF+*:E[RYP M_59$87)L;_P$QYVK^02';(*4LSBGR\4T[OJ8AKMX.))'QA]5H^35IG,$B"U& MSN%H#C`O"8!&B]HYYS;US>VJ"/)[/9_ZDGI&U-VM[J,-?/B/7G:(<\?_ M^;Q<%-%&_KFGDCI4U+QB35FOM\_%`[P,S8Z^*$@FHL4J.6868VV]!JRR+9"@ M(#G:-W+\]@"UM\$\C)Z2DJ[_B3(OEH^/RT<_^U$\G&2M._WA()2*+I%DP/F2 M4K7L2US=!L@3F-H,>HQ9K+T!J#/Q9G$[=SV'UKO^0[NG$_5<\I8=6A&=/\DN MC@U,>@<\I!*6I3F""4*JR#=WZ?2;5^6HOCK'LU^QIE,M]E MA^T6?PY=%\<&7+*(>FB9I=@*!Q21E22Y]B)?M/8&T-6UM),NL#?36\M>4_&R MK=YRSSZ1)LP2,*(8`8&85TXXC`%2U9G,H1R&S^V]H:A_N>=Q`38-+?@7GPM< M48]!O-$MAE9Z&J_R*I3,.4PVF5J'5&_0`$\7<]+Q<]A2Q=;U9E'1J=[L[28( MC@KJ8!2[HM&A!I2S.A^%:Z%3N[2/D'"MYT.G+Y$G`>BEB?9VW\[/RQ=GXZ6+ M+'&ZH)R1B"G)N89.>,HTK>*"7`B3>B*-,2FR7W#E44!^0[SV&8Y=N-O:XZ>G M"$02"$')[V]4M!>=!:XV%*G^/_:N=<=M7$F_RS[`.;Q?@/W#ZR#8S"3(-,YB M?Q%.6YTVCML*;'6^TLP4@/&L/1>>J29 MX.;I3.MM`X( MHVY%<`"J__[G(???QV=V/S__=3_^!?_6V;=BCO^XS1]V,CB8:WDDK:88F;-/ M''PJ4[_Y<5K9]VVVFF?S_^K?NK.+S>TRWSRNLS.NQX\/"!HXC2WT3K*XF+H36237AXO2'!Z0"A"%Z"AC&EHO"88($.J&4M' M4X\Z4U?W;>7W\I#3GKF368)J/B]O:&?+@Z`9FVUGB^6;7IW&(V=)W%V-TL2K M*`'%2W$0YX"$C3ZC_JA[.H[<-.0<'WDZ2*F1,!0Q&N$K.&,LGECV=,6])34& M^HVNX;.E?.2DV(ZS0_@AB@(1VWV!B)OX5?5]<2K%Z-CC05'E!0#."NX5@4)# MXBJJ.""I.983+/O62J9YYZP<`R`V?Y@M3A7;.#X@0`HA]IH9#`A#7%EFT!-E MR9T6)PB2=H)M0$D2-X>+6RDM@F*NOV#Q$0!)H1F1&+'E..6 M5'0Y%IS=7B<_#%[:-YX7AL2$.#.80<)D((YSI3BOJ9.N/Y[3D\!,Y?) M^21DDEF;=LOQ5WYSGS]N9JOYS?UBO$2@Q%$!)'(XD,4TETI45[PU$ MJ?ZXJ1>6[L_F367M\+#QL]ML%U%R-FZ>A@1%.<;>$NJ0+H)YM>0U=11>D\^E MM7Q/XB69I2,X7LYWN02&N3628&L0XA9)$/^L:(DJ-+7_UH1VJ;[@T8Z3DX@O M+`OI;HH`@-.Q]9>]*#ANL#8,8ZZUD\Q#!"H%[:6QJ?>_$TPPZT/E],;H0131 M%C_]?47.# MSE55MZQ-.GV5@40[X-K'(@%@5W1L!^@J$REOS".[\#5%2)3&1F#&%28<4X6A MJ2CS+KD#T`03R;H"S0!L'D(3O3PN^MEB799^^G!WXBQY0D.EOC)@I"U!MG"@ M48,MY$+[I^5E4\M!M,I&FS8(!V;Y$(#\;;98;=[GFTVV^;!RWXM(SL?%YGY7 M[J7!:F\<&ZAE`$,.@>2"&&ZY@;7U22E(O1.;>D6OKO'6-:.'`%95.!F+:\W,(C*B'/!Y5 M_U-*:`?D(LJM\&9\7&'$XAI'!LTY5(:C:W7&`LA+9&PYAU+3IR].+GL M+>*G:^Z.I''<]]OE8W&6.*3G,C5T]!6!@4@HM9(PH+%'+AJ7]=$$")L<#33! M7+,!5%,7/.XSIMSFM[M(A=76[":[_<>7_-L_Y]FB6*VD^$M!(SE8I/&GL)O= MI^S+HIC4[C[_"%&O/1HBPD`\QD$LL-)*12(0K&@@'*6>FJ<:!-&#(<8V(5)7!C;0UJ2$&4^T[,"1OUG<=,[P/CW91>>QIVB2 M86N;U`4LRM)@A?-_MBLJ5U9E*2NOEJS[/-MD\ZI1[CDU4%J]N`A7--@B`AA# MRF'"N*^NSCD`KM$--#*W]"%1I\HC=?3FH!%RTE,A,"`:*QG_J_)9N`!HE-#] M(6(Z!D+9\]C;0:75O^J97,6EB6HEP9DEG-*B!SU'R%."]GVUD":(-`;G]<.M M/V_OL_GC,I+TA+E#XE01>/FE;!:VT7^_P*7Z:[:>-]5]ZNP;`6,O((@K@%/N M%.!*5L4FHSTOP2]-U0YYSSM.CB2W(4)+_GS\O%G,%[/UWW_.2@K+ICJG2X2\ M.B8P+;5C2'#I&"=&,$Q411_2Z95GIQ<[,@(F7O1![48*@Z#L:8;%;?R'NYO( MG4U?#[I0L!`12(1@`F.N M&*SHDG$E7Y$6ZT:^SS.A.N#J,*4(:O?L&?4?GST;M%.\:&4(D17*2&R9J;GC M,!O,\-6=?A8`!9@RKFCPAJK(,(0UCLP MI`%I1`D"RI3-U5U6: M-%^!1!(KVQ[#BK8G^6-98&RG.=]%HWU59/T6TSK[\'7.:X(&&#(N%"@2VIF/ M?T6UZM2D.8?CC8/D4OF^T/0R!EH@9-1T5JD M`'085_00JU-S_2=XDNH/+1TPMDMM\_!UF?^=9:5M]7'?EBU9YYQ^66#0,0,H M4$)K8X#U2M7FGS8VM1[7!&LG]:AL.N7Q$,;,S6);F'H1]XMOB_GC;-E@(1]] M/G#IO$7"QO2_O)R.;-O>+ MKS?Y+JRJT8Z^\$W!*LVIB4=8`HHB")AX7F_L"H(KNGMKB84F9'7*YR$P9Q?K M[#8*L]'_\^.#`1(ME*?00\"``=@24NME3W&JZ?06$-.5C%_$-+5@\"!U24I- MW-QSZH?G`J*$V+B()#92*.>4,;4IZ"`>I:C;3^$3:B.&02['DOGR1-EJ?K9K MJ8_/!0W&[W M_7D;-]JCSP>`@-0&>>WBWJ(,]%[63#:27M%^.RXL\NZ%,_5K''M_1AN-]B\/PBN! MG.:*0P8T8(@)5GN)($K=AZ>:8SX=(W-PV0T<%G%.?N$YPP(W1"K#-.<*"`N< M(P)45%J,4WW%DPR6&!(4KT=6M)5!TJW$QW5^FV7S3<&4*E@QOSN,]YA]7SP\ M/E3/J>4R_RN;QW_,;O/5?+;^^\-=E.9QH'7\A8`M49&K$FNCA``$6E5[*J04 M5]#U:D1$CBNL)/#N)U-,;[$IFEJ4[,A7OZWSS:8,NUEXO"5(;]TWP2FTL2`XAEV%BJT]T/?@C^ZO\I]-!UN>\(%`-K=8N MDDHIYG&MH?A'%7_#;6I9@"E>U(VW;?/Q_7B]LL3KS\K>F\8EEB4ZE5L M5=/M:B`VA$@F[5V,FKL(4IU]B2OJX*!_>++JP^]XQF>#)]G/YX+*(M]G?GF_J@Y/-U27,?RZ?A MDX&0N(,K[@CRAF&$K:NC2"SAZ%2W)A]WB MWI68W/PXE9^\QJ0#198KLT#X"">.C??[#GZ>,&]:]83[66I,,J&DHE9S(;E" M$@+#6,5#[UEJ;?ZIQT4/A;S>:DQ>)K>IEB%Q0"*)'$;$*4Z()13`B@J!DIW. M4XR5'E[RIRJ/7,;X*5<>\9`Y"!PBT`)))471M*@HD50E=[*='H32!'BZV,AE MW'NKZ?\Z+A:MG5&12PQ(@FS5\3$RR]%1&J_VBY%+Q=L^_?\R'D^_X@B3$CHH MO4'(4J?C3@]110\P.M6E/L&0R_XPTP%CIYLNJW%$N:&`.R>(CY0(6_-)4)9: MS6CR#H#1#9DV8IB$F^L-I,M230I/B(SF!2JTN4&JYFI1+^A*CX6)T!HB7?8R MB0R>R;CS05^6SW@X)FBKF;9>$XHQ,$43U6A/5-J`@VMU1(R+E5,ICBVDDV3= M_9&O+D%4XYA`C4`".R(T(TI02R"JCTC1.DT]&4Y^@YX"HKJ6SMO(S.:.&:V< M%,8[:!W%2-1N00]5ZJ[Y%G-B1E-;2:*8A%DX\&LY-`*RJ$6E3E. M!8>C@/>G.,\,+KO!T/ZYF:C/SXDZ=OGIOG_-BLH>-]GZ`3:M@EX^&AS$0@!! MM>,"(V.UE:[B,!3C-%J8@C'1(3:/+8LI"'/2F\,I8O^5%Z7OEA$AGV;;QCRW M?K\>/.?0&X,5@9'K,-I^!%<\!T+XG]4:[WD!34JJ;VXE?5IL_NW76?9N%6&3 M;;9#KJ-CWP[`*V(]`5A2;8!U1%E5\=L@F7J3-7DC[4I640-C'YX+%4&'%`5(T6FQ$&PJ,IBCR5QBIV155D!\*@B\JD8XNM4&B)II)>I]O M-A4EI^(J+GM3T%IHRYR2"EA`-39,VDHP!B67GKH8P5]WI6^VL_6V5QR/"ZCG MT1>]"FL(X)Z:ML[N\G7VG.'[GT^CN,UK`Q>$$`%E/`,0*;"#UK**2\7)X'JB MS28%Y@%E-@2RN^#M.5#O]#M!**V0!(0A120Q&@(%*SXZH_NO)"AWV%]E7V8[ M%_'/M`3&E.78VOX,V^2L/0Z1HLJG`1PY33BSG#A440T%&LZCD&]GRY\'NCW( MYKH-9V,]%=`X)X$#1:5ZRFM;C%.3>@=S<=7"G>'L5O.?!ZO]BFI(AU899?/" MF5=XY5:;7ZZL(WX$0J/V\=HC!R2)!R`BC"]]DS1:C-@U1K;VG:9[N+#R+ZO%?[+Y;I&4##@_9;G#[X7(2&DPCXO#4N*PP$+1 MFK?$I>Z\4P_+&`J1KZ8OCR?#(7;HG3[^,\*BO)UXOZ>B(3WHQ*C`2!'EBIEW MW#$B1+2*846CD;+1G?U&<3HR8/*^!#0B"!OS@4Z."\HS9HR7F!),3%%K:Y]] M%^ED6(Z2+CT`$#L1_7EP2F+T,-ZA31:_\/MG&9W3:.# MXYA@XPAQ10RL9%*A>F%&EHY2SF$\<%T*A)<-[3IF^""A(]DROO/+;]DJ6\^6 M<>YJ_K!8+0K#8QM/.OOI;QKA=M%[@L"0*B(910PS132EKC)HG!,X-3IWZL&% M_0"O3]8/FL?3RM1X?T;61<=?"MAZ9R-13#J#'=22F6HY.P7HM<)X6E;BN$(= MQ`&YFWPV/T[;?H&?\CN>]8(0]R.!A+,2:RN$-CH>+6O58'"JN_'R>_I\LR@T MUW"('@U#S[V.?0BJ?V=CN8!_.1%_J#C'@>!6.BP]$]A)Z!'8B0@[))4=VXEX M/'[S(.UW4\1Q[G#_%,M9"OHFBE8O3[?(Z?9#`2A%A(E$>:Z@0Y0QPBMN.B2N M-9MK*`R>4?5P,.$-A"?M#TIL#MQ!*B)F+AA5F&#K.2<4K;VSJ/=($*S>,#O,A M!-2GB5KGI/R>S0HVEOP9Q5:M9_(DTW,LT5/#@B:24X6(Q5HJBB2V;%_&T0K) M?./]P'"4GJ,63HX+SB)-D.?6"A^/44:3O>,_T@JL2PVZG;H5V(W\\_XX/?CJ M?5).]3_'ORY6<>ABMCQHN;$+;[F:Q>X!-)Y&@4,N`>88$KJOZN6(1__/WI4M MMY$CVU_"OCQBG7&$;3G:W=&/"%HJ2YR62#<73^M^_05(5E&61581K(WTO#@4 M-%$LG#S(3"02F:8V\[;CF<8M0+%:[@1U=Q--U.UZD7H.1Z]HNOQC-O^2.F\E M._%N]FV]2NY0%-CC=,.*NGR4%G\EQ"T(3"4D#$6.<*`E=J;$45&3ZS%?M")I MS*U#BJ1WN?3A`5>ST\\O%)!?%'^OB]GM)4N9GLN"1:FK.OFJ%3B6DM[ MMDJ'0U1K#?:AJ+:L%FAM3D"3X<$+!63*;/24K(X(Q!IR&'#H%58D#0]9=NVYLB25-U&-+ M,NB5BYOEN=P``IL;XY]'!6V)$)HHS^)2EH@0`LJ]'X7.7WU@K5TB'*+;V<`/ M12Z412Y4.AJI0)K!1&/%H`!``%;:"NJMR;U*,<)2"N/.#[(->'R7_FBU2;?GGSU19?5FJV MZ[K].;FTT]6T6-9L&1H^(7`+")+,.ND&W#-T(Z*1 MT+-VP]#X&<%([PEACC.DE53&Z!HZ_0XG7Y9`NB%@/-9\?QA MLOBK6/GU[*[^%L_;`P+3"$.LL35284*9X**,>E+`_165(.Q`VJ_YU`;$?9#G MC\__FG\O%K--VN=]$=5YG'N$9(]$+9V:/B(0SHS7!F*$N=+(.>&JV5/I<@,= M)^\1XLM^F5\\Q3J"_3CI#G0)L\5B^GUS#^W]=/)E4XC^<[%:/6[\U^/-PAH, M#91X2`Q.S8.<,0YAQ%$5`[*D^UIDHS5ZF1SJ"/E>MYI;9S5B4K[]AO$_N:[Q M"Q_GL\4/GNS[!K<(6_V=()0W6C,ND&/24B\-WG5D<,P;>JW5S<>PLQA2D$,= M6OPY73W\!.KR1U1_%,$&G,UC3CS7..>G@H=:,64!],)KI7$T4;9$4V(Q2-V+ M7E9"7RQL<"C2HP#[6`XO8'TC$^X(N8\/#%(PY2E1$E">/'B<2BCO9FI,=G^* M"SM/'HBWKS7RNA&7!AM:`^"AY8#*5V:E?R M`A"O;&WR3\@FN:M/)SV+98=L MXC#"&4F(NJ43%,P4P$8;B`0SWBG%#"_G[AF[UO#TJT%]UJG1_8QRFD"&&-0TD,A+"(0$,%Q*E].N"UG M`+"_UB*W'8CXU*#D:>"`B#**&[BF3)&4,6C#JC6/,GN MI7TQ&]RA3?<(A'IA2\5,'F]3R8(4H)H_/OKY(M6MZ6?=O/W;04BK&%$4"Q'W M'T!XXEF)-[%TD#NGHU\W&73M;NVT(M@QQ_V7O[T*SNW,;%?!_Z._%P`!`/G4 ME$AIXQBQC*O*E@/<6W'BG[L&7I;M.9>V+1T4M"GL,2^B`]/\5_1[4YF<=[/; MQ_5=.4@BI28IS*#22=G)K43_.NZUM);4JW]X/%`2OR=G%. MF)H":FV%-!@RRZ2!JBQXC'6#(@'=S/2-,E0-S\(WC,HHEMC"[P3LO496(..- M=P#)%'FHL+3DESPA;,RO@U42^Y?,`"F5N=&O4RK_M?-+@6CID"11/5O@-,9* M"%)BB83/+2MR,0YMFRP?5C9=VLYWLRB?8KEZU4*A5WNY*:JZK:.:3DQVW5H: M6,SC`P-2"FN-(/$81X=$`*SDKH8C]PJP86QFB7CUWJ]$L.=M$ZV1\;1``-7` M2LP)A)X@+Y@H:UMRPW0M+A=J_]IBRT]-U;J60(_KOTK'>_6Y?C:3Y<,V@3'] ME4H@SV<#Y^-UI3>8,C3N:S0E@'D2_R)NU[L$0>KH0$5&7].J^!+_3+&,E%GZ M-%^LIO^W$7\#95'WB"`I4192#HV'R"#.($4E`I;@W`)1S36$W+)S5MRGJMN= M[MO;(L,!M=`RUGWXO&^\>H-%=614T`!A;@PRBFIE+&*>PW*.C/#<2VIC]T7[ MHU8FTEFY0V_\_+OE M=VO$%J0Z[P[O-KCRYV2QF$0)I0:A92[3KHU#>KWD*LW7L\84:OJXH.*^#S+E M*(,@8N@T<[*8FRA`JCT\A!!,I=/S2\Y5WSJ M,8>C359U!74O0>3M/;;9_8%HVUO1X`-#@N!&4)PJD6&I*#06"U?.3L;/,HE$ M6W"2+H=$+:';BL&:?)NN)H^I)UI36[4?$2#%%++4'MLPY*500MKR?:W*;EC+ MSBL;'$0AF/G3 MTW2U;=8ZNS/S6=K+[6KU51@VT`\G/2,4EMTXY+X&Q&B)+>9E4*)16M<=* M7:?.[B+GGR:+U?/OB\EL&5\Z95_KYQ_^IZ:.3M;S0K1"&EHM(X.I@^F>$6(E M-HY?;4/AC@AT,#>V.Y'TL=E,%0UNOJITYG._U2O'"^*\^?V4\T@-PU$C8D@Y MQ0!+7,[+.W.M944Z)L&\?>C[H-2+-UQNL\HF^T]>@E-;8?O$)X6X$Z=QRD`J M`ZEFR&-=I@`+XL2U=CX^DQCS/D'/BJ#NG)]/#Y/HY]P6Z]7T=O)HYHMO\\5& M5L>+VC0;'1"P'&$%#$$$>F"@(=6R-"R[#LC8R=.9N.==BZ`/7;;/@=B7J?QM MNORKQDH>&Q8H<091Y)U"6#//,(2VG"75+C=%>^P)<_T:RQ8ET"_/DL.:/-.D MU&L+OQT;%E<3CA:`>H05.2\5Y%'[=]=>.")%Y@2E*#1FR1Y)PS7;Z[)?I:/?=VY#GO#ND^ ME(Z)PIENUD8)0JU'?FA(D-):18014B-N`(^+3%68:90;;!B[46N51RV#G*5H M7@089RD!Z&DZJRW/UVQ@```HR:5$7B"@`?&0TO+MM8'=IUU>L]_3B0S.9=#] MHMC^\912AALPY\0L]6GR?/+,\K7U*@=&*`VDD&>>GTACK434)4.G532YQ;>'JO=Z9(B M;8/=APOSZNQ.W=XNUI-'M3*3Q>(Y?EA7'*G1^.`]WO28-@A+8)AP#%1P2N!S M=U)CM5P=D:Q+S/O@VFX5+/U\\;ZXGSSN$3H6"CHR*E`LF%=**@NHUY82CTLC M+R'2N5=QS^J.=E%4:@_'!`@0 M\Y#'"5N.,811W5;JU<=-8N?I_SWT">W4@+6&;;\AOQ>UE%*2\GJQ>-LE:C@R M0,&-C%-USGCG/;3&\FJ;2$`NCTZ^.'"Q:J5=@/LN9;5^^K;A?,I9O-U>XWDZ MPJ:ZH<&GBU4<(4@8!L![*QBL++$1N?VQFU\]N"KOIV6XAR)7BD[YN%\H$V1_ MFZP:%2&M>4104FO-@4%*`**]9\J1:O:$Y>8SB_^1K478>R7=MGJIB_N%U?,^ M,MJ$:V^/#$YIQBRR@E(""7;00%QI;ZISKU+)7YQBK:#=90IMNFW6VQ^\^9J*>=Y&)6BGC^MM\8WM99]3'CU@FGV; M"D)!)C1!T&C#B"1<1_'J:`.T$H0Q65LKN9L9_B`1]3T"?4@,&U$>F?B)3PJ> M\7[L]GR+Q/Y/MP/YO/8*=(6N'A[EE! M>D<((D(8A)$@A"LF2SR@L-W7M/H%F9B'_;BXN#5N]28A\XE!0B"UUU9IC##V M5%@-2FRB;'I+X?B5>'F.!/I@YVMHZJSRF]\/)/JL##`M`(,<0(6I/\174]&(3.Z+C^N46GGS=?/6RYOU:IEJ7Z8,WGHS>NJC`N-. ML,ZDG/"91KA[SR."YFC)F3 MS+`2!TM,;YO4R98=M6#<6=CZ+X(31\ M+"1\)2%?9)F#V(JHS5;3NR2&Z??B<^J_M4F] M.2BQGXXM&A=2:>.'`E*IV5ATF0EQ@`)G!)M/3SVP^HN87>X:\&2Z+Q0:E(CHK1CI_Y03'U=HV,T MDAUN]7R_&R2BB!$<#2-BRB"N-?7E?!R$W?=$&A/WP MN/[::9>\[M4O\ M+.F-Z$!EP,XR;1Y^.(20Y`8(3Q6S`'L@MBX=<9))5^LV=WWX\69RUOZJ0N-F M,IE/#%(J8*6S"ENMHFE@$.,2GU26]4JUR_E\.7BU+7Q^R:J(<#(P+TG,M( M9.^]0%)XZ;RNYB>&:8?42^71\Z3]4\F3-M`==IFZY;+X9]?<=?/M`9-VVEJ] M`B`F/++8$`4P=Y12$F6+B8&P23V,[F:WKZY=EW7SQK>#10(P`1DEAD3&(NE< M-2_DX;7F#YPKY3=6[7G(]E/IZN5;UK9.>/WE("CG#"BG>-RM>T:IL;J:D577 MS)5LX1XE2@:J_?.D47['H2'!,@N%D<((01V!&FMBRMD)(7X-SIPFYZ.4R88V MZ_QT8\DW)OSX8>GK[P5ID>&&07NH]J\J MFAQ!'1@1.(HS$<1YRE#4JM%?UK"B?1[FBU4J MOJSR>S;<.]?5CCF$ZJ&QL`X9I8#S%UU(-HG_W>SY-*Y590&&N1^LXT M5+A\2!C=?$R:U&0F'!P4DG&#((P6QE`0):O=>8UQ-O=6E M[[(0>5?\:0W67BH+-5,^/]#?.0^X`W'G2"S0@GN[@6J[&8`Z]TSMY"KUEV>\ MSH"Q#S*8Q\ER>?-UERU]L_@M71=N=M6[;FC`#D`+@$<`.T890PCRBOK.Y:86 MC*@D?5>D:1G:/HA4NF6?)M-C%7M>?BT(YIW$WO"H')474G-8P2-I=KSNY"+S MEVARS@`R+SKW]WKZ+;UZF>1\]^7Y]X?I8MN_[MWL=E'$#^TZ]<&,#OET_A8+ M,I\4N$/4*0\DI=H":F5D?3F_.-5<-_>L`O'CIDD_2'?`I#S6!`@8XH!J22'T M1KCH:57^N+9\B)J&:QX7VBX(?)*B45/1_H6O+V%X/5(#)4:,8X M(H(R@USE6B,!<^^N0/"+['Y;@35+Z/N(S[ M4\MEL5(K-[O;?7*('F<\,G@2X4&8(D4L0D"PU">J!$[5%\T_1*1?)>#;LP#Z M<&?+)G._S]5MU)&+HM*4-[-#/&P\-D3GG4E-I5$^H@N5<;3:!VI+LJ]T_`+! MX+;!'39[[=]QT:P?4Y^Q_3>O(($-,*L8Q(YB1JD%EABQO4I)C$Y_7FH"FQ-: M(2R$0\)!)A3'PI?S0E9E>QP78"?.D7*#!+;3D+V$!#9*N>0$4LV58$D'*0;* M&?U_>=>VV\B-1#]I>;\`^\(K$"")@\PDP#X1&JGM$5:6LI(]L]ZO7U)6MSVR M6MVB^B(I+TDF0[98AX=5++)8Q3"XM3KFG4QN6P`;XXQP`*/[[0"' M3!,B8"D=5N!6$Z*?,\]M`]A.@S;+JSEDS(^'LM7W",[)"('EFF""N+.*ORE7 M"[*S1E\7%7+F;]4'OD,HDC\GZWD:8`IL:#`W^TV#\YPI)P25"DG+!*:[2L=1 M&NETKN*X>'_B//MR)HQ#DZ+1KGQL'`@$UCAG$21(6()3NJ-2(L";'X+UH4;Z M(4;^9!YA11:*@YQ/K.>/VQ$V)@'::QFL(!P2"KB.[K=E(.JZ2I%"-T[RP_X9 M<>I$[I\ZG`7B=05'XP@$1R1[O#!\?:?`%6,V94OC&&.BN="L5*S&QW4XQD;V"AG4&<*W&(D/.=,Z M[@0<1,9$C](K1$L$&&6YMR_79>"ZYEB'B`_/N92B9_,ISMYD=K=\OVV$K1E7 M_XF@HJP$`&N-APIJB*%AI?3`9(>YG95C\^KYUAG>P[,MJ>&[>S]?Q]52;.\P M9[M;S?9T._*-H#525COI*&!<<40-1M5J0SKWZ/"L8.VKYUMW@&>=+>^=BV[+ M.*WN?UDMG[XN7LH[\;ICYE:=@X"4.>*,DP8"((U#2I=2.&]S:7-6N/85T:8W MI(=74*^QH//I;L"ME=)>OZB(D8H_Z)E#T>AS[)FI()3,RJ'BNZ^447V`G!>C MN5H^I-#`-)#?UL5?M;0XTCIHXB0UA"E`&:7>:PQP);T`N8^JSXKAOB(R=`=M M!_;';X/[7G^]]LUAJWZ!<62%\`PKY;&#`OCJE#[JQ>SDWF<%;E\;+3H&.8L@ M9;V-GS:;YV+F5^LR]O/N?IM5^+749!U-VO4.5#%)N1>62$:LIY16E\"IRE#V MW<6U1GQGL:47K/->@ORW6$_GF^*W]7Q:E-E"ZRARL'%`WJ5:4T98%VV@DX#2 M:BMEI,IFQ'7%29S)B"Z@S2)`5$_KI_G_RE*LNS##8_:DOD>@P#E+5)33<'M9%_'_%Y]739.&?GY[7Q2_SY?SQ^7'[ MKJ#TWO]8QFD^\*$;"-MGA+"XK'FJG&=AG$2P.\>BS%-\>M;H&JU_`+P?X"Z1 M_C7"]_E[L?A6;`]0:C>/N=\+"&M#H"!<"LNY4U#M_";*@=)JE#Q?_:WY#ND.@?K`1@5/U5TR*GJ%Q/:L2"<9T5WJ"IPHECS$DN*2;< MNYWC:K$7U'7D`)65E5;W]6YF'<#'JN9T]_$@4D4RPH".^W+#N(U.O"R1,`K? M\O.S^[MO[:)-!5_K^(%JL];HN`2K/$;#`:^.$ M18Y"":P$S')EF&E^8CF,A*VJZ-7U"8@X:GV4B!D,(GETU$511IY>-3`CS^63] M\FFR*"_5&QYTU_8)*:$]8UH[S!'A3#KF12D?=.2&'O">-[T'N-(%H(,0YFV$ M*>'!W?WG]62YB2LEW2HUO?EN[ARXP]1`HQV*FT<"O.<$5A@*/TJ)Y_XH=.:L M[_.H:WB'(-3=MV*M%HO5TS8MVE]IK(W/Q&O[!$3C]D8Y3H2EBA)D/+6E?`33 M6]I"=CC9JW[@'40?I>=;:9PIM=[32ZKMO%IN+7B#$3O6+WA,-#$*4,X$9M&) M5MY7*Y"X46IN78,AZQ#4(0RTUL9P;)3Q'NA2+LIORF1U M,[_[!4DZ0'4(ML01/JZ66XW;:*$^M`V">H\1DU8HC:,S08FHC+HP?+!TC$/4 M#SAS1O<+3)R)Y1#<4-\GZ]GG^',-9N>'=H%[IX&4U%"MHF;EV,)*S\;MWPU= ME'=J9LX!<9`]20I)UBE[=%H"1=R5O4Y0W*`];-7G1K^\M2E?/R2AWB1;SGY; M3):M,C3V\7,!4XVD1Y@YR0R/\,:U6BU6FGU=>H%&+9--'ZJRC3X)@^R8'O]: MK%Z*8JN-6WIKM7V"\U%?1]GBK#'`=/0L!*K<"2X;KS"OAV3CTF-_P]71A`Q! MN-^+S=-Z/GTJ9NTV7@?;QU6-G:)1#J,H5HP0Y\B;I=$W%.=X443K8C*&(-F? M<9SSY4-3(M.W5@$+DQZ2&,&4D8A[@P5]\W64NIU@M$YW;OD0#DB#YM2E[]L% M+A'U40SM-;-62QZ=DE(.8^T-!>9GS=YA!F1A-^+>?:L;HPZ=?BWNELUY3$_X M2G`\^KZ2``%,M+=,.H1YB8&2X(8NS3+GOMU.NP-L+X-?G[^O.N!7]97`K'=Q M'^>I%6D_%S=W!I<86&5O*-WV4/S*Q7:H"_WWYKKY2*JF1[!&*((LUL([:;C" M@%9K!P&2F]WR`LLH=WZ9?SZ<(U&E^:RIKD\@TC@.M2>XF3%9F([`F69#=:A]7%M,84R@QPA*HHVP0)9R,;U?9_[&N'+JW!YG M2Q:B(S#EYQ9)WNNZ!&*@1-)JR!6"S%`&575B8*G,C4.\P.+L?9JB7#R'">-8 M3?_]FN3G?8GGU_0^OQ;?MW]U/)ZCS0>"E@#'/9KT("X72J50JG);"<&YYS87 M>0M[_O1_"._H`>/!G*Y=#JFF_$V-?0+CVG,)/8+I*:302'E0R6=%KC8ZV:&Z M3@YU!.L0M'E?VJ!,&G-W_RX6G\<1HM77O6=4E@^4@P#23%&F$OO!7E]WXY)5#:-I3AZTBK' M<&_U'K/5!X*PC'*JE8$<<8XTY9*5TG.*1KFF&."1=1=\V%<'?0`^_AJ_J;7N MG8#>(>`19599SH![+0)#$5,(-Z9J[4?*/U+>6Q<-P6,T"<>\X1\;1FD\P4@B M$/F$K*6:`%5*8YR[H2OJ+J9TU2&6@\2E3S9?U7*6_I4"K[]-%BG,9RO_2QL# MT*I_\-0KQ:``3'JK`)?45G)+GGUR30FDZU M?8*,OA@0%&K&$4*".;Y+TASE0Y3DNA`7&.[>`X6Z@G4(VOC)?/WG9/&\+4*T M31HS6;QE\=WQ_@B%6O4/7FJ``9:2>&"198HZ7,I-\ZW:!7JD/="I#XB'H-:O MQ?=W:*Q7R_B?T^+=F-LKJE,_%1`T'")EA!5622P`=ZQ$0_/L_/T7&!'1`^%Z M1KM/_Z-P^_#Y_^/JT2F+)8AB&^$U0DF@]:XR MCP/,R$9]NB]_0_&5QN1P'QH&X*%([_LPA\(3(YWGM!PADNQ6$[UU/H&'*JSD MHCS$PE.SV3QU3B;J?K5^'#N'_7!KTA@336[I$7QY6#%V"]T7;-QUXI*.86'N9>LE\ZL+F;^I-P>I^%\/;D]*&5& M"V1CR6Z5Z.,TB"\_T8?%#NVC!O;2"0*0UQP9#(*`MY=`T M^[GH!1Z>=\N(.V(!@H2[8#WBFJ`=&6DNCUVM4V=W]IV+Z'&=B7FS,9+$H9OJE=%%W#4]6:>V_ M'*C$@DAN+8,88NR(P=6N$G*;N]6^R+#J(?G8VQ0TG?S]\Q^I<0IJC'_X/U!+ M`P04````"`!SB6I'7-&&U^'-D M550)``.::T)6FFM"5G5X"P`!!"4.```$.0$``.T=VV[C-O9]@?T'KI]:H![; MN4R;P:2%)Y=N@"0VDLQ.]ZF@)0,2A+B;S\]['Q_[X\>+FIO?;K__\Q_M_ M]?M_?'BX!9?4"9:("'#!$!3(!<]8+,`G%_'/P&-T"3Y1]AFO8;\?88'PZH6[ M[[BS0$L(H!`,SP*!KBE;7B(/!KXX[P7D2P!][&'D2BE\I)AD`%*/!61S).[A M$O$5=-!Y;R'$ZMU@\/S\_(:A-20.>N/0Y>!H.#H=GAU+M:2BA+_S,?F<`7Z9 M,?\-97,).3P>J,4"4`V'.%!/M.H`>_/(5QI)?K#4?]XU`-A,[BE#A2ZW44X6@LKX@#Y@IL[ M_834&RE##PP:RL.HC_B.!-*TMI9(-8E=2:1IM9*HK"45R+.)HO[U#5Y?W>J/ MCK84(^F6S<0P>#L1XVP`F:/<+3WGB#YZ6?F00$'9Z[7\7T\TG[$,E:N$B)+Q M3,DX>KN-C)HT07,5F>O+E,;:K2`-#&,PMA?`'IKKR)'&O`\1=RE..U&VD"/M MDU/]SZWID12"XGS:D"='SILY70\<&A#!7E6(.JX3VVQXYD\_(=)6FH`Q6=]H MLB>-Q$DCQO_Z"9F6`KD(-Y;%X*B+[25`+\ZB=N;90-)7K9)-AAXF:\1%XT:2 M0HNNMV\B!&)'I^)1$TD2K/"RGQ!H*0?'3F,I#(ZZV($$8L6:BV"0]%69$)`0 M*C0E?<_<7:TP\6AT2]Y4.?R=2>0/R`.Z7GT79='RJG:P8G2%F,"RN$J5]IK` M@B'OO*?J[KZIK_]TH/]&UL$&9(-!ML30^4JB.(&OU;A-A#045/P^[W%I;Q\9 MY?_O6KG(:ZJ51,$$=UDI'\Z:*B51D-]5?58,-=5'HG`Y1&[7]A2%)PD!L!SP M74"^N/H2R$&[+PGR,7%O=#15(W#>`PKVX\--X?A42U-.(^9N^"CT?!D M-!R"/KC$W/$I#QB2?Q1!D*((('%!BN;[09Y0GD?`D3LAO^KKO+$B[`BD##/7 MP^LC9CN1'2^Z:[S1VDF72$#L[\17AE2IRTZ&)R?#HZ8N`S]$Q'\\."]EEB#AJ[KJ0]OYYCBZ7.+2!M/4%)0*3N2S^<7V/E5"HB(MG MMKB8D--.RA`\>"9+7"6^50^3]B! M%#\33@]],C&6FJ%V`Q]-O.M`2./>2;[+8'F+9'$TA:\:YR-Q$;NGY$*YVU=A M;2)+-:B(:#B^JU:R2V&J6]5QTU9EQ`/4`Z&`()(0:-;`R`@")2204O83,4$L M9PC-#\UQLP4T2^V5="H2^YDML9^(AZ/3C:[8BW_'K+]9@N0V8=( M='G!J8]=M4KU`?K*D8\+A.I/4503*O.J[+'RIWKMHS2GWIZ@XVM$%*2I@H@L M".D>7):W]!0RJ>(""2QEWIG_LE2KG'FJNVAC9X(?,FP._5'9*+;BQ(OJ0OE0 M5S%+J?%"PN,UNJ5\J[Y:GTF%ZX]J]^,$1,;IA&E42J78`L5W#YO"IG-D$E6S M2=<^?6[@[0HZ%0X]L3K4XD:=;_5DEZ:[APY;JU4)6?3?4X'X)\@8#,<;#W)8 M)TUUB1A>2T'7#88M36A6U,4_6V>\8@9`<_@)&!X_Z8X8L0$I/@?'ECAA%V7S MCMA5E-$_6\KH-LWA4%7G&XS9QBL]=D4$%J\IH]1L!*4DRAP[C"OI>#-QZE*Y M,*27=M2^^4>MQ8C7FIZ(@,MCZ\@VYQ!B[J=QMP^#U73*X]MH9%D,"(D>(I;= M:=<0L_]`/T!CSH/E2E?CS5:_J^E4.VUCKCUVFJ(+-&&0HKR_*]^A89*5D+$C MPWR@$_1$#J%99A!U0Z274!MWMF)0[>?30C^G%T]2+('FF1L:AEP/;<"XZ%%0 MY_,'J$?WRY4TDA;QZD5=;NG]6J2K_7Y2R^^:65_MNPHG`PP[$/';=X\W6OW* MH)0O=(U&EH6NR$/[NJ(5Y[,[!)5%FNS=L^-6C-1/+=5D*OFE21U\(8V0V@Q@ M'LM+3*0KL*H-JYKRJIB$'YJ*5(+/)W?59!`J7]&`I`286_+6;OG M@N42LM>)=[&`9([X#?GZC:4ER^I&LU$DES2:4`@].1N*`3`Y-)^FS:=1PBVC M4+'1Y-22?XNFYX:U_#YAURL8/Y(Q(B/`*DIBK?=(J/TI4\0>%Y"A<70`CPHQ3U1M M$:9$3V8MJ.\B5C?Z-:5:L3YU9.F1DH7>60-6B`'-!:39`$%!R`BD.1W<6^J( M9'Y`I?\@U'SBJ?VHCBQ1+K$?".1*HN'$=1/2C2)#Y\2NF!@^LA1A[1IH;IXD MI8_ZJS72=5JDD^9B5A$4MQ_!M!&[0]RKU\+BN9#D4>JER*L7QP]3M[HK;$SOM.\*J=F?%$#F?52C2WC&7*[#U.DFARY0JTDU&OZT MHUVQN'-D&1ZU;%K[.HC2V^*F\%5I+S-C-'-*YI.9C^=-MGC5(%0QS'IK*^H4 M51"1U7DN)@P2R@>GY6U]Q3EZN8`K+*"OH9OEEM;T*P9E;VVYH):+U;*MX@DB MIA':WH;J2@_]&S$I*>)IR!TW@A(6U>U@LSRNVPX,VQS&H2D4^2FN_<;S.=-' M-SY1V84JWC2W$-IQ^]FU7-6-;F.S3NU&ERH\8VF!%K?6"_%B@>R4#ZVVJ'4T M*R_KDJN8<']KJRCKM9%]K2`?@QE'7P*IQ-6ZP4ZB#;2**3_;)'Q"`X1$]MWV MS79$%F%7#.AM,^L;GMC?#8UQ5GO$9?Q9'U''HTE#]+%ZSK4/"#N=J[SFE>_ZOIM1B\ M(CD-+1W,X.ZKB;=?#JY#J2)7#2VYRI#=Z[7?]X/\&Q9R_JDY>@+*P#. MN�$><]P0+4T]Y69]/^.59G:>LR^6HY0ZZ;?J?W%L,9]K%XO4/R&>OILZ3/ M>\U0L*\/$C.,N:PV!!:!$O-W1H/5>4]_Z>0=%FC9`^%YMN$76=ZY=`DQN9$/ ME/8]$`*N)#/J/FE`-V#11.>@ERK2+__XV^F2R.XXDK=[A^5X15""DE$, MC^4O!6FC0WAG*6D)F:;R2LS"@U/.>PY#LD_:=`L_%2(J5)-C/Q<>4Q M2D0T(H\5K`'X3=2LZ<(E90+_95;IT$RH&*LR?7 MPMPITZ%^=0"_A9JUFJD27$I;*G]\:N)4LKP.B/K4UA-BRVBB*6V'[4FUMY1Q MZ_9A*=S/CY.W"JB7.L%ARI"'&%/'OE#G\8;S0+&<(N:HZF.NWEQE2!\B']EF)Z3:VXIK;F7-HUZ72=30 M'GY`*AG*ABP#G0QJX[6LV)2$@L[0(_5=B_IU\3J7W@JKD)1RIJS-UB%E`!VH M1,).RG6*LO92GMD=D`S?C'9MT3N<`','YCRA%_'!E])GE;8#;.%28YKEB@Y'V@.A7U[F0!N?!?S?*/7=-BX/;J8B+0 M'+'=#W0LX[*D9,X&FWJ@'1S,E9U/-(Z08B7KP6Z1+P63V6G[7JBJP96Z-0V8 MLU!'#\Q>GQ:8N5/(U'E!H3J54!TNDLIE-\7+9:#L.=74ZVE=@-D]2Q0V:+U7 M1F>';`^UW.]`%7#U(BM.S&6=CG7UJ>O36.2"AZWDED*O(A*[$%L-J0+,%^H^ M]:+R(HY]'U?J/)%0>NI-`S%9A42-8FW1NUN\Q"OC>A=$,FET3TGX*41Q+PMM M[R*\GJH9BL0@;9&[6R-8]B%$TF_H;(/XKA3+;-LQ)Z:@63J`!?U M/1I5[,HB0&HGX$O>%@WPNF>%PE+>MLLZ6]270G2@O,\=?1!-0N._4#P<*X7H MGJ\*-R(K6"2XH%T4ZVN"^&R6C<`E):E-"?%AYLHY: MI'L#]`Z;)')>YHU1-2258=2,2B=>/BTUQNIRY[;I4DOA[V*=(2UY^4JI5=EJ ME`Z[5D\PW$%90JJ#1!&+%]-M#[JP-'Y+PP5[%3^DP5?9O2R%3SOL@COXHDIW M_=%!KE;P]%&\6B[.'Z$L9ZCWB!Q*7+UM5C8Q6?\;A=LB;S%GJ%;$VZYA%]9V MT8$TTP5D2^B@0'\FZH*R%0U-F*WS:D-W<(7EGI*KY]&[;V$_C20PU+'-+-,5=0$H<.=-5)CXZ#"C)*;3[N;_)(M M+A-OPO!<+SU'2T'AVO/$T[G`'7..Q%A<$3>Z8[3>CL0WBD2)`1AU$'*Y.O## MI'7J75/?I\\3DH^WM:$[Y_'"@&144FM!:C.0*EOFEC7M&G`="$Q&2B_CH%1) M&F5,`S=6GE,9LS#%[I1B9_=A/J`U](-HCVRJJ'U`+D)+6%D1;X'?N:X2&\6< M-T5+/D9>](;MQFZE71'KQLZFU-&$9O]X=DM3&4#W$GQA=$RI05PUM)`>BEXS MT0OGW*)O(>"WWPJC^YZ*8LA-[^D(]\$F:^SYWMT<[6ONDJVG:LH'U$N5T0]H M%14G#WB^$%'-9C1MC/4=M>6G9_JTH(':$J^.!J`!$PAE1QJF;E/;X[/IORUR M!X=@!:KHCZ'<$%55XG5]"Y2@?3>ZWQ`W<#1F7;4+,+JM\37VE.QC\;1`=Y!] M1O',O)XJB1-5H0$:$^BV/=1&/Z5/?AVF4/]*A`[J^U&__8/:`=&.2;1ABGYFC(3>J.O>86)V:A5&_K;)^WX;85\]6Q[T(U*^!-E MG]7D5?1&4!GYAD23U/CE+P2S1CDVA3\+`#-5#XTC:78ZPE ME'__!U!+`0(>`Q0````(`'.):D>-3PL`Q0````(`'.):D=$Z%:#,!P``)H@`0`5`!@```````$```"D@>OO M``!R=FYC+3(P,34P.3,P7V-A;"YX;6Q55`4``YIK0E9U>`L``00E#@``!#D! M``!02P$"'@,4````"`!SB6I'#\55MBTV``#5?0(`%0`8```````!````I(%J M#`$`&UL550%``.::T)6=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@``Q0````(`'.):D=1(\/!\V```(F>!``5`!@```````$```"D M@9C>`0!R=FYC+3(P,34P.3,P7W!R92YX;6Q55`4``YIK0E9U>`L``00E#@`` M!#D!``!02P$"'@,4````"`!SB6I'7-&&U^`L``00E#@``!#D! 8``!02P4&``````8`!@`:`@``#%`"```` ` end XML 50 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Income Statement [Abstract]

Revenue $ 75 $ 75 $ 225 $ 308

Operating expenses:

Research and development 13,016 8,600 32,573 24,261

General and administrative 5,827 5,300 18,183 14,250

Total operating expenses 18,843 13,900 50,756 38,511

Loss from operations (18,768) (13,825) (50,531) (38,203)

Interest income 68 14 144 18

Interest expense (390) (228) (834) (10,336)

Change in fair value of derivative liabilities associated with the convertible notes 0 0 0 4,032

Changes in fair value of derivative liabilities associated with Medicis settlement 13 67 60 (426)

Change in fair value of common stock warrant liability 0 0 0 (2,151)

Change in fair value of convertible preferred stock warrant liability 0 0 0 (210)

Loss on settlement of preferred stock warrant 0 0 0 (1,356)

Other expense, net (98) (5) (221) (73)

Net loss (19,175) (13,977) (51,382) (48,705)

Unrealized gain on available for sale securities 22 0 10 0

Comprehensive loss (19,153) (13,977) (51,372) (48,705)

Net loss attributable to common stockholders (Note 12):

Basic (19,175) (13,977) (51,382) (48,705)

Diluted $ (19,175) $ (13,977) $ (51,382) $ (48,705)

Net loss per share attributable to common stockholders:

Basic (in dollars per share) $ (0.81) $ (0.60) $ (2.17) $ (2.70)

Diluted (in dollars per share) $ (0.81) $ (0.60) $ (2.17) $ (2.70)

Weighted-average number of shares used in computing net loss per share attributable to common stockholders:

Basic (in shares) 23,755,199 23,331,104 23,625,869 18,009,537

Diluted (in shares) 23,755,199 23,331,104 23,625,869 18,009,537

X

- Definition
Change in Fair Value of Convertible Preferred Stock Warrant
+ References
No definition available.
+ Details

Name: rvnc_ChangeinFairValueofConvertiblePreferredStockWarrant

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Gain or Loss on settlement of warrants to purchase preferred stock upon exercise of put option.
+ References
No definition available.
+ Details

Name: rvnc_GainLossOnSettlementInExchangeOfPreferredStockWarrants

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Gain (Loss) on Derivative Instruments, Contract, Net, Pretax
+ References
No definition available.
+ Details

Name: rvnc_GainLossonDerivativeInstrumentsContractNetPretax

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeNonoperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 51 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes, Warrants, and Related Derivatives
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Convertible Notes, Warrants, and Related Derivatives
Convertible Notes, Warrants, and Related Derivatives
2013 Convertible Notes, Common Stock Warrants, and Related Derivatives
In February 2014, in connection with the Company’s IPO, the 2013 Notes with a principal amount of $23.7 million, accrued interest through the date of the IPO, remaining interest due through October 7, 2014, and derivative liability totaling $26.2 million converted into 1,637,846 shares of the Company’s common stock.
In connection with the issuance of the 2013 Notes, the Company issued warrants to purchase 409,450 shares of common stock, which were net exercised for 405,594 shares of common stock upon the IPO.
Additionally, the 2013 Notes had conversion and redemption features which were determined to be embedded derivatives, requiring bifurcation and separate fair value accounting. Immediately prior to the conversion, the Company determined that the fair value of the derivative liabilities associated with the convertible notes was reduced to $1.9 million, the value of interest due to note holders from the date of the IPO through the maturity date of the loan in October 2014.
Upon the conversion of the 2013 Notes into shares of common stock, the Company applied extinguishment accounting resulting in a loss of $8.3 million. As of the date of conversion, the Company was in compliance with all covenants in the 2013 Notes.
During the three months ended March 31, 2014, the Company recognized non-cash interest expense of $9.6 million related to the 2013 Notes, including amortization of warrant-related debt discount of approximately $0.4 million up to the date of conversion, amortization of the derivative-related debt discount of $0.6 million up to the date of conversion, accrued interest of $0.3 million up to the date of conversion and a loss on extinguishment of $8.3 million upon conversion of the 2013 Notes into common stock.

X

- Definition
Convertible Notes
+ References
No definition available.
+ Details

Name: rvnc_ConvertibleNotesTextBlock

Namespace Prefix: rvnc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Payable and Financing Obligation
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Notes Payable and Financing Obligation
Notes Payable and Financing Obligation
Hercules Notes Payable
In September 2011, the Company entered into a loan and security agreement with Hercules Technology Growth Capital for $22.0 million, referred to as the Hercules Notes Payable.
The Hercules Notes Payable, which matured in March 2015 and has been repaid in full, was collateralized by all assets of the Company, and bore interest at the greater of (i) 9.85% per annum or (ii) 9.85% per annum plus the difference of the prime rate less 3.25% per annum and contained covenants that required, among other things, that the Company seek consent from Hercules prior to certain corporate changes and provide certain unaudited financial information within 45 days after the end of each quarter and within 90 days after each year end. Starting in July 2012, the loan was repaid in 33 equal monthly payments of principal and interest of $0.8 million plus an end of term payment of $0.5 million if the loan is prepaid, or $0.4 million if paid upon maturity. In March 2015, the Hercules Notes Payable was repaid in full, including the end of term payment of $0.4 million.
In connection with the Hercules Notes Payable, the Company issued warrants to purchase 17,977 shares of Series D convertible preferred stock at $66.75 per share, which converted to warrants to purchase common stock upon the Company's initial public offering, or IPO. The fair value of the warrants of $0.1 million was recorded as a debt discount and was amortized to interest expense using the straight-line method over the loan term. The Company incurred $0.5 million of debt issuance costs in connection with the Hercules Notes Payable which was also amortized to interest expense over the loan term.
The Company made principal and interest payments on the Hercules Notes Payable of $0 and $2.6 million and $2.3 million and $6.9 million during the three and nine months ended September 30, 2015 and 2014, respectively.

Essex Capital Notes
On December 20, 2013, the Company signed a Loan and Lease Agreement to borrow up to $10.8 million in the form of Secured Promissory Notes from Essex Capital, or the Essex Notes, to finance the completion and installation of the Company’s RT001 commercial fill/finish line, or the Fill/Finish Line. Under the Loan and Lease Agreement, with the issuance of each Note, the Company issued warrants to purchase its capital stock. The Essex Notes incurred interest at 11.5% per annum through the completion of the IPO in February 2014 and 10.375% per annum thereafter. In December 2013, the Company drew down $2.5 million under short-term notes pursuant to the Loan and Lease Agreement, and an additional $2.5 million in January 2014. In May 2014, pursuant to the terms of this agreement, the Company sold equipment to Essex Capital, resulting in partial settlement of the outstanding loan balance of $1.1 million, and sold and leased the equipment back from Essex Capital for fixed monthly payments to be paid over 3 years. This transaction did not qualify for sale-leaseback accounting due to the Company’s continuing involvement in the equipment. Therefore, the Company accounted for this transaction as a financing obligation using the effective interest rate method.
On December 17, 2014, the Company entered into the First Amendment to the Loan and Lease Agreement with Essex Capital. Under the terms of this Amendment, the Company repaid the outstanding debt balance of $3.9 million and issued warrants to purchase 44,753 shares of common stock. Additionally, the Company made interest payments on the Essex Notes in the amount of $0.1 million and $0.3 million for the three and nine months ended September 30, 2014. In February 2015, the Company executed the Second Amendment to the Loan and Lease Agreement, under which the term of the facility was extended to April 15, 2015, and the purchase price of the equipment was increased by $0.1 million to approximately $9.8 million. In accordance with the terms of the Loan and Lease Agreement, in April 2015, the Company sold equipment to Essex Capital for approximately $9.8 million, and concurrently with this sale, entered into a lease for the equipment with a fixed monthly payment to be paid over 3 years. This transaction also did not qualify for sale-leaseback accounting due to the Company’s continuing involvement in the equipment. Therefore, the Company accounted for this transaction as a financing obligation using the effective interest rate method.
In June 2015, the Company exercised its option to purchase all equipment sold and leased back from Essex Capital for 10% of the original purchase amount, or approximately $1.1 million, at the conclusion of the lease terms.
As of September 30, 2015, the aggregate total future minimum lease payments under the financing obligation were as follows (in thousands):
Year Ending December 31,

2015
$
1,054

2016
4,217

2017
3,971

2018
949

Total payments
$
10,191

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Interest Expense (Tables)
9 Months Ended

Sep. 30, 2015

Other Income and Expenses [Abstract]

Summary of Interest Expense by Cash and Non-Cash Components
The interest expense by cash and non-cash components is as follows (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2015

2014

2015

2014
Interest expense

Cash related interest expense (1)
$
(264
)

$
(276
)

$
(564
)

$
(971
)

Non-cash interest expense

Non-cash interest expense — debt issuance costs
—

(48
)

(39
)

(148
)
Non-cash interest expense — warrant and derivative related debt discounts
—

(76
)

(5
)

(219
)
Non-cash interest expense — convertible notes
—

—

—

(1,250
)
Loss on extinguishment of 2013 Notes
—

—

—

(8,331
)
Effective interest on financing obligation
(126
)

(66
)

(226
)

(66
)
Non-cash capitalized interest expense (2)
—

238

—

649

Total non-cash interest expense
(126
)

48

(270
)

(9,365
)

Total interest expense
$
(390
)

$
(228
)

$
(834
)

$
(10,336
)

(1)
Cash related interest expense includes interest payments to Hercules Notes Payable, Essex Notes, and Financing Obligations.
(2)
Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.

X

- Definition
Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates

Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investment securities with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents may include cash on deposit, money market funds, and debt securities.

Investments
Investments
Short-term investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. All of its investments are classified as available-for-sale and carried at fair value, with the change in unrealized gains and losses reported as a separate component of other comprehensive income (loss) on the Condensed Consolidated Statements of Operations and Comprehensive Loss and accumulated as a separate component of stockholders' equity on the Condensed Consolidated Balance Sheets. Interest income, net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of investments, if any. The cost of securities sold is based on the specific-identification method. The Company monitors its investment portfolio for potential impairment on a quarterly basis. If the carrying amount of an investment in debt securities exceeds its fair value and the decline in value is determined to be other-than-temporary, the carrying amount of the security is reduced to fair value and a loss is recognized in operating results for the amount of such decline. In order to determine whether a decline in value is other-than-temporary, the Company evaluates, among other factors, the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, and its intent and ability to hold the security to maturity or forecasted recovery. The Company mitigates its credit risk by investing in money market funds and U.S. government agency obligations which limits the amount of investment exposure as to credit quality and maturity.

Fair Value of Financial Instruments
Fair Value of Financial Instruments
The Company uses fair value measurements to record fair value adjustments to certain financial and non-financial assets and liabilities to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
The three levels of inputs that may be used to measure fair value are as follows:

Level 1
—
Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

Level 2
—
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3
—
Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

Accounting Pronouncements
Accounting Pronouncements
In August 2014, the FASB issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), which will require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year of the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The guidance defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. The guidance is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Company’s financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2,12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Warrants
9 Months Ended

Sep. 30, 2015

Warrants and Rights Note Disclosure [Abstract]

Warrants
Warrants

As of September 30, 2015, the Company has warrants to purchase 198,662 shares of common stock outstanding and no convertible preferred stock warrants outstanding.

X

- Definition
Warrants [Text Block]
+ References
No definition available.
+ Details

Name: rvnc_WarrantsTextBlock

Namespace Prefix: rvnc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Interest Expense
9 Months Ended

Sep. 30, 2015

Other Income and Expenses [Abstract]

Interest Expense
Interest Expense

Interest expense, includes cash and non-cash components with the non-cash components consisting of (i) interest recognized from the amortization of debt issuance costs, which were capitalized on the Condensed Consolidated Balance Sheets and are generally derived from cash payments related to the issuance of convertible notes and notes payable, (ii) interest recognized from the amortization of debt discounts, which were capitalized on the Condensed Consolidated Balance Sheets and derived from the issuance of warrants and derivatives issued in conjunction with convertible notes and notes payable, (iii) interest recognized on the 2013 convertible notes, or 2013 Notes, which was not paid but rather converted into shares of common stock, (iv) interest capitalized for assets constructed for use in operations, (v) interest related to the extinguishment of debt, which is classified as a loss on debt extinguishments, and (vi) effective interest recognized on the financing obligation. The capitalized amounts related to the debt issuance costs and debt discounts are generally amortized to interest expense over the term of the related debt instruments.
The interest expense by cash and non-cash components is as follows (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2015

2014

2015

2014
Interest expense

Cash related interest expense (1)
$
(264
)

$
(276
)

$
(564
)

$
(971
)

Non-cash interest expense

Non-cash interest expense — debt issuance costs
—

(48
)

(39
)

(148
)
Non-cash interest expense — warrant and derivative related debt discounts
—

(76
)

(5
)

(219
)
Non-cash interest expense — convertible notes
—

—

—

(1,250
)
Loss on extinguishment of 2013 Notes
—

—

—

(8,331
)
Effective interest on financing obligation
(126
)

(66
)

(226
)

(66
)
Non-cash capitalized interest expense (2)
—

238

—

649

Total non-cash interest expense
(126
)

48

(270
)

(9,365
)

Total interest expense
$
(390
)

$
(228
)

$
(834
)

$
(10,336
)

(1)
Cash related interest expense includes interest payments to Hercules Notes Payable, Essex Notes, and Financing Obligations.
(2)
Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.

X

- Definition
The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.1-12)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
Facility Lease
In January 2010, the Company entered into a non-cancelable facility lease that requires monthly payments through January 2022. This facility will be used for research, manufacturing, and administrative functions.

In February 2014, the Company extended the term of the Lease by thirty-six (36) months to January 2025. Under the terms of the lease agreement, the payments escalate over the term of the lease with the exception of a decrease in payments at the beginning of 2022; however, the Company recognizes the expense on a straight-line basis over the life of the lease.
Rent expense was $1.3 million and $3.9 million for each of the three and nine months ended September 30, 2015 and 2014. As of September 30, 2015, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands):

Year Ending December 31,

2015
$
1,269

2016
5,222

2017
5,394

2018
5,578

2019 and thereafter
32,354

Total payments
$
49,817

Other Milestone-Based Commitments
The Company has one remaining obligation to make a future milestone payment to List Laboratories that becomes due and payable on the achievement of a certain regulatory milestone. The Company is obligated to pay royalties to List Laboratories on future sales of botulinum toxin products. The Company also has one remaining future milestone payment of $4.0 million due and payable to Valeant Pharmaceuticals International, Inc. upon the achievement of regulatory approval for RT001 or RT002 (Note 3).
Purchase Commitments
The Company has certain commitments from outstanding purchase orders primarily related to clinical trial development and other costs related to the Company’s manufacturing facility. These agreements, which total $22.4 million, are cancellable at any time with the Company required to pay all costs incurred through the cancellation date.
Contingencies
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. As of May 2015, the Company became subject to a securities class action complaint, captioned City of Warren Police and Fire Retirement System v. Revance Therapeutics Inc., et al, CIV 533635, which was filed on behalf of City of Warren Police and Fire Retirement System in the Superior Court for San Mateo County, California against the Company and certain of its directors and executive officers at the time of the June 2014 follow-on public offering, and the investment banking firms that acted as the underwriters in the follow-on public offering. In general, the complaint alleges that the defendants misrepresented the then-present status of the RT001 clinical program and made false and misleading statements regarding the formulation, manufacturing and efficacy of its drug candidate, RT001, for the treatment of lateral canthal lines at the time of the follow-on public offering. The complaint has been brought as a purported class action on behalf of those who purchased common stock in the follow-on public offering and seeks unspecified monetary damages and other relief.

The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. At this time, neither the outcome of this matter, nor an estimate of the maximum potential exposure or the range of possible loss can be determined. The Company believes that the class action lawsuit is without merit and intends to vigorously defend the action. Nevertheless, this litigation, as any other litigation, is subject to uncertainty and there can be no assurance that this litigation will not have a material adverse effect on the Company's business, results of operations, financial position or cash flows.

Indemnification
The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.
The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.
No amounts associated with such indemnifications have been recorded to date.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Equity
9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity
Equity
Common Stock Outstanding
As of September 30, 2015, the Company had 24,313,222 shares of common stock outstanding. In March 2015, the Company entered into an At-The-Market Issuance Sales Agreement, or the ATM agreement, with Cowen and Company, LLC, or Cowen, under which the Company may offer and sell our common stock having aggregate proceeds of up to $50.0 million from time to time through Cowen as our sales agent. Sales of common stock through Cowen will be made by means of ordinary brokers’ transactions on the NASDAQ Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by the Company and Cowen. Cowen will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions we may impose). The Company agreed to pay Cowen a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the ATM agreement. As of September 30, 2015, the Company sold 352,544 shares of common stock under the ATM agreement at a weighted average price of $30.76 per share resulting in net proceeds of approximately $10.1 million, after underwriting discounts, commissions, and other offering expenses. As of September 30, 2015, common stock for aggregate gross proceeds of $39.2 million remained available under this facility, subject to certain conditions as specified in the ATM agreement.
2014 Equity Incentive Plan
On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Equity Incentive Plan, or 2014 EIP, automatically increased by 4% of the total number of shares of the Company’s common stock outstanding on December 31, 2014, or 950,978 shares. During the nine months ended September 30, 2015, the Company granted stock options for 725,838 shares of common stock and 157,286 restricted stock awards under the 2014 EIP, including a stock option grants for 90,000 shares to non-employee directors. As of September 30, 2015, there were 286,984 shares available for issuance under the 2014 EIP.
2014 Inducement Plan
As of September 30, 2015, there were 145,571 shares available for issuance under the 2014 Inducement Plan, or 2014 IN.
The fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Three Months Ended
September 30,

Nine Months Ended September 30,

2015

2014

2015

2014
Expected term (in years)
6.1

6.2

6.3

6.1

Expected volatility
61.3
%

61.5
%

62.7
%

57.4
%
Risk-free interest rate
1.7
%

1.6
%

1.5
%

1.9
%
Expected dividend rate
—
%

—
%

—
%

—
%

Fair Value of Common Stock. The fair value of the shares of common stock is based on the Company's stock price as quoted by the NASDAQ. Prior to the IPO, the fair value of the shares of common stock underlying the stock options had historically been determined by the Board of Directors. Because there was no public market for the Company’s common stock, the Board of Directors had determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, amongst other factors.

Expected Term. The expected term for employees and directors is based on the simplified method, as the Company’s stock options have the following characteristics: (i) granted at-the-money; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable, or “plain vanilla” options, and the Company has limited history of exercise data. The expected term for non-employees is based on the remaining contractual term.
Expected Volatility. Since the Company was a private entity until February 2014 with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available.
Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury constant maturity rates with remaining terms similar to the expected term of the options.
Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend rate of zero in the valuation model.
Forfeitures. The Company is required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.
The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions:

Three Months Ended
September 30,

Nine Months Ended September 30,

2015

2014

2015

2014
Expected term (in years)
8.2

8.9

8.4

9.1

Expected volatility
73.5
%

57.2
%

72.4
%

57.5
%
Risk-free interest rate
2.0
%

2.5
%

2.0
%

2.5
%
Expected dividend rate
—
%

—
%

—
%

—
%

2014 Employee Stock Purchase Plan
On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Employee Stock Purchase Plan, or 2014 ESPP, automatically increased by 1% of the total number of shares of the Company’s capital stock outstanding on December 31, 2014, or 237,744 shares. As of September 30, 2015, there were 404,073 shares available for issuance under the 2014 ESPP.
The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Three Months Ended
September 30,

Nine Months Ended September 30,

2015

2014

2015

2014
Expected term (in years)
0.5

0.5

0.5

0.5

Expected volatility
50.8
%

42.5
%

50.5
%

46.4
%
Risk-free interest rate
0.1
%

0.1
%

0.1
%

0.1
%
Expected dividend rate
—
%

—
%

—
%

—
%

Fair Value of Common Stock. The fair value of the shares of common stock is based on the Company’s stock price as quoted by the NASDAQ.
Expected Term. The expected term is based on the term of the purchase period under the 2014 ESPP.
Expected Volatility. Since the Company was a private entity until February 2014 with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available.
Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury constant maturity treasury rates with remaining terms similar to the expected term.
Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend rate of zero in the valuation model.

Total Stock-Based Compensation
Total stock-based compensation expense related to options and restricted stock awards granted to employees and nonemployees and the employee stock purchase plan was allocated as follows (in thousands):

Three Months Ended
September 30,

Nine Months Ended September 30,
2015

2014

2015

2014
Research and development
$
1,182

$
557

$
2,879

$
1,644

General and administrative
1,408

1,728

4,435

2,967

Total stock based compensation expense
$
2,590

$
2,285

$
7,314

$
4,611

Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):

Unrealized Gains and Losses on Available-for-Sale Securities
Balance at December 31, 2014
$
—

Other comprehensive income (loss) before reclassifications
10

Reclassifications from accumulated other comprehensive income (loss)
—

Net current period other comprehensive income (loss)
10

Balance at September 30, 2015
$
10

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Payable and Financing Obligation - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail)
$ in Thousands

Sep. 30, 2015

USD ($)

Debt Disclosure [Abstract]

2015 $ 1,054

2016 4,217

2017 3,971

2018 949

Total payments $ 10,191

X

- Definition
Financing Obligation, Future Minimum Payments Due
+ References
No definition available.
+ Details

Name: rvnc_FinancingObligationFutureMinimumPaymentsDue

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Financing Obligation, Future Minimum Payments, Due in Four Years
+ References
No definition available.
+ Details

Name: rvnc_FinancingObligationFutureMinimumPaymentsDueinFourYears

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Financing Obligation, Future Minimum Payments, Due in Three Years
+ References
No definition available.
+ Details

Name: rvnc_FinancingObligationFutureMinimumPaymentsDueinThreeYears

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Financing Obligation, Future Minimum Payments, Due in Two Years
+ References
No definition available.
+ Details

Name: rvnc_FinancingObligationFutureMinimumPaymentsDueinTwoYears

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Financing Obligation, Future Minimum Payments, Next Twelve Months
+ References
No definition available.
+ Details

Name: rvnc_FinancingObligationFutureMinimumPaymentsNextTwelveMonths

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Financial Instruments
The fair value of these instruments was as follows (in thousands):

As of September 30, 2015

Fair Value

Level 1

Level 2

Level 3
Assets

Money market funds
$
72,454

$
72,454

$
—

$
—

U.S. government agency obligations
53,721

—

53,721

—

Total assets measured at fair value
$
126,175

$
72,454

$
53,721

$
—

Liabilities

Derivative liabilities associated with the Medicis settlement
$
1,481

$
—

$
—

$
1,481

Total liabilities measured at fair value
$
1,481

$
—

$
—

$
1,481

As of December 31, 2014

Fair Value

Level 1

Level 2

Level 3
Assets

Money market funds
$
166,038

$
166,038

$
—

$
—

Total assets measured at fair value
$
166,038

$
166,038

$
—

$
—

Liabilities

Derivative liabilities associated with the Medicis settlement
$
1,541

$
—

$
—

$
1,541

Total liabilities measured at fair value
$
1,541

$
—

$
—

$
1,541

Summary of Changes in Fair Value of Financial Instruments
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):

Derivative Liability Associated with the Medicis Settlement
Fair value as of December 31, 2014
$
1,541

Change in fair value
(60
)
Fair value as of September 30, 2015
$
1,481

X

- Definition
Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share Attributable to Common Stockholders (Tables)
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders
The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2015 and 2014 (in thousands, except for share and per share amounts):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2015

2014

2015

2014
Net loss attributable to common stockholders, basic
$
(19,175
)

$
(13,977
)

$
(51,382
)

$
(48,705
)
Net loss attributable to common stockholders, diluted
$
(19,175
)

$
(13,977
)

$
(51,382
)

$
(48,705
)
Net loss per share attributable to common stockholders

Basic
$
(0.81
)

$
(0.60
)

$
(2.17
)

$
(2.70
)
Diluted
$
(0.81
)

$
(0.60
)

$
(2.17
)

$
(2.70
)
Weighted-average shares used in computing net loss per share attributable to common stockholders:

Basic
23,755,199

23,331,104

23,625,869

18,009,537

Diluted
23,755,199

23,331,104

23,625,869

18,009,537

Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share
The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

As of September 30,

2015

2014
Stock options
2,374,055

1,877,949

Common stock warrants
198,662

153,909

Unvested restricted stock awards
308,193

253,625

Shares expected to be purchased on December 31 under the 2014 ESPP
7,945

6,426

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

Equity - Fair Value Assumptions (Details)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

2014 Employee Stock Purchase Plan | Employee Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected term (in years) 6 months 6 months 6 months 6 months

Expected volatility (percent) 50.80% 42.50% 50.50% 46.40%

Risk-free interest rate 0.10% 0.10% 0.10% 0.10%

Expected dividend rate 0.00% 0.00% 0.00% 0.00%

2014 Inducement Plan | Employee Stock Option

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected term (in years) 6 years 1 month 6 years 2 months 6 years 3 months 6 years 1 month

Expected volatility (percent) 61.30% 61.50% 62.70% 57.40%

Risk-free interest rate 1.70% 1.60% 1.50% 1.90%

Expected dividend rate 0.00% 0.00% 0.00% 0.00%

2014 Inducement Plan | Non-employee Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected term (in years) 8 years 2 months 8 years 11 months 8 years 5 months 9 years 1 month

Expected volatility (percent) 73.50% 57.20% 72.40% 57.50%

Risk-free interest rate 2.00% 2.50% 2.00% 2.50%

Expected dividend rate 0.00% 0.00% 0.00% 0.00%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenInducementPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=rvnc_NonEmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss $ (51,382) $ (48,705)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation 1,586 1,561

Amortization of premium on investment 364 0

Amortization of discount on debt and capital leases 5 1,198

Amortization of debt issuance cost 39 148

Change in fair value of derivative liabilities associated with the convertible notes 0 (4,032)

Changes in fair value of derivative liabilities associated with Medicis settlement (60) 426

Change in fair value of common stock warrant liability 0 2,151

Change in fair value of convertible preferred stock warrant liability 0 210

Loss on settlement of preferred stock warrant 0 1,356

Loss on extinguishment of 2013 Notes 0 8,331

Stock-based compensation expense 7,314 4,611

Interest for 2013 Notes and Essex Notes upon issuance, non-cash 0 271

Capitalized interest 0 (649)

Effective interest on financing obligation 226 66

Loss on disposal of fixed assets 29 0

Changes in operating assets and liabilities:

Prepaid expenses and other current assets (134) (2,654)

Other non-current assets 24 (1,238)

Accounts payable (477) (3,524)

Accruals and other current liabilities 3,096 1,178

Payments against Medicis liabilities 0 (7,073)

Deferred rent 152 500

Deferred revenue 0 (83)

Net cash used in operating activities (39,218) (45,951)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of property and equipment (2,849) (5,444)

Purchases of investments (54,087) 0

Change in restricted cash 75 75

Net cash used in investing activities (56,861) (5,369)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issuance of common stock, net of deferred follow-on public offering costs 0 131,882

Proceeds from issuance of common stock, net of deferred initial public offering costs 0 102,672

Proceeds from issuance of convertible notes and notes payable 0 6,750

Proceeds from issuance of common stock, net of deferred at-the-market offering costs 10,154 0

Principal payments made on capital leases and financing obligation (1,768) (146)

Net settlement of restricted stock awards to settle employee taxes (762) 0

Principal payments made on notes payable (2,652) (6,230)

Proceeds from sale and leaseback financing 9,831 0

Proceeds from the exercise of stock options and employee stock purchase plan 738 1,402

Payments to settle warrants 0 (1,438)

Net cash provided by financing activities 15,541 234,892

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (80,538) 183,572

CASH AND CASH EQUIVALENTS — Beginning of period 171,032 3,914

CASH AND CASH EQUIVALENTS — End of period 90,494 187,486

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest 564 971

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:

Property and equipment purchases included in accounts payable and accruals and other current liabilities 95 832

Write-off of fixed assets 28 0

Conversion of Series E-1, E-2, E-3, E-4 and E-5 preferred stock into common stock 0 123,982

Conversion of 2013 Notes into common stock 0 26,206

Issuance of common stock upon net exercise of common stock warrants in connection with IPO 0 6,490

Fair value in excess of debt host for derivative liabilities associated with convertible notes 0 1,050

Deferred initial public offering costs 84 4,574

Conversion of preferred stock warrants to common stock warrants 0 1,441

Conversion of Essex Notes into financing obligations 0 1,095

Termination of stock option repurchase right 0 58

Issuance of common stock warrants in connection with the 2013 Notes 0 981

Issuance of convertible preferred stock warrants $ 0 $ 80

X

- Definition
Conversion Of Preferred Stock Warrants To Common Stock Warrants
+ References
No definition available.
+ Details

Name: rvnc_ConversionOfPreferredStockWarrantsToCommonStockWarrants

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Extinguishment of Warrant Liability Upon Exercise of Put Option
+ References
No definition available.
+ Details

Name: rvnc_ExtinguishmentofWarrantLiabilityUponExerciseofPutOption

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gain (Loss) on Derivative Instruments, Contract, Net, Pretax
+ References
No definition available.
+ Details

Name: rvnc_GainLossonDerivativeInstrumentsContractNetPretax

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest Expense Capitalized
+ References
No definition available.
+ Details

Name: rvnc_InterestExpenseCapitalized

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Issuance Of Common Stock Upon Net Exercise Of Warrants
+ References
No definition available.
+ Details

Name: rvnc_IssuanceOfCommonStockUponNetExerciseOfWarrants

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Issuance Of Common Stock Warrants
+ References
No definition available.
+ Details

Name: rvnc_IssuanceOfCommonStockWarrants

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Issuance Of Convertible Preferred Stock Warrants
+ References
No definition available.
+ Details

Name: rvnc_IssuanceOfConvertiblePreferredStockWarrants

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Deferred initial public offering costs paid in a previous period.
+ References
No definition available.
+ Details

Name: rvnc_NoncashDeferredInitialPublicOfferingCosts

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds From Issuance of Follow-On Offering
+ References
No definition available.
+ Details

Name: rvnc_ProceedsFromIssuanceofFollowOnOffering

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revaluation Of Convertible Redeemable Preferred Stock Warrants
+ References
No definition available.
+ Details

Name: rvnc_RevaluationOfConvertibleRedeemablePreferredStockWarrants

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Termination of Stock Option Repurchase Right, Noncash
+ References
No definition available.
+ Details

Name: rvnc_TerminationofStockOptionRepurchaseRightNoncash

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Write-off of Fixed Assets
+ References
No definition available.
+ Details

Name: rvnc_WriteoffofFixedAssets

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents interest incurred for borrowed money which was used to produce goods or render services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_FinancingInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of notes assumed in noncash investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_NotesAssumed1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the purchase of all investments (debt, security, other) during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with security instruments that either represent a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes repayments of (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow after closing and deferred financing costs received by a seller-lessee in a sale-leaseback recognized in financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 55

-Paragraph 51

-URI http://asc.fasb.org/extlink&oid=28365400&loc=d3e51840-112757

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 55

-Paragraph 50

-URI http://asc.fasb.org/extlink&oid=28365400&loc=d3e51831-112757

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=28365400&loc=d3e51843-112757

+ Details

Name: us-gaap_SaleLeasebackTransactionNetProceedsFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements
Fair Value Measurements
The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. These liabilities, consisting of the Medicis settlement, are considered Level 3 instruments, while the assets, consisting of money market funds and U.S. government agency obligations, are considered Level 1 and Level 2 instruments, respectively. The fair value of these instruments was as follows (in thousands):

As of September 30, 2015

Fair Value

Level 1

Level 2

Level 3
Assets

Money market funds
$
72,454

$
72,454

$
—

$
—

U.S. government agency obligations
53,721

—

53,721

—

Total assets measured at fair value
$
126,175

$
72,454

$
53,721

$
—

Liabilities

Derivative liabilities associated with the Medicis settlement
$
1,481

$
—

$
—

$
1,481

Total liabilities measured at fair value
$
1,481

$
—

$
—

$
1,481

As of December 31, 2014

Fair Value

Level 1

Level 2

Level 3
Assets

Money market funds
$
166,038

$
166,038

$
—

$
—

Total assets measured at fair value
$
166,038

$
166,038

$
—

$
—

Liabilities

Derivative liabilities associated with the Medicis settlement
$
1,541

$
—

$
—

$
1,541

Total liabilities measured at fair value
$
1,541

$
—

$
—

$
1,541

The fair value of the U.S. government agency obligations are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. The Company did not transfer any assets or liabilities measured at fair value on a recurring basis to or from Level 1 and Level 2 during the nine months ended September 30, 2015 and the year ended December 31, 2014.
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):

Derivative Liability Associated with the Medicis Settlement
Fair value as of December 31, 2014
$
1,541

Change in fair value
(60
)
Fair value as of September 30, 2015
$
1,481

The fair value of the derivative liability resulting from the Medicis litigation settlement, specifically the derivative related to the Product Approval Payment (Note 3), was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment. The significant unobservable inputs used in the fair value measurement of the Product Approval Payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

The Company and Basis of Presentation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended

Nov. 30, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Subsequent Event [Line Items]

Company's incorporation date Aug. 10, 1999

Commencement date of operations Jun. 30, 2002

Change of entity name date Apr. 19, 2005

Net loss $ 19,175 $ 13,977 $ 51,382 $ 48,705

Net cash used in operating activities 39,218 45,951

Working capital surplus 131,800 131,800

Accumulated deficit (310,179) (310,179) $ (258,797)

Cash, cash equivalents, and investments $ 144,200 $ 144,200

Cash and cash equivalents, and investments, expected funding term for operating plan 12 months

Proceeds from issuance of common stock $ 10,154 $ 0

Subsequent Event

Subsequent Event [Line Items]

Common stock issued, Share price (in usd per share) $ 36.00

Proceeds from issuance of common stock $ 134,600

Common Stock | Subsequent Event

Subsequent Event [Line Items]

Common stock issued, Shares 3,737,500

Over-Allotment Option | Common Stock | Subsequent Event

Subsequent Event [Line Items]

Common stock issued, Shares 487,500

X

- Definition
Date when an entity was incorporated
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationDateOfIncorporation

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when Former Legal or Registered Name was changed
+ References
No definition available.
+ Details

Name: dei_EntityInformationDateToChangeFormerLegalOrRegisteredName

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash, Cash Equivalents, and Investments
+ References
No definition available.
+ Details

Name: rvnc_CashCashEquivalentsandInvestments

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum
+ References
No definition available.
+ Details

Name: rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum

Namespace Prefix: rvnc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Working Capital Surplus
+ References
No definition available.
+ Details

Name: rvnc_WorkingCapitalSurplus

Namespace Prefix: rvnc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Date the operations of the entity commenced, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_OperationsCommencedDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 135 229 1 false 41 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.revance.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.revance.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.revance.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss Sheet http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLoss Condensed Consolidated Statement of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.revance.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 2101100 - Disclosure - The Company and Basis of Presentation Sheet http://www.revance.com/role/CompanyAndBasisOfPresentation The Company and Basis of Presentation Notes 6 false false R7.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.revance.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 2103100 - Disclosure - Medicis Settlement Sheet http://www.revance.com/role/MedicisSettlement Medicis Settlement Notes 8 false false R9.htm 2104100 - Disclosure - Cash Equivalents and Investments Sheet http://www.revance.com/role/CashEquivalentsAndInvestments Cash Equivalents and Investments Notes 9 false false R10.htm 2105100 - Disclosure - Fair Value Measurements Sheet http://www.revance.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 2106100 - Disclosure - Notes Payable and Financing Obligation Notes http://www.revance.com/role/NotesPayableAndFinancingObligation Notes Payable and Financing Obligation Notes 11 false false R12.htm 2107100 - Disclosure - Convertible Notes, Warrants, and Related Derivatives Notes http://www.revance.com/role/ConvertibleNotesWarrantsAndRelatedDerivatives Convertible Notes, Warrants, and Related Derivatives Notes 12 false false R13.htm 2108100 - Disclosure - Interest Expense Sheet http://www.revance.com/role/InterestExpense Interest Expense Notes 13 false false R14.htm 2109100 - Disclosure - Commitments and Contingencies Sheet http://www.revance.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2110100 - Disclosure - Warrants Sheet http://www.revance.com/role/Warrants Warrants Notes 15 false false R16.htm 2111100 - Disclosure - Equity Sheet http://www.revance.com/role/Equity Equity Notes 16 false false R17.htm 2112100 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholders Net Loss per Share Attributable to Common Stockholders Notes 17 false false R18.htm 2113100 - Disclosure - Subsequent Events Sheet http://www.revance.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.revance.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.revance.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 2304301 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://www.revance.com/role/CashEquivalentsAndInvestmentsTables Cash Equivalents and Investments (Tables) Tables http://www.revance.com/role/CashEquivalentsAndInvestments 20 false false R21.htm 2305301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.revance.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.revance.com/role/FairValueMeasurements 21 false false R22.htm 2306301 - Disclosure - Notes Payable and Financing Obligation (Tables) Notes http://www.revance.com/role/NotesPayableAndFinancingObligationTables Notes Payable and Financing Obligation (Tables) Tables http://www.revance.com/role/NotesPayableAndFinancingObligation 22 false false R23.htm 2308301 - Disclosure - Interest Expense (Tables) Sheet http://www.revance.com/role/InterestExpenseTables Interest Expense (Tables) Tables http://www.revance.com/role/InterestExpense 23 false false R24.htm 2309301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.revance.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.revance.com/role/CommitmentsAndContingencies 24 false false R25.htm 2311301 - Disclosure - Equity (Tables) Sheet http://www.revance.com/role/EquityTables Equity (Tables) Tables http://www.revance.com/role/Equity 25 false false R26.htm 2312301 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholdersTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholders 26 false false R27.htm 2401401 - Disclosure - The Company and Basis of Presentation - Additional Information (Detail) Sheet http://www.revance.com/role/CompanyAndBasisOfPresentationAdditionalInformationDetail The Company and Basis of Presentation - Additional Information (Detail) Details 27 false false R28.htm 2403401 - Disclosure - Medicis Settlement - Additional Information (Detail) Sheet http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail Medicis Settlement - Additional Information (Detail) Details 28 false false R29.htm 2404402 - Disclosure - Cash Equivalents and Investments (Details) Sheet http://www.revance.com/role/CashEquivalentsAndInvestmentsDetails Cash Equivalents and Investments (Details) Details http://www.revance.com/role/CashEquivalentsAndInvestmentsTables 29 false false R30.htm 2405402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) Sheet http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) Details 30 false false R31.htm 2405403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) Sheet http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) Details 31 false false R32.htm 2406402 - Disclosure - Notes Payable and Financing Obligation - Hercules Notes Payable (Detail) Notes http://www.revance.com/role/NotesPayableAndFinancingObligationHerculesNotesPayableDetail Notes Payable and Financing Obligation - Hercules Notes Payable (Detail) Details 32 false false R33.htm 2406403 - Disclosure - Notes Payable and Financing Obligation - Essex Capital Notes (Detail) Notes http://www.revance.com/role/NotesPayableAndFinancingObligationEssexCapitalNotesDetail Notes Payable and Financing Obligation - Essex Capital Notes (Detail) Details 33 false false R34.htm 2406404 - Disclosure - Notes Payable and Financing Obligation - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) Notes http://www.revance.com/role/NotesPayableAndFinancingObligationSummaryOfAggregateTotalFutureMinimumLeasePaymentsUnderFinancingObligationDetail Notes Payable and Financing Obligation - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) Details 34 false false R35.htm 2407401 - Disclosure - Convertible Notes, Warrants, and Related Derivatives - Additional Information (Detail) Notes http://www.revance.com/role/ConvertibleNotesWarrantsAndRelatedDerivativesAdditionalInformationDetail Convertible Notes, Warrants, and Related Derivatives - Additional Information (Detail) Details 35 false false R36.htm 2408402 - Disclosure - Interest Expense - Summary of Interest Expense by Cash and Non-Cash Components (Detail) Sheet http://www.revance.com/role/InterestExpenseSummaryOfInterestExpenseByCashAndNonCashComponentsDetail Interest Expense - Summary of Interest Expense by Cash and Non-Cash Components (Detail) Details 36 false false R37.htm 2409402 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 37 false false R38.htm 2409403 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) Sheet http://www.revance.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) Details 38 false false R39.htm 2410401 - Disclosure - Warrants - Additional Information (Detail) Sheet http://www.revance.com/role/WarrantsAdditionalInformationDetail Warrants - Additional Information (Detail) Details 39 false false R40.htm 2411402 - Disclosure - Equity - Additional Information (Detail) Sheet http://www.revance.com/role/EquityAdditionalInformationDetail Equity - Additional Information (Detail) Details 40 false false R41.htm 2411403 - Disclosure - Equity - Fair Value Assumptions (Details) Sheet http://www.revance.com/role/EquityFairValueAssumptionsDetails Equity - Fair Value Assumptions (Details) Details 41 false false R42.htm 2411404 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details) Sheet http://www.revance.com/role/EquityScheduleOfStockBasedCompensationExpenseDetails Equity - Schedule of Stock-based Compensation Expense (Details) Details 42 false false R43.htm 2411405 - Disclosure - Equity - Schedule of Accumulated Other Comprehensive Income (Details) Sheet http://www.revance.com/role/EquityScheduleOfAccumulatedOtherComprehensiveIncomeDetails Equity - Schedule of Accumulated Other Comprehensive Income (Details) Details 43 false false R44.htm 2412402 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) Sheet http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholdersDetail Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) Details 44 false false R45.htm 2412403 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) Sheet http://www.revance.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfCommonStockEquivalentsExcludedFromComputationOfDilutedNetIncomeLossPerShareDetail Net Loss per Share Attributable to Common Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) Details 45 false false R46.htm 2413401 - Disclosure - Subsequent Events (Details) Sheet http://www.revance.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.revance.com/role/SubsequentEvents 46 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Consolidated Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. rvnc-20150930.xml rvnc-20150930_cal.xml rvnc-20150930_def.xml rvnc-20150930_lab.xml rvnc-20150930_pre.xml rvnc-20150930.xsd true true XML 67 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail)
$ in Thousands

Sep. 30, 2015

USD ($)

Commitments and Contingencies Disclosure [Abstract]

2015 $ 1,269

2016 5,222

2017 5,394

2018 5,578

2019 and thereafter 32,354

Total payments $ 49,817

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 68 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Equivalents and Investments (Tables)
9 Months Ended

Sep. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities
The following table is a summary of amortized cost, unrealized gain and loss, and fair value (in thousands):

September 30, 2015

December 31, 2014

Gross Unrealized

Gross Unrealized

Cost

Gains

Losses

Fair Value

Cost

Gains

Losses

Fair Value
Money market funds
$
72,454

$
—

$
—

$
72,454

$
166,038

$
—

$
—

$
166,038

U.S. government agency obligations
53,711

12

(2
)

53,721

—

—

—

—

Total cash equivalents and available-for-sale securities
$
126,165

$
12

$
(2
)

$
126,175

$
166,038

$
—

$
—

$
166,038

Classified as:

Cash equivalents

$
72,454

$
166,038

Short-term investments

51,364

—

Long-term investments

2,357

—

Total cash equivalents and available-for-sale securities

$
126,175

$
166,038

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended
	Oct. 31, 2015	Nov. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Subsequent Event [Line Items]
Proceeds from issuance of common stock			$ 10,154	$ 0
Subsequent Event
Subsequent Event [Line Items]
Common stock issued, Share price (in usd per share)		$ 36.00
Proceeds from issuance of common stock		$ 134,600
Employee Stock Option \| Employed through November 31, 2015 \| Subsequent Event
Subsequent Event [Line Items]
Accelerated vesting awards, number of options and awards	76,286
Employee Stock Option \| Employed through December 15, 2015 \| Subsequent Event
Subsequent Event [Line Items]
Accelerated vesting awards, number of options and awards	114,428
Restricted Stock Award \| Employed through November 31, 2015 \| Subsequent Event
Subsequent Event [Line Items]
Accelerated vesting awards, number of options and awards	23,740
Restricted Stock Award \| Employed through December 15, 2015 \| Subsequent Event
Subsequent Event [Line Items]
Accelerated vesting awards, number of options and awards	35,610
Common Stock \| Subsequent Event
Subsequent Event [Line Items]
Common stock issued, Shares		3,737,500
Over-Allotment Option \| Common Stock \| Subsequent Event
Subsequent Event [Line Items]
Common stock issued, Shares		487,500

Notes Payable and Financing Obligation - Essex Capital Notes (Detail) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended	9 Months Ended
	Jun. 30, 2015	Apr. 30, 2015	Feb. 28, 2015	May. 31, 2014	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 17, 2014	Feb. 28, 2014	Jan. 31, 2014	Dec. 31, 2013	Dec. 20, 2013
Debt Instrument [Line Items]
Short-term notes											$ 2,500
Cash paid for interest						$ 564	$ 971
Essex Notes
Debt Instrument [Line Items]
Secured promissory notes, able to borrow, maximum												$ 10,800
Interest rate, percentage									10.375%			11.50%
Short-term notes										$ 2,500
Settlement of outstanding loan balance				$ 1,100
Notes payable								$ 3,900
Shares available for purchase under common stock warrants								44,753
Cash paid for interest					$ 100		$ 300
Equipment purchased by third party, increase during period			$ 100
Equipment purchased by third party		$ 9,800
Lease period		3 years		3 years
Percentage of original purchase amount of asset at end of lease	10.00%
Purchase of equipment sold and leased back	$ 1,100

Equity - Schedule of Accumulated Other Comprehensive Income (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at December 31, 2014	$ 0
Other comprehensive income (loss) before reclassifications	10
Reclassifications from accumulated other comprehensive income (loss)	0
Net current period other comprehensive income (loss)	10
Balance at September 30, 2015	$ 10

Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 126,165	$ 166,038
Gross unrealized gain	12	0
Gross unrealized loss	(2)	0
Available-for-sale securities, fair value	126,175	166,038
Cash equivalents
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, fair value	72,454	166,038
Short-term investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, fair value	51,364	0
Long-term investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, fair value	2,357	0
Money market funds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	72,454	166,038
Gross unrealized gain	0	0
Gross unrealized loss	0	0
Available-for-sale securities, fair value	72,454	166,038
U.S. government agency obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	53,711	0
Gross unrealized gain	12	0
Gross unrealized loss	(2)	0
Available-for-sale securities, fair value	$ 53,721	$ 0

Medicis Settlement - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2012	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Settlement And Termination [Line Items]
Derivative liabilities associated with Medicis settlement		$ 1,481	$ 1,541
Medicis Pharmaceutical Corporation
Settlement And Termination [Line Items]
Settlement consideration payable	$ 25,000
Upfront payment paid	7,000
Medicis Pharmaceutical Corporation \| Proceeds Sharing Arrangement
Settlement And Termination [Line Items]
Settlement agreement, payable	14,000
Settlement payment			$ 7,100	$ 6,900
Medicis Pharmaceutical Corporation \| Product Approval Payment Derivative
Settlement And Termination [Line Items]
Accrued milestone obligations	$ 4,000
Remaining contractual term (in years)		3 years 9 months
Risk-free interest rate		1.09%
Fair value assumptions, credit risk adjustment (percent)		7.25%

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 72,454	$ 166,038
Total liabilities measured at fair value	0	0
Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	72,454	166,038
Level 1 \| U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Level 1 \| Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	53,721	0
Total liabilities measured at fair value	0	0
Level 2 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 \| U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	53,721
Level 2 \| Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	1,481	1,541
Level 3 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 \| U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Level 3 \| Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	1,481	1,541
Recurring
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	126,175	166,038
Total liabilities measured at fair value	1,481	1,541
Recurring \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	72,454	166,038
Recurring \| U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	53,721
Recurring \| Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	$ 1,481	$ 1,541

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) - Derivative liabilities associated with the Medicis settlement $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value as of December 31, 2014	$ 1,541
Change in fair value	(60)
Fair value as of September 30, 2015	$ 1,481

Medicis Settlement	9 Months Ended
Medicis Settlement	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Medicis Settlement	Medicis Settlement In October 2012, the Company entered into a settlement and termination agreement with Medicis Pharmaceutical Corporation, or Medicis. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to $25.0 million, comprised of (i) an upfront payment of $7.0 million, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of $14.0 million due upon specified capital raising achievements by the Company, of which $6.9 million was paid in 2013 and the remaining $7.1 million was paid in 2014, and (iii) $4.0 million to be paid upon the achievement of regulatory approval for RT001 or RT002 by the Company, or Product Approval Payment. As of September 30, 2015, the Company determined the fair value of its liability for the Product Approval Payment was $1.5 million, which was measured by assuming a term of 3.75 years, a risk-free rate of 1.09% and a credit risk adjustment of 7.25%. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2019. The Company did not make any payments under the Product Approval Payment during the nine months ended September 30, 2015.

Notes Payable and Financing Obligation - Hercules Notes Payable (Detail)	1 Months Ended	3 Months Ended			9 Months Ended
	Sep. 30, 2011 USD ($)	Sep. 30, 2015 USD ($)	Mar. 31, 2015 USD ($) monthly_payment $ / shares shares	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)
Debt Instrument [Line Items]
Proceeds from notes payable					$ 0	$ 6,750,000
Hercules Notes Payable
Debt Instrument [Line Items]
Proceeds from notes payable	$ 22,000,000
Notes payable maturity			Mar. 31, 2015
Interest rate, percentage			9.85%
Notes payable repayment start date			Jul. 31, 2012
Notes payable repayment terms (payments) \| monthly_payment			33
Payment of notes payable principal and interest		$ 0	$ 800,000	$ 2,300,000	$ 2,600,000	$ 6,900,000
Prepayment charge on end of term payment			500,000
End of term payment			$ 400,000
Warrants issued to purchase shares \| shares			17,977
Exercise price per share (usd per share) \| $ / shares			$ 66.75
Debt discount amortized			$ 100,000
Debt issuance costs			$ 500,000
Hercules Notes Payable \| Prime Rate
Debt Instrument [Line Items]
Plus (minus) difference from the prime rate (percent)			3.25%

Equity - Additional Information (Detail) - USD ($)		9 Months Ended
Equity - Additional Information (Detail) - USD ($)	Jan. 01, 2015	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding		24,313,222			23,774,465
Proceeds from issuance of common stock, Maximum				$ 50,000,000
Maximum commission based on gross sales of common stock (as a percent)		3.00%
Proceeds from issuance of common stock, net of deferred at-the-market offering costs		$ 10,154,000	$ 0
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock	4.00%
2014 Equity Incentive Plan \| Restricted Stock Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted		157,286
2014 Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock	1.00%
Common stock shares outstanding increase during period	237,744
Shares available for issuance		404,073
Common Stock \| 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares outstanding increase during period	950,978
Shares underlying stock options granted		725,838
Shares available for issuance		286,984
Common Stock \| 2014 Equity Incentive Plan \| Board Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted		90,000
Common Stock \| 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance		145,571
2015 ATM Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued in connection with ATM Agreement (in shares)		352,544
Stock issued in connection with ATM Agreement , Weighted average price per share (in usd per share)		$ 30.76
Proceeds from issuance of common stock, net of deferred at-the-market offering costs		$ 10,100,000
Common stock remaining amount available to be sold		$ 39,200,000

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 90,494	$ 171,032
Short-term investments	51,364	0
Restricted cash, current portion	35	75
Prepaid expenses and other current assets	1,604	1,624
Total current assets	143,497	172,731
Property and equipment, net	19,254	19,274
Long-term investments	2,357	0
Restricted cash, net of current portion	400	435
Other non-current assets	6	29
TOTAL ASSETS	165,514	192,469
CURRENT LIABILITIES
Accounts payable	2,731	3,149
Accruals and other current liabilities	5,990	4,145
Financing obligation, current portion	3,018	307
Notes payable, current portion and net of discount	0	2,635
Total current liabilities	11,739	10,236
Financing obligation, net of current portion	6,176	598
Derivative liabilities associated with Medicis settlement	1,481	1,541
Deferred rent	3,762	3,725
TOTAL LIABILITIES	$ 23,158	$ 16,100
Commitments and Contingencies (Note 9)
STOCKHOLDERS’ EQUITY
Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of September 30, 2015 and December 31, 2014, respectively; 24,313,222 and 23,774,465 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 24	$ 24
Additional paid-in capital	452,501	435,142
Accumulated other comprehensive income	10	0
Accumulated deficit	(310,179)	(258,797)
TOTAL STOCKHOLDERS’ EQUITY	142,356	176,369
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 165,514	$ 192,469

The Company and Basis of Presentation	9 Months Ended
The Company and Basis of Presentation	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation Revance Therapeutics, Inc., or the Company, was incorporated in Delaware on August 10, 1999 under the name Essentia Biosystems, Inc. The Company commenced operations in June 2002 and on April 19, 2005, changed its name to Revance Therapeutics, Inc. The Company is a clinical-stage specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The Company is leveraging its proprietary portfolio of botulinum toxin type A compounds, combined with its patented TransMTS® peptide delivery system to address unmet needs in large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin type A through two investigational drug product candidates, RT001, also referred to as RTT150 (Botulinum Toxin Type A) Topical Gel, and RT002, or RTT150 (Botulinum Toxin Type A) for Injection. The Company is pursuing clinical development for RT001 and RT002 in a broad spectrum of aesthetic and therapeutic indications. The Company holds worldwide rights for all indications of RT001, RT002, and its TransMTS technology platform. Since commencing operations in 2002, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, and raising capital. The Company has devoted predominantly all of its resources to preclinical, clinical, and manufacturing development of RT001 and RT002. The Company has never been profitable and has not commenced commercial operations. Since the Company's inception, the Company has incurred losses and negative cash flows from operations. The Company has not generated significant revenue from product sales to date and will continue to incur significant research and development and other expenses related to its ongoing operations. For the three and nine months ended September 30, 2015, the Company had a net loss of $19.2 million and $51.4 million and used $39.2 million of cash for operating activities during the nine months ended September 30, 2015. As of September 30, 2015, the Company had a working capital surplus of $131.8 million and an accumulated deficit of $310.2 million. The Company has funded its operations primarily through the sale and issuance of common stock, convertible preferred stock, notes payable, and convertible notes. As of September 30, 2015, the Company had capital resources consisting of cash, cash equivalents, and investments of $144.2 million. The Company believes that its existing cash, cash equivalents, and investments will allow the Company to fund its operations for at least the next 12 months. Follow-on Public Offering In November 2015, the Company completed a public offering, pursuant to which the Company issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements, in the opinion of management, include all adjustments which the Company considers necessary for the fair statement of the Condensed Consolidated Results of Operations and Comprehensive Loss and Cash Flows for the interim periods covered and the Condensed Consolidated Financial Position of the Company at the date of the balance sheets. The December 31, 2014 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America, or US GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2015, or any other future period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission, or SEC, on March 4, 2015. The Condensed Consolidated Financial Statements of the Company include the Company’s accounts and those of the Company’s wholly-owned subsidiary and have been prepared in conformity with US GAAP.

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	95,000,000	95,000,000
Common stock, shares issued (in shares)	24,313,222	23,774,465
Common stock, shares outstanding (in shares)	24,313,222	23,774,465

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 09, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Revance Therapeutics, Inc.
Entity Central Index Key	0001479290
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common stock outstanding		28,062,233

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In November 2015, the Company completed a public offering, pursuant to which the Company issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million. On October 31, 2015, we entered into a separation agreement with Arthur P. Bertolino, M.D., Ph.D., our Chief Medical Officer and Executive Vice President, pursuant to which he resigned his employment with the Company, effective as of December 31, 2015. Dr. Bertolino will not be entitled to cash severance payments in connection with his departure; however, the Company agreed to accelerate vesting for a portion of his outstanding stock options and restricted stock awards, such that if he remains employed with the Company through November 15, 2015, an aggregate of 76,286 stock options and 23,740 restricted stock awards will have vested. If he remains employed through December 31, 2015, an aggregate of 114,428 stock options and 35,610 restricted stock awards will have vested.

Convertible Notes, Warrants, and Related Derivatives	9 Months Ended
Convertible Notes, Warrants, and Related Derivatives	Sep. 30, 2015
Debt Disclosure [Abstract]
Convertible Notes, Warrants, and Related Derivatives	Convertible Notes, Warrants, and Related Derivatives 2013 Convertible Notes, Common Stock Warrants, and Related Derivatives In February 2014, in connection with the Company’s IPO, the 2013 Notes with a principal amount of $23.7 million, accrued interest through the date of the IPO, remaining interest due through October 7, 2014, and derivative liability totaling $26.2 million converted into 1,637,846 shares of the Company’s common stock. In connection with the issuance of the 2013 Notes, the Company issued warrants to purchase 409,450 shares of common stock, which were net exercised for 405,594 shares of common stock upon the IPO. Additionally, the 2013 Notes had conversion and redemption features which were determined to be embedded derivatives, requiring bifurcation and separate fair value accounting. Immediately prior to the conversion, the Company determined that the fair value of the derivative liabilities associated with the convertible notes was reduced to $1.9 million, the value of interest due to note holders from the date of the IPO through the maturity date of the loan in October 2014. Upon the conversion of the 2013 Notes into shares of common stock, the Company applied extinguishment accounting resulting in a loss of $8.3 million. As of the date of conversion, the Company was in compliance with all covenants in the 2013 Notes. During the three months ended March 31, 2014, the Company recognized non-cash interest expense of $9.6 million related to the 2013 Notes, including amortization of warrant-related debt discount of approximately $0.4 million up to the date of conversion, amortization of the derivative-related debt discount of $0.6 million up to the date of conversion, accrued interest of $0.3 million up to the date of conversion and a loss on extinguishment of $8.3 million upon conversion of the 2013 Notes into common stock.

Warrants	9 Months Ended
Warrants	Sep. 30, 2015
Warrants and Rights Note Disclosure [Abstract]
Warrants	Warrants As of September 30, 2015, the Company has warrants to purchase 198,662 shares of common stock outstanding and no convertible preferred stock warrants outstanding.

Notes Payable and Financing Obligation - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) $ in Thousands	Sep. 30, 2015 USD ($)
Debt Disclosure [Abstract]
2015	$ 1,054
2016	4,217
2017	3,971
2018	949
Total payments	$ 10,191

Equity - Fair Value Assumptions (Details)	3 Months Ended		9 Months Ended
Equity - Fair Value Assumptions (Details)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
2014 Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 months	6 months	6 months	6 months
Expected volatility (percent)	50.80%	42.50%	50.50%	46.40%
Risk-free interest rate	0.10%	0.10%	0.10%	0.10%
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
2014 Inducement Plan \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 1 month	6 years 2 months	6 years 3 months	6 years 1 month
Expected volatility (percent)	61.30%	61.50%	62.70%	57.40%
Risk-free interest rate	1.70%	1.60%	1.50%	1.90%
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
2014 Inducement Plan \| Non-employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	8 years 2 months	8 years 11 months	8 years 5 months	9 years 1 month
Expected volatility (percent)	73.50%	57.20%	72.40%	57.50%
Risk-free interest rate	2.00%	2.50%	2.00%	2.50%
Expected dividend rate	0.00%	0.00%	0.00%	0.00%

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (51,382)	$ (48,705)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,586	1,561
Amortization of premium on investment	364	0
Amortization of discount on debt and capital leases	5	1,198
Amortization of debt issuance cost	39	148
Change in fair value of derivative liabilities associated with the convertible notes	0	(4,032)
Changes in fair value of derivative liabilities associated with Medicis settlement	(60)	426
Change in fair value of common stock warrant liability	0	2,151
Change in fair value of convertible preferred stock warrant liability	0	210
Loss on settlement of preferred stock warrant	0	1,356
Loss on extinguishment of 2013 Notes	0	8,331
Stock-based compensation expense	7,314	4,611
Interest for 2013 Notes and Essex Notes upon issuance, non-cash	0	271
Capitalized interest	0	(649)
Effective interest on financing obligation	226	66
Loss on disposal of fixed assets	29	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(134)	(2,654)
Other non-current assets	24	(1,238)
Accounts payable	(477)	(3,524)
Accruals and other current liabilities	3,096	1,178
Payments against Medicis liabilities	0	(7,073)
Deferred rent	152	500
Deferred revenue	0	(83)
Net cash used in operating activities	(39,218)	(45,951)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(2,849)	(5,444)
Purchases of investments	(54,087)	0
Change in restricted cash	75	75
Net cash used in investing activities	(56,861)	(5,369)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of deferred follow-on public offering costs	0	131,882
Proceeds from issuance of common stock, net of deferred initial public offering costs	0	102,672
Proceeds from issuance of convertible notes and notes payable	0	6,750
Proceeds from issuance of common stock, net of deferred at-the-market offering costs	10,154	0
Principal payments made on capital leases and financing obligation	(1,768)	(146)
Net settlement of restricted stock awards to settle employee taxes	(762)	0
Principal payments made on notes payable	(2,652)	(6,230)
Proceeds from sale and leaseback financing	9,831	0
Proceeds from the exercise of stock options and employee stock purchase plan	738	1,402
Payments to settle warrants	0	(1,438)
Net cash provided by financing activities	15,541	234,892
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(80,538)	183,572
CASH AND CASH EQUIVALENTS — Beginning of period	171,032	3,914
CASH AND CASH EQUIVALENTS — End of period	90,494	187,486
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	564	971
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accruals and other current liabilities	95	832
Write-off of fixed assets	28	0
Conversion of Series E-1, E-2, E-3, E-4 and E-5 preferred stock into common stock	0	123,982
Conversion of 2013 Notes into common stock	0	26,206
Issuance of common stock upon net exercise of common stock warrants in connection with IPO	0	6,490
Fair value in excess of debt host for derivative liabilities associated with convertible notes	0	1,050
Deferred initial public offering costs	84	4,574
Conversion of preferred stock warrants to common stock warrants	0	1,441
Conversion of Essex Notes into financing obligations	0	1,095
Termination of stock option repurchase right	0	58
Issuance of common stock warrants in connection with the 2013 Notes	0	981
Issuance of convertible preferred stock warrants	$ 0	$ 80

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) $ in Thousands	Sep. 30, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2015	$ 1,269
2016	5,222
2017	5,394
2018	5,578
2019 and thereafter	32,354
Total payments	$ 49,817